Type
stringclasses 2
values | Section_id
stringclasses 4
values | Primary_id
stringlengths 11
11
| Secondary_id
stringlengths 0
11
| Statement
stringlengths 34
385
| Label
stringclasses 2
values | Primary_evidence_index
listlengths 1
65
| Secondary_evidence_index
listlengths 0
73
| Primary_ct
stringlengths 1.11k
16.3k
| Secondary_ct
stringlengths 101
16.3k
| __index_level_0__
stringlengths 36
36
|
|---|---|---|---|---|---|---|---|---|---|---|
Single
|
Results
|
NCT00368875
|
the primary trial results indicate that the Recommended Phase II Dose for paclitaxel, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 90 mg/m2 .
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] |
[] |
{'Clinical Trial ID': 'NCT00368875', 'Intervention': ['INTERVENTION 1: ', ' Phase I', ' Vorinostat dose (200 or 300 mg BID) was assigned at the time of registration. Vorinostat was administered orally twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.', ' All patients also received paclitaxel at 90 mg/m2 as 1-hour infusion on days 2, 9, and 16 of every 28-day cycle. Bevacizumab was administered on day 2 and day 16 of the 28 day cycle at 10 mg/kg dose. Vorinostat dose escalation was carried out in the standard 3 + 3 phase I trial design based upon toxicity observed during the first cycle of therapy.'], 'Eligibility': ['Inclusion Criteria:', ' histologically or cytologically confirmed adenocarcinoma of the breast; effective with version 2.2 (1/26/09), only patients with disease that is accessible to biopsy and consent to serial biopsy are eligible', ' stage IV disease, locally recurrent inoperable chest wall disease; at least one bidimensional and/or unidimensional, measurable indicator lesion must be present (patients with only non-measurable disease are eligible for the phase I trial only); all sites of disease should be noted and followed', ' ECOG performance status =< 1 (Karnofsky >= 70%)', ' Absolute neutrophil count >= 1,500/ul', ' Platelets >= 100,000/ul', ' Total bilirubin within normal institutional limits', ' AST(SGOT)/ALT(SGPT) =< 2.5 x institutional upper limit of normal', ' PTT and either INR or PT < 1.5 x normal', ' Creatinine within normal institutional limits OR creatinine clearance >= mL/min/1.73 m^2 for patients with creatinine levels above institutional normal', ' Urine protein should be screened by urine analysis for Urine Protein Creatinine (UPC) ratio; for UPC ratio > 0.5, 24-hour urine protein should be obtained and the level should be < 1000 mg for patient enrollment;', ' LVEF must be at or above the lower institutional limit of the normal range (on MUGA or Echo obtained within 12 weeks of registration, or within 4 weeks of prior Herceptin)', ' Not pregnant/lactating', 'Exclusion criteria:', ' chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study', ' may not be receiving any other investigational agents.', ' history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or other agents used in the study (e.g., paclitaxel, bevacizumab, quinolones)', ' uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.'], 'Results': ['Outcome Measurement: ', ' Recommended Phase II Dose as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I)', ' Dose-limiting toxcities (DLT) were defined as grade 3-4 febrile neutropenia, thrombocytopenia and non-hemtological toxicity attributed to therapy (nausea, vomiting and diarrhea would be considered dose limiting only if not adequately controlled with therapy). Any toxicity occurring during cycle 1 that resulted in dose reduction of vorinostat or paclitaxel or failure to complete all protocol specificed doses in the first cycle was also considered a DLT', ' Time frame: 28 days', 'Results 1: ', ' Arm/Group Title: Phase I', ' Arm/Group Description: Vorinostat dose (200 or 300 mg BID) was assigned at the time of registration. Vorinostat was administered orally twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.', ' All patients also received paclitaxel at 90 mg/m2 as 1-hour infusion on days 2, 9, and 16 of every 28-day cycle. Bevacizumab was administered on day 2 and day 16 of the 28 day cycle at 10 mg/kg dose. Vorinostat dose escalation was carried out in the standard 3 + 3 phase I trial design based upon toxicity observed during the first cycle of therapy.', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Number', ' Unit of Measure: mg 300'], 'Adverse Events': ['Adverse Events 1:', ' Total: 27/54 (50.00%)', ' Neutropenia 15/54 (27.78%)', ' Anemia 3/54 (5.56%)', ' Diarrhea 3/54 (5.56%)', ' Vomiting 4/54 (7.41%)', ' Headache 3/54 (5.56%)', ' Fatigue 10/54 (18.52%)', ' Neuropathy 12/54 (22.22%)', ' Proteinuria 1/54 (1.85%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
b250a17c-9d4d-405d-ba64-40f7eda16707
|
|
Single
|
Adverse Events
|
NCT00082641
|
At least one patient in the primary trial suffered from impaired mobility.
|
Entailment
|
[
8,
14
] |
[] |
{'Clinical Trial ID': 'NCT00082641', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).', ' autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules', 'INTERVENTION 2: ', ' Arm II', ' Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.', ' autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed invasive breast cancer meeting the following criteria:', ' Clinically locally advanced disease (stage III) with a primary tumor at least 4 cm by mammogram, ultrasound, or palpation AND/OR palpable axillary nodes larger than 1 cm', ' Planned neoadjuvant chemotherapy', ' p53-overexpressing tumor by immunohistochemistry', ' Delayed-type hypersensitivity to at least 1 of 3 standard antigens', ' Hormone receptor status:', ' Not specified', ' PATIENT CHARACTERISTICS:', ' Age', ' 19 and over', ' Sex', ' Female', ' Menopausal status', ' Not specified', ' Performance status', ' ECOG 0-1', ' Life expectancy', ' Not specified', ' Hematopoietic', ' WBC > 4,000/mm^3', ' Platelet count > 100,000/mm^3', ' Hepatic', ' Bilirubin < 2 times upper limit of normal (ULN)', ' Hepatitis B surface antigen negative', ' Hepatitis C antibody negative', ' Renal', ' Creatinine < 2 times ULN', ' Immunologic', ' HIV negative', ' No prior or concurrent autoimmune disorder', ' Other', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception during and for at least 6 months after study participation', ' No other concurrent illness that would preclude study participation', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' Not specified', ' Chemotherapy', ' See Disease Characteristics', ' No prior chemotherapy', ' Endocrine therapy', ' Not specified', ' Radiotherapy', ' Not specified', ' Surgery', ' See Disease Characteristics', ' Other', ' No concurrent participation in another therapeutic clinical trial'], 'Results': ['Outcome Measurement: ', ' Number of Participants Who Experienced Toxicity to the Vaccine', ' This outcome measure looks at the safety of the vaccine by documenting the number of grade 2, 3, or toxicities experienced by participants related to the vaccine.', ' Time frame: 1 week after each vaccine dose.', 'Results 1: ', ' Arm/Group Title: Arm I', ' Arm/Group Description: Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).', ' autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules', ' Overall Number of Participants Analyzed: 11', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%', 'Results 2: ', ' Arm/Group Title: Arm II', ' Arm/Group Description: Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.', ' autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules', ' Overall Number of Participants Analyzed: 12', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/11 (45.45%)', ' Nausea 1/11 (9.09%)', ' Vomiting 1/11 (9.09%)', ' Fever 1/11 (9.09%)', ' skin infection [1]1/11 (9.09%)', ' Hip fracture 0/11 (0.00%)', ' Confusion 1/11 (9.09%)', 'Adverse Events 2:', ' Total: 1/12 (8.33%)', ' Nausea 0/12 (0.00%)', ' Vomiting 0/12 (0.00%)', ' Fever 0/12 (0.00%)', ' skin infection [1]0/12 (0.00%)', ' Hip fracture 1/12 (8.33%)', ' Confusion 0/12 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
698849c5-78fa-4c15-a1dc-f44eb9c970c2
|
|
Single
|
Adverse Events
|
NCT00075764
|
The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] |
[] |
{'Clinical Trial ID': 'NCT00075764', 'Intervention': ['INTERVENTION 1: ', ' Arm I Anastrozole', ' Patients receive oral anastrozole once daily on days 1-28.', ' anastrozole: Given orally', 'INTERVENTION 2: ', ' Arm II Anastrozole and Fulvestrant', ' Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.', ' anastrozole: Given orally', ' fulvestrant: Given intramuscularly'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed breast cancer meeting 1 of the following criteria:', ' Metastatic disease (M1)', ' Multiple sites of new disease that is clinically obvious metastatic disease (e.g., multiple sites of new osseous disease)', ' Measurable or nonmeasurable disease', ' No known brain or CNS metastases', ' Hormone receptor status:', ' Estrogen-receptor positive* AND/OR', ' Progesterone-receptor positive* NOTE: *Positivity defined as estrogen binding of > 10 fmol/mg cytosol protein by ligand binding assay or positive by immunohistochemistry', ' PATIENT CHARACTERISTICS:', ' Age', ' Not specified', ' Sex', ' Female', ' Menopausal status', ' Postmenopausal, as defined by 1 of the following:', ' Prior bilateral oophorectomy', ' More than 12 months since last menstrual period with no prior hysterectomy', ' At least 55 years of age with prior hysterectomy', ' Under 55 years of age with a prior hysterectomy without oophorectomy and with estradiol and follicle-stimulating hormone levels consistent with menopause', ' Performance status', ' Zubrod 0-2', ' Life expectancy', ' Not specified', ' Hematopoietic', ' No bleeding diathesis (e.g., disseminated intravascular coagulation or clotting factor deficiency)', ' Hepatic', ' INR 1.6', ' Renal', ' Not specified', ' Other', ' HIV negative', ' No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' No prior immunotherapy for recurrent or metastatic disease', ' Chemotherapy', ' No prior chemotherapy for recurrent or metastatic disease', ' More than 12 months since prior adjuvant or neoadjuvant chemotherapy', ' No concurrent chemotherapy for malignancy', ' Endocrine therapy', ' Prior adjuvant hormonal therapy allowed', ' At least 12 months since prior adjuvant luteinizing hormone-releasing hormone (LHRH) analogues', ' Menstrual periods must not have resumed since LHRH therapy', ' More than 12 months since prior adjuvant or neoadjuvant aromatase inhibitors (e.g., anastrozole, letrozole, or exemestane)', ' More than 12 months since prior fulvestrant', ' No prior hormonal therapy for recurrent or metastatic disease', ' No other concurrent hormonal therapy for malignancy', ' No concurrent hormone replacement therapy', ' Radiotherapy', ' Not specified', ' Surgery', ' Not specified', ' Other', ' No long-term anticoagulant therapy (except antiplatelet therapy)'], 'Results': ['Outcome Measurement: ', ' Time to Tumor Progression', ' Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target measurable lesions over the smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Unequivocal progression of non-measurable disease in the opinion of the treating physician. Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration. From date of randomization to time of first documentation of progression, symptomatic deterioration or death due to any cause. Patients last known to be alive and progression free are considered at last date of contact.', ' Time frame: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.', 'Results 1: ', ' Arm/Group Title: Arm I Anastrozole', ' Arm/Group Description: Patients receive oral anastrozole once daily on days 1-28.', ' anastrozole: Given orally', ' Overall Number of Participants Analyzed: 345', ' Median (95% Confidence Interval)', ' Unit of Measure: months 13.5 (12.1 to 15.1)', 'Results 2: ', ' Arm/Group Title: Arm II Anastrozole and Fulvestrant', ' Arm/Group Description: Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.', ' anastrozole: Given orally', ' fulvestrant: Given intramuscularly', ' Overall Number of Participants Analyzed: 349', ' Median (95% Confidence Interval)', ' Unit of Measure: months 15.0 (13.2 to 18.4)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 21/337 (6.23%)', ' Blood/Bone Marrow-Other 0/337 (0.00%)', ' Febrile neutropenia 0/337 (0.00%)', ' Hemoglobin 2/337 (0.59%)', ' Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%)', ' Cardiac-ischemia/infarction 1/337 (0.30%)', ' Left ventricular diastolic dysfunction 0/337 (0.00%)', ' Left ventricular systolic dysfunction 1/337 (0.30%)', ' Restrictive cardiomyopathy 1/337 (0.30%)', 'Adverse Events 2:', ' Total: 48/348 (13.79%)', ' Blood/Bone Marrow-Other 1/348 (0.29%)', ' Febrile neutropenia 1/348 (0.29%)', ' Hemoglobin 1/348 (0.29%)', ' Atrioventricular block - 2nd degree Mobitz Type II 1/348 (0.29%)', ' Cardiac-ischemia/infarction 2/348 (0.57%)', ' Left ventricular diastolic dysfunction 1/348 (0.29%)', ' Left ventricular systolic dysfunction 0/348 (0.00%)', ' Restrictive cardiomyopathy 0/348 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
4b4e6ac7-107c-46f4-adbb-c77c01f51935
|
|
Single
|
Eligibility
|
NCT00579826
|
Participants of the primary trial cannot be currently receiving treatment for rheumatoid arthritis, experiencing poorly controlled migraines or have any prior history of invasive breast cancer in the last 3 years.
|
Entailment
|
[
6,
8,
10,
11
] |
[] |
{'Clinical Trial ID': 'NCT00579826', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Letrozole, 2.5 mg daily for 6 months', ' Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.', 'INTERVENTION 2: ', ' Placebo', ' Placebo, daily for 6 months', ' Placebo: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.'], 'Eligibility': ['Inclusion Criteria:', ' Post-menopausal women at high risk for development of breast cancer', ' On a stable dose of hormone replacement therapy', ' have cytomorphologic evidence of hyperplasia +/- atypia and Ki-67 expression >1.5% in benign breast epithelial cells acquired by RPFNA', ' Serum level of 25-OH vitamin D of at least 30 ng/ml prior to study entry', ' Willing to have a repeat random periareolar fine needle aspiration (RPFNA) and mammogram at 6 months and 12 months (if participating in the open label portion of the study) following initiation of study drug', 'Exclusion Criteria:', ' Prior history of osteoporosis or osteoporotic fracture.', ' Prior history of invasive breast cancer or other invasive cancer within five years from date of study entry.', ' Current and chronic use of cyclooxygenase-2 (COX-2) specific inhibitors or NSAIDs', ' Receiving treatment for rheumatoid arthritis or fibromyalgia', ' Current history of poorly controlled migraines or perimenopausal symptoms', ' Currently receiving other investigational agents.', ' Receipt of more than 6 months of an aromatase inhibitor (anastrozole, exemestane, letrozole, etc.) at any time in the past.'], 'Results': ['Outcome Measurement: ', ' Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months', ' Change in proliferation rate (percent positively stained cells for Ki-67 antigen by immunocytochemistry) in benign breast epithelial cells acquired by random periareolar fine needle aspiration from women at high risk for the development of breast cancer.', ' Time frame: Baseline to 6 Months', 'Results 1: ', ' Arm/Group Title: Letrozole', ' Arm/Group Description: Letrozole, 2.5 mg daily for 6 months', ' Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.', ' Overall Number of Participants Analyzed: 28', ' Mean (Standard Deviation)', ' Unit of Measure: percentage of cells stained positive -1.5 (2.8)', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Placebo, daily for 6 months', ' Placebo: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.', ' Overall Number of Participants Analyzed: 25', ' Mean (Standard Deviation)', ' Unit of Measure: percentage of cells stained positive -1.1 (3.9)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/29 (0.00%)', 'Adverse Events 2:', ' Total: ']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
6b73dee4-0291-455e-90c2-786f0c2371d4
|
|
Single
|
Results
|
NCT00324259
|
Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] |
[] |
{'Clinical Trial ID': 'NCT00324259', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (6 mg Estradiol)', ' 6 mg of estradiol daily (2 mg tid).', 'INTERVENTION 2: ', ' Arm 2 (30 mg Estradiol)', ' 30 mg of estradiol. (10 mg tid)'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women with advanced hormone receptor positive (ER and or PgR) breast cancer, has received prior treatment with an aromatase inhibitor in the advanced disease setting, and experienced at least 24 weeks of progression free survival. As long as the patient experienced an aromatase inhibitor response as defined this way, she is still eligible even if she has received further lines of endocrine therapy, which may include other aromatase inhibitors or tamoxifen, even if these subsequent lines of treatment were unsuccessful (see below for permitted chemotherapy and trastuzumab therapy).', ' OR', ' Postmenopausal women with systemic or unresectable local relapse after taking at least two years of adjuvant aromatase inhibitor therapy.', ' Clinical diagnosis of postmenopausal status is defined as either:', ' Age greater than 50 years and amenorrhea for 1 year', ' Bilateral Surgical ovariectomy', ' Serum FSH and estradiol level in the postmenopausal range before the initiation of AI therapy.', ' If the patient was receiving an LHRH agonist to maintain a postmenopausal state during AI therapy this should be continued since recovery of menses would lead to uncontrolled estrogen exposure and pregnancy during estrogen therapy is contraindicated.', ' Tumor cell expression of ER and/or PgR can be ascertained on either the primary or the metastatic site. However when both types of tissue are available, the metastatic site should be used to determine eligibility. ER and/or PgR positive are defined as at least 10% of malignant cells with positive nuclear staining.', ' The patients may have received adjuvant and/or neoadjuvant chemotherapy.', ' Prior radiotherapy is permitted as long as it was planned before the start of the study medication and is completed within 3 weeks of trial medication starting.', ' Prior tamoxifen therapy is also permitted as adjuvant or advanced disease therapy.', ' Patients with ER+ HER2+ disease are eligible even of they have received trastuzumab in the past (and even if it was administered in combination with endocrine treatment) as long as they meet all other eligibility criteria. Trastuzumab therapy must be held during estradiol treatment.', ' Use of prior experimental agents alone or in combination with endocrine therapy is also permissible, but a wash out of one month is required if the immediate prior therapy involved a study medication that had not been subject to regulatory approval.', ' Prior adjuvant chemotherapy is permitted as well as one line of chemotherapy for advanced disease.', ' Patient must have at least one measurable lesion defined by RECIST criteria. To be considered measurable, a baseline lesion must have a minimum diameter to compensate for measurement error: 1 cm for soft tissue lesions, 1 cm for lung lesions including pleural lesions measured by CT scan, 1 cm for liver lesions measured by CT scan.', ' Patients with bone only disease can also be enrolled if they meet the following criteria:', ' Four or more lesions more than one cm, measurable on CT scan bone windows.', ' At least one tumor marker that is elevated to at least two times the upper limit of normal.', ' All patients should have a baseline bone scan with X-ray evaluation of all hot spots, CT chest abdomen and pelvis (with bone windows), and tumor marker assessment. Also CT scan of the extremities should be done on suspicious areas seen on X-ray evaluation of all hot spots if these extremity lesions are to be followed for response.', ' The patient must have an ECOG performance status of 0-2', ' The patient should have a life expectancy of > 6 months.', ' The patient must have adequate hematologic function, defined as ANC >1000/mm3 and platelets > 75,000/mm3.', ' The patient must have adequate renal function, defined as serum creatinine less than or equal to 1.5 times the upper limit of normal.', ' The patient must have adequate liver function defined as serum bilirubin less than or equal to 1.5 times the upper limit of normal (three times the upper limit of normal for patients with hereditary benign hyperbilirubinaemia), transaminases (ALT, AST) less than or equal to 2.5 times the upper limit of normal in patients without liver metastasis or less than or equal to 5 times the upper limit of normal in patients with liver metastasis.', ' For patients with bone metastasis, treatment with i.v. bisphosphonates during the trial is mandatory because of the risk of hypercalcemia. Bisphosphonate therapy must be started before the patient begins protocol therapy.', ' Preexisting hypercalcemia should be treated and calcium normalized prior to study entry.', ' The patient must give written informed consent prior to initiation of any invasive study-related procedures that would otherwise not be performed, and must be able to comply with scheduled visits and evaluations.', ' Inclusion of Women and Minorities: Entry to this study is open to women of all racial and ethnic subgroups.', ' Patients with fasting blood glucose level 200 mg/dL. If greater, hyperglycemia must be treated before initiation of study investigations.', 'Exclusion Criteria:', ' Patients with CNS involvement with metastatic breast cancer or life threatening lymphangitic or large volume lung or liver disease that threatens organ function.', ' Patients with history of deep venous thrombosis, pulmonary embolism, stroke, acute myocardial infarction, congestive cardiac failure, untreated hypertension.', ' Ischemic changes on a baseline EKG or other evidence of ischemic heart disease.', ' Undiagnosed abnormal genital bleeding', ' Untreated cholelithiasis', ' Fasting serum triglycerides greater than 400. Patients should be treated and triglycerides controlled prior to study entry.', ' Treatment with fulvestrant within 12 months of study initiation (fulvestrant has been shown to antagonize estradiol induced apoptosis in preclinical models (5).', " The patient's only qualifying lesion (s) have been previously irradiated or are scheduled for irradiation following study entry.", ' Severe or uncontrolled concomitant disease from other causes.', ' EGOG Performance status 3 or 4.', ' The patient has previous malignancies other than breast cancer except a) adequately treated in situ carcinoma of the cervix, b) localized basal or squamous cell carcinoma of the skin c) any previous malignancy treated with curative intent with a recurrence risk of less than 30%.', ' The patient is unable to understand the informed consent or is unlikely to be compliant with the protocol.', ' More than one line of palliative chemotherapy for advanced disease.'], 'Results': ['Outcome Measurement: ', ' Clinical Benefit Rate (CR Plus PR Plus SD)', ' Complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0', ' CR = disappearance of all target lesions', ' PR = at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter', ' SD = neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for progressive disease', ' SD is defined as lack of disease progression by 24 weeks.', ' Time frame: 24 weeks after start of treatment', 'Results 1: ', ' Arm/Group Title: Arm 1 (6 mg Estradiol)', ' Arm/Group Description: 6 mg of estradiol daily (2 mg tid).', ' Overall Number of Participants Analyzed: 34', ' Measure Type: Number', ' Unit of Measure: participants Complete response (CR): 0', ' Partial response (PR): 3', ' Stable disease (SD): 7', 'CR+PR+SD: 10', 'Results 2: ', ' Arm/Group Title: Arm 2 (30 mg Estradiol)', ' Arm/Group Description: 30 mg of estradiol. (10 mg tid)', ' Overall Number of Participants Analyzed: 32', ' Measure Type: Number', ' Unit of Measure: participants Complete response (CR): 0', ' Partial response (PR): 1', ' Stable disease (SD): 8', 'CR+PR+SD: 9'], 'Adverse Events': ['Adverse Events 1:', ' Total: 8/34 (23.53%)', ' Hemoglobin 0/34 (0.00%)', ' Eye pain 0/34 (0.00%)', ' Vison loss 0/34 (0.00%)', ' Abdominal pain 2/34 (5.88%)', ' Constipation 0/34 (0.00%)', ' Diarrhea 2/34 (5.88%)', ' GI hemorrhage 1/34 (2.94%)', ' Nausea 2/34 (5.88%)', ' Vomiting 2/34 (5.88%)', ' Fatigue 0/34 (0.00%)', ' Fever 2/34 (5.88%)', ' Pain 0/34 (0.00%)', ' Pneumonia 1/34 (2.94%)', ' Neutropenia 0/34 (0.00%)', 'Adverse Events 2:', ' Total: 8/32 (25.00%)', ' Hemoglobin 1/32 (3.13%)', ' Eye pain 1/32 (3.13%)', ' Vison loss 1/32 (3.13%)', ' Abdominal pain 1/32 (3.13%)', ' Constipation 2/32 (6.25%)', ' Diarrhea 1/32 (3.13%)', ' GI hemorrhage 0/32 (0.00%)', ' Nausea 3/32 (9.38%)', ' Vomiting 3/32 (9.38%)', ' Fatigue 1/32 (3.13%)', ' Fever 0/32 (0.00%)', ' Pain 1/32 (3.13%)', ' Pneumonia 0/32 (0.00%)', ' Neutropenia 1/32 (3.13%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
2a1d9064-fde9-4645-95ab-7ddaea4ad322
|
|
Single
|
Intervention
|
NCT00509587
|
Patients in the primary trial receive 300 mg pazopanib once daily intravenously every day, continuing until disease progression or unacceptable toxicity.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5
] |
[] |
{'Clinical Trial ID': 'NCT00509587', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Pazopanib Hydrochloride)', ' Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.', ' pazopanib hydrochloride: Given orally', ' pharmacological study: Correlative studies', ' laboratory biomarker analysis: Correlative studies'], 'Eligibility': ['Criteria:', ' No prior bevacizumab', ' Histologically or cytologically confirmed invasive breast carcinoma (recurrent or metastatic disease)', ' Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques or >= 10 mm by spiral CT scan', ' Patients who may still benefit from hormonal therapy are ineligible (patients with hormone receptor-positive breast cancer should have received appropriate sequential hormonal therapy for metastatic disease until disease progression)', ' Patients with HER-2 positive disease who have not yet received trastuzumab (Herceptin®) to maximal benefit are ineligible (patients with disease progression during trastuzumab therapy are eligible)', ' No known brain metastases', ' ECOG performance status (PS) 0-1 or Karnofsky PS 60-100%', ' Life expectancy > 12 weeks', ' Absolute neutrophil count >= 1,500/mm³', ' Platelets >=100,000/mm³', " Total bilirubin normal (exception made for patients with known Gilbert's disease)", ' AST/ALT =< 2.5 times upper limit of normal (ULN)', ' No proteinuria > +1 on two consecutive dipsticks taken >= 1 week apart', ' PT/INR/PTT =< 1.2 times ULN', ' No allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other study agents', ' No QTc prolongation (defined as a QTc interval >= 500 msecs) or other significant ECG abnormalities', ' No condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, or active peptic ulcer disease) that would impair ability to swallow and retain study drug', ' No poorly controlled hypertension (systolic blood pressure [BP] >= 140 mm Hg or diastolic BP >= 90 mm Hg) Initiation or adjustment of BP medication is allowed prior to study entry provided that the average of 3 BP readings prior to study entry is < 140/90 mm Hg', ' No serious or non-healing wound, ulcer, or bone fracture', ' No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the last 4 weeks', ' No cerebrovascular accident within the last 6 months', ' No myocardial infarction, cardiac arrhythmia, hospital admission for unstable angina within the last 12 weeks', ' No venous thrombosis within the last 12 weeks', ' No NYHA class III-IV heart failure Patients with a history of class II heart failure may be considered eligible provided they are asymptomatic on treatment', ' No concurrent uncontrolled illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would preclude study compliance', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, or surgery', ' No cardiac angioplasty or stenting within the last 12 weeks', ' No more than 1 prior chemotherapy regimen for recurrent disease', ' No prior surgical procedures affecting absorption', ' No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:', ' Therapeutic warfarin Low molecular weight heparin or prophylactic low-dose warfarin are allowed', ' No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:', ' Erectile dysfunction agents: sildenafil, tadalafil, or vardenafil', ' Antiarrhythmics: bepridil, flecainide, lidocaine, mexilitine, amiodarone, or quinidine', ' Immune modulators: cyclosporine, tacrolimus, or sirolimus', ' Miscellaneous: theophylline, quetiapine, or risperidone', ' No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:', 'Oral hypoglycemics: glipizide, glyburide, or tolbutamide', ' Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, or methylergonovine', ' Neuroleptics: pimozide', ' No concurrent combination antiretroviral therapy for HIV-positive patients', ' No other concurrent investigational agents', ' No other concurrent anticancer therapy', ' WBC >= 3,000/mm³', ' No more than 2 prior palliative systemic chemotherapy regimens for de novo metastatic disease', ' Creatinine normal OR creatinine clearance >= 60 mL/min', ' At least 3 months since prior trastuzumab'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Partial and Complete Response.', ' Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT / MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR', ' Time frame: Up to 3 years', 'Results 1: ', ' Arm/Group Title: Treatment (Pazopanib Hydrochloride)', ' Arm/Group Description: Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.', ' pazopanib hydrochloride: Given orally', ' pharmacological study: Correlative studies', ' laboratory biomarker analysis: Correlative studies', ' Overall Number of Participants Analyzed: 21', ' Measure Type: Number', ' Unit of Measure: participant 1'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/21 (4.76%)', ' Intra abdominal hemorrhage 1/21 (4.76%)', ' Esophagitis 1/21 (4.76%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
847de3fe-b584-4d43-b82d-93263ce88830
|
|
Comparison
|
Eligibility
|
NCT00149214
|
NCT01004744
|
Prior use of Anthracycline drugs in the last 6 months for anticancer therapy is prohibted for patients in the primary trial, but not for patients in the secondary trial.
|
Contradiction
|
[
4,
5
] |
[
0,
4
] |
{'Clinical Trial ID': 'NCT00149214', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed Plus Doxorubicin, Followed by Docetaxel', ' pemetrexed: 500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)', 'INTERVENTION 2: ', ' Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel', ' cyclophosphamide: 600 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed diagnosis of primary early breast cancer, tumor size greater than or equal to 2 centimeters (cm), of Stages T2-T4/N0-2.', ' Performance status 0-2 Eastern Cooperative Oncology Group (ECOG).', ' Adequate organ function (bone marrow, hepatic, renal, cardiac).', 'Exclusion Criteria:', ' Prior anthracyclines as part of prior anticancer therapy.', ' Concurrent antitumor therapy.', ' Second primary malignancy.', ' Serious concomitant systemic disorder.', ' Pre-existing sensorial or motor neuropathy', 'Grade 1.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With a Pathological Complete Response', ' pathological assessment of tissue removed during surgery to determine if tumor tissue is still present after chemotherapy', ' Time frame: surgery after eight 21-day cycles of chemotherapy', 'Results 1: ', ' Arm/Group Title: Pemetrexed Plus Doxorubicin, Followed by Docetaxel', ' Arm/Group Description: pemetrexed: 500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)', ' Overall Number of Participants Analyzed: 127', ' Measure Type: Number', ' Unit of Measure: participants Pathological Complete Response: 21', ' Tumor Cells Still Present: 99', 'Not evaluable: 7', 'Results 2: ', ' Arm/Group Title: Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel', ' Arm/Group Description: cyclophosphamide: 600 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)', ' Overall Number of Participants Analyzed: 119', ' Measure Type: Number', ' Unit of Measure: participants Pathological Complete Response: 24', ' Tumor Cells Still Present: 89', 'Not evaluable: 6'], 'Adverse Events': ['Adverse Events 1:', ' Total: 15/134 (11.19%)', ' Anaemia 0/134 (0.00%)', ' Chronic lymphocytic leukaemia 0/134 (0.00%)', ' Febrile neutropenia 4/134 (2.99%)', ' Leukopenia 4/134 (2.99%)', ' Neutropenia 1/134 (0.75%)', ' Cardiovascular insufficiency 0/134 (0.00%)', ' Myocardial infarction 0/134 (0.00%)', ' Diarrhoea 1/134 (0.75%)', ' Nausea 2/134 (1.49%)', ' Stomatitis 1/134 (0.75%)', ' Vomiting 3/134 (2.24%)', 'Adverse Events 2:', ' Total: 25/123 (20.33%)', ' Anaemia 1/123 (0.81%)', ' Chronic lymphocytic leukaemia 1/123 (0.81%)', ' Febrile neutropenia 5/123 (4.07%)', ' Leukopenia 9/123 (7.32%)', ' Neutropenia 3/123 (2.44%)', ' Cardiovascular insufficiency 1/123 (0.81%)', ' Myocardial infarction 1/123 (0.81%)', ' Diarrhoea 1/123 (0.81%)', ' Nausea 0/123 (0.00%)', ' Stomatitis 0/123 (0.00%)', ' Vomiting 0/123 (0.00%)']}
|
{'Clinical Trial ID': 'NCT01004744', 'Intervention': ['INTERVENTION 1: ', ' Presurgical Oral Anastrozole', ' 1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.', ' Anastrozole: 1mg PO daily for two weeks prior to scheduled surgery'], 'Eligibility': ['Inclusion Criteria:', ' Histologically-confirmed operable ER+ and/or PR+ invasive breast cancer or ductal carcinoma in situ (DCIS), who undergo core needle biopsy followed by surgical excision at least 2 weeks after enrollment', ' Postmenopausal status defined as cessation of menses for >1 year or FSH > 20 mIU/mL (within the past month)', ' Age 21 years', ' No prior chemotherapy, radiation therapy, or surgery within 6 months of study entry', ' Signed informed consent', 'Exclusion Criteria:', ' Treatment with other investigational drugs within 6 months of study entry', ' Other serious intercurrent medical illness'], 'Results': ['Outcome Measurement: ', ' Number of Subjects That Completed Oral Anastrozole 1mg Daily for Two Weeks in the Interval Between Diagnostic Breast Biopsy and Definitive Breast Surgery', ' The number of subjects who complete oral anastrozole for the length of the study is analyzed. The subjects receive oral anastrozole 1mg daily for two weeks in the interval between the biopsy and the surgery.', ' Time frame: Two weeks', 'Results 1: ', ' Arm/Group Title: Presurgical Oral Anastrozole', ' Arm/Group Description: 1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.', ' Anastrozole: 1mg PO daily for two weeks prior to scheduled surgery', ' Overall Number of Participants Analyzed: 10', ' Measure Type: Number', ' Unit of Measure: participants 10'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/10 (0.00%)']}
|
3c798991-6366-43e2-94ca-0523629930c2
|
Single
|
Adverse Events
|
NCT01764022
|
Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia.
|
Contradiction
|
[
10,
13
] |
[] |
{'Clinical Trial ID': 'NCT01764022', 'Intervention': ['INTERVENTION 1: ', ' BCD-022 (CJSC BIOCAD)', ' BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).', 'INTERVENTION 2: ', ' Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)', ' In this arm patients will receive 6 courses of treatment with Herceptin in combination with paclitaxel. Patients will receive Herceptin at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent and ability to follow the Protocol procedures;', ' Age from 18 years to 75 years inclusive;', ' Female gender;', ' Histologically confirmed breast cancer (BC);', ' Metastatic BC (stage IV according to TNM classification version 6);', ' Grade 3+ HER2 overexpression confirmed by immunohistochemical (IHC) staining or grade 2+ HER2 overexpression accompanied by HER2 gene amplification confirmed by fluorescent hybridization in situ (FISH) ;', ' Documented results of oestrogen and progesterone receptors expression analysis;', ' Eastern Cooperative Oncology Group (ECOG) status 0, 1 or 2, not increasing within 2 weeks prior to randomization;', ' Life expectancy - 20 weeks or more from the moment of randomization;', ' Presence of at least 1 tumour with a size not less than 1 cm (revealed with computed tomography (CT) slice thickness not more than 5 mm). Patients having bone metastasis as the only measurable tumour are not eligible for the trial;', ' Patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior to inclusion into the trial and until 6 months after the last administration of the study drug.', 'Exclusion Criteria:', ' Previous anticancer therapy for metastatic BC, including cytotoxic chemotherapy, or previous anticancer therapy with signal transduction inhibitors (e.g. lapatinib), biological drugs (e.g. trastuzumab, bevacizumab), experimental (not approved for BC therapy) anticancer drugs. Any previous hormonal therapy is allowed;', ' Disease progression within 6 months after adjuvant and/or neoadjuvant anti BC therapy;', ' Surgery, radiation therapy, use of any experimental medications within 4 weeks (28 days) prior to randomization;', ' Hypersensitivity to paclitaxel and all medications containing polyoxyethylated castor oil, hypersensitivity to dexamethasone, diphenhydramine, ranitidine/cimetidine, recombinant murine proteins, contrast agents or excipients of study medications;', ' BC metastases in central nervous system, progressing or clinically manifested (e.g. cerebral oedema, spinal cord injury), with exception of non-progressing metastases not requiring treatment with glucocorticosteroids and/or anticonvulsants within 4 weeks prior to randomization;', ' Cardiovascular system pathology (congestive heart failure (CHF) stage III-IV according to New York Heart Association (NYHA) classification, unstable angina pectoris, myocardial infarction) within 12 months prior to randomization;', ' Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medicamental correction methods (low salt diet, physical exercise);', ' Left ventricular ejection fraction <50% according to electrocardiography;', ' Neutrophils 1500/mm3;', ' Platelets 100 000/mm3;', ' Hemoglobin 90 g/L;', ' Creatinine level 1.5 × upper limit of normal (ULN);', ' Bilirubin level 1.5 × ULN;', ' Asparagine transferase (AST) and alanine transferase (ALT) levels 2.5 × ULN (5 × ULN for patients with liver metastases);', ' Alkaline phosphatase level 5 × ULN;', ' Pregnancy or lactation;', ' Any other concomitant cancer including contralateral breast cancer revealed within 5 years prior to screening, except curatively treated intraductal carcinoma in situ, curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma;', " Conditions limiting patient's adherence to protocol requirements (dementia, neurologic or psychiatric disorders, drug addiction, alcoholism and others);", ' Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0;', ' Concomitant participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial;', ' Acute or active chronic infections;', ' Hepatitis C virus, hepatitis B virus, HIV or syphilis infections;', ' Obstacles in intravenous administration of study drugs'], 'Results': ['Outcome Measurement: ', ' Overall Response Rate', ' Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', ' The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.', ' Time frame: Day 127', 'Results 1: ', ' Arm/Group Title: BCD-022 (CJSC BIOCAD)', ' Arm/Group Description: BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).', ' Overall Number of Participants Analyzed: 113', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 56 49.6%', 'Results 2: ', ' Arm/Group Title: Herceptin (F. Hoffmann-La Roche Ltd., Switzerland)', ' Arm/Group Description: In this arm patients will receive 6 courses of treatment with Herceptin in combination with paclitaxel. Patients will receive Herceptin at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).', ' Overall Number of Participants Analyzed: 110', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 48 43.6%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 8/113 (7.08%)', ' Febrile neutropenia [1]0/113 (0.00%)', ' Anemia with trombocytopenia 0/113 (0.00%)', ' Neutropenia 1/113 (0.88%)', ' Paroxism of atrial fibrillation 0/113 (0.00%)', ' Ventricular extrasystolone RYAN-1 0/113 (0.00%)', ' Gastrointestinal hemorrhage 1/113 (0.88%)', ' Death for unknown reason 1/113 (0.88%)', ' Diarrhea with vomiting and weakness 0/113 (0.00%)', 'Adverse Events 2:', ' Total: 13/110 (11.82%)', ' Febrile neutropenia [1]1/110 (0.91%)', ' Anemia with trombocytopenia 1/110 (0.91%)', ' Neutropenia 1/110 (0.91%)', ' Paroxism of atrial fibrillation 2/110 (1.82%)', ' Ventricular extrasystolone RYAN-1 1/110 (0.91%)', ' Gastrointestinal hemorrhage 0/110 (0.00%)', ' Death for unknown reason 1/110 (0.91%)', ' Diarrhea with vomiting and weakness 1/110 (0.91%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
64fe54a2-8897-4324-af88-f627c1c208ed
|
|
Single
|
Results
|
NCT01328249
|
The Percentage of Participants With Feasibility was 70% higher in cohort 1 of the primary trial than in cohort 2.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] |
[] |
{'Clinical Trial ID': 'NCT01328249', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Eribulin Mesylate With Filgrastim as Needed', " Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles. Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors, subcutaneous pegfilgrastim (6 mg) or filgrastim, could be used with eribulin therapy at the physician's discretion if neutropenia occurred that recovered to Grade 2.", 'INTERVENTION 2: ', ' Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim', ' Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) IV on Day 1, of every 14-day cycle for 4 cycles. Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort filgrastim was used with eribulin therapy at a dose of 300 micrograms for participants 60 kg or 480 micrograms for participants >60 kg, administered subcutaneously on Days 3 and 4 and Days 10 and 11 of each eribulin cycle.'], 'Eligibility': ['Inclusion Criteria', ' Male and female subjects aged greater than or equal to (>=) 18 years', ' Histologically confirmed Stage I to III invasive breast cancer. Subjects may have more than one synchronous primary breast tumor.', ' HER-2 normal as determined by fluorescence in situ hybridization (FISH) or 0 or 1+ by immunohistochemistry (IHC) staining.', ' Subject is a candidate for chemotherapy in the adjuvant setting. Adjuvant therapy must begin within 84 days of the final surgical procedure for breast cancer.', ' Adequate cardiac function, defined by baseline LVEF >=50 percent (%) by Multiple Gated Acquisition (MUGA) scan or echocardiogram.', ' ECOG performance status of 0 or 1.', ' Adequate renal function as evidenced by serum creatinine less than or equal to (<=) 1.5 mg/dL or calculated creatinine clearance >=40 mL/min per the Cockcroft and Gault formula.', ' Adequate bone marrow function as evidenced by ANC >=1.5 x 10^9/L, hemoglobin >=10.0 g/dL, and platelet count >=100 x 10^9/L.', ' Adequate liver function as evidenced by bilirubin <=1.5 times the upper limits of normal (ULN) and alkaline phosphatase (AP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <=3 x ULN.', ' Females of childbearing potential must have a negative urine or beta-human chorionic gonadotropin serum pregnancy test within 2 weeks prior to Cycle 1, Day 1. A urine pregnancy test should be repeated prior to chemotherapy if not conducted within 72 hours of start of treatment. Female subjects of childbearing potential must agree to be abstinent or to use a highly effective method of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, intrauterine device (IUD), or have a vasectomized partner) having started for at least one menstrual cycle prior to starting study drug and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Perimenopausal women must be amenorrheic for at least 12 months to be considered of nonchildbearing potential. Male subjects who are not abstinent or who have undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use, a highly effective method of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, IUD) starting for at least one menstrual cycle prior to starting study drug and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Subjects with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously).', ' Subjects willing and able to comply with the study protocol for the duration of the study and provide written informed consent prior to any study-specific screening procedures with the understanding that the subject may withdraw consent at any time without prejudice.', ' Exclusion Criteria', ' Stage IV breast cancer.', ' Prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer.', ' Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study therapy drugs.', ' Subjects with a concurrently active second malignancy other than adequately treated nonmelanoma skin cancers or in situ cervical cancer.', ' Subjects with known positive human immunodeficiency virus (HIV) status.', ' Pregnancy or breast feeding at the time of study enrollment. Eligible subjects of reproductive potential (both sexes) must agree to use adequate contraceptive methods during study therapy.', ' Subjects with known allergy or hypersensitivity to doxorubicin, cyclophosphamide, or eribulin mesylate.', ' Inability to comply with the study and/or follow-up procedures.'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Feasibility', ' The regimen was considered feasible if the participant was able to complete the eribulin portion without dose delay or reduction. Dose delay was defined as a delay due to eribulin-related adverse event (AE) for more than 2 days for subsequent doses (cycles after the initiation of full dose of eribulin, except holidays, scheduling difficulties and nonclinical logistical issues). If a participant had more than 1 dose omission, delay or reduction due to eribulin-related AE, these events were collectively counted as one entity in the same participant. Participants were followed for approximately 3 years after the last dose of the study treatment. Feasibility rates were calculated with or without growth factor support. In both cohorts, the percentage of participants who completed the eribulin portion of the regimen without a dose omission, delay or reduction due to eribulin-related AE was estimated via the observed completion rate and an exact 90% confidence interval (CI) was constructed.', ' Time frame: From date of first dose, up to 3 years after the last dose of study treatment, or up to approximately 4 years 2 months', 'Results 1: ', ' Arm/Group Title: Cohort 1: Eribulin Mesylate With Filgrastim as Needed', " Arm/Group Description: Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles. Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors, subcutaneous pegfilgrastim (6 mg) or filgrastim, could be used with eribulin therapy at the physician's discretion if neutropenia occurred that recovered to Grade 2.", ' Overall Number of Participants Analyzed: 54', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 70.4 (58.5 to 80.4)', 'Results 2: ', ' Arm/Group Title: Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim', ' Arm/Group Description: Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) IV on Day 1, of every 14-day cycle for 4 cycles. Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort filgrastim was used with eribulin therapy at a dose of 300 micrograms for participants 60 kg or 480 micrograms for participants >60 kg, administered subcutaneously on Days 3 and 4 and Days 10 and 11 of each eribulin cycle.', ' Overall Number of Participants Analyzed: 25', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 60.0 (41.7 to 76.4)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/55 (10.91%)', ' Febrile neutropenia 2/55 (3.64%)', ' Nausea 2/55 (3.64%)', ' Oesophagitis 2/55 (3.64%)', ' Vomiting 2/55 (3.64%)', ' Mucosal inflammation 0/55 (0.00%)', ' Pyrexia 2/55 (3.64%)', ' Breast abscess 0/55 (0.00%)', ' Catheter site cellulitis 0/55 (0.00%)', ' Genital herpes 1/55 (1.82%)', ' Lung infection 0/55 (0.00%)', ' Upper respiratory tract infection 1/55 (1.82%)', 'Adverse Events 2:', ' Total: 4/26 (15.38%)', ' Febrile neutropenia 1/26 (3.85%)', ' Nausea 0/26 (0.00%)', ' Oesophagitis 0/26 (0.00%)', ' Vomiting 0/26 (0.00%)', ' Mucosal inflammation 1/26 (3.85%)', ' Pyrexia 1/26 (3.85%)', ' Breast abscess 1/26 (3.85%)', ' Catheter site cellulitis 1/26 (3.85%)', ' Genital herpes 0/26 (0.00%)', ' Lung infection 1/26 (3.85%)', ' Upper respiratory tract infection 0/26 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
4eac6a2d-64cd-4289-a545-211eb835f0e9
|
|
Comparison
|
Results
|
NCT02435680
|
NCT01743560
|
the secondary trial and the primary trial use best Overall Response (OR) as their evaluation metrics, however they use significantly different time frames.
|
Contradiction
|
[
0,
1,
2,
3
] |
[
0,
1,
2,
3
] |
{'Clinical Trial ID': 'NCT02435680', 'Intervention': ['INTERVENTION 1: ', ' All MCS110+Carboplatin+Gemcitabine', ' experimental. all MCS110 treated patients, with 10mg/kg intravenous infusion, on day 1 and days 1 & 8', 'INTERVENTION 2: ', ' Carboplatin+Gemcitabine', ' comparator. Gemcitabine: Intravenous infusion 1000 mg/m2 Days 1 & 8 Carboplatin: Intravenous infusion AUC 2 Days 1 & 8'], 'Eligibility': ['Inclusion Criteria:', ' Adult women ( 18 years of age) with advanced TNBC.', ' Histological or cytological evidence of estrogen-receptor negative (ER-), progesterone receptor negative (PgR-) and human epidermal growth factor-2 receptor negative (HER2-) Breast Cancer by local laboratory testing, based on last available tumor tissue.', ' ER/PgR negativity to follow local guidelines', ' If IHC HER2 2+, a negative FISH test is required', ' A pre-treatment tumor biopsy demonstrating high TAM content as assessed per the central laboratory', 'Patients must have:', ' At least one measurable lesion per RECIST 1.1. (Note: Measurable lesions include lytic or mixed (lytic + blastic) bone lesions, with an identifiable soft tissue component that meets the measurability criteria)', 'Exclusion Criteria:', ' Prior chemotherapy for advanced BC. Previous adjuvant/neoadjuvant chemotherapy is allowed (carboplatin, cisplatin or gemcitabine only if > 12 months has passed since last administration).', ' Therapy for underlying malignancy within 2 weeks prior to start of study treatment:', ' Chemotherapy, biologic therapy (antibodies and biologically targeted small molecules)', ' Radiotherapy', ' Major surgery', ' Patients receiving concomitant immunosuppressive agents or chronic corticosteroids ( 10 mg of prednisone or equivalent) at the time of first study dose.', ' Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening.', ' Known history of human immunodeficiency virus or active infection with hepatitis virus or any uncontrolled active systemic infection.', ' Patients with the following laboratory values during screening and on Day 1 predose:', ' Absolute Neutrophil Count (ANC) < 1.5x109/L', ' Hemoglobin < 9 g/dL', ' Platelets < 100x109/L', ' Serum creatinine > 1.5 x ULN', ' Serum total bilirubin > 1.5 x ULN', ' AST/SGOT and ALT/SGPT > 3.0 x ULN'], 'Results': ['Outcome Measurement: ', ' Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment)', ' PFS Results presented for all MCS110 treated patients (with and without day 8 dose), in line with phase 2 study design.', ' Time frame: 4 years', 'Results 1: ', ' Arm/Group Title: All MCS110+Carboplatin+Gemcitabine', ' Arm/Group Description: experimental. all MCS110 treated patients, with 10mg/kg intravenous infusion, on day 1 and days 1 & 8', ' Overall Number of Participants Analyzed: 34', ' Median (90% Confidence Interval)', ' Unit of Measure: months 5.6 (4.5 to 8.7)', 'Results 2: ', ' Arm/Group Title: Carboplatin+Gemcitabine', ' Arm/Group Description: comparator. Gemcitabine: Intravenous infusion 1000 mg/m2 Days 1 & 8 Carboplatin: Intravenous infusion AUC 2 Days 1 & 8', ' Overall Number of Participants Analyzed: 16', ' Median (90% Confidence Interval)', ' Unit of Measure: months 5.5 (3.5 to 7.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 10/19 (52.63%)', ' Anaemia 0/19 (0.00%)', ' Atypical haemolytic uraemic syndrome 1/19 (5.26%)', ' Thrombocytopenia 0/19 (0.00%)', ' Myocardial ischaemia 0/19 (0.00%)', ' Nausea 0/19 (0.00%)', ' Obstructive pancreatitis 1/19 (5.26%)', ' Vomiting 0/19 (0.00%)', ' Fatigue 0/19 (0.00%)', ' Generalised oedema 1/19 (5.26%)', ' Pyrexia 1/19 (5.26%)', ' Device related infection 1/19 (5.26%)', 'Adverse Events 2:', ' Total: 7/15 (46.67%)', ' Anaemia 1/15 (6.67%)', ' Atypical haemolytic uraemic syndrome 0/15 (0.00%)', ' Thrombocytopenia 3/15 (20.00%)', ' Myocardial ischaemia 1/15 (6.67%)', ' Nausea 1/15 (6.67%)', ' Obstructive pancreatitis 0/15 (0.00%)', ' Vomiting 2/15 (13.33%)', ' Fatigue 1/15 (6.67%)', ' Generalised oedema 0/15 (0.00%)', ' Pyrexia 0/15 (0.00%)', ' Device related infection 0/15 (0.00%)']}
|
{'Clinical Trial ID': 'NCT01743560', 'Intervention': ['INTERVENTION 1: ', ' Everolimus and Exemestane', ' Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o. and exemestane 25mg daily p.o.'], 'Eligibility': ['Inclusion Criteria:', ' Histological or cytological confirmation of oestrogen receptor positive (ER+) and/or progesterone receptor positive (PgR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer.', ' Availability of archival tumour tissue (the tissue block or slides will be sent to the central laboratory for analysis).', ' Postmenopausal women. The investigator must confirm postmenopausal status. Postmenopausal status is defined either by:', ' Age 55 years and one year or more of amenorrhea', ' Age < 55 years and one year or more of amenorrhea and postmenopausal levels of FSH and LH per local institutional standards', ' Prior hysterectomy and has postmenopausal levels of Follicle stimulating hormone (FSH) and Luteinizing Hormone (LH) per local institutional standards Surgical menopause with bilateral oophorectomy', ' Disease progression following prior therapy with NSAI, defined as:', ' Recurrence while on or after completion of an adjuvant treatment including letrozole or anastrozole, or', ' Progression while on or following the completion of letrozole or anastrozole treatment for locally advanced or metastatic breast cancer', ' Note: Non-steroidal aromatase inhibitors (i.e. letrozole or anastrozole) do not have to be the last treatment prior to enrollment. Other prior anticancer therapy, e.g. tamoxifen, fulvestrant, exemestane are also allowed. Patients must have recovered to grade 1 or better from any adverse events (except alopecia) related to previous therapy prior to enrollment.', ' - Radiological evidence of recurrence or progression on last systemic therapy prior to enrollment.', 'Patients must have:', ' At least one lesion that can be accurately measured or', ' Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable disease', ' - Adequate bone marrow and coagulation function as shown by:', ' Absolute neutrophil count (ANC) 1.5 109/L', ' Platelets 100 ×109/L', ' Hemoglobin (Hb) 9.0 g/dL', ' International Normalized Ratio (INR) 2 .', ' - Adequate liver function as shown by:', ' Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5 ULN (or 5 if hepatic metastases are present)', ' Total serum bilirubin 1.5 × ULN ( 3 × ULN for patients known to have Gilbert Syndrome)', ' - Adequate renal function as shown by:', ' Serum creatinine 1.5 × ULN', ' Fasting serum cholesterol 300 mg/dl or 7.75 mmol/L and fasting triglycerides 2.5 × ULN. In case one or both of these thresholds are exceeded, the patient can only be included after initiation of statin therapy and when the above mentioned values have been achieved', ' Eastern Cooperative Oncology Group (ECOG) performance status of PS </ 2', ' Written informed consent obtained before any screening procedure and according to local guidelines.', 'Exclusion Criteria:', ' HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).', ' Pre-menopausal, pregnant, lactating women.', ' Known hypersensitivity to mammilian target of Rapamycin (mTOR) inhibitors, e.g. sirolimus (rapamycin) or to their excipients.', ' Known hypersensitivity to exemestane, to the active substance or to any of the excipients.', ' Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption.', ' Radiotherapy within four weeks prior to enrollment except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within two weeks prior to enrollment. Patients must have recovered from radiotherapy toxicities prior to enrollment.', ' Currently receiving hormone replacement therapy, unless discontinued prior to enrollment.', ' Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use, at the time of study entry except in cases outlined below:', ' Prolonged systemic corticosteroid treatment during study, except for topical applications (e.g. rash),inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) should not be given. However:', ' short duration (<2 weeks) of systemic corticosteroids is allowed (e.g. chronic obstructive pulmonary disease, anti-emetic)', ' low doses of corticosteroids for brain metastasis treatment is allowed', ' Patients with symptomatic visceral metastasis (e.g. significant dyspnoea related to pulmonary lymphangitic carcinomatosis and lung metastases or clinically meaningful symptomatic liver metastasis)', ' Symptomatic brain or other Central Nervous system (CNS) metastases.', ' Active, bleeding diathesis, or on oral anti-vitamin K medication (except low dose warfarin, low molecular weight heparin (LMWH) and acetylsalicylic acid or equivalent, as long as the INR is 2.0)', ' Any severe and / or uncontrolled medical conditions such as:', ' Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction 6 months prior to enrollment, serious uncontrolled cardiac arrhythmia', ' Uncontrolled diabetes as defined by fasting serum glucose > 1.5 × ULN', ' Acute and chronic, active infectious disorders (except for Hep B and Hep C positive patients) and nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy', ' Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome)', ' Significant symptomatic deterioration of lung function. If clinically indicated, pulmonary function tests including measures of predicted lung volumes, DLco, O2 saturation at rest on room air should be considered to exclude restrictive pulmonary disease, pneumonitis or pulmonary infiltrates.', ' Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A (rifabutin, rifampicin, clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir, telithromycin) within the last 5 days prior to enrollment', ' History of non-compliance to medical regimens', ' Patients unwilling to or unable to comply with the protocol', ' Another malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer'], 'Results': ['Outcome Measurement: ', ' Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer', ' The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.', ' Time frame: At 48 weeks', 'Results 1: ', ' Arm/Group Title: Everolimus and Exemestane', ' Arm/Group Description: Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o. and exemestane 25mg daily p.o.', ' Overall Number of Participants Analyzed: 49', ' Measure Type: Number', ' Unit of Measure: participants Patients with measurable disease at baseline: 39', ' Patients with non-measurable disease at baseline: 10', ' Best at WK 48 - Complete Response (CR): 0', ' Best at WK 48 - Partial Response (PR): 7', ' Best at WK 48 - Stable Disease (SD): 18', ' Best at WK 48 - Progressive Disease (PD): 15', 'Unknown: 1', 'Missing: 8'], 'Adverse Events': ['Adverse Events 1:', ' Total: 22/49 (44.90%)', ' Anaemia 2/49 (4.08%)', ' Pericardial effusion 1/49 (2.04%)', ' Tachycardia 1/49 (2.04%)', ' Abdominal pain 1/49 (2.04%)', ' Abdominal pain upper 1/49 (2.04%)', ' Colitis 1/49 (2.04%)', ' Duodenal ulcer 1/49 (2.04%)', ' Gastric ulcer 1/49 (2.04%)', ' Haematemesis 1/49 (2.04%)', ' Oral pain 1/49 (2.04%)', ' Vomiting 2/49 (4.08%)', ' Mucosal inflammation 1/49 (2.04%)']}
|
3ee1c60e-46ce-4f25-af52-31d5c6d8eba1
|
Comparison
|
Eligibility
|
NCT01340300
|
NCT00671918
|
Patients cannot do more than half an hour of physical exercise in a day, if they are to participate in the primary trial, however, this is not a requirement for the secondary trial.
|
Contradiction
|
[
0,
5
] |
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] |
{'Clinical Trial ID': 'NCT01340300', 'Intervention': ['INTERVENTION 1: ', ' Exercise Training With Metformin', ' Exercise training with exercise physiologist with oral metformin', ' Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID', 'INTERVENTION 2: ', ' Exercise Training', ' Exercise training with exercise physiologist', ' Exercise training: Two supervised exercise sessions per week'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed stage I-III colorectal or breast cancer', ' Undergone curative-intent complete surgical resection and completed all adjuvant therapy (if indicated) at least 2 months prior to enrollment', ' Note: Breast cancer subjects on hormonal therapy or trastuzumab only therapy and colorectal cancer subjects on adjunctive therapies not considered cytotoxic chemotherapy (including those participating in CALGB 80702 receiving only celecoxib/placebo) are eligible.', ' Participants will be allowed to receive concomitant adjuvant endocrine therapy for breast cancer; however, all endocrine agents must be initiated at least 1 month prior to enrollment in the study and continued throughout the duration of study participation.', ' Less than 120 minutes of exercise per week', ' Approval by oncologist or surgeon', ' English speaking and able to read English', ' No planned surgery anticipated in the 3 month intervention period', ' At least one month from any major surgery to start of intervention including colostomy reversal', 'Exclusion Criteria:', ' Concurrent other malignancy or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer or in-situ cervical cancer)', ' Metastatic disease', ' Scheduled to receive any form of further adjuvant cancer therapy', ' Currently on medication for diabetes treatment', ' Pregnant or breast-feeding', ' Any condition associated with increased risk of metformin-associated lactic acidosis (prior renal failure or liver failure, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)', ' Known hypersensitivity or intolerance to metformin'], 'Results': ['Outcome Measurement: ', ' Change in Fasting Insulin Level', ' Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting insulin level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer. Fasting insulin levels in blood will be drawn at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.', ' Time frame: 0 and 3 months (change between 0 and 3 months)', 'Results 1: ', ' Arm/Group Title: Exercise Training With Metformin', ' Arm/Group Description: Exercise training with exercise physiologist with oral metformin', ' Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID', ' Overall Number of Participants Analyzed: 33', ' Least Squares Mean (Standard Error)', ' Unit of Measure: mU/L -2.47 (1.07)', 'Results 2: ', ' Arm/Group Title: Exercise Training', ' Arm/Group Description: Exercise training with exercise physiologist', ' Exercise training: Two supervised exercise sessions per week', ' Overall Number of Participants Analyzed: 34', ' Least Squares Mean (Standard Error)', ' Unit of Measure: mU/L -0.08 (1.06)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/35 (0.00%)', 'Adverse Events 2:', ' Total: 0/35 (0.00%)']}
|
{'Clinical Trial ID': 'NCT00671918', 'Intervention': ['INTERVENTION 1: ', ' Intent-To-Treat', ' Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 1.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.'], 'Eligibility': ['Inclusion Criteria:', ' The patient has provided written informed consent with HIPAA authorization before participating in the study, as has his/her responsible caregiver, if applicable.', ' The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.', ' The patient is at least 18 years of age at the time of consent.', ' The patient has an ECOG performance status of Grade 0 - 2 [8].', ' The patient has a clinical negative node status at the time of study entry.', ' If of child bearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.', ' The patient is currently not participating in another investigational drug study.', ' Melanoma Patients', ' The patient has a diagnosis of primary melanoma.', ' Breast Cancer Patients', ' The patient has a diagnosis of primary breast cancer.', ' Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan.', 'Exclusion Criteria:', ' The patient is pregnant or lactating;', ' The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0);', ' The patient has a known hypersensitivity to Lymphazurin or Patent Bleu V.', ' Melanoma Patients', ' The patient has a tumor with a Breslow depth less than 0.75mm.;', ' Patients that have had preoperative chemotherapy, immunotherapy or radiation therapy;', ' Patients diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin;', ' Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma;', ' Patients who have undergone a wide excision for their primary melanoma (>1 cm in dimension) or complex reconstruction (rotation, free flap or skin graft of any type).', ' Breast Cancer Patients', ' The patient has bilateral primary breast cancers or multiple tumors within their breast;', ' Patients that have had prior surgical procedures such as breast implants, reduction mammoplasty or axillary surgery;', ' Patients scheduled for bilateral mastectomy for any reason;', ' Patients that have had preoperative radiation therapy to the affected breast or axilla'], 'Results': ['Outcome Measurement: ', ' Concordance of Blue Dye and Lymphoseek', ' The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek.', ' Time frame: Surgery after injections of Lymphoseek and blue dye', 'Results 1: ', ' Arm/Group Title: Intent-To-Treat', ' Arm/Group Description: Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 1.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.', ' Overall Number of Participants Analyzed: 136', ' Overall Number of Units Analyzed', ' Type of Units Analyzed: Lymph Nodes Measure Type: NumberNumber (95% Confidence Interval)Unit of Measure: Proportion of Lymph Nodes: 0.9767 (0.9466 to 0.9924)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/179 (2.23%)', ' Myocardial Infarction [1]1/179 (0.56%)', ' Nausea [1]1/179 (0.56%)', ' Vomiting [1]1/179 (0.56%)', ' Cellulitis [1]1/179 (0.56%)', ' Modified Radical Mastectomy [1]1/179 (0.56%)']}
|
da1e1019-adb5-47bf-8093-e03352ca9e51
|
Single
|
Eligibility
|
NCT01042938
|
Patients must be english to participate in the primary trial.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] |
[] |
{'Clinical Trial ID': 'NCT01042938', 'Intervention': ['INTERVENTION 1: ', ' Curcumin C3 Complex', ' Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks).', 'INTERVENTION 2: ', ' Placebo', ' Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT)(~4-7 weeks).'], 'Eligibility': ['Inclusion Criteria:', ' Female with a diagnosis of, non-inflammatory breast adenocarcinoma and be referred for post-operative radiotherapy without concurrent chemotherapy.', ' Participants must be at least 21 years of age.', ' Participants must not be pregnant.', ' Participants can be from any racial or ethnic origin.', ' Breast adenocarcinoma could have been treated by either lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment.', ' Participants with in situ breast cancer are eligible.', ' Participants who are prescribed concurrent hormone treatment with radiation treatment are eligible.', ' Participants must be scheduled to receive five sessions of radiation therapy per week (1 session per day) for at least four weeks using standard (1.8-2.0 Gy per session)or Canadian (2.2-2.5 Gy per session)irradiation fractionation.', ' A time period of three weeks must elapse after chemotherapy and surgery before beginning the study.', ' The total dose prescribed to the whole breast should be 50 Gy or greater.', ' Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English).', ' Participants must be able to swallow medication.', ' Topical skin agents, e.g., Aquaphor, Cetaphil, or other emollients, are allowed either PRN or prophylactically.', ' Participant must give informed consent.', 'Exclusion Criteria:', ' Patients with bilateral breast cancer are not eligible.', ' Patients who have had previous radiation therapy to the breast or chest are not eligible.', ' Patients who are prescribed chemotherapy concurrently with radiation treatment are not eligible.', ' Patients who will be receiving treatment with Herceptin (trastuzumab), anti-coagulants, or anti-human epidermal growth factor receptor (EGFR) drugs, e.g. Iressa (gefitinib), Erbitux (cetuximab, C225), concurrently with their radiation therapy are not eligible.', ' Patients cannot have had breast reconstructions, implants, and/or expanders.', ' Patients with known radiosensitivity syndromes (e.g., Ataxia-telangiectasia) are not eligible.', ' Patients with collagen vascular disease, vasculitis, unhealed surgical sites, or breast infections are not eligible.', ' Patients whose baseline blood tests meet the following criteria are not eligible: greater than or equal to Grade 2 change Hemoglobin (i.e., 25% decrease from baseline); greater than or equal to Grade 1 change in Platelets (i.e., less than 75,000/mm3); greater than or equal to Grade 2 change in PT and PTT(i.e., 1.5-2x upper level normal (ULN)); greater than or equal to Grade 1 change in AST, ALT (i.e., greater than 2.5x ULN); greater than or equal to Grade 1 change in Bilirubin (i.e., greater than 1.5x ULN); greater than or equal to Grade 1 change in Creatinine (i.e., greater than 2x ULN).'], 'Results': ['Outcome Measurement: ', ' Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients', ' The severity of radiation dermatitis was measured using the Radiation Dermatitis Severity (RDS)Scale which ranges from 0.0 to 4.0 with increments of 0.5. The RDS scale is a revised form of the NIH Common Toxicity Criteria to account for color and subtle texture changes in the skin. The worst dermatitis (i.e., highest RDS score) at the end of treatment was used for the primary analysis of severity of radiation dermatitis in each treatment group. Additionally, we performed repeated measure analyses to examine the severity of dermatitis over time in each arm.', ' Time frame: 4-7 weeks (prescribed course of radiation)', 'Results 1: ', ' Arm/Group Title: Curcumin C3 Complex', ' Arm/Group Description: Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks).', ' Overall Number of Participants Analyzed: 14', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 2.6 (0.994)', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT)(~4-7 weeks).', ' Overall Number of Participants Analyzed: 16', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 3.4 (0.554)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/14 (0.00%)', 'Adverse Events 2:', ' Total: 0/16 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
e7fb6490-1ec7-48ff-95b1-715d79faec92
|
|
Comparison
|
Adverse Events
|
NCT00618826
|
NCT02040857
|
the primary trial and the secondary trial only record 2 of the same adverse events.
|
Contradiction
|
[
0,
3,
8,
10,
5
] |
[
0,
9,
3,
6,
11
] |
{'Clinical Trial ID': 'NCT00618826', 'Intervention': ['INTERVENTION 1: ', ' Treatment', ' Paclitaxel / Gemcitabine'], 'Eligibility': ['Inclusion Criteria:', ' Patient must be 18 years of age or older with histologically confirmed breast cancer and clinical evidence of metastatic disease.', ' Patients must have measurable or non-measurable disease. X-rays, scans or physical examinations used to assess measurable disease must be performed within 28 days prior to registration. X-rays, scans or physical examinations to assess non-measurable disease must be completed within 42 days prior to registration. Patients with effusions or ascites as the only sites of disease are ineligible.', ' Patients must meet the following requirements regarding prior and concurrent chemotherapy:Patients must not have received prior chemotherapy regimens for metastatic breast cancer. Patients may have received adjuvant/neoadjuvant chemotherapy, for a total of 3 prior regimens.', ' Prior therapy with paclitaxel or docetaxel is allowed in the adjuvant or neoadjuvant setting, if given > 6 months prior to registration.', ' Patients must have >14 days delay between the conclusion of any radiation and the start of gemcitabine, provided the acute effects of radiation treatment have resolved.', ' Patients may have received any number of exogenous hormonal therapies and/or trastuzumab in the adjuvant, neoadjuvant or metastatic setting. Last dose of prior hormonal therapy at least 14 days prior to registration.', ' Patients may receive concomitant bisphosphonate therapy for bone metastasis.', ' Patients must have recovered from any prior surgery. Two weeks must have elapsed from the time of any minor surgery and 4 weeks of any major surgery.', ' Patients must have adequate bone marrow reserve as evidenced by the following: ANC > 1500/mcL, platelets > 100, 000/mcL, and hemoglobin > 9.0 gm/dL. These results must be obtained within 28 days prior to registration.', ' Patients must have serum creatinine < 1.5 mg/dL, obtained within 28 days prior to registration.', ' Urine Protein: creatinine ratio 1.0 at screening.', ' Patients must have adequate liver function.', ' Patients must have a Zubrod performance status of 0-1.', 'Exclusion Criteria:', ' Patients must not have tumors that carry HER-2 gene amplifications as determined by (i) fluorescence in situ hybridization (FISH) or (ii) overexpression of HER-2 protein 3+ level assessed by immunohistochemistry; or may have tumors that carry HER=2 gene amplification and have had disease progression while on trastuzumab. Patients who have previously been treated with trastuzumab must be off treatment at least 28 days prior to registration.', ' Patients must not have CNS metastasis, leptomeningeal disease or lymphatic pulmonary metastases.', ' Patients must not have had prior therapy with gemcitabine or bevacizumab.', ' Patient must not have major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to start of treatment, anticipation of need for major surgical procedure during the course of the study.', ' Patients must not have received radiation to > 50% of the marrow-bearing bone.', ' Patients must not have a history of significant symptomatic cardiac disease or left ventricular ejection fraction (LVEF) < 50% of the institutional lower limit of normal (ILLN). An isotope cardiac scan (MUGA) and ECG must be obtained within 28 days.', ' Patients with uncontrolled hypertension are NOT eligible (BP>150/100).', ' Patients must not have pr-existing clinically significant (Grade 2 or greater per CTCAE Version 3.0 motor or sensory neuropathy except for abnormalities due to cancer.', ' Patients known to be HIV positive.', ' Patients must not be nursing or pregnant. Men and women of reproductive potential must agree to use an effective contraceptive method.', ' No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or Stage II cancer from which the patient has been disease free for 5 years.', ' Patients must not have had a Stroke or Myocardial Infarction in the past 6 months. Patients with unstable agina, significant peripheral vascular disease, history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the last 6 months should be excluded.'], 'Results': ['Outcome Measurement: ', ' Progression-free Survival', ' Time from study entry to disease progression or death', ' Time frame: maximum 50 months', 'Results 1: ', ' Arm/Group Title: Treatment', ' Arm/Group Description: Paclitaxel / Gemcitabine', ' Overall Number of Participants Analyzed: 13', ' Median (95% Confidence Interval)', ' Unit of Measure: months 43 (7 to 45)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 10/14 (71.43%)', ' Hemoglobin 2/14 (14.29%)', ' Lymphopenia 1/14 (7.14%)', ' Cardiac ischemia/infarction 1/14 (7.14%)', ' Hypertension 2/14 (14.29%)', ' Hypotension 1/14 (7.14%)', ' Constipation 1/14 (7.14%)', ' Diarrhea 1/14 (7.14%)', ' Heartburn/dyspepsia 1/14 (7.14%)', ' Fatigue (asthenia, lethargy, malaise) 2/14 (14.29%)', ' Rigors/chills 1/14 (7.14%)']}
|
{'Clinical Trial ID': 'NCT02040857', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib With Adjuvant Endocrine Therapy', ' Palbociclib 125 mg PO qd 21 days on, 7 days off', ' Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd'], 'Eligibility': ['Inclusion Criteria:', ' Participants must have histologically confirmed hormone receptor positive (HR+) HER2 negative stage II (except T2N0) or stage III invasive breast cancer. Evaluation for metastatic disease is not required in the absence of symptoms.', ' Men and both pre- and postmenopausal women are eligible.', ' Prior Treatment:', ' Participants may have received (neo)adjuvant chemotherapy, but must be at least 30 days after last dose, with no more than grade 1 residual toxicity at time of screening.', ' Participants may have received adjuvant radiotherapy, but must be at least 30 days after last dose , with no more than grade 1 residual toxicity at the time of screening.', ' If most recent therapy was surgery, participants must be at least 30 days out from definitive surgery with no active wound healing complications.', ' Participants must have demonstrated ability to tolerate endocrine therapy by prior successful completion of at least 1 month of tamoxifen or aromatase inhibitor (AI) therapy without significant adverse events, and in the opinion of the treating physician any ongoing toxicity does not preclude ability to continue on tamoxifen or AI for at least a projected 2 year continuous duration. Ongoing use of any endocrine therapy, including tamoxifen, letrozole, anastrozole, or exemestane, is allowed. Patients may enroll within 2 years of beginning endocrine therapy, as long as there is a plan for at least 2 more years of adjuvant endocrine therapy.', ' ECOG performance status 0-1', ' Age 18 years.', ' Normal organ and marrow function', ' Baseline QTc 480 ms', ' The effects of palbociclib on the developing human fetus are unknown. Women who might become pregnant must use adequate contraception', ' Ability to understand and the willingness to sign a written informed consent document', 'Exclusion Criteria:', ' Concurrent therapy with other investigational agents.', ' Prior therapy with any CDK4/6 inhibitor.', ' History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib.', ' Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A isoenzymes are ineligible.', ' Current use of drugs that are known to prolong the QT interval', ' Subjects with organ allograft requiring immunosuppression.', ' Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.', ' Pregnant women are excluded from this study. Breastfeeding should be discontinued prior to entry onto the study.', ' Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: ductal carcinoma in situ of the breast, cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.', ' No ongoing combination antiretroviral therapy'], 'Results': ['Outcome Measurement: ', ' 2-Year Treatment Discontinuation Rate', ' The 2-year treatment discontinuation rate is the percentage of participants who do not complete the palbociclib treatment per protocol for reasons due to toxicity, withdrawal of consent to be treated, or other events related to tolerability in uncensored participants. Participants who discontinued palbociclib early for reasons that were not treatment-related were censored.', ' Time frame: Evaluate upon completion of palbociclib, up to 2 years of treatment completion.', 'Results 1: ', ' Arm/Group Title: Palbociclib With Adjuvant Endocrine Therapy', ' Arm/Group Description: Palbociclib 125 mg PO qd 21 days on, 7 days off', ' Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd', ' Overall Number of Participants Analyzed: 152', ' Measure Type: Number', ' Unit of Measure: percentage of participants 31 (24 to 39)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 96/162 (59.26%)', ' Cardiac disorders - Other, specify 2/162 (1.23%)', ' Diarrhea 1/162 (0.62%)', ' Mucositis oral 2/162 (1.23%)', ' Nausea 1/162 (0.62%)', ' Fatigue 6/162 (3.70%)', ' Breast infection 2/162 (1.23%)', ' Soft tissue infection 1/162 (0.62%)', ' Lymphocyte count decreased 2/162 (1.23%)', ' Neutrophil count decreased 78/162 (48.15%)', ' Hypertension 1/162 (0.62%)']}
|
d5ea3443-103f-4d29-9be3-522210b84152
|
Single
|
Eligibility
|
NCT00193050
|
Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial.
|
Entailment
|
[
0,
3,
11,
13
] |
[] |
{'Clinical Trial ID': 'NCT00193050', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles', ' Patients then had either mastectomy or breast conservation surgery and pathologic treatment responses were assessed.', ' After surgery, 4 cycles of adjuvant gemcitabine (1000 mg/m2 IV days 1 and 8) and docetaxel (35 mg/m2 IV days 1 and 8) were administered at 21 day intervals.', ' After completion of chemotherapy, local regional radiation therapy and/or anti-estrogen therapy was administered per standard guidelines.'], 'Eligibility': ['Inclusion Criteria:', ' To be included in this study, you must meet the following criteria:', ' Adenocarcinoma of the breast confirmed by biopsy', ' Female Patients >18 years of age', ' Normal cardiac function', ' Ability to perform activities of daily living with minimal assistance', ' Chemotherapy naïve or have received prior chemotherapy > 5 years ago', ' Adequate bone marrow, liver and kidney function', ' Be informed of the investigational nature of this study', ' Sign an informed consent form', ' Sentinel lymph node and/or axillary dissection prior to enrollment', 'Exclusion Criteria:', ' You cannot participate in this study if any of the following apply to you:', ' Life expectancy of < than 6 months', ' History of significant heart disease', ' Prior chemotherapy or hormonal therapy', ' Concurrent Trastuzumab therapy', ' History of significant psychiatric disorders', ' History of active uncontrolled infection', ' Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.'], 'Results': ['Outcome Measurement: ', ' Pathologic Complete Response (pCR)', ' For the purpose of this study, a Pathologic complete response (pCR) was defined as no evidence of residual invasive tumor in the breast (pT0). Residual ductal or lobular carcinoma in situ was not considered in pCR assessments. Percentage of participants who experienced pCR is reported.', ' Time frame: 18 Months', 'Results 1: ', ' Arm/Group Title: Intervention', ' Arm/Group Description: In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles', ' Patients then had either mastectomy or breast conservation surgery and pathologic treatment responses were assessed.', ' After surgery, 4 cycles of adjuvant gemcitabine (1000 mg/m2 IV days 1 and 8) and docetaxel (35 mg/m2 IV days 1 and 8) were administered at 21 day intervals.', ' After completion of chemotherapy, local regional radiation therapy and/or anti-estrogen therapy was administered per standard guidelines.', ' Overall Number of Participants Analyzed: 110', ' Measure Type: Number', ' Unit of Measure: percentage of participants 18 (11 to 26)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 17/110 (15.45%)', ' Hemoglobin [1]1/110 (0.91%)', ' Esophagitis 1/110 (0.91%)', ' Dysphagia 1/110 (0.91%)', ' Nausea/Vomiting 1/110 (0.91%)', ' Nausea 1/110 (0.91%)', ' Fever 1/110 (0.91%)', ' Febrile Neutropenia 11/110 (10.00%)', ' Infection - Other [2]1/110 (0.91%)', ' Infection - Pneumonia 1/110 (0.91%)', ' Dyspnea 2/110 (1.82%)', ' Hypoxia 1/110 (0.91%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
d54cae08-3ac9-4460-bf6d-7338b45d8cd7
|
|
Single
|
Adverse Events
|
NCT00086957
|
All of the patients in cohort 1 of the primary trial experienced an adverse event.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] |
[] |
{'Clinical Trial ID': 'NCT00086957', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dose Level 1 - Docetaxel 75 mg/m^2', ' Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 75 mg/m^2 intravenously every 3 weeks.', 'INTERVENTION 2: ', ' Phase I: Dose Level 2 - Docetaxel 60 mg/m^2', ' Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 60 mg/m^2 intravenously every 3 weeks.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed adenocarcinoma of the breast', ' Metastatic disease', ' HER-2/neu overexpression (3+ by immunohistochemistry OR 2+ by fluorescence in situ hybridization)', ' Measurable or evaluable disease', ' Hormone receptor status:', ' Not specified', ' PATIENT CHARACTERISTICS:', ' Age', ' 18 and over', ' Sex', ' Male or female', ' Menopausal status', ' Not specified', ' Performance status', ' ECOG 0-2', ' Life expectancy', ' Not specified', ' Hematopoietic', ' Absolute granulocyte count 1,500/mm^3', ' Platelet count 100,000/mm^3', ' Hepatic', ' AST and ALT < 2.5 times upper limit of normal (ULN) (5.0 times ULN in the presence of liver metastases)', ' Bilirubin < 1.5 times ULN', ' No unstable or uncompensated hepatic disease', ' Renal', ' Creatinine < 1.6 mg/dL', ' No unstable or uncompensated renal disease', ' Cardiovascular', ' LVEF > 45% by echocardiogram or MUGA', ' No prior New York Heart Association class I-IV heart disease', ' No prolonged PR interval or atrioventricular block on ECG', ' No unstable or uncompensated cardiac disease', ' Pulmonary', ' No unstable or uncompensated respiratory disease', ' No clinically active interstitial lung disease', ' Patients who are asymptomatic and have chronic stable radiographic changes are allowed', ' Immunologic', ' No autoimmune disorders', ' No conditions of immunosuppression', ' No severe hypersensitivity to taxane or gefitinib or any of its excipients', ' Other', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' No other prior or concurrent malignancy within the past 5 years except basal cell carcinoma or carcinoma in situ of the cervix', ' No other severe or uncontrolled systemic disease', ' No other acute or chronic medical condition that would preclude study participation', ' No other significant clinical disorder or laboratory finding that would preclude study participation', ' No psychiatric illness that would preclude study compliance', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' Prior adjuvant trastuzumab (Herceptin®) allowed if > 6 months elapsed before disease recurrence', ' No prior trastuzumab for metastatic breast cancer', ' No prior monoclonal antibodies directed at the epidermal growth factor receptor (EGFR)', ' Chemotherapy', ' Prior adjuvant chemotherapy (or as first-line therapy for metastatic breast cancer) allowed', ' Prior adjuvant taxane allowed if completed > 6 months before diagnosis of metastatic breast cancer', ' No prior docetaxel for metastatic breast cancer', ' Endocrine therapy', ' Prior adjuvant hormonal therapy (or as first-line therapy for metastatic breast cancer) allowed', ' No concurrent hormonal therapy', ' Concurrent steroids allowed provided dose is stable', ' Radiotherapy', ' Not specified', ' Surgery', ' Fully recovered from prior oncologic or other major surgery', ' No concurrent surgery within 7 days of gefitinib administration', ' Other', ' Recovered from prior anticancer therapy (alopecia allowed)', ' More than 30 days since prior non-approved drug or investigational agent', ' No other prior EGFR-directed therapy (i.e., tyrosine kinase inhibitors)', ' No concurrent use of any of the following medications:', ' Phenytoin', ' Carbamazepine', ' Barbiturates', ' Rifampin', " Hypericum perforatum (St. John's wort)", ' No other concurrent anticancer therapy', ' No concurrent cardioprotective drugs', ' No concurrent oral retinoids', ' Concurrent participation in the City of Hope indium-labeled trastuzumab imaging study allowed'], 'Results': ['Outcome Measurement: ', ' Number of Participants With at Least One Dose Limiting Toxicity in Phase I', ' Dose Limiting Toxicity (DLT) defined as any treatment-related grade 3 or greater except for hematological toxicities which must be grade 4. Interstitial Lung Disease (ILD) related to treatment should be considered as a DLT regardless of the grade.', ' Time frame: 4 weeks from start of treatment, up to 2 years', 'Results 1: ', ' Arm/Group Title: Phase I: Dose Level 1 - Docetaxel 75 mg/m^2', ' Arm/Group Description: Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 75 mg/m^2 intravenously every 3 weeks.', ' Overall Number of Participants Analyzed: 2', ' Measure Type: Number', ' Unit of Measure: participants with DLTs 2', 'Results 2: ', ' Arm/Group Title: Phase I: Dose Level 2 - Docetaxel 60 mg/m^2', ' Arm/Group Description: Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 60 mg/m^2 intravenously every 3 weeks.', ' Overall Number of Participants Analyzed: 7', ' Measure Type: Number', ' Unit of Measure: participants with DLTs 0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/2 (100.00%)', ' Febrile neutropenia * 2/2 (100.00%)', ' Haemorrhage NOS * 0/2 (0.00%)', ' Abdominal pain * 0/2 (0.00%)', ' Diarrhea * 0/2 (0.00%)', ' Melaena * 0/2 (0.00%)', ' Mucositis oral * 0/2 (0.00%)', ' Nausea * 0/2 (0.00%)', ' Vomiting * 0/2 (0.00%)', ' Catheter related infection * 0/2 (0.00%)', ' Infection NOS * 0/2 (0.00%)', ' Leukopenia * 1/2 (50.00%)', 'Adverse Events 2:', ' Total: 7/29 (24.14%)', ' Febrile neutropenia * 1/29 (3.45%)', ' Haemorrhage NOS * 1/29 (3.45%)', ' Abdominal pain * 1/29 (3.45%)', ' Diarrhea * 2/29 (6.90%)', ' Melaena * 1/29 (3.45%)', ' Mucositis oral * 1/29 (3.45%)', ' Nausea * 1/29 (3.45%)', ' Vomiting * 1/29 (3.45%)', ' Catheter related infection * 1/29 (3.45%)', ' Infection NOS * 2/29 (6.90%)', ' Leukopenia * 0/29 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
608c5521-c9a6-47de-9ebf-791ce317a02d
|
|
Comparison
|
Eligibility
|
NCT00593827
|
NCT00478257
|
Patients with HER2 negative MBC are eligible for both the primary trial and the secondary trial.
|
Contradiction
|
[
0,
1,
2
] |
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] |
{'Clinical Trial ID': 'NCT00593827', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 16 mg/m^2', ' ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest', 'INTERVENTION 2: ', ' Ixabepilone 40 mg/m^2', ' ixabepilone 40 mg/m^2 every 3 weeks'], 'Eligibility': ['Inclusion Criteria:', ' Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) 50', ' Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer', ' Prior chemotherapy is permitted with no limit on the number of prior regimens', ' Two weeks or more have elapsed since last chemotherapy or radiation treatment', ' Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2', ' Is female, 18 yrs of age', ' Protocol defined appropriate laboratory values', ' Negative pregnancy test within 7 calendar days prior to registration', ' Has signed a patient informed consent', 'Exclusion Criteria:', ' Had prior treatment with ixabepilone or other epothilones', ' Has HER2+ disease', ' Has a known, prior, severe (National Cancer Institute Common Terminology Criteria Adverse Events [NCI CTCAE] Grade 3-4) history of hypersensitivity reaction to a drug formulated in Cremophor ® EL (polyoxyethylated castor oil)', ' Is receiving concurrent immunotherapy, hormonal therapy or radiation therapy', ' Is receiving concurrent investigational therapy or has received such therapy within the past 30 days', ' Has peripheral neuropathy > Grade 1', ' Has evidence of central nervous system (CNS) involvement requiring radiation or steroid treatment. Participants with stable brain metastases who are off steroids at least 2 weeks are eligible', ' Is pregnant or breast feeding'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression Free at 6 Months', ' PFS at 6 months was defined as proportion of participants who neither progressed nor died before 6 months. Computed using Kaplan-Meier estimates.', ' Time frame: From the date of randomization to 6-months on study', 'Results 1: ', ' Arm/Group Title: Ixabepilone 16 mg/m^2', ' Arm/Group Description: ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest', ' Overall Number of Participants Analyzed: 85', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants 28.6 (18.9 to 38.9)', 'Results 2: ', ' Arm/Group Title: Ixabepilone 40 mg/m^2', ' Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks', ' Overall Number of Participants Analyzed: 91', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants 42.7 (31.5 to 53.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 25/82 (30.49%)', ' neutropenia 1/82 (1.22%)', ' anemia 1/82 (1.22%)', ' thrombocytopenia 1/82 (1.22%)', ' febrile neutropenia 0/82 (0.00%)', ' tachycardia 3/82 (3.66%)', ' fibrillation atrial 0/82 (0.00%)', ' supraventricular tachycardia 1/82 (1.22%)', ' ventricular tachycardia 1/82 (1.22%)', ' angina attack 0/82 (0.00%)', ' congestive heart failure 0/82 (0.00%)', ' flutter atrial 0/82 (0.00%)', 'Adverse Events 2:', ' Total: 30/89 (33.71%)', ' neutropenia 5/89 (5.62%)', ' anemia 1/89 (1.12%)', ' thrombocytopenia 1/89 (1.12%)', ' febrile neutropenia 2/89 (2.25%)', ' tachycardia 1/89 (1.12%)', ' fibrillation atrial 1/89 (1.12%)', ' supraventricular tachycardia 0/89 (0.00%)', ' ventricular tachycardia 0/89 (0.00%)', ' angina attack 1/89 (1.12%)', ' congestive heart failure 1/89 (1.12%)', ' flutter atrial 1/89 (1.12%)']}
|
{'Clinical Trial ID': 'NCT00478257', 'Intervention': ['INTERVENTION 1: ', ' Effect of Bright Light', ' Effect of bright light on fatigue in women with breast cancer', 'INTERVENTION 2: ', ' Effect of Red Light', ' effect of red light on fatigue in women with breast cancer'], 'Eligibility': ['Inclusion Criteria:', ' stage I-III breast cancer', ' adjuvant or neoadjuvant anthracycline-based chemotherapy', 'Exclusion Criteria:', ' under age 18', ' pregnancy', ' metastatic or inoperable (including inflammatory) breast cancer', ' confounding underlying medical illnesses', ' history of mania', ' history of other axis-I psychiatric disorder', ' other physical or psychological impairments -'], 'Results': ['Outcome Measurement: ', ' Fatigue', ' The Short Form of the Multidimensional Fatigue Symptom Inventory (MFSI-sf) was used to measure fatigue. The range of possible score for each subscale is 0 to 24, and the range for total score is -24 to 96, with a higher score indicating more severe fatigue, except for the Vigor subscale, where larger score indicates less fatigue.', ' Time frame: four cycles of chemotherapy', 'Results 1: ', ' Arm/Group Title: Effect of Bright Light', ' Arm/Group Description: Effect of bright light on fatigue in women with breast cancer', ' Overall Number of Participants Analyzed: 23', ' Mean (Standard Error)', ' Unit of Measure: units on a scale 15.25 (5.5)', 'Results 2: ', ' Arm/Group Title: Effect of Red Light', ' Arm/Group Description: effect of red light on fatigue in women with breast cancer', ' Overall Number of Participants Analyzed: 16', ' Mean (Standard Error)', ' Unit of Measure: units on a scale 21.6 (7.2)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/23 (0.00%)', 'Adverse Events 2:', ' Total: 0/16 (0.00%)']}
|
14a8e9e9-0a46-4537-bc07-53c786bcbe97
|
Comparison
|
Adverse Events
|
NCT01048099
|
NCT02502864
|
the primary trial recorded 2 more total adverse events than the secondary trial
|
Contradiction
|
[
0,
1
] |
[
0,
1
] |
{'Clinical Trial ID': 'NCT01048099', 'Intervention': ['INTERVENTION 1: ', ' Patients Treated', ' Patients who received study treatment'], 'Eligibility': ['Inclusion Criteria:', ' Part I', ' Women with HER2-negative breast cancer, as defined by FISH testing. (FISH testing may have been performed on the primary tumor, or subsequently on a biopsy of a metastatic lesion.)', ' Patients should be currently receiving chemotherapy, or scheduled to start chemotherapy (second-line or subsequent), for HER2-negative metastatic breast cancer.', ' To begin protocol treatment, patients must have progressed after at least 1 previous chemotherapy regimen for metastatic breast cancer.', ' Patients who are ER/PR positive or negative are eligible. ER/PR positive patients should be refractory to hormonal therapy, or not good candidates for hormonal therapy due to clinical features.', ' ECOG performance status of 0, 1 or 2.', ' Adequate recovery from recent surgery; 1 week must have elapsed from the time of a minor surgery; 4 weeks must have elapsed from the time of a major surgery.', ' Patients must have measurable disease per RECIST criteria.', ' Laboratory values as follows: Absolute neutrophil count (ANC) 1500/μL Hemoglobin (Hgb) 10 g/dL Platelets 100,000/L AST or ALT and alkaline phosphatase (ALP) must be <2.5 x ULN, or <5 x ULN in patients with liver metastases. Total bilirubin <1.5 x the institutional ULN Serum creatinine <1.5 x institutional ULN or calculated creatinine clearance 45 mL/min', ' Patients from Part 1 who have HER2 overexpression/activation identified by the PRO Onc Assay may enter the treatment portion of Part 2, if they meet all Part 2 eligibility criteria.', ' Life expectancy of 12 weeks.', ' Patient must be accessible for treatment and follow-up.', ' Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry.', ' Part II', ' Women with HER2-negative breast cancer, as defined by FISH testing. (FISH testing may have been performed on the primary tumor, or subsequently on a biopsy of a metastatic lesion.)', ' Patients should be currently receiving chemotherapy, or scheduled to start chemotherapy, for HER2-negative metastatic breast cancer.', ' Patients who are ER/PR positive or negative are eligible. ER/PR positive patients should be refractory to hormonal therapy, or not good candidates for hormonal therapy due to clinical features.', ' ECOG performance status of 0, 1 or 2.', ' Adequate recovery from recent surgery; 1 week must have elapsed from the time of a minor surgery; 4 weeks must have elapsed from the time of a major surgery.', ' Patients must have measurable disease per RECIST criteria.', ' Laboratory values as follows:', ' Absolute neutrophil count (ANC) 1500/μL', ' Hemoglobin (Hgb) 10 g/dL', ' Platelets 100,000/uL', ' AST or ALT and alkaline phosphatase (ALP) must be <2.5 x ULN, or <5 x ULN in patients with liver metastases.', ' Total bilirubin <1.5 x the institutional ULN', ' Serum creatinine <1.5 x institutional ULN or calculated creatinine clearance 45 mL/min', ' Life expectancy of 12 weeks.', ' Patient must be accessible for treatment and follow-up.', ' Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry.', ' Patients who are eligible for HER2-targeted treatment will begin this treatment at the first time a treatment change is necessary (i.e. at the next progression of metastatic breast cancer). This may occur immediately after PRO Onc assay results are received, or may be several months later, for patients responding well to their current chemotherapy.', ' Patients must continue to meet all inclusion and exclusion criteria for the Part 2 screening population at the time they are ready to start HER2-targeted treatment.', ' Ejection fraction 50%, as measured by echocardiogram (ECHO) or MUGA.', 'Exclusion Criteria:', ' Part I:', ' Patients currently responding to hormonal therapy.', ' Previous treatment with any HER2-targeted agent.', ' Patients with meningeal metastases.', ' Patients who are not considered likely candidates for subsequent therapy after next progression of metastatic breast cancer.', ' Women who are pregnant or lactating.', ' Patients with New York Heart Association class II or greater congestive heart failure.', ' Any of the following 6 months prior to starting study treatment:', ' myocardial infarction;', ' severe unstable angina;', ' ongoing cardiac dysrhythmia', ' Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements.', ' Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study.', ' Use of any non-approved or investigational agent 30 days of administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.', ' Part II', ' Patients currently responding to hormonal therapy.', ' Previous treatment with any HER2-targeted agent.', ' Patients with meningeal metastases.', ' Patients with active brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if there is no evidence of central nervous system (CNS) disease progression, and at least 4 weeks have elapsed since treatment. Ideally, patients should not still require use of seizure medication or steroids.', ' Patients who are not considered likely candidates for subsequent therapy after next progression of metastatic breast cancer.', ' Women who are pregnant or lactating.', ' Patients with New York Heart Association class II or greater congestive heart failure.', ' Any of the following 6 months prior to starting study treatment:', ' myocardial infarction;', ' severe unstable angina;', ' ongoing cardiac dysrhythmia.', ' Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements.', ' Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study.', ' Use of any non-approved or investigational agent 30 days of administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.', ' Past or current history of neoplasm other than the entry diagnosis with the exception of treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancers cured by local therapy alone and a DFS 5 years.'], 'Results': ['Outcome Measurement: ', ' Part II: Objective Response Rate of HER2-negative Metastatic Breast Cancer (by FISH Testing)', ' The percentage of HER2-negative metastatic breast cancer (MBC) patients having an objective benefit from treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Includes patients with HER2 overexpression/activation as detected by PRO Onc Assay.', ' Time frame: 18 months', 'Results 1: ', ' Arm/Group Title: Patients Treated', ' Arm/Group Description: Patients who received study treatment', ' Overall Number of Participants Analyzed: 14', ' Measure Type: Number', ' Unit of Measure: percentage of participants 7'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/14 (35.71%)', ' Ileus 1/14 (7.14%)', ' General disorders and administration site conditions - Other, disease progression 2/14 (14.29%)', ' Infections and infestations - Other, pneumonia 1/14 (7.14%)', ' Acute kidney injury 1/14 (7.14%)']}
|
{'Clinical Trial ID': 'NCT02502864', 'Intervention': ['INTERVENTION 1: ', ' Standard of Care + Surveys', ' Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys.'], 'Eligibility': ['Inclusion Criteria:', ' Must have histologically confirmed localized or locally advanced breast cancer for which the treatment plan includes chemotherapy with 4 cycles of standard TC (docetaxel 75 mg/m^2 and cyclophosphamide 600mg/m^2)', ' Age >/= 65 years (Senior adult focused study given increased risk for toxicity)', ' Participants must be female', ' Eastern Cooperative Oncology Group (ECOG) performance status <2', ' Must have normal organ and marrow function', ' No pre-existing neuropathy grade > 1 per the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0', ' Be postmenopausal (defined as amenorrheic for at least 12 months)', ' Must be informed of the investigational nature of this study and be willing to provide written informed consent in accordance with Institutional guidelines and Good Clinical Practice (GCP) indicating that they understand the purpose of and procedures required for the study and are willing to participate prior to the beginning of any specific study procedures.', 'Exclusion Criteria:', ' Have uncontrolled illness (including, but not limited to, ongoing or active infection, congestive heart failure, angina pectoris, or cardiac arrhythmia) that would limit compliance with study requirements', ' Have psychiatric illness that would limit compliance with study requirements', ' Have history of allergic reactions attributed to compounds of similar chemical or biologic composition to taxanes (docetaxel or paclitaxel) or cyclophosphamide', ' Have known seropositivity for human immunodeficiency virus, hepatitis C virus, hepatitis B surface antigen, or syphilis. Does not require serologic confirmation as a study procedure.', ' Not willing to follow protocol requirements or to give informed consent'], 'Results': ['Outcome Measurement: ', ' Rate of Achieving Targeted Area Under the Curve (AUC)', ' Rate of PK guided dosing of docetaxel chemotherapy improving the ability to achieve a targeted AUC ( 2.5-3.7 mg*hr/L) within 4 cycles of therapy in patients > 65 years of age with breast cancer receiving TC (docetaxel and cyclophosphamide) as compared with historical non-PK guided therapy from patients receiving a similar regimen.', ' Time frame: Cycle 4 - Up to 6 months', 'Results 1: ', ' Arm/Group Title: Standard of Care + Surveys', ' Arm/Group Description: Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys.', ' Overall Number of Participants Analyzed: 8', ' Measure Type: Count of Participants', ' Unit of Measure: Participants AUC mg*hr/L: 2.5-3.7: 5 62.5%', ' AUC mg*hr/L: <2.5: 3 37.5%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/9 (33.33%)', ' Fatigue * 1/9 (11.11%)', ' Non-cardiac chest pain * 1/9 (11.11%)', ' Sepsis * 1/9 (11.11%)', ' Urinary tract infection * 1/9 (11.11%)', ' Syncope * 1/9 (11.11%)', ' Anxiety * 1/9 (11.11%)', ' Thromboembolic event * 1/9 (11.11%)']}
|
2d97bfa0-336f-4976-95e5-1262327a730b
|
Single
|
Results
|
NCT00003199
|
The patient group with the highest percent of Event-free Survival in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20
] |
[] |
{'Clinical Trial ID': 'NCT00003199', 'Intervention': ['INTERVENTION 1: ', ' TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer', ' See Detailed Description.', ' tamoxifen citrate: Given orally', ' busulfan: Given orally', ' thiotepa: Given IV', ' melphalan: Given IV', ' aldesleukin: Given SC', ' sargramostim: Given SC', ' peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion', ' radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF'], 'Eligibility': ['Inclusion Criteria:', ' Patients with inflammatory (stage IIIb) or responsive stage IV breast cancer with metastasis to soft tissue and/or bone; responsive stage IV disease is defined as patients who achieve a PR (>= 50% reduction in measurable tumor burden) or CR following initial chemotherapy for metastatic disease or patients with locally recurrent disease (chest wall/axillary nodes) who are rendered disease-free following surgery or radiation therapy without receiving chemotherapy; bone disease is categorized as responsive if there is demonstrated sclerosis of prior lesions with no new lesions', ' Patients should have received 4-7 cycles of an Adriamycin and/or taxane-based regimen for stage IIIb or stage IV disease; locally recurrent (chest wall/axillary nodes) patients rendered NED by RT or surgery do not need to receive chemotherapy for stage IV disease prior to Cytoxan/Taxol', ' Patient has received Cytoxan 4 gm/m^2 x 1 and Taxol 250 mg/m^2 x 1 per FHCRC protocol 506.03; Cytoxan/Taxol must be given after all other chemotherapy is completed and before transplant', " Stem cells were collected after mobilization with Cytoxan/Taxol or after mobilization from an FHCRC approved cytokine protocol; if syngeneic collection, PBSC's were collected by using G-CSF according to FHCRC protocol 753; patient has an adequate number of peripheral blood stem cells stored (>= 2.5 x 10^6 CD34+ cells/kg)", ' The patient must have the capacity to give informed consent; the patient must have signed an approved consent form conforming with federal and institutional guidelines', ' Hepatic function: Bilirubin =< 2 mg%; SGOT or SGPT =< 2.5 x institutional normal', ' Renal function: Creatinine =< 2.0 mg/dl or a creatinine clearance >= 50 mg/min', ' Pre-Study tests have been performed as outlined in the Study Calendar', ' Patients will begin IL-2/GM-CSF therapy if they meet the following criteria post-transplant:', ' Can start therapy 30 to 100 days after transplant', ' Karnofsky performance status > 60', ' ANC > 1,000 cells/mm^3 and platelets > 30,000/cells/mm^3 (transfusion independent) for at least 5 days before starting therapy', ' Total bilirubin =< 2.5 x upper limit of normal', ' SGOT =< 2.5 x upper limit of normal', ' Creatinine =< 2.0 mg/dl', 'Exclusion Criteria:', ' Patients with a Karnofsky Performance Score less than 70', ' Patients with a left ventricular ejection fraction less than 50 % (LVEF must be performed in patients with symptoms of CHF, abnormal cardiac exam or history of Adriamycin therapy total dose > 400 mg/m^2)', ' Patient is pregnant', ' Patient is seropositive for the human immunodeficiency virus', ' Patients with a history of seizures', ' Patients with hypersensitivity to E.coli preparations', ' Patients with active auto-immune disease', ' Patients with clinically significant pulmonary disease, i.e., diffusion capacity corrected < 60% of predicted; patients with pulmonary problems should be evaluated with appropriate pulmonary studies and/or consult', ' Patients with a history of CNS lesion (brain or carcinoid meningitis)', ' Patients with significant active infection precluding transplant', ' Patients who have had more than one prior chemotherapy regimen for stage IV disease or a prior transplant for any stage disease', ' Patients who have had CD34+ selection of their PBSC products', ' Patients will not receive IL-2/GM-CSF therapy if they:', ' Are > 100 days from transplant', ' Have documented disease progression after transplant', ' Have an active infection', ' Manifested cardiac complications during the initial transplant period, including arrhythmias (that required therapy), congestive heart failure, angina, myocardial infarct, or decreased LVEF to < 45%', ' Currently have pericardial effusions, pleural effusions or ascites', ' Manifested pulmonary toxicity during the initial transplant period and have a diffusion capacity corrected =< 60%', ' Are on steroids', ' Currently have a Grade 3 toxicity from BuMelTT', ' If the patient does not wish to receive the therapy'], 'Results': ['Outcome Measurement: ', ' Event-free Survival', ' Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF.', ' Time frame: 11 years', 'Results 1: ', ' Arm/Group Title: TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer', ' Arm/Group Description: See Detailed Description.', ' tamoxifen citrate: Given orally', ' busulfan: Given orally', ' thiotepa: Given IV', ' melphalan: Given IV', ' aldesleukin: Given SC', ' sargramostim: Given SC', ' peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion', ' radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF', ' Overall Number of Participants Analyzed: 50', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Stage IIIB Disease: 18 participants', ' 11 61.1%', ' Stage IV Disease: 32 participants', '9 28.1%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/50 (4.00%)', ' Prolonged hospitalization for post-transplant complications [1]1/50 (2.00%)', ' Pulmonary Emboli [2]1/50 (2.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
e68dddc8-ea04-49b2-ae91-ff7b4fcb1240
|
|
Single
|
Intervention
|
NCT03765996
|
Participants in group 2 of the primary trial receive the same Complex Decongestive Physiotherapy as those in group 1, with the addition of applying taping to anastomosis regions.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7
] |
[] |
{'Clinical Trial ID': 'NCT03765996', 'Intervention': ['INTERVENTION 1: ', ' Decongestive Physiotherapy', ' This group received Complex Decongestive Physiotherapy.', ' Decongestive Physiotherapy: This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.', 'INTERVENTION 2: ', ' Decongestive Physiotherapy Plus Taping', ' This group received Complex Decongestive Physiotherapy, and also applying taping to anastomosis regions.', ' Decongestive Physiotherapy plus taping: This group received CDP as same protocol of active comparator. In addition, taping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.'], 'Eligibility': ['Inclusion Criteria:', " Patients who had unilateral BCRL and women aged over 18 who were 'significant', 'marked', or 'severe' lymphoedema.", 'Exclusion Criteria:', ' Patients with paralysis on part of the affected arm,', ' Patients who had undergone CDP more than once within six months,', ' Patients who had an active infection,', ' Patients who had a skin disease.'], 'Results': ['Outcome Measurement: ', ' Change of the Limb Volume, (Last Value of the Follow-up - Baseline Value)', ' Limb size was quantified by using circumferential limb measurements. Measurements were taken with patients in a prone position and the arm abducted at 30°. The circumference was measured every 5cm, starting at the ulnar styloid and continuing 45cm proximally for both limbs. Limb volume was calculated for each segment by using the frustum formula. Frustum formula is a mathematical method for calculating limb volume based on the circumference measures, and this formula gives the result in milliliters. Limb measuring was carried out at the beginning of and after treatment (twenty sessions).', ' Time frame: At baseline and at 4 weeks', 'Results 1: ', ' Arm/Group Title: Decongestive Physiotherapy', ' Arm/Group Description: This group received Complex Decongestive Physiotherapy.', ' Decongestive Physiotherapy: This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.', ' Overall Number of Participants Analyzed: 14', ' Median (Inter-Quartile Range)', ' Unit of Measure: milliliter 160.01 (81.50 to 650.56)', 'Results 2: ', ' Arm/Group Title: Decongestive Physiotherapy Plus Taping', ' Arm/Group Description: This group received Complex Decongestive Physiotherapy, and also applying taping to anastomosis regions.', ' Decongestive Physiotherapy plus taping: This group received CDP as same protocol of active comparator. In addition, taping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.', ' Overall Number of Participants Analyzed: 18', ' Median (Inter-Quartile Range)', ' Unit of Measure: milliliter 148.28 (52.29 to 552.85)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/18 (0.00%)', 'Adverse Events 2:', ' Total: 0/18 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
8c83330f-f2f3-48e1-9905-dc2ba1970c54
|
|
Comparison
|
Intervention
|
NCT04080297
|
NCT02780713
|
Cohort 2 of the primary trial receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants.
|
Entailment
|
[
3,
4,
5
] |
[
0,
1,
2,
3,
4,
5
] |
{'Clinical Trial ID': 'NCT04080297', 'Intervention': ['INTERVENTION 1: ', ' 100 mg Q-122', ' Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.', 'INTERVENTION 2: ', ' 200 mg Q-122', ' Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.'], 'Eligibility': ['Inclusion Criteria:', ' Be a female of any race between the ages of 30-70 years.', ' History of breast cancer and presently taking an aromatase inhibitor or tamoxifen.', ' Naturally menopausal: 12 months spontaneous amenorrhea or > 6 but < 12 months amenorrhea with a serum follicle stimulating hormone (FSH) level of > 40 mIU/mL (Milli-international Units Per Milliliter).', ' Surgically menopausal with an FSH level > 40 mIU/mL.', ' Have a minimum of 7 moderate to severe hot flushes/day or 50 moderate to severe hot flushes per week, as verified for both weeks during the 14-day Screening Phase, prior to enrollment into the treatment phase of the study.', ' Able to read, understand and complete the required subject diary.', ' Willing and able to complete the daily subject diary, attend all study visits, and participate in all study procedures, including PK blood draws.', 'Exclusion Criteria:', ' Childbearing potential, including pregnancy, or lactation.', ' Undiagnosed abnormal genital bleeding.', ' Significant day-to-day variability in hot flushes.', ' Participation in another clinical trial within 30 days prior to screening or during the study.', ' Legal incapacity or limited legal capacity.', ' Chronic renal (serum creatinine > 2.0 mg/dL) or hepatic disease [SGPT (ALT) or SGOT (AST) > 2X normal limits].', ' Gastrointestinal, liver, kidney or other conditions which could interfere with the absorption, distribution, metabolism or excretion of Q-122.', ' Untreated overt hyperthyroidism.', ' Use of thyroid medication of less than 12 weeks on a stable dose.', ' Any clinically important systemic disease in the judgement of the investigator.', ' Inability to complete all study visits and study assessments for scheduling or other reasons.', " Any other reason which in the investigator's opinion makes the subject unsuitable for a clinical trial.", ' Abnormal laboratory findings including:', ' Hematocrit < 30% or hemoglobin < 9.5 gm/dL', ' Fasting blood sugar > 140 mg/dL', ' Fasting serum triglycerides > 300 mg/dL', ' Fasting SGOT, SGPT, GGT, or bilirubin greater than twice the upper limit of normal (a subject will not be excluded if a second measurement is less than twice the upper limit of normal)', ' Creatinine > 2.0 mg/dL'], 'Results': ['Outcome Measurement: ', ' Adverse Event (AE) Reporting of Q-122', ' Number of participants with indicated AE receiving Q-122', ' Time frame: 4 weeks', 'Results 1: ', ' Arm/Group Title: 100 mg Q-122', ' Arm/Group Description: Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.', ' Overall Number of Participants Analyzed: 10', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 7 70.0%', 'Results 2: ', ' Arm/Group Title: 200 mg Q-122', ' Arm/Group Description: Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.', ' Overall Number of Participants Analyzed: 11', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 7 63.6%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/10 (0.00%)', ' Breast pain 0/10 (0.00%)', 'Adverse Events 2:', ' Total: 1/11 (9.09%)', ' Breast pain 1/11 (9.09%)']}
|
{'Clinical Trial ID': 'NCT02780713', 'Intervention': ['INTERVENTION 1: ', ' Treatment Period 1', ' Participants received AZD9496 - Variant A (100 mg).', 'INTERVENTION 2: ', ' Treatment Period 2', ' Participants received AZD9496 - Reference (100 mg).'], 'Eligibility': ['Inclusion Criteria:', ' Provision of signed and dated, written informed consent prior to any study specific procedures.', ' Healthy male and/or female subjects aged 18 to 65 years with suitable veins for cannulation or repeated venipuncture.', ' Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at screening by fulfilling 1 of the following criteria: Post-menopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and FSH levels in the post-menopausal range (OR) Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation', ' Male subjects aged 18 to 39 years must be vasectomized. Male subjects aged 40 to 65 years must either be vasectomized or have no intention of fathering a child for a period of 6 months after receiving the last dose of IMP.', ' Have a body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive, and weigh at least 50 kg and no more than 100 kg, inclusive.', ' Values for AST, ALT, TBL, GGT and ALP must be at or below the upper limit of normal ranges at screening.', 'Exclusion Criteria:', " History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.", ' History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.', ' Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.', ' Previous history of venous or arterial thromboembolism or thrombophilia.', ' History of endometrial polyps, endometrial cancer, atypical endometrial hyperplasia, or other endometrial disorders unless subjects have undergone total hysterectomy and there is no evidence of active disease (females only).', ' Any clinically significant abnormalities in clinical chemistry (other than Inclusion no.6), hematology, or urinalysis results at screening, as judged by the investigator.', ' Any clinically significant abnormal findings in supine vital signs, after 10 minutes of supine rest, at screening and/or admission to the unit, defined as: (a) Systolic blood pressure < 90 mmHg or 150 mmHg (b) Diastolic blood pressure < 50 mmHg or 95 mmHg and (c) Heart rate < 45 or > 90 beats per minute', ' Any clinically important abnormalities in rhythm, conduction or morphology of the resting 12-lead ECG that, as judged by the investigator, that may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology or pronounced left ventricular hypertrophy.', ' Prolonged QTcF > 460 ms for females and QTcF > 450 ms for males or family history of long QT syndrome.', ' PR (PQ) interval shortening < 110 ms or evidence of ventricular pre-excitation).', ' PR (PQ) interval prolongation > 240 ms, intermittent second (Wenckebach block while asleep is not exclusive) or third degree AV block.', ' Persistent or intermittent complete bundle branch block with QRS > 120 ms or evidence of pronounced ventricular hypertrophy or pre-excitation.', ' Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) antibody.', ' Known or suspected history of drug abuse, as judged by the investigator.', ' Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening.', ' Known or suspected history of alcohol or drug abuse or excessive intake of alcohol, as judged by the investigator.', ' Positive screen for drugs of abuse, alcohol or cotinine at screening or on each admission to the unit.', ' History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9496.', ' Excessive intake of caffeine/xanthine containing drinks or food (e.g., coffee, tea, chocolate), as judged by the investigator.', " Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.", ' Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life Note: Hormonal replacement therapy is not allowed for females.', ' Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening', ' Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion is 3 months after the final dose from previous study or 1 month after the last visit of previous study, whichever is the longest. ote: Subjects consented and screened, but not dosed in this study or a previous phase I study, are not excluded.', ' Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives', ' Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.', ' Subjects who are vegans or have medical dietary restrictions.', ' Subjects who cannot communicate reliably with the investigator.', ' Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.'], 'Results': ['Outcome Measurement: ', ' Pharmacokinetics: Maximum Plasma Concentration (Cmax) for AZD9496 and Its Metabolites at Each Treatment Period.', ' To evaluate maximum observed plasma concentration (Cmax) for AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation.', ' Time frame: Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period', 'Results 1: ', ' Arm/Group Title: Treatment Period 1', ' Arm/Group Description: Participants received AZD9496 - Variant A (100 mg).', ' Overall Number of Participants Analyzed: 14', ' Geometric Mean (Geometric Coefficient of Variation)', ' Unit of Measure: ng/mL AZD9496: 64.85 (73.54%)', ' M3: 10.30 (98.93%)', ' M5: 1.102 (85.27%)', 'Results 2: ', ' Arm/Group Title: Treatment Period 2', ' Arm/Group Description: Participants received AZD9496 - Reference (100 mg).', ' Overall Number of Participants Analyzed: 14', ' Geometric Mean (Geometric Coefficient of Variation)', ' Unit of Measure: ng/mL AZD9496: 381.0 (55.83%)', ' M3: 62.98 (76.91%)', ' M5: 7.409 (75.18%)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/14 (0.00%)', 'Adverse Events 2:', ' Total: ']}
|
4613834d-c178-475c-b9fd-c9c66d5681eb
|
Single
|
Results
|
NCT00259090
|
the primary trial studies the impact of Fulvestrant, Docetaxel on Oestrogen Receptor H-score.
|
Contradiction
|
[
1
] |
[] |
{'Clinical Trial ID': 'NCT00259090', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant', ' Fulvestrant 500 mg once monthly injection', 'INTERVENTION 2: ', ' Fulvestrant + Anastrozole', ' Fulvestrant 500 mg once monthly injection + Anastrozole 1 mg once daily tablet'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women.', ' Biopsy confirmation of primary breast cancer.', ' Oestrogen receptor positive tumour.', ' Fit for surgery within one month.', ' Written informed consent to participate in the study', 'Exclusion Criteria:', ' Previous treatment with any anti-hormonal therapy for breast cancer.', ' Previous radiotherapy to the primary tumour.', ' Previous chemotherapy for the primary tumour.'], 'Results': ['Outcome Measurement: ', ' Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score.', ' For each sample, the ER H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = [(0.5 x percent +/-) + (1 x percent +) + (2 x percent ++) + (3 x percent +++)]. Range 0-300. The greater the change from baseline (randomization) in ER H-score, the greater the blockage of ER expression and the greater the potential anti-tumour activity. Percentage change from baseline=[(SRG - BL)/BL]x100', ' Time frame: Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)', 'Results 1: ', ' Arm/Group Title: Fulvestrant', ' Arm/Group Description: Fulvestrant 500 mg once monthly injection', ' Overall Number of Participants Analyzed: 35', ' Mean (Standard Error)', ' Unit of Measure: Percentage change from baseline -37 (4)', 'Results 2: ', ' Arm/Group Title: Fulvestrant + Anastrozole', ' Arm/Group Description: Fulvestrant 500 mg once monthly injection + Anastrozole 1 mg once daily tablet', ' Overall Number of Participants Analyzed: 31', ' Mean (Standard Error)', ' Unit of Measure: Percentage change from baseline -38 (5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/40 (0.00%)', ' Pancytopenia 0/40 (0.00%)', ' Atrial Fibrillation 0/40 (0.00%)', ' Unevaluable Event 0/40 (0.00%)', ' Subcutaneous Abscess 0/40 (0.00%)', ' Procedural Complication 0/40 (0.00%)', 'Adverse Events 2:', ' Total: 3/40 (7.50%)', ' Pancytopenia 0/40 (0.00%)', ' Atrial Fibrillation 1/40 (2.50%)', ' Unevaluable Event 1/40 (2.50%)', ' Subcutaneous Abscess 0/40 (0.00%)', ' Procedural Complication 1/40 (2.50%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
b4555685-6e25-4797-8616-bcab5b06a135
|
|
Comparison
|
Eligibility
|
NCT00290732
|
NCT02748213
|
Patients whose breast tumour is 0.1 cm across or less are eligible for the secondary trial, but not the primary trial.
|
Contradiction
|
[
2,
8
] |
[
0,
1
] |
{'Clinical Trial ID': 'NCT00290732', 'Intervention': ['INTERVENTION 1: ', ' Intraductal Arm', ' Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed infiltrating carcinoma of the breast meeting any of the following criteria:', ' T1-3, any N disease', ' Proven ductal carcinoma in situ', ' Unresected disease', ' Planned mastectomy as definitive surgical procedure', ' Known or suspected metastatic disease allowed provided mastectomy is planned', ' Nonpalpable tumor allowed (e.g., initial T2-3 tumor that responded to preoperative therapy)', ' No inflammatory breast cancer or other T4 features', ' Successful baseline ductogram', ' Baseline nipple aspiration procedure must identify a duct productive of nipple aspirate fluid', ' No severe nipple retraction', ' Hormone receptor status not specified', ' PATIENT CHARACTERISTICS:', ' Female patients', ' Menopausal status not specified', ' ECOG performance status 0-2', ' Absolute neutrophil count 1,500/mm^3', ' Platelet count 100,000/mm^3', ' Hemoglobin 9.0 g/dL', ' Creatinine 2 times upper limit of normal (ULN)', ' Bilirubin 2 times ULN', ' AST and ALT 2.5 times ULN', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' No significant history of severe allergy to iodinated contrast material or debilitating anxiety that may not allow for a ductogram', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' Prior preoperative chemotherapy, trastuzumab (Herceptin®), or hormonal therapy allowed provided it was completed 7-14 days prior to study treatment', ' No prior radiation therapy, excisional biopsy, breast reduction, areolar surgery, or breast implant (present or past history of implant that was removed)', ' No other prior procedure that may have altered the breast ductal system in the ipsilateral breast', ' No other concurrent chemotherapy, radiotherapy, endocrine therapy, or biologic agents for breast cancer', ' No other concurrent investigational drugs', ' Concurrent bisphosphonates allowed'], 'Results': ['Outcome Measurement: ', ' Maximum Tolerated Dose (MTD)', ' Maximum tolerated dose (MTD) of administering pegylated liposomal doxorubicin (PLD) into one duct of women with breast cancer awaiting mastectomy. MTD reflects highest dose of drug that did not cause Dose Limiting Toxicity (DLT) in more than 30% of patients.', ' Time frame: Until up to 30 days after PLD administration', 'Results 1: ', ' Arm/Group Title: Intraductal Arm', ' Arm/Group Description: Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.', ' Overall Number of Participants Analyzed: 15', ' Measure Type: Number', ' Unit of Measure: milligrams 10'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/3 (0.00%)', ' Dermatology other (right areolar eschar) [1]0/3 (0.00%)']}
|
{'Clinical Trial ID': 'NCT02748213', 'Intervention': ['INTERVENTION 1: ', ' Herceptin + Taxotere + Xeloda', ' Participants received triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal. Herceptin and Taxotere were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 75 mg/m^2, with adjustments allowed only for toxicity. Xeloda was given orally as 950 mg/m^2 twice a day on Days 1 to 14 of each 21-day cycle, with adjustments allowed only for toxicity.', 'INTERVENTION 2: ', ' Herceptin + Taxotere', ' Participants received dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal. Treatments were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 100 mg/m^2, with adjustments allowed only for toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed, HER2-positive advanced and/or metastatic breast cancer not amenable to curative therapy', ' At least one measurable lesion according to RECIST', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Baseline left ventricular ejection fraction (LVEF) at least 50%', 'Exclusion Criteria:', ' Pregnant, lactating, or women of childbearing potential who are not surgically sterile or not willing to use adequate contraceptive methods', ' Previous treatment with Herceptin or other anti-HER therapies, or any previous chemotherapy for advanced or metastatic disease', ' Past medical history significant for any cardiac or central nervous system (CNS) disorders', ' Poor hematologic, renal, or hepatic function', ' Chronic corticosteroid therapy'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST)', ' Tumor response was assessed by RECIST during the study. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. PR was defined as greater than or equal to ( ) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed 4 weeks after the initial assessment of CR or PR. The percentage of participants with a best overall response for CR or PR was reported. The exact 95% confidence interval (CI) for one-sample binomial was determined using the Pearson-Clopper method.', ' Time frame: Tumor assessments at Baseline, then every 6 weeks until Cycle 8 (cycle length of 21 days), then every 12 weeks until progressive disease and/or one year after enrollment; thereafter according to routine clinical practice (up to 66 months overall)', 'Results 1: ', ' Arm/Group Title: Herceptin + Taxotere + Xeloda', ' Arm/Group Description: Participants received triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal. Herceptin and Taxotere were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 75 mg/m^2, with adjustments allowed only for toxicity. Xeloda was given orally as 950 mg/m^2 twice a day on Days 1 to 14 of each 21-day cycle, with adjustments allowed only for toxicity.', ' Overall Number of Participants Analyzed: 112', ' Measure Type: Number', ' Unit of Measure: percentage of participants 70.5 (61.18 to 78.77)', 'Results 2: ', ' Arm/Group Title: Herceptin + Taxotere', ' Arm/Group Description: Participants received dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal. Treatments were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 100 mg/m^2, with adjustments allowed only for toxicity.', ' Overall Number of Participants Analyzed: 110', ' Measure Type: Number', ' Unit of Measure: percentage of participants 72.7 (63.41 to 80.78)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 52/112 (46.43%)', ' Febrile neutropenia * 16/112 (14.29%)', ' Neutropenia * 7/112 (6.25%)', ' Anaemia * 1/112 (0.89%)', ' Cardiac failure * 1/112 (0.89%)', ' Coronary artery disease * 1/112 (0.89%)', ' Left ventricular dysfunction * 1/112 (0.89%)', ' Pericardial effusion * 0/112 (0.00%)', ' Hyperthyroidism * 1/112 (0.89%)', ' Diarrhoea * 5/112 (4.46%)', ' Vomiting * 3/112 (2.68%)', 'Adverse Events 2:', ' Total: 51/110 (46.36%)', ' Febrile neutropenia * 26/110 (23.64%)', ' Neutropenia * 7/110 (6.36%)', ' Anaemia * 1/110 (0.91%)', ' Cardiac failure * 0/110 (0.00%)', ' Coronary artery disease * 0/110 (0.00%)', ' Left ventricular dysfunction * 0/110 (0.00%)', ' Pericardial effusion * 1/110 (0.91%)', ' Hyperthyroidism * 0/110 (0.00%)', ' Diarrhoea * 0/110 (0.00%)', ' Vomiting * 1/110 (0.91%)']}
|
c1b90c18-45f4-4e28-b50a-a00b0eadc523
|
Single
|
Eligibility
|
NCT00232479
|
Only patients with HER2 positive breast carcinoma are eligible for the primary trial.
|
Entailment
|
[
0,
1
] |
[] |
{'Clinical Trial ID': 'NCT00232479', 'Intervention': ['INTERVENTION 1: ', ' Group 1', ' patients received dose dense herceptin, carboplatin and taxotere'], 'Eligibility': ['Inclusion Criteria:', ' HER-2 overexpressing breast cancer', ' Clinical stage 2-3B', ' Normal ejection fraction', 'Exclusion Criteria:', ' Metastatic disease', ' Low ejection fraction'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Pathologic Complete Response (pCR)', ' pCR is defined as the absence of invasive tumor from the surgical specimen of breast and axilla which is obtained after the chemotherapy regimen has been delivered.', ' Time frame: determined at the time of surgery which is approximately 16 weeks from the beginning of treatment', 'Results 1: ', ' Arm/Group Title: Group 1', ' Arm/Group Description: patients received dose dense herceptin, carboplatin and taxotere', ' Overall Number of Participants Analyzed: 44', ' Measure Type: Number', ' Unit of Measure: participants 19'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/46 (2.17%)', ' hospitalization [1]1/46 (2.17%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
33ef3abf-97c0-4d15-909d-258fb47ac54a
|
|
Comparison
|
Results
|
NCT01323530
|
NCT01106040
|
the secondary trial and the primary trial results indicate that the PFS of participants is partially linked to age, cancer grade and ethnicity.
|
Contradiction
|
[
0,
1,
2,
3
] |
[
0,
1,
2,
3
] |
{'Clinical Trial ID': 'NCT01323530', 'Intervention': ['INTERVENTION 1: ', ' Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2)', ' Participants received eribulin mesilate 1.2 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD, undue toxicity, the presence of other medical conditions that prohibit continuation of therapy, pregnancy, a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).', 'INTERVENTION 2: ', ' Phase 1b (Schedule 1): Eribulin Mesilate (1.6 mg/m^2)', ' Participants received eribulin mesilate 1.6 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD, undue toxicity, the presence of other medical conditions that prohibit continuation of therapy, pregnancy, a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).'], 'Eligibility': ['Inclusion Criteria', ' Subjects who meet all of the following criteria will be included in the study:', ' Dose-escalation cohorts (Phase 1b):', ' Histologically or cytologically confirmed cancer that is advanced and/or metastatic', ' Resistant/refractory to approved therapies (defined as progressive disease during or within 6 months after the last anti-cancer therapy) or for whom single agent capecitabine at this dose level and schedule would be a reasonable treatment option in the opinion of the investigator', ' For subjects that previously received capecitabine, all capecitabine related toxicities must have completely resolved', ' Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L, hemoglobin greater than or equal to 10.0 g/dL (this may have been corrected by growth factor or transfusion), and platelet count greater than or equal to 100 x 10^9/L', ' Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the upper limit of normal (ULN) and alkaline phosphatase (AP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 x ULN (in the case of liver metastases less than or equal to 5 x ULN). In case AP is greater than 3 x ULN (in absence of liver metastases) or greater than 5 x ULN (in presence of liver metastases) AND subject also is known to have bone metastases, the liver specific AP must be separated from the total and used to assess the liver function instead of the total AP.', ' Adequate renal function as evidenced by calculated creatinine clearance greater than or equal to 50 mL/min as per the Cockcroft-Gault formula (Appendix 1) or radioisotope measurement.', ' Females of childbearing potential must have a negative urine or serum beta human chorionic gonadotropin (hCG) at Visit 1 (Screening) and prior to starting study drugs on Day 1. Female subjects of childbearing potential must agree to be abstinent or to use highly effective methods of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, intrauterine device (IUD), or have a vasectomized partner) having starting for at least one menstrual cycle prior to starting study drug(s) and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those women using hormonal contraceptives must also be using an additional approved method of contraception (as described previously). Perimenopausal women must be amenorrheic for at least 12 months to be considered of nonchildbearing potential.', ' Male subjects who are not abstinent or have not undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use, a highly affective method of contraception (e.g. condom + spermicide, condom + diaphragm with spermicide, IUD) starting for at least one menstrual cycle prior to starting study drug(s) and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously)', ' Life expectancy of greater than 3 months', ' Willing and able to comply with all aspects of the protocol', ' Provide written informed consent', ' Eastern Cooperative Oncology Group (ECOG) performance status (PS) less than or equal to 2', ' Males and females, age greater than or equal to18 years', ' Dose-confirmation cohorts (Phase 2):', ' Histologically or cytologically confirmed carcinoma of the breast that is advanced and/or metastatic', ' Received up to three prior chemotherapy regimens in any setting (sequential neoadjuvant/ adjuvant treatment counting as one regimen)', ' Chemotherapy regimens must have included an anthracycline (unless anthracycline containing chemotherapy is inappropriate) and a taxane, either in combination or in separate regimens', ' No prior treatment with capecitabine in any setting', ' At least one lesion of greater than or equal to 1.5cm in longest diameter for non-lymph nodes and greater than or equal to 1.5cm in shortest diameter for lymph nodes which is serially measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 7', ' Adequate bone marrow function as evidenced by ANC greater than or equal to 1.5 x 10^9/L, hemoglobin greater than or equal to 10.0 g/dL (this may have been corrected by growth factor or transfusion), and platelet count greater than or equal to 100 x 10^9/L', ' Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the upper limits of normal (ULN) and alkaline phosphatase (AP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal 3 x ULN (in the case of liver metastases less than or equal to 5 x ULN). In case AP is greater than 3 x ULN (in absence of liver metastases) or greater than 5 x ULN (in presence of liver metastases) AND subject also is known to have bone metastases, the liver specific AP must be separated from the total and used to assess the liver function instead of the total AP.', ' Adequate renal function as evidenced by calculated creatinine clearance greater than or equal to 50 mL/min as per the Cockcroft-Gault formula (Appendix 1) or radioisotope measurement.', ' Females of childbearing potential must have a negative urine or serum beta hCG at Visit 1 (Screening) and prior to starting study drugs on Day 1. Female subjects of childbearing potential must agree to be abstinent or to use highly effective methods of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, IUD, or have a vasectomized partner) having starting for at least one menstrual cycle prior to starting study drug(s) and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those women using hormonal contraceptives must also be using an additional approved method of contraception (as described previously). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential', ' Life expectancy of greater than 3 months', ' Willing and able to comply with all aspects of the protocol', ' ECOG-PS 0 or 1', ' Females, age greater than or equal to 18 years', ' Exclusion Criteria', ' Subjects who meet any of the following criteria will be excluded from participation in the study:', ' Radiotherapy, chemotherapy, biological therapy or investigational agents within 4 weeks prior to the start of study treatment; subjects must have recovered from any previous therapy related toxicity to less than Grade 1 at study entry (except for stable sensory neuropathy less than or equal to Grade 2 and alopecia)', ' Treatment with mitomycin C or nitrosourea within 6 weeks prior to commencing on study treatment', ' Hormonal treatment within 2 weeks prior to start of study treatment (continued use of antiandrogens and/or gonadorelin analogues for treatment of prostate cancer permitted)', ' Prior participation in an eribulin clinical study, even if not assigned to eribulin treatment', ' Subject with hypersensitivity to halochondrin B and /or halochondrin B chemical derivates or capecitabine or any of the excipients', ' Suspected dihydropyrimidine dehydrogenase (DPD) deficiency', ' Previous radiotherapy encompassing greater than 30% of marrow', ' Previous organ allograft requiring immunosuppression', ' Subjects with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment; radiographic stability should be determined by comparing contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) brain scan performed during screening to a prior scan performed at least 4 weeks earlier', ' Meningeal carcinomatosis', ' Significant cardiovascular impairment (history of congestive heart failure greater than New York Heart Association [NYHA] grade II, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia)', " Electrocardiogram (ECG) with QT interval corrected for heart rate (QTc) interval greater than 470 msec (as measured either by Bazett's or Fredericia's formula)", ' Pre-existing neuropathy greater than Grade 2', ' Anti-coagulant therapy with warfarin or related compounds, other than for line patency, that cannot be changed to heparin-based therapy for the duration of the study', ' Subjects with known positive serology for Human Immunodeficiency Virus (HIV), or Hepatitis B or C', " Subjects with other significant disease or disorder that, in the Investigator's opinion, would exclude the subject from the study", ' Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study', ' Unable to swallow tablets'], 'Results': ['Outcome Measurement: ', ' Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0)', ' DLTs as per NCI CTCAE v3.0 were defined as:1) Neutropenia Grade 4 that lasted at least 7 days, 2) Neutropenia Grade 3 or 4 complicated by fever and/or infection (absolute neutrophil count [ANC] less than 1.0*10^9/liter [L], fever of at least 38.5 degree celsius [°C]), 3)Thrombocytopenia Grade 4, 4) Thrombocytopenia Grade 3 complicated by bleeding and/or requiring platelet or blood transfusion, 5) Non-hematological toxicity Grade 3 or higher (excluding Grade 3 nausea, and Grade 3 or 4 vomiting or diarrhea in participants who had not received optimal treatment with antiemetic and/or antidiarrheal medication; excluding laboratory abnormalities without clinical symptoms), 6) Delayed recovery from treatment-related toxicity resulting in dose delay greater than 14 days, 7) Failure to administer at least 75 percent (%) of planned study drugs during Cycle 1 as result of Grade 2 or higher treatment-related toxicity that constituted increase of at least 2 grades from baseline.', ' Time frame: Cycle 1 (21 days)', 'Results 1: ', ' Arm/Group Title: Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2)', ' Arm/Group Description: Participants received eribulin mesilate 1.2 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD, undue toxicity, the presence of other medical conditions that prohibit continuation of therapy, pregnancy, a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).', ' Overall Number of Participants Analyzed: 8', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 1 12.5%', 'Results 2: ', ' Arm/Group Title: Phase 1b (Schedule 1): Eribulin Mesilate (1.6 mg/m^2)', ' Arm/Group Description: Participants received eribulin mesilate 1.6 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD, undue toxicity, the presence of other medical conditions that prohibit continuation of therapy, pregnancy, a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 1 16.7%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/8 (25.00%)', ' Febrile neutropenia 1/8 (12.50%)', ' Heparin-induced Thrombocytopenia 0/8 (0.00%)', ' Neutropenia 0/8 (0.00%)', ' Constipation 0/8 (0.00%)', ' Dysphagia 0/8 (0.00%)', ' Nausea 0/8 (0.00%)', ' Vomiting 0/8 (0.00%)', ' Abdominal Pain 0/8 (0.00%)', ' Diarrhoea 0/8 (0.00%)', ' Intestinal Ischaemia 0/8 (0.00%)', ' Small intestine obstruction 0/8 (0.00%)', ' Fatigue 0/8 (0.00%)', 'Adverse Events 2:', ' Total: 4/6 (66.67%)', ' Febrile neutropenia 0/6 (0.00%)', ' Heparin-induced Thrombocytopenia 0/6 (0.00%)', ' Neutropenia 2/6 (33.33%)', ' Constipation 0/6 (0.00%)', ' Dysphagia 1/6 (16.67%)', ' Nausea 0/6 (0.00%)', ' Vomiting 0/6 (0.00%)', ' Abdominal Pain 0/6 (0.00%)', ' Diarrhoea 0/6 (0.00%)', ' Intestinal Ischaemia 0/6 (0.00%)', ' Small intestine obstruction 0/6 (0.00%)', ' Fatigue 0/6 (0.00%)']}
|
{'Clinical Trial ID': 'NCT01106040', 'Intervention': ['INTERVENTION 1: ', ' Intent-To-Treat', ' Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.'], 'Eligibility': ['Inclusion Criteria:', ' The patient has provided written informed consent with HIPAA authorization.', ' The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.', ' The patient is at least 18 years of age at the time of consent.', ' The patient has an ECOG performance status of Grade 0 - 2 (see Appendix A).', ' The patient has a clinical negative node status at the time of study entry (i.e. T0-4, N0, M0, see Appendix D and E).', ' If of childbearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.', ' Melanoma Patients', ' The patient has a diagnosis of primary melanoma. Breast Cancer Patients', ' The patient has a diagnosis of primary breast cancer.', ' Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan.', 'Exclusion Criteria:', ' The patient is pregnant or lactating.', ' The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0, see Appendix D and E).', ' The patient has a known hypersensitivity to Lymphazurin.', ' The patient has participated in another investigational drug study within 30 days of scheduled surgery.', ' Melanoma Patients', ' The patient has a tumor with a Breslow depth less than 0.75mm.', ' Patient has had preoperative chemotherapy, immunotherapy, or radiation therapy.', ' Patient has been diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin.', ' Patient has undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma.', ' Patient has undergone a wide excision for their primary melanoma (>1 cm in dimension) or complex reconstruction (rotation, free flap, or skin graft of any type).', ' Breast Cancer Patients', ' The patient has bilateral primary breast cancers or multiple tumors within their breast.', ' Patient has had prior surgical procedures such as breast implants, reduction mammoplasty, or axillary surgery.', ' Patient is scheduled for bilateral mastectomy unless for cosmetic reasons and the contraindicated breast will not undergo lymph node mapping.', ' Patient has had preoperative radiation therapy to the affected breast or axilla.'], 'Results': ['Outcome Measurement: ', ' Concordance of Blue Dye and Lymphoseek', ' The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek.', ' Time frame: Surgery after injections of Lymphoseek and blue dye', 'Results 1: ', ' Arm/Group Title: Intent-To-Treat', ' Arm/Group Description: Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.', ' Overall Number of Participants Analyzed: 133', ' Overall Number of Units Analyzed', ' Type of Units Analyzed: Lymph Nodes Measure Type: NumberNumber (95% Confidence Interval)Unit of Measure: Proportion of Lymph Nodes: 1.0000 (0.9840 to 1.0000)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 8/153 (5.23%)', ' Bradycardia [1]1/153 (0.65%)', ' Tachycardia [1]1/153 (0.65%)', ' Cellulitis [1]2/153 (1.31%)', ' Herpes Zoster Ophthalmic [1]1/153 (0.65%)', ' Seroma [1]1/153 (0.65%)', ' Syncope [1]1/153 (0.65%)', ' Asthma [1]1/153 (0.65%)']}
|
a381e340-18b1-4baa-91ce-0c420bcb411c
|
Single
|
Intervention
|
NCT00383500
|
the primary trial is not testing a drug based intervention, it is testing a Medical device called Manual Lymphatic Drainage.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5
] |
[] |
{'Clinical Trial ID': 'NCT00383500', 'Intervention': ['INTERVENTION 1: ', ' Flexitouch Device', ' Lymphedema management via Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)', 'INTERVENTION 2: ', ' Manual Lymphatic Drainage (MLD)', ' Lymphedema management via self-administered manual lymphatic drainage therapy'], 'Eligibility': ['Inclusion Criteria:', ' Unilateral breast cancer', ' Scheduled to undergo breast surgery and axillary lymph node dissection, with or without breast conserving techniques.', ' Referred to the surgeons of the Stanford University Breast Cancer Program', ' Capacity to provide informed consent.', ' All experimental protocols will be reviewed and approved by the Stanford Institutional Review Board for the Protection of Human Subjects.', 'Exclusion Criteria:', " Other serious systemic illness (renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would confound the study or impair the patients' ability to participate.", ' Recurrent breast cancer or other forms of pre-existing lymphedema.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy', ' Successful, serial multiple frequency bioimpedance assessment for newly developing lymphedema in the 3 study groups', ' Time frame: 36 months', 'Results 1: ', ' Arm/Group Title: Flexitouch Device', ' Arm/Group Description: Lymphedema management via Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)', ' Overall Number of Participants Analyzed: 19', ' Measure Type: Number', ' Unit of Measure: participants 19', 'Results 2: ', ' Arm/Group Title: Manual Lymphatic Drainage (MLD)', ' Arm/Group Description: Lymphedema management via self-administered manual lymphatic drainage therapy', ' Overall Number of Participants Analyzed: 21', ' Measure Type: Number', ' Unit of Measure: participants 21'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/19 (0.00%)', 'Adverse Events 2:', ' Total: ']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
15e6b2b9-ba8f-4ca5-99d7-a1bbf9497b4b
|
|
Single
|
Results
|
NCT00436566
|
Not a single patient in the primary trial suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] |
[] |
{'Clinical Trial ID': 'NCT00436566', 'Intervention': ['INTERVENTION 1: ', ' AC/PTL', ' Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed diagnosis of early-stage breast cancer', ' HER2 positive by immunohistochemistry (IHC) (3+) or fluorescent in situ hybridization (FISH)', ' Ductal carcinoma in situ (DCIS) components should not be counted in the determination of degree of IHC staining or FISH amplification', ' No locally advanced tumors (i.e., T4) at diagnosis, including the following:', ' Tumors fixed to chest wall', " Peau d'orange", ' Skin ulcerations or nodules', ' Clinical inflammatory changes (e.g., diffuse brawny cutaneous induration with an erysipeloid edge)', ' Has undergone mastectomy or lumpectomy with axillary node or sentinel node dissection within the past 84 days', ' Patients who have undergone a mastectomy must meet the following criteria:', ' No evidence of gross or microscopic tumor (i.e., invasive DCIS) at the surgical resection margins noted in final surgery or pathology reports', ' Patients with close margins are eligible', ' Radiation therapy is required for 4 or more positive lymph nodes and must be started after completion of chemotherapy', ' Patients who have undergone a lumpectomy with axillary node or sentinel node dissection must meet the following criteria:', ' No evidence of invasive cancer or DCIS at the surgical resection margins', ' No gross residual adenopathy', ' Planning to undergo radiation therapy to the breast with or without regional lymphatics after completion of chemotherapy', ' No active hepatic or biliary disease', " Patients with liver metastases, stable chronic liver disease, Gilbert's syndrome, or asymptomatic gallstones are eligible", ' Hormone receptor status:', ' Estrogen receptor and progesterone receptor status known', ' PATIENT CHARACTERISTICS:', ' Male or female', ' Menopausal status not specified', ' ECOG performance status 0-2', ' Absolute neutrophil count 1,500/mm³', ' Platelet count 100,000/mm³', ' Hemoglobin 10.0 g/dL', ' Bilirubin 1.5 times upper limit of normal (ULN)', ' AST and ALT 2.5 times ULN', ' Alkaline phosphatase 2.5 times ULN', ' Creatinine normal OR creatinine clearance 60 mL/min', ' LVEF 50% by MUGA scan or echocardiogram', ' Able to complete questionnaire(s) by themselves or with assistance', ' Able and willing to provide blood and tissue samples', ' No known sensitivity to benzyl alcohol', ' No sensory neuropathy grade 2', ' No active cardiac disease, including any of the following:', ' Myocardial infarction within the past 6 months', ' Prior or concurrent congestive heart failure', ' Prior or concurrent arrhythmia or cardiac valvular disease requiring medications or that is clinically significant', ' Uncontrolled hypertension, defined as diastolic blood pressure (BP) >100 mm Hg or systolic BP > 200 mm Hg on 2 separate occasions 14 days apart', ' Clinically significant pericardial effusion', ' Prior or concurrent uncontrolled or symptomatic angina', ' Other cardiac condition that, in the opinion of the treating physician, would put the patient at hazardous risk', ' No history of allergic reactions attributed to compounds of similar chemical or biologic composition as lapatinib ditosylate', ' No uncontrolled intercurrent illness including, but not limited to, the following:', ' Ongoing or active infection', ' Psychiatric illness or social situations that would preclude study compliance', ' Able to swallow and retain oral medication', ' No history of gastrointestinal (GI) disease resulting in an inability to take oral medication, including any of the following:', ' Malabsorption syndrome', ' Requirement for IV alimentation', ' Prior surgical procedures affecting absorption', " Uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)", ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception during and for 6 months after completion of study treatment', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' No prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer', ' No primary breast radiation therapy as part of breast-conserving treatment', ' No prior anthracycline or taxane therapy for any malignancy', ' No prior epidermal growth factor receptor-targeting therapies (e.g., gefitinib, cetuximab, erlotinib hydrochloride, rituximab, trastuzumab [Herceptin®], lapatinib ditosylate, panitumumab, or nimotuzumab)', ' At least 14 days since prior and no concurrent CYP3A4 inducers, including the following:', ' Rifamycin-class antibiotics (e.g., rifampin, rifabutin, or rifapentine)', ' Anticonvulsants (e.g., phenytoin, carbamazepine, or barbiturates [e.g., phenobarbital])', ' Antiretrovirals (e.g., efavirenz or nevirapine)', ' Glucocorticoids (e.g., oral cortisone, hydrocortisone, prednisone, methylprednisolone, or dexamethasone)', ' Daily oral dexamethasone 1.5 mg (or equivalent) allowed', ' Modafinil', " Hypericum perforatum (St. John's wort)", ' At least 7 days since prior and no concurrent CYP3A4 inhibitors, including the following:', ' Antibiotics (e.g., clarithromycin, erythromycin, or troleandomycin)', ' Antifungals (e.g., itraconazole, ketoconazole, fluconazole [> 150 mg daily], or voriconazole)', ' Antiretrovirals and protease inhibitors (e.g., delaviridine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, or lopinavir)', ' Calcium channel blockers (e.g., verapamil or diltiazem)', ' Antidepressants (e.g., nefazodone or fluvoxamine)', ' Gastrointestinal agents (e.g., cimetidine or aprepitant)', ' Grapefruit and grapefruit juice', ' At least 6 months since prior and no concurrent amiodarone', ' No herbal or alternative medicines or supplements 14 days before, during, and for 30 days after completion of study treatment', ' No concurrent hormonal agents (e.g., birth control pills, ovarian hormonal replacement therapy, or raloxifene)', ' Adjuvant hormonal agents (e.g., tamoxifen, aromatase inhibitors) allowed after completion of chemotherapy as part of treatment for breast cancer', ' No concurrent antiretroviral therapy for HIV-positive patients', ' No concurrent digitalis or beta-blockers for congestive heart failure', ' No concurrent arrhythmia or angina pectoris medication', ' No other concurrent investigational agents or anticancer therapies, including cytotoxic agents or immunotherapy'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment', ' [Not Specified]', ' Time frame: 6 months', 'Results 1: ', ' Arm/Group Title: AC/PTL', ' Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months.', ' Overall Number of Participants Analyzed: 109', ' Measure Type: Number', ' Unit of Measure: participants 0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 17/108 (15.74%)', ' Febrile neutropenia 1/108 (0.93%)', ' Left ventricular failure 1/108 (0.93%)', ' Diarrhea 6/108 (5.56%)', ' Fatigue 1/108 (0.93%)', ' Pneumonia 1/108 (0.93%)', ' Skin infection 1/108 (0.93%)', ' Urinary tract infection 1/108 (0.93%)', ' Alanine aminotransferase increased 1/108 (0.93%)', ' Aspartate aminotransferase increased 1/108 (0.93%)', ' Leukopenia 2/108 (1.85%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
8e246d8f-e063-4f2e-a382-5d201a946b87
|
|
Single
|
Eligibility
|
NCT00097721
|
Patients of any ethnicity can participate in the primary trial.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36
] |
[] |
{'Clinical Trial ID': 'NCT00097721', 'Intervention': ['INTERVENTION 1: ', ' E7389 28 Day Schedule', ' E7389 1.4 mg/m^2 intravenous bolus on Days 1, 8 and 15 of a 28 day cycle.', 'INTERVENTION 2: ', ' E7389 21 Day Schedule', ' E7389 1.4 mg/m^2 intravenous bolus on Days 1 and 8 of a 21 day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Female patients with histologically or cytologically confirmed carcinoma of the breast', ' Patients with advanced/metastatic disease that is not amenable to curative therapy (either surgery or radiation therapy)', ' Patients must have measurable disease by the RECIST criteria, defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter (LD) by spiral computer tomography (CT) scan, or at least 20 mm by standard techniques; If the only measurable lesion is a lymph node, it must measure at least 20 mm in LD. If a single lesion is identified as the target lesion, a cytological or histological confirmation of breast carcinoma is required.', ' Patients must have had prior treatment with an anthracycline and a taxane (either sequential or in combination) and may have had prior treatment with other agents as well.', ' Patients must have progressed within six months of the last dose of chemotherapy, or experienced disease progression while receiving chemotherapy for advanced/metastatic disease.', ' Resolution of all chemotherapy or radiation-related toxicities to less than grade 1 severity', ' Age 18 years', ' Eastern Cooperative Oncology Group (ECOG) Performance Status (APPENDIX 4) of 0 or 1', ' Life expectancy of 3 months', ' Adequate renal function as evidenced by serum creatinine 1.5 mg/dL or calculated creatinine clearance 50 mL/minute (min) per the Cockcroft and Gault formula', ' Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) 1.5 x 10^9/L, hemoglobin 10.0 g/dL (a hemoglobin <10.0 g/dL would be acceptable if it can be corrected by growth factor or transfusion), and platelet count 100 x 10^9/L', ' Adequate liver function as evidenced by bilirubin 1.5 mg/dL and alkaline phosphatase, alanine transaminase (ALT), and aspartate transaminase (AST) 3 times the upper limits of normal (ULN) (in the case of liver metastases 5 x ULN)', ' Patients willing and able to complete the FACT-B questionnaire, Analgesic Diary, Pain VAS, and the tumor-related symptomatic assessment', ' Patients willing and able to comply with the study protocol for the duration of the study', ' A sample from the diagnostic biopsy (paraffin block) must be available', ' Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice', 'Exclusion Criteria:', ' Patients who have received chemotherapy, radiation, hormonal therapy, or Herceptin within 2 weeks of E7389 treatment start', ' Radiation therapy encompassing > 10% of marrow', ' Failure to recover from any chemotherapy related or other therapy related toxicity at study entry that is deemed to be clinically significant by the study investigator', ' Prior treatment with Mitomycin C or nitrosoureas', ' Prior high dose chemotherapy with hematopoietic stem cell rescue in the past two years', ' Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen', ' Active symptomatic brain metastasis; Patients with central Nervous System (CNS) metastasis are considered eligible if they have completed local therapy and discontinued from corticosteroids for at least two weeks before starting treatment with E7389', ' Patients with meningeal carcinomatosis', ' Patients who require therapeutic anti-coagulant therapy with Warfarin or related compounds; Mini dose warfarin for catheter related thrombosis prophylaxis is permitted', ' Women who are pregnant or breast-feeding; Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.', ' Severe /uncontrolled intercurrent illness/infection', ' Significant cardiovascular impairment (history of congestive heart failure > NYHA grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia)', ' Patients with organ allografts', ' Patients with known positive HIV status', ' Patients who have had a prior malignancy, other than carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated 5 years previously with no subsequent evidence of recurrence', ' Patients with pre-existing neuropathy > Grade 1', ' Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative', ' Patients who participated in a prior E7389 clinical trial', " Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study"], 'Results': ['Outcome Measurement: ', ' Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST)', ' Defined as the percentage of subjects with CR or PR from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions).', ' Time frame: Confirmed 4 to 8 weeks after first observed', 'Results 1: ', ' Arm/Group Title: E7389 28 Day Schedule', ' Arm/Group Description: E7389 1.4 mg/m^2 intravenous bolus on Days 1, 8 and 15 of a 28 day cycle.', ' Overall Number of Participants Analyzed: 59', ' Measure Type: Number', ' Unit of Measure: percentage of participants Complete Response:: 0', ' Partial Response: 10.2', 'Results 2: ', ' Arm/Group Title: E7389 21 Day Schedule', ' Arm/Group Description: E7389 1.4 mg/m^2 intravenous bolus on Days 1 and 8 of a 21 day cycle.', ' Overall Number of Participants Analyzed: 28', ' Measure Type: Number', ' Unit of Measure: percentage of participants Complete Response:: 0', ' Partial Response: 14.3'], 'Adverse Events': ['Adverse Events 1:', ' Total: 23/70 (32.86%)', ' Febrile Neutropenia2/70 (2.86%)', ' Neutropenia1/70 (1.43%)', ' Thrombocytopenia1/70 (1.43%)', ' Inner Ear Disorder1/70 (1.43%)', ' Abdominal Pain1/70 (1.43%)', ' Abdominal Pain Upper1/70 (1.43%)', ' Ascites1/70 (1.43%)', ' Diarrhea1/70 (1.43%)', ' Gastrointestinal Hemorrhage0/70 (0.00%)', ' Nausea1/70 (1.43%)', ' Small Intestinal Obstruction1/70 (1.43%)', ' Vomiting1/70 (1.43%)', 'Adverse Events 2:', ' Total: 18/33 (54.55%)', ' Febrile Neutropenia1/33 (3.03%)', ' Neutropenia0/33 (0.00%)', ' Thrombocytopenia0/33 (0.00%)', ' Inner Ear Disorder0/33 (0.00%)', ' Abdominal Pain1/33 (3.03%)', ' Abdominal Pain Upper0/33 (0.00%)', ' Ascites0/33 (0.00%)', ' Diarrhea0/33 (0.00%)', ' Gastrointestinal Hemorrhage1/33 (3.03%)', ' Nausea0/33 (0.00%)', ' Small Intestinal Obstruction0/33 (0.00%)', ' Vomiting0/33 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
8154bd8c-90a2-4b2f-8090-fcc89aeae30c
|
|
Single
|
Results
|
NCT02657889
|
the primary trial indicates that varying Pembrolizumab dosage has no effect on the Number of Subjects Reporting Dose-Limiting Toxicities (DLTs).
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] |
[] |
{'Clinical Trial ID': 'NCT02657889', 'Intervention': ['INTERVENTION 1: ', ' Phase 1: Niraparib 200mg + Pembrolizumab', ' Niraparib 200 mg/day orally (PO). Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.', 'INTERVENTION 2: ', ' Phase 1: Niraparib 300mg + Pembrolizumab', ' Niraparib 300 mg/day orally (PO). Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.'], 'Eligibility': ['Main Inclusion Criteria:', ' Patient has histologically proven advanced (unresectable) or metastatic cancer as outlined below according to study phase and disease type:', ' Phase 1 patients (breast or ovarian cancer)', ' Patients with advanced or metastatic breast cancer must have disease that is HER2-negative, estrogen receptor-negative, and progesterone receptor-negative (ie, TNBC). Patients with advanced or metastatic disease may have up to 4 lines of cytotoxic therapy. Neoadjuvant and adjuvant therapies are not counted towards lines of therapy.', " Patients must have any epithelial (ie, serous, endometroid, mucinous, clear cell) ovarian, fallopian tube, or primary peritoneal cancer. Patients must have experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered to have platinum-resistant disease per investigator's assessment (e.g, patient is not eligible for further platinum containing treatment). Patients may have received up to 5 lines of cytotoxic therapy for advanced or metastatic cancer. Neoadjuvant and adjuvant therapies are not counted towards lines of therapy.", ' Phase 2 patients (breast or ovarian cancer)', ' Patients with advanced or metastatic breast cancer must have TNBC. Patients with advanced or metastatic disease may have received up to 2 lines of cytotoxic therapy. Adjuvant and/or neoadjuvant therapies are not counted in the number of lines of therapy. TNBC patients who have previously received platinum chemotherapy in the metastatic setting are allowed to enroll in the study as long as they did not progress while on or within 8 weeks from the day of the last platinum administration.', " Patients must have with high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer. Patients must have experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered to have platinum-resistant disease per investigator's assessment (e.g, patient is not eligible for further platinum containing treatment). Patients may have had up to 4 lines of cytotoxic therapy for advanced or metastatic cancer. Neoadjuvant, adjuvant, and the combination of both will be considered as one line of therapy.", ' Archival tumor tissue available or a fresh biopsy must be obtained prior to study treatment initiation', ' Measurable lesions by RECIST v1.1', ' Eastern Cooperative Oncology Group (ECOG) 0 or 1', ' Adequate organ function', ' Able to take oral medications', ' Female patient, if of childbearing potential, has a negative serum pregnancy test within 72 hours of taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment', ' Male patient agrees to use an adequate method of contraception', ' Main Exclusion Criteria:', ' Patients with primary platinum refractory ovarian cancer (ie, progressive disease on or within 6 months of first-line platinum therapy)', ' Known active central nervous system (CNS) metastases and/or carcinomatous meningitis Note: Patients previously treated for brain metastases may be able to participate provided they are stable', ' Patient has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer', ' Poor medical risk', " Condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.", ' Pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study', ' Immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment', ' Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)', ' Known active hepatitis B or hepatitis C', ' Active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment', ' Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent', ' Prior treatment with a known poly(ADP-ribose) polymerase (PARP) inhibitor', ' Heart-rate corrected QT interval (QTc) prolongation > 470 msec at screening', ' Known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)'], 'Results': ['Outcome Measurement: ', ' Phase 1: Number of Subjects Reporting Dose-Limiting Toxicities (DLTs)', ' DLTs are defined as: Any treatment-related Grade 3 non-hematologic clinical (non-laboratory) AE Any treatment-related Grade 3 or Grade 4 non-hematologic lab abnormality if: - Medical intervention is required to treat the patient, or - The abnormality leads to hospitalization, or - The abnormality persists for 7 days. Any treatment-related hematologic toxicity specifically defined as: - Thrombocytopenia Grade 4 for 7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion; - Neutropenia Grade 4 for 7 days, or Grade 3 or 4 associated with infection or febrile neutropenia; - Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion. Any treatment-related AE leading to niraparib dose interruption per the following criteria: - A dose interruption for a non-DLT lab abnormality lasting 14 days. - A dose in interruption per dose modification rules for nonhematologic AE leading to < 80% of an intended dose being administered.', ' Time frame: During Cycle 1, ie, during the first 21 days of treatment', 'Results 1: ', ' Arm/Group Title: Phase 1: Niraparib 200mg + Pembrolizumab', ' Arm/Group Description: Niraparib 200 mg/day orally (PO). Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 1 16.7%', 'Results 2: ', ' Arm/Group Title: Phase 1: Niraparib 300mg + Pembrolizumab', ' Arm/Group Description: Niraparib 300 mg/day orally (PO). Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 1 16.7%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/7 (85.71%)', ' Anemia * 1/7 (14.29%)', ' Febrile neutropenia * 0/7 (0.00%)', ' Leukopenia * 0/7 (0.00%)', ' Neutropenia * 1/7 (14.29%)', ' Pancytopenia * 0/7 (0.00%)', ' Thrombocytopenia * 1/7 (14.29%)', ' Cardiac failure congestive * 0/7 (0.00%)', ' Cardiac tamponade * 0/7 (0.00%)', ' Pericardial effusion * 0/7 (0.00%)', ' Tachycardia * 0/7 (0.00%)', ' Adrenal insufficiency * 0/7 (0.00%)', 'Adverse Events 2:', ' Total: 4/7 (57.14%)', ' Anemia * 0/7 (0.00%)', ' Febrile neutropenia * 0/7 (0.00%)', ' Leukopenia * 0/7 (0.00%)', ' Neutropenia * 0/7 (0.00%)', ' Pancytopenia * 1/7 (14.29%)', ' Thrombocytopenia * 3/7 (42.86%)', ' Cardiac failure congestive * 0/7 (0.00%)', ' Cardiac tamponade * 0/7 (0.00%)', ' Pericardial effusion * 0/7 (0.00%)', ' Tachycardia * 0/7 (0.00%)', ' Adrenal insufficiency * 0/7 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
537781f9-3693-479e-af22-824cdd827b9c
|
|
Single
|
Adverse Events
|
NCT02748213
|
2 patients, in cohort 1 of the primary trial was recorded as having an overactive pituitary gland.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] |
[] |
{'Clinical Trial ID': 'NCT02748213', 'Intervention': ['INTERVENTION 1: ', ' Herceptin + Taxotere + Xeloda', ' Participants received triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal. Herceptin and Taxotere were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 75 mg/m^2, with adjustments allowed only for toxicity. Xeloda was given orally as 950 mg/m^2 twice a day on Days 1 to 14 of each 21-day cycle, with adjustments allowed only for toxicity.', 'INTERVENTION 2: ', ' Herceptin + Taxotere', ' Participants received dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal. Treatments were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 100 mg/m^2, with adjustments allowed only for toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed, HER2-positive advanced and/or metastatic breast cancer not amenable to curative therapy', ' At least one measurable lesion according to RECIST', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Baseline left ventricular ejection fraction (LVEF) at least 50%', 'Exclusion Criteria:', ' Pregnant, lactating, or women of childbearing potential who are not surgically sterile or not willing to use adequate contraceptive methods', ' Previous treatment with Herceptin or other anti-HER therapies, or any previous chemotherapy for advanced or metastatic disease', ' Past medical history significant for any cardiac or central nervous system (CNS) disorders', ' Poor hematologic, renal, or hepatic function', ' Chronic corticosteroid therapy'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST)', ' Tumor response was assessed by RECIST during the study. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. PR was defined as greater than or equal to ( ) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed 4 weeks after the initial assessment of CR or PR. The percentage of participants with a best overall response for CR or PR was reported. The exact 95% confidence interval (CI) for one-sample binomial was determined using the Pearson-Clopper method.', ' Time frame: Tumor assessments at Baseline, then every 6 weeks until Cycle 8 (cycle length of 21 days), then every 12 weeks until progressive disease and/or one year after enrollment; thereafter according to routine clinical practice (up to 66 months overall)', 'Results 1: ', ' Arm/Group Title: Herceptin + Taxotere + Xeloda', ' Arm/Group Description: Participants received triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal. Herceptin and Taxotere were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 75 mg/m^2, with adjustments allowed only for toxicity. Xeloda was given orally as 950 mg/m^2 twice a day on Days 1 to 14 of each 21-day cycle, with adjustments allowed only for toxicity.', ' Overall Number of Participants Analyzed: 112', ' Measure Type: Number', ' Unit of Measure: percentage of participants 70.5 (61.18 to 78.77)', 'Results 2: ', ' Arm/Group Title: Herceptin + Taxotere', ' Arm/Group Description: Participants received dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal. Treatments were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 100 mg/m^2, with adjustments allowed only for toxicity.', ' Overall Number of Participants Analyzed: 110', ' Measure Type: Number', ' Unit of Measure: percentage of participants 72.7 (63.41 to 80.78)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 52/112 (46.43%)', ' Febrile neutropenia * 16/112 (14.29%)', ' Neutropenia * 7/112 (6.25%)', ' Anaemia * 1/112 (0.89%)', ' Cardiac failure * 1/112 (0.89%)', ' Coronary artery disease * 1/112 (0.89%)', ' Left ventricular dysfunction * 1/112 (0.89%)', ' Pericardial effusion * 0/112 (0.00%)', ' Hyperthyroidism * 1/112 (0.89%)', ' Diarrhoea * 5/112 (4.46%)', ' Vomiting * 3/112 (2.68%)', 'Adverse Events 2:', ' Total: 51/110 (46.36%)', ' Febrile neutropenia * 26/110 (23.64%)', ' Neutropenia * 7/110 (6.36%)', ' Anaemia * 1/110 (0.91%)', ' Cardiac failure * 0/110 (0.00%)', ' Coronary artery disease * 0/110 (0.00%)', ' Left ventricular dysfunction * 0/110 (0.00%)', ' Pericardial effusion * 1/110 (0.91%)', ' Hyperthyroidism * 0/110 (0.00%)', ' Diarrhoea * 0/110 (0.00%)', ' Vomiting * 1/110 (0.91%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
5feefe8b-ddca-4eb8-af68-d1e211963d1f
|
|
Single
|
Intervention
|
NCT00956813
|
All the primary trial subjects are required to take the intervention tablet PO daily.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5
] |
[] |
{'Clinical Trial ID': 'NCT00956813', 'Intervention': ['INTERVENTION 1: ', ' Flaxseed', ' Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans,once daily.', 'INTERVENTION 2: ', ' Placebo', ' Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily.'], 'Eligibility': ['Bothersome hot flashes, defined by their occurrence 28 times per week and of sufficient severity to make the patient desire therapeutic intervention', ' Presence of hot flashes for 1 month', ' Meets 1 of the following criteria:', ' History of breast cancer or other cancer (currently without malignant disease)', ' No history of breast cancer and wishes to avoid estrogen due to a perceived increased risk of breast cancer', ' Hormone receptor status not specified', ' Postmenopausal as defined by 1 of the following*:', ' NOTE: *Women with 1 ovary but without a uterus should be deemed postmenopausal by either age > 55 OR a combination of estrogen within a postmenopausal range (per local lab) and follicle-stimulating hormone > 40 mIU/mL', ' Absence of a period in the past 12 months', ' Bilateral oophorectomy', ' ECOG performance status 0-1', ' Life expectancy 6 months', ' Able to complete questionnaire(s) alone or with assistance', ' No diabetes requiring oral or injectable antihyperglycemics', ' No hypotension', ' No history of allergic or other adverse reaction to flaxseed', ' No irritable bowel syndrome, colitis, Crohn disease, or any gastrointestinal condition where the patient should not consume and/or has an intolerance/allergies to seeds or nuts', ' At least 4 weeks since prior and no concurrent or planned androgens, estrogens, or progestational agents', ' Tamoxifen, raloxifene, or aromatase inhibitors are allowed provided the patient has been on a constant dose for 4 weeks and is not expected to stop the medication during study treatment', ' At least 4 weeks since prior and no concurrent anti-cancer therapies of any kind', ' Trastuzumab allowed', ' No concurrent treatment with other anti-cancer therapies of any kind except for trastuzumab or endocrine therapies', ' No concurrent ( 7 days prior to registration) or planned use of other agents for treating hot flashes (i.e., gabapentin, clonidine, antidepressants, estrogen treatment, megestrol acetate, or Bellergal)', ' Stable dose of vitamin E (as a general vitamin supplement) allowed provided it is 800 IU/day, it was started > 30 days before study initiation, and is to be continued through study period', ' Patients who have been using antidepressants for mood and have been on a stable dose for over a month and meet the eligibility criteria for hot flash frequency and duration are eligible', ' No concurrent anticoagulants or anti-platelets (1 mg of Coumadin for central line patency allowed)', ' Aspirin allowed ( 81 mg)', ' No concurrent anti-hypertensives', ' No other concurrent herbal supplements for any reason, including soy and soy supplements (i.e., powders, pills, or milk)'], 'Results': ['Outcome Measurement: ', ' To Evaluate the Efficacy of Flaxseed on Hot Flash Scores in Women as Measured by a Daily Prospective Hot Flash Diary.', ' The intra-patient difference in hot flash activity between baseline (study week 1) and treatment termination (study week 7) is the primary endpoint. The hot flash activity will be measured by the weekly average hot flash score which is a composite entity of both frequency and severity of hot flashes.', ' The hot flash severities are graded from 1 to 4, ranging from mild, to moderate, to severe to very severe. The daily hot flash score is computed by multiplying the mean grade of severity by the frequency during every 24 hour period. Therefore, a score of zero is the lowest possible score and can be interpreted as having no hot flashes. The average daily hot flash score during the baseline week was compared to the average daily value during week 7.', ' The primary method of analysis will be the independent sample t-test to examine the change of weekly average hot flash score from baseline to treatment termination between flaxseed and placebo arms.', ' Time frame: Baseline and 7 weeks', 'Results 1: ', ' Arm/Group Title: Flaxseed', ' Arm/Group Description: Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans,once daily.', ' Overall Number of Participants Analyzed: 69', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale -4.9 (6.41)', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily.', ' Overall Number of Participants Analyzed: 77', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale -3.5 (6.47)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/101 (0.00%)', 'Adverse Events 2:', ' Total: ']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
2a5d8ca7-1608-4607-b996-490fc447b593
|
|
Single
|
Adverse Events
|
NCT00258960
|
4 patients in the primary trial experienced a grade 3 or above adverse event.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8
] |
[] |
{'Clinical Trial ID': 'NCT00258960', 'Intervention': ['INTERVENTION 1: ', ' Caelyx,Cyclophosphamide,Trastuzumab', ' Caelyx (Liposomal Doxorubicin) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab weekly for 24 weeks, at dose of 2mg/kg (day 1 loading dose of 4mg/kg)', ' Liposomal Doxorubicin', ' Cyclophosphamide', 'Trastuzumab'], 'Eligibility': ['Inclusion Criteria:', ' Patients must sign an informed consent before of specific procedures of clinical trial.', ' Patients with histologically confirmed breast cancer and overexpression of Her2neu.', ' Age> 18 years.', ' Eastern Cooperative Oncology Group (ECOG) equal or < 2.', ' Patients have not been treated previously with chemotherapy for metastatic disease.', ' Patients must have at least one measurable lesion according to RECIST criteria.', ' Patients should have an adequate organ function to tolerate chemotherapy.', 'Exclusion Criteria:', ' Patients with hypersensitivity reactions to any of the medications of the clinical trial.', ' Patients who are pregnant or lactating are not eligible.', ' Hepatic disease.', ' Not controlled active infection', ' Symptomatic metastatic brain cancer', ' Previous adjuvant treatment with anthracyclines with a total accumulated dose > 300 mg/m2 (Doxorubicin) or > 600 mg/m2 (Epirubicin)'], 'Results': ['Outcome Measurement: ', ' Objective Response Rate (ORR)', ' ORR is the sum of the Complete Responses (CR) and Partial Responses (PR) according to the RECIST criteria, experienced for each patient during treatment (recorded from the start of the treatment until disease progression). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan (computed tomography) or MRI (magnetic resonance imaging): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response Rate (ORR) = CR + PR.', ' Time frame: Up to cycle 6 (24 weeks)', 'Results 1: ', ' Arm/Group Title: Caelyx,Cyclophosphamide,Trastuzumab', ' Arm/Group Description: Caelyx (Liposomal Doxorubicin) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab weekly for 24 weeks, at dose of 2mg/kg (day 1 loading dose of 4mg/kg)', ' Liposomal Doxorubicin', ' Cyclophosphamide', ' Trastuzumab', ' Overall Number of Participants Analyzed: 48', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 33 68.8%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 16/48 (33.33%)', ' Febrile neutropenia grade 3 3/48 (6.25%)', ' Neutropenia grade 3 1/48 (2.08%)', ' Holocraneal cephalea 1/48 (2.08%)', ' Hypersensibility reaction grade 3 2/48 (4.17%)', ' Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%)', ' Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%)', ' Catheter - related infection grade 3 1/48 (2.08%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
178c50cc-49ee-4083-bc8e-b5832037498a
|
|
Comparison
|
Adverse Events
|
NCT01026142
|
NCT00846027
|
There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial.
|
Contradiction
|
[
0,
7,
12,
19
] |
[
0,
4
] |
{'Clinical Trial ID': 'NCT01026142', 'Intervention': ['INTERVENTION 1: ', ' A: Capecitabine + Trastuzumab', ' Capecitabine [Xeloda]: 1250 mg/m2 po twice daily for 14 days every 3 weeks. Trastuzumab [Herceptin]: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks.', 'INTERVENTION 2: ', ' B: Capecitabine + Trastuzumab + Pertuzumab', ' Capecitabine [Xeloda]: 1000 mg/m2 po twice daily for 14 days every 3 weeks. Pertuzumab [Perjeta]: 840 mg iv loading, then 420 mg iv every 3 weeks. Trastuzumab [Herceptin]: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' Adult female patients >/=18 years of age', ' Metastatic HER2 positive breast cancer', ' Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1', ' Disease progression during or following trastuzumab-based therapy for 1st line metastatic breast cancer (trastuzumab must have been part of the last prior treatment regimen)', ' Prior treatment with taxane-containing regimen', ' Left ventricular ejection fraction (LVEF) >/=50 percent', ' For women of childbearing potential agreement to use highly effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by patient and/or partner. Contraception must continue for duration of study treatment and for at least 6 months after last dose of study drug treatment', 'Exclusion Criteria:', ' Prior treatment with pertuzumab or capecitabine', ' Concurrent treatment with other experimental drug', ' Concurrent immunotherapy or anticancer hormonal therapy', ' Serious concurrent disease (e.g. active infection, uncontrolled hypertension, cardiovascular disease)', ' Central nervous system (CNS) metastases, which are not well controlled', ' History of exposure to anthracycline cumulative dose equivalent to 360mg/m2', ' History of congestive heart failure of any New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment', ' History of myocardial infarction within 6 months prior to randomization', ' History of LVEF decline to below 50% during or after prior trastuzumab therapy or other cardiac toxicity during previous trastuzumab treatment that necessitated discontinuation of trastuzumab', ' History of another cancer which could affect compliance or result interpretation', ' Inadequate organ function', ' Pregnant or breastfeeding women', ' life expectancy < 12 weeks'], 'Results': ['Outcome Measurement: ', ' Progression Free Survival (Independent Assessment)', ' Progression Free Survival (PFS) was defined as the time from randomization to first documented disease progression (PD), as determined by an Independent Review Facility (IRF) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. IRF review of tumor assessment ceased after the primary PFS analysis. The primary endpoint was analyzed after approximately 337 IRF-assessed PFS events were observed.', ' Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).', 'Results 1: ', ' Arm/Group Title: A: Capecitabine + Trastuzumab', ' Arm/Group Description: Capecitabine [Xeloda]: 1250 mg/m2 po twice daily for 14 days every 3 weeks. Trastuzumab [Herceptin]: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks.', ' Overall Number of Participants Analyzed: 224', ' Median (95% Confidence Interval)', ' Unit of Measure: months 9.0 (8 to 10)', 'Results 2: ', ' Arm/Group Title: B: Capecitabine + Trastuzumab + Pertuzumab', ' Arm/Group Description: Capecitabine [Xeloda]: 1000 mg/m2 po twice daily for 14 days every 3 weeks. Pertuzumab [Perjeta]: 840 mg iv loading, then 420 mg iv every 3 weeks. Trastuzumab [Herceptin]: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks.', ' Overall Number of Participants Analyzed: 228', ' Median (95% Confidence Interval)', ' Unit of Measure: months 11.1 (9 to 13)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 53/218 (24.31%)', ' Febrile Neutropenia 2/218 (0.92%)', ' Neutropenia 2/218 (0.92%)', ' Anaemia 1/218 (0.46%)', ' Thrombocytopenia 1/218 (0.46%)', ' Pancytopenia 0/218 (0.00%)', ' Left Ventricular Dysfunction 4/218 (1.83%)', ' Atrial Fibrillation 0/218 (0.00%)', ' Angina Unstable 0/218 (0.00%)', ' Arteriospasm Coronary 1/218 (0.46%)', ' Cardiac Arrest 1/218 (0.46%)', 'Adverse Events 2:', ' Total: 58/228 (25.44%)', ' Febrile Neutropenia 1/228 (0.44%)', ' Neutropenia 1/228 (0.44%)', ' Anaemia 0/228 (0.00%)', ' Thrombocytopenia 1/228 (0.44%)', ' Pancytopenia 1/228 (0.44%)', ' Left Ventricular Dysfunction 13/228 (5.70%)', ' Atrial Fibrillation 2/228 (0.88%)', ' Angina Unstable 1/228 (0.44%)', ' Arteriospasm Coronary 0/228 (0.00%)', ' Cardiac Arrest 0/228 (0.00%)']}
|
{'Clinical Trial ID': 'NCT00846027', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab + Paclitaxel + Gemcitabine', ' Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.'], 'Eligibility': ['Inclusion Criteria:', ' Female patients, 18 years of age.', ' Breast cancer, with measurable, locally recurrent or metastatic lesions, or patients with bone metastasis only.', ' HER-2 negative disease.', ' Candidates for chemotherapy.', ' Eastern Cooperative Oncology Group (ECOG) performance status 2.', 'Exclusion Criteria:', ' Previous chemotherapy for metastatic or locally advanced breast cancer.', ' Previous radiotherapy for treatment of metastatic breast cancer.', ' Any prior adjuvant treatment with anthracyclines completed < 6 months prior to enrollment.', ' Chronic daily treatment with corticosteroids ( 10 mg/day), aspirin (> 325 mg/day) or clopidogrel (> 75mg/day).'], 'Results': ['Outcome Measurement: ', ' Progression-free Survival', ' Progression-free survival was defined as the time from enrollment in the study to the first documented disease progression using Response Evaluation Criteria In Solid Tumors (RECIST) or death from any cause, whichever occurred first.', ' Time frame: Baseline to the end of the study (up to 2 years 10 months)', 'Results 1: ', ' Arm/Group Title: Bevacizumab + Paclitaxel + Gemcitabine', ' Arm/Group Description: Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.', ' Overall Number of Participants Analyzed: 90', ' Median (95% Confidence Interval)', ' Unit of Measure: Months 11.51 (9.01 to 17.59)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 21/82 (25.61%)', ' Neutrophils count decreased 1/82 (1.22%)', ' Cardiac ischemia/infarction 1/82 (1.22%)', ' Left ventricular systolic dysfunction 1/82 (1.22%)', ' Hypertension 1/82 (1.22%)', ' Supraventricular and nodal arrhythmia 1/82 (1.22%)', ' Anorexia 1/82 (1.22%)', ' Gastrointestinal perforation 1/82 (1.22%)', ' Vomiting 1/82 (1.22%)', ' Dehydration 1/82 (1.22%)', ' Diarrhoea 1/82 (1.22%)']}
|
92ace4fa-4426-4f34-af52-ee62913e60aa
|
Single
|
Results
|
NCT01823107
|
At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] |
[] |
{'Clinical Trial ID': 'NCT01823107', 'Intervention': ['INTERVENTION 1: ', ' Meso BioMatrix Acellular Peritoneum Matrix', ' All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction. After tissue expansion, the tissue expander was replaced with a breast implant during the second stage of reconstruction.'], 'Eligibility': ['Inclusion Criteria:', ' Non-smoker', ' Undergoing unilateral or bilateral, two-stage, tissue expander-assisted breast reconstruction', ' Life expectancy greater than 18 months', ' Agreement to return for the trial required follow-up visits', 'Exclusion Criteria:', ' Body mass index 35', ' Prior reconstructive breast surgery, breast augmentation, mastopexy or reduction mammoplasty', ' History of chronic corticosteroid use', ' Type I Diabetes', ' History of radiation therapy to the chest', ' Pre-operative treatment with induction chemotherapy for breast cancer', ' Pregnancy', ' Participating in another investigational drug or device trial that has not completed the follow-up period'], 'Results': ['Outcome Measurement: ', ' Rate of Breast Related Adverse Events', ' Investigators evaluated each subject and each reconstructed breast for the occurrence of an adverse event from the first stage of reconstruction through the final follow-up visit. A breast related adverse event was defined as any untoward medical occurrence related to a reconstructed breast.', ' Time frame: 18 months', 'Results 1: ', ' Arm/Group Title: Meso BioMatrix Acellular Peritoneum Matrix', ' Arm/Group Description: All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction. After tissue expansion, the tissue expander was replaced with a breast implant during the second stage of reconstruction.', ' Overall Number of Participants Analyzed: 25', ' Overall Number of Units Analyzed', ' Type of Units Analyzed: Reconstructed breasts Measure Type: NumberUnit of Measure: Reconstructed breasts affected: 12'], 'Adverse Events': ['Adverse Events 1:', ' Total: 7/25 (28.00%)', ' Hematoma 1/25 (4.00%)', ' Fever 1/25 (4.00%)', ' Seroma 1/25 (4.00%)', ' Wound dehiscence 4/25 (16.00%)', ' Skin flap necrosis 1/25 (4.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
7dbde84d-f1c9-4197-9d44-500fd337bebd
|
|
Single
|
Adverse Events
|
NCT02340221
|
A total of 89 patients in the primary trial had Supraventricular tachycardia.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] |
[] |
{'Clinical Trial ID': 'NCT02340221', 'Intervention': ['INTERVENTION 1: ', ' Placebo+Fulvestrant', ' Participants received placebo taken orally QD beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.', 'INTERVENTION 2: ', ' Taselisib+Fulvestrant', ' Participants received taselisib 4 mg taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women with histologically or cytologically confirmed locally advanced or metastatic estrogen receptor (ER) positive breast cancer', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Participants for whom endocrine therapy (example [e.g.], fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study', ' Radiologic/objective evidence of recurrence or progression to the most recent systemic therapy for breast cancer', ' Radiologic/objective evidence of breast cancer recurrence or progression while on or within 12 months of the end of adjuvant treatment with an aromatase inhibitor (AI), or progression while on or within 1 month of the end of prior AI treatment for locally advanced or metastatic breast cancer', ' Measurable disease via Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) or non-measurable, evaluable disease with at least one evaluable bone lesion via RECIST v1.1', ' Consent to provide a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block (preferred) or a minimum of 20 (25 preferred) freshly cut unstained tumor slides from the most recently collected, available tumor tissue for oncogene that encodes for phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA)-mutation testing', ' A valid cobas PIK3CA mutation result by central testing is required', ' Adequate hematologic and end-organ function within 28 days prior to treatment initiation', 'Exclusion Criteria:', ' Human epidermal growth factor receptor 2 (HER2)-positive disease by local laboratory testing (immunohistochemistry 3 positive [IHC 3+] staining or in situ hybridization positive)', ' Prior treatment with fulvestrant', ' Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, mammalian target of rapamycin (mTOR) inhibitor (e.g. everolimus), or protein kinase B (AKT) inhibitor', ' Prior anti-cancer therapy within 2 weeks prior to Day 1 of Cycle 1', ' Prior radiation therapy within 2 weeks prior to Day 1 of Cycle 1', ' All acute treatment-related toxicity must have resolved to Grade less than or equal to (</=) 1 or be deemed stable by the Investigator', ' Prior treatment with greater than (>) 1 cytotoxic chemotherapy regimen for metastatic breast cancer', ' Concurrent hormone replacement therapy', ' Known untreated or active central nervous system (CNS) metastases', ' Type 1 or Type 2 diabetes mellitus requiring anti-hyperglycemic medications', ' History of inflammatory bowel disease or active bowel inflammation', ' Clinically significant cardiac or pulmonary dysfunction', ' Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B or C virus'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)', ' PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression.', ' Time frame: From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)', 'Results 1: ', ' Arm/Group Title: Placebo+Fulvestrant', ' Arm/Group Description: Participants received placebo taken orally QD beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.', ' Overall Number of Participants Analyzed: 176', ' Median (95% Confidence Interval)', ' Unit of Measure: months 5.39 (3.68 to 7.29)', 'Results 2: ', ' Arm/Group Title: Taselisib+Fulvestrant', ' Arm/Group Description: Participants received taselisib 4 mg taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.', ' Overall Number of Participants Analyzed: 340', ' Median (95% Confidence Interval)', ' Unit of Measure: months 7.43 (7.26 to 9.07)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 19/213 (8.92%)', ' Pancytopenia 0/213 (0.00%)', ' Anaemia 1/213 (0.47%)', ' Atrial fibrillation 0/213 (0.00%)', ' Cardiac failure congestive 0/213 (0.00%)', ' Myocardial infarction 0/213 (0.00%)', ' Supraventricular tachycardia 0/213 (0.00%)', ' Diarrhoea 0/213 (0.00%)', ' Colitis 0/213 (0.00%)', ' Vomiting 1/213 (0.47%)', ' Nausea 1/213 (0.47%)', ' Enterocolitis 0/213 (0.00%)', 'Adverse Events 2:', ' Total: 133/416 (31.97%)', ' Pancytopenia 1/416 (0.24%)', ' Anaemia 0/416 (0.00%)', ' Atrial fibrillation 2/416 (0.48%)', ' Cardiac failure congestive 1/416 (0.24%)', ' Myocardial infarction 1/416 (0.24%)', ' Supraventricular tachycardia 1/416 (0.24%)', ' Diarrhoea 32/416 (7.69%)', ' Colitis 14/416 (3.37%)', ' Vomiting 4/416 (0.96%)', ' Nausea 3/416 (0.72%)', ' Enterocolitis 2/416 (0.48%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
824da29f-b2ff-440e-8b78-7a8291cbd6d2
|
|
Single
|
Adverse Events
|
NCT02748213
|
1 patient, in cohort 1 of the primary trial was recorded as having an overactive thyroid gland.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] |
[] |
{'Clinical Trial ID': 'NCT02748213', 'Intervention': ['INTERVENTION 1: ', ' Herceptin + Taxotere + Xeloda', ' Participants received triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal. Herceptin and Taxotere were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 75 mg/m^2, with adjustments allowed only for toxicity. Xeloda was given orally as 950 mg/m^2 twice a day on Days 1 to 14 of each 21-day cycle, with adjustments allowed only for toxicity.', 'INTERVENTION 2: ', ' Herceptin + Taxotere', ' Participants received dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal. Treatments were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 100 mg/m^2, with adjustments allowed only for toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed, HER2-positive advanced and/or metastatic breast cancer not amenable to curative therapy', ' At least one measurable lesion according to RECIST', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Baseline left ventricular ejection fraction (LVEF) at least 50%', 'Exclusion Criteria:', ' Pregnant, lactating, or women of childbearing potential who are not surgically sterile or not willing to use adequate contraceptive methods', ' Previous treatment with Herceptin or other anti-HER therapies, or any previous chemotherapy for advanced or metastatic disease', ' Past medical history significant for any cardiac or central nervous system (CNS) disorders', ' Poor hematologic, renal, or hepatic function', ' Chronic corticosteroid therapy'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST)', ' Tumor response was assessed by RECIST during the study. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. PR was defined as greater than or equal to ( ) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed 4 weeks after the initial assessment of CR or PR. The percentage of participants with a best overall response for CR or PR was reported. The exact 95% confidence interval (CI) for one-sample binomial was determined using the Pearson-Clopper method.', ' Time frame: Tumor assessments at Baseline, then every 6 weeks until Cycle 8 (cycle length of 21 days), then every 12 weeks until progressive disease and/or one year after enrollment; thereafter according to routine clinical practice (up to 66 months overall)', 'Results 1: ', ' Arm/Group Title: Herceptin + Taxotere + Xeloda', ' Arm/Group Description: Participants received triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal. Herceptin and Taxotere were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 75 mg/m^2, with adjustments allowed only for toxicity. Xeloda was given orally as 950 mg/m^2 twice a day on Days 1 to 14 of each 21-day cycle, with adjustments allowed only for toxicity.', ' Overall Number of Participants Analyzed: 112', ' Measure Type: Number', ' Unit of Measure: percentage of participants 70.5 (61.18 to 78.77)', 'Results 2: ', ' Arm/Group Title: Herceptin + Taxotere', ' Arm/Group Description: Participants received dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal. Treatments were given via IV infusion on Day 1 of each 21-day cycle. The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 through the end of treatment. The dose of Taxotere was 100 mg/m^2, with adjustments allowed only for toxicity.', ' Overall Number of Participants Analyzed: 110', ' Measure Type: Number', ' Unit of Measure: percentage of participants 72.7 (63.41 to 80.78)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 52/112 (46.43%)', ' Febrile neutropenia * 16/112 (14.29%)', ' Neutropenia * 7/112 (6.25%)', ' Anaemia * 1/112 (0.89%)', ' Cardiac failure * 1/112 (0.89%)', ' Coronary artery disease * 1/112 (0.89%)', ' Left ventricular dysfunction * 1/112 (0.89%)', ' Pericardial effusion * 0/112 (0.00%)', ' Hyperthyroidism * 1/112 (0.89%)', ' Diarrhoea * 5/112 (4.46%)', ' Vomiting * 3/112 (2.68%)', 'Adverse Events 2:', ' Total: 51/110 (46.36%)', ' Febrile neutropenia * 26/110 (23.64%)', ' Neutropenia * 7/110 (6.36%)', ' Anaemia * 1/110 (0.91%)', ' Cardiac failure * 0/110 (0.00%)', ' Coronary artery disease * 0/110 (0.00%)', ' Left ventricular dysfunction * 0/110 (0.00%)', ' Pericardial effusion * 1/110 (0.91%)', ' Hyperthyroidism * 0/110 (0.00%)', ' Diarrhoea * 0/110 (0.00%)', ' Vomiting * 1/110 (0.91%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1
|
|
Single
|
Adverse Events
|
NCT00244933
|
the primary trial does not monitor the occurrence of Hemoglobin C Disease in its adverse events.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] |
[] |
{'Clinical Trial ID': 'NCT00244933', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine & Genistein', ' Gemcitabine, genistein (Novasoy), Tumor biopsy Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically or cytologically confirmed breast cancer', ' Stage IV disease', ' Clinical and/or radiological evidence of metastatic disease', ' Measurable disease', ' Prior radiotherapy allowed provided there is 1 measurable disease site outside the radiation field', ' No active CNS metastases', ' Previously treated CNS metastases allowed provided disease is stable for 3 months without steroids or antiseizure medications', ' Hormone receptor status:', ' Not specified', ' PATIENT CHARACTERISTICS:', ' Sex', ' Female', ' Menopausal status', ' Not specified', ' Performance status', ' SWOG 0-2', ' Life expectancy', ' Not specified', ' Hematopoietic', ' Absolute neutrophil count 1,500/mm^3', ' Platelet count 100,000/mm^3', ' Hemoglobin 10 g/dL', ' Hepatic', ' Bilirubin 3.0 mg/dL', ' AST and ALT 2.5 times upper limit of normal', ' Renal', ' Creatinine 1.5 mg/dL', ' Other', ' Not pregnant or nursing', ' Fertile patients must use effective contraception', ' No serious systemic disorder that would preclude study compliance', ' No history of another malignancy except curatively treated carcinoma of the cervix or basal cell or squamous cell skin cancer in complete remission', ' No unresolved bacterial infection requiring antibiotic treatment', ' No known HIV-1 positivity', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' At least 3 weeks since prior biologic therapy', ' Chemotherapy', ' Prior adjuvant chemotherapy allowed', ' Prior adjuvant or neoadjuvant taxane-based therapy or taxane therapy for metastatic disease allowed', ' Patient must have failed therapy within 2 years after completion of treatment', ' At least 3 weeks since prior chemotherapy', ' No more than 2 prior cytotoxic chemotherapy regimens for metastatic disease', ' No prior gemcitabine hydrochloride', ' No other concurrent chemotherapy', ' Endocrine therapy', ' See Disease Characteristics', ' At least 2 weeks since prior and no concurrent hormonal therapy', ' Must have documented disease progression during prior hormonal therapy', ' Radiotherapy', ' See Disease Characteristics', ' At least 4 weeks since prior radiotherapy and recovered', ' No concurrent radiotherapy', ' Surgery', ' At least 3 weeks since prior surgery', ' Other', ' At least 3 weeks since prior investigational therapy', ' At least 1 week since prior soy supplements (e.g., soy-based pills, liquids, or concentrates)', ' Dietary soy as part of a meal (e.g., tofu) allowed once a week', ' No concurrent nutritional supplements, herbal agents, or high doses of antioxidants (e.g., vitamins C, D, or E) that may interact with, antagonize, alter, or imitate the potential effects of gemcitabine hydrochloride or genistein', ' A single daily multivitamin is allowed', ' No other concurrent immunotherapy', ' No other concurrent experimental medication', ' Concurrent anticoagulants, appetite stimulants, and replacement steroids allowed'], 'Results': ['Outcome Measurement: ', ' Objective Response Rate by RECIST Criteria Following', ' Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', ' Time frame: every 2 courses until disease progression or death, up to 24 weeks', 'Results 1: ', ' Arm/Group Title: Gemcitabine & Genistein', ' Arm/Group Description: Gemcitabine, genistein (Novasoy), Tumor biopsy Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.', ' Overall Number of Participants Analyzed: 17', ' Measure Type: Number', ' Unit of Measure: participants 0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/19 (26.32%)', ' Pain 3/19 (15.79%)', ' White blood cells (WBC) 5/19 (26.32%)', ' Hemoglobin (Hgb) 1/19 (5.26%)', ' Absolute neutrophil count (ANC) 5/19 (26.32%)', ' Platelets 3/19 (15.79%)', ' Elevated Aspartate Aminotransferase (AST) 1/19 (5.26%)', ' Elevated Alanine Aminotransferase (ALT) 1/19 (5.26%)', ' Dyspnea 3/19 (15.79%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
052ee533-7daa-4cbf-a64c-bc9a50444173
|
|
Single
|
Adverse Events
|
NCT00444587
|
A total of 7 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.
|
Entailment
|
[
3,
6,
8
] |
[] |
{'Clinical Trial ID': 'NCT00444587', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + 2nd Line Chemotherapy', ' Eligible participants were administered trastuzumab 6 mg/kg of body weight (except in Israel, where the dose was 2 mg/kg body weight), IV infusion, every three weeks until disease progression, unacceptable toxicities, or withdrawal from study in combination with second line chemotherapy.'], 'Eligibility': ['Inclusion Criteria:', ' female patients, >= 18 years of age;', ' metastatic breast cancer;', ' HER2 overexpression (IHC 3+ and/or FISH positive);', ' disease progression during or after previous 1st line chemotherapy + Herceptin;', ' scheduled to receive 2nd line chemotherapy.', 'Exclusion Criteria:', ' concurrent immunotherapy or hormonal therapy;', ' anthracyclines as part of previous 1st line chemotherapy or planned 2nd line chemotherapy;', ' cardiac toxicity during previous 1st line chemotherapy + Herceptin;', ' history of other malignancy within last 5 years.'], 'Results': ['Outcome Measurement: ', ' Median Time to Disease Progression', " Time to disease progression (TTP) in days was defined as the time from enrollment to objective disease progression (all categories other than objective disease progression was set to be censored including death before progression). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions. Tumor assessments were performed using computer tomography or magnetic resonance imaging. TTP as assessed by investigator, along with a recalculation done by computer algorithm is presented below. Median time was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.", ' Time frame: Up to 5 years', 'Results 1: ', ' Arm/Group Title: Trastuzumab + 2nd Line Chemotherapy', ' Arm/Group Description: Eligible participants were administered trastuzumab 6 mg/kg of body weight (except in Israel, where the dose was 2 mg/kg body weight), IV infusion, every three weeks until disease progression, unacceptable toxicities, or withdrawal from study in combination with second line chemotherapy.', ' Overall Number of Participants Analyzed: 73', ' Median (95% Confidence Interval)', ' Unit of Measure: Days By Computer (n = 65): 171 (136 to 322)', ' By Investigator (n = 73): 171 (136 to 265)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 20/93 (21.51%)', ' Granulocytosis 1/93 (1.08%)', ' Leukopenia 2/93 (2.15%)', ' Angina pectoris 0/93 (0.00%)', ' Atrial fibrillation 1/93 (1.08%)', ' Cardiopulmonary failure 2/93 (2.15%)', ' Retinal detachment 1/93 (1.08%)', ' Diarrhoea 3/93 (3.23%)', ' Nausea 1/93 (1.08%)', ' Vomiting 1/93 (1.08%)', ' Chest pain 1/93 (1.08%)', ' Death 0/93 (0.00%)', ' Pyrexia 1/93 (1.08%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
1d7dbb44-049d-4887-8bd6-6aefc77aa1e9
|
|
Single
|
Eligibility
|
NCT00571987
|
occupational exposure to ionizing irradiation will not disqualify a patient from entry to the primary trial.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26
] |
[] |
{'Clinical Trial ID': 'NCT00571987', 'Intervention': ['INTERVENTION 1: ', ' Margin Status', ' AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe): Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.'], 'Eligibility': ['Inclusion Criteria:', ' Female, 18-100 years old', ' Not pregnant or breastfeeding', ' Pre-study radiologic documentation of:', ' size 5 cm', ' unicentric, unilateral', ' suspicious mass or calcification', ' BIRADS classification IV', ' location of abnormality > 1 cm from skin', ' Ductal or Infiltrating Ductal Carcinoma', ' Grade I-III on final pathology', ' Good general health', ' Zubrod Performance Status of 0,1, or 2', ' No previous chemotherapy', ' No palpable axillary or supraclavicular lymph nodes', ' If prior non-breast malignancy, must have > 5 year disease-free survival', 'Exclusion Criteria:', ' Patient < 18 y/o or > 100 y/o', ' Pregnant or breastfeeding', ' Male', ' Breast implants', ' Multicentric disease or bilateral disease', ' Lesions > 5 cm in diameter', ' Lesions < 1.0 cm from the skin', ' Previous prior radiation to the breast', ' Need for mastectomy', ' Diffuse microcalcifications (as determined by the Investigator)'], 'Results': ['Outcome Measurement: ', ' Number of Patients Requiring 2nd Surgery for Close or Positive Margins', ' A "close" surgical margin implies that cancer cells are found on pathology to be very close to the surgical margin, and a "wide" surgical margin implies the tumor exists far from the cut edge or the surgical margin. For this study, we defined "close" as less than 3 mm.', ' Time frame: Margins assessed at Final Pathology, approximately 1 week post-RF surgery', 'Results 1: ', ' Arm/Group Title: Margin Status', ' Arm/Group Description: AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe): Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.', ' Overall Number of Participants Analyzed: 100', ' Measure Type: Number', ' Unit of Measure: participants 22'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/107 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
9b622b9b-3ad3-4cff-acb3-4127d0304de0
|
|
Comparison
|
Eligibility
|
NCT02673918
|
NCT01042938
|
African American patients are eligible for both the primary trial and the secondary trial.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] |
[
0,
4
] |
{'Clinical Trial ID': 'NCT02673918', 'Intervention': ['INTERVENTION 1: ', ' Part 1: Home-based Rehabilitation', ' Participants in part 1 and part 2 will receive home-based upper-body rehabilitation with online support: Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.', ' On average, participants will complete three rehabilitation exercises a minimum of 4 times weekly with an anticipated duration of approximately 20 minutes.', 'INTERVENTION 2: ', ' Part 2: Home-based Rehabilitation', ' Participants in both Part 1 and Part 2 received the same home-based upper-body rehabilitation with online support: Participants received written educational material, in which the physiotherapist marked the exercises specifically recommended for the individual patient. In addition, participants were provided with a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.', ' On average, participants were asked to complete three rehabilitation exercises a minimum of 4 times weekly with an anticipated duration of approximately 20 minutes.'], 'Eligibility': ['Inclusion Criteria:', ' Diagnosis of breast cancer', ' Part 1 only: Surgery for breast cancer within the past eight weeks (mastectomy or lumpectomy with either sentinel or axillar dissection), including those women with a history of previous surgery for breast cancer, radiation therapy or chemotherapy', ' Part 2 only: Completion of surgery and radiation therapy for breast cancer within the past six weeks.', ' Home access to internet from stationary computer, lab top or tablet', ' Ability to use internet', ' Ability to read and understand Danish', 'Exclusion Criteria:', ' Surgery for breast cancer with immediate breast reconstruction', ' Diagnosis of primary lymphedema', ' Metastatic or inflammatory breast cancer', ' Planned use of chemotherapy within the next 6 weeks', ' Surgical complications: infection, drainage issues, seroma, hematoma', ' Severe physical, cognitive, or psychiatric illness causing inability to follow the study protocol: i.e. severe depression, anxiety, dementia, poor physical health with likely possibility of hospitalization within the next twelve weeks.', ' Planned hospitalization or surgery within the next twelve weeks', ' Participation in another clinical trial with a rehabilitation or exercise intervention'], 'Results': ['Outcome Measurement: ', ' Recruitment Rate', ' This outcome represent the number and proportion (%) of eligible patients who consented to participate in the study. Recruitment was open for 10 weeks for participants in Part 1 and for 20 weeks for participants in Part 2.', ' Time frame: 10 weeks for part 1 and 20 weeks for part 2', 'Results 1: ', ' Arm/Group Title: Part 1: Home-based Rehabilitation', ' Arm/Group Description: Participants in part 1 and part 2 will receive home-based upper-body rehabilitation with online support: Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.', ' On average, participants will complete three rehabilitation exercises a minimum of 4 times weekly with an anticipated duration of approximately 20 minutes.', ' Overall Number of Participants Analyzed: 44', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 35 79.5%', 'Results 2: ', ' Arm/Group Title: Part 2: Home-based Rehabilitation', ' Arm/Group Description: Participants in both Part 1 and Part 2 received the same home-based upper-body rehabilitation with online support: Participants received written educational material, in which the physiotherapist marked the exercises specifically recommended for the individual patient. In addition, participants were provided with a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.', ' On average, participants were asked to complete three rehabilitation exercises a minimum of 4 times weekly with an anticipated duration of approximately 20 minutes.', ' Overall Number of Participants Analyzed: 28', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 24 85.7%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/35 (0.00%)', 'Adverse Events 2:', ' Total: 0/24 (0.00%)']}
|
{'Clinical Trial ID': 'NCT01042938', 'Intervention': ['INTERVENTION 1: ', ' Curcumin C3 Complex', ' Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks).', 'INTERVENTION 2: ', ' Placebo', ' Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT)(~4-7 weeks).'], 'Eligibility': ['Inclusion Criteria:', ' Female with a diagnosis of, non-inflammatory breast adenocarcinoma and be referred for post-operative radiotherapy without concurrent chemotherapy.', ' Participants must be at least 21 years of age.', ' Participants must not be pregnant.', ' Participants can be from any racial or ethnic origin.', ' Breast adenocarcinoma could have been treated by either lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment.', ' Participants with in situ breast cancer are eligible.', ' Participants who are prescribed concurrent hormone treatment with radiation treatment are eligible.', ' Participants must be scheduled to receive five sessions of radiation therapy per week (1 session per day) for at least four weeks using standard (1.8-2.0 Gy per session)or Canadian (2.2-2.5 Gy per session)irradiation fractionation.', ' A time period of three weeks must elapse after chemotherapy and surgery before beginning the study.', ' The total dose prescribed to the whole breast should be 50 Gy or greater.', ' Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English).', ' Participants must be able to swallow medication.', ' Topical skin agents, e.g., Aquaphor, Cetaphil, or other emollients, are allowed either PRN or prophylactically.', ' Participant must give informed consent.', 'Exclusion Criteria:', ' Patients with bilateral breast cancer are not eligible.', ' Patients who have had previous radiation therapy to the breast or chest are not eligible.', ' Patients who are prescribed chemotherapy concurrently with radiation treatment are not eligible.', ' Patients who will be receiving treatment with Herceptin (trastuzumab), anti-coagulants, or anti-human epidermal growth factor receptor (EGFR) drugs, e.g. Iressa (gefitinib), Erbitux (cetuximab, C225), concurrently with their radiation therapy are not eligible.', ' Patients cannot have had breast reconstructions, implants, and/or expanders.', ' Patients with known radiosensitivity syndromes (e.g., Ataxia-telangiectasia) are not eligible.', ' Patients with collagen vascular disease, vasculitis, unhealed surgical sites, or breast infections are not eligible.', ' Patients whose baseline blood tests meet the following criteria are not eligible: greater than or equal to Grade 2 change Hemoglobin (i.e., 25% decrease from baseline); greater than or equal to Grade 1 change in Platelets (i.e., less than 75,000/mm3); greater than or equal to Grade 2 change in PT and PTT(i.e., 1.5-2x upper level normal (ULN)); greater than or equal to Grade 1 change in AST, ALT (i.e., greater than 2.5x ULN); greater than or equal to Grade 1 change in Bilirubin (i.e., greater than 1.5x ULN); greater than or equal to Grade 1 change in Creatinine (i.e., greater than 2x ULN).'], 'Results': ['Outcome Measurement: ', ' Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients', ' The severity of radiation dermatitis was measured using the Radiation Dermatitis Severity (RDS)Scale which ranges from 0.0 to 4.0 with increments of 0.5. The RDS scale is a revised form of the NIH Common Toxicity Criteria to account for color and subtle texture changes in the skin. The worst dermatitis (i.e., highest RDS score) at the end of treatment was used for the primary analysis of severity of radiation dermatitis in each treatment group. Additionally, we performed repeated measure analyses to examine the severity of dermatitis over time in each arm.', ' Time frame: 4-7 weeks (prescribed course of radiation)', 'Results 1: ', ' Arm/Group Title: Curcumin C3 Complex', ' Arm/Group Description: Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks).', ' Overall Number of Participants Analyzed: 14', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 2.6 (0.994)', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT)(~4-7 weeks).', ' Overall Number of Participants Analyzed: 16', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 3.4 (0.554)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/14 (0.00%)', 'Adverse Events 2:', ' Total: 0/16 (0.00%)']}
|
825ba6fd-8c08-49d2-941b-3338ef01e7fd
|
Single
|
Eligibility
|
NCT01730729
|
Patients with severe malabsorption disorders are ineligible for the primary trial, even if they are able to receive intravenous (IV) alimentation.
|
Entailment
|
[
24,
31,
30
] |
[] |
{'Clinical Trial ID': 'NCT01730729', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Cabergoline)', ' Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.', ' cabergoline: Given orally'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically confirmed metastatic breast cancer; tissue (a minimum of 3 slides) from the most recent biopsy is required for review and confirmation of eligibility; NOTE: material should ideally be from the metastatic disease, however material from the primary tumor is acceptable if that is all that is available', ' Patients must have stage IV breast cancer', ' Patients must have tumors (primary or metastatic) that stain positively for the prolactin receptor', ' Patients may have measurable or evaluable disease', ' Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan', ' Evaluable disease is disease that does not meet the criteria for measurable disease; examples would include patients with effusions or bone-only disease', ' Women of childbearing potential must commit to the use of effective barrier (non-hormonal) contraception while on study', ' Patients must have a life expectancy of greater than 12 weeks', ' Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2', ' Patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment', ' Leukocytes >= 3,000/uL (microliter)', ' Absolute neutrophil count >= 1,500/uL', ' Platelets >= 100,000/uL', ' Child Pugh score =< 10', ' Patients must be able to swallow and retain oral medication', ' All patients must have given signed, informed consent prior to registration on study', 'Exclusion Criteria:', ' Women who are pregnant or lactating are not eligible for study treatment', ' Patients who are undergoing concomitant radiotherapy are NOT eligible for participation', ' Patients who are receiving any other investigational agents or concurrent anticancer therapy are NOT eligible for participation; previous systemic treatment is allowed with a 2 week washout period prior to registration', ' Patients who are taking any herbal (alternative) medicines are NOT eligible for participation; patients must be off any such medications by the time of registration', ' Patients who are receiving concomitant D2-antagonists (such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide) are NOT eligible for participation; patients must be off any such medications by the time of registration', ' Patients with known brain metastases are NOT eligible for participation', ' Patients with any of the following conditions or complications are NOT eligible for participation:', ' Uncontrolled hypertension', ' Known hypersensitivity to ergot derivatives', ' History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve (to be determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis)', ' History of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders', ' Gastrointestinal (GI) tract disease resulting in an inability to take oral medication', ' Malabsorption syndrome', ' Require intravenous (IV) alimentation', ' History of prior surgical procedures affecting absorption', " Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)"], 'Results': ['Outcome Measurement: ', ' Overall Response Rate (ORR) at 2 Months', ' Overall Response Rate (ORR) is defined as the number of patients that achieved Complete Response (CR) or Partial Response (PR) and will be assessed after 8 weeks (2 cycles) of therapy using CT scan images and RECIST guidelines.', ' Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LD.', ' Progressive Disease (PD): At least a 20% increase in the sum o the LD of target lesions, taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more new lesions.', ' Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of LD since the treatment started', ' Time frame: After 8 weeks (2 cycles) of treament', 'Results 1: ', ' Arm/Group Title: Treatment (Cabergoline)', ' Arm/Group Description: Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.', ' cabergoline: Given orally', ' Overall Number of Participants Analyzed: 18', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/20 (20.00%)', ' Death NOS 1/20 (5.00%)', ' Pain 1/20 (5.00%)', ' Dyspnea 2/20 (10.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
0421750d-66c6-47be-bde7-0c41ee43a28b
|
|
Comparison
|
Eligibility
|
NCT02872103
|
NCT02995980
|
Adequate renal, hepatic and blood work is required for entry to the primary trial, this includes the following criteria; hemoglobin 11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN. These conditions are not explicitly required for the secondary trial.
|
Entailment
|
[
6,
7
] |
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] |
{'Clinical Trial ID': 'NCT02872103', 'Intervention': ['INTERVENTION 1: ', ' F-627', ' F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.', 'INTERVENTION 2: ', ' Placebo', ' Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.'], 'Eligibility': ['Inclusion Criteria:', ' Show evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.', ' Females 18 years of age and < 75 years of age.', ' Diagnosed with Stage II-IV breast cancer.', ' Subject is scheduled to undergo 4 cycles of TA chemotherapy (docetaxel, doxorubicin, 75, and 60 mg/m2, respectively).', ' ECOG Performance status of 2.', ' White Blood Cell count (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and a platelet count 150 109/L.', ' Demonstrate adequate renal, hepatic function (Liver function tests (ALT, AST, alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.', ' All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.', 'Exclusion Criteria:', ' Subject is <18 or 75 years of age.', ' Disease progression has occurred while receiving a taxane regimen.', ' Subject has undergone radiation therapy within 4 weeks of enrollment.', ' Subject has undergone bone marrow or stem-cell transplantation.', ' Subject has a history of prior malignancy other than breast cancer that is NOT in remission.', ' Subjects that have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e. lithium) within 6 weeks of the screening period are excluded.', ' Subject has had chemotherapy within 365 days of screening.', ' Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, ECG test, or any other relevant test.', ' History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.', ' Unwillingness to participate in the study.', " Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.", ' Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment.', ' Any condition, which can cause splenomegaly.', ' Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.', ' ALT, AST, alkaline phosphatase, total bilirubin 2.5 upper limit of normal.', ' Subject with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.', ' Women who are pregnant or breast-feeding.', ' Subject known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.', ' Subject with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.', ' Subjects with Sickle Cell disease', " Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug."], 'Results': ['Outcome Measurement: ', ' The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo', " Subjects will be randomized to F-627 or Placebo at 2:1 ratio. About 24 hours after chemotherapy, subjects will either receive 20mg fixed dose F-627 or Placebo. The subject's absolute neutrophil count (ANC) will be monitored each day post chemotherapy administration until the ANC level exceeds 2.0x10^9/L, then the value will be monitored every three days until the next chemotherapy cycle is entered. The duration of grade 4 neutropenia (ANC <0.5x10^9/L) in this cycle is the primary efficacy endpoint.", ' Time frame: The first of 4, 21 Day Chemotherapy Cycles, an average of 3 weeks', 'Results 1: ', ' Arm/Group Title: F-627', ' Arm/Group Description: F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.', ' Overall Number of Participants Analyzed: 83', ' Mean (Standard Deviation)', ' Unit of Measure: days 1.3 (1.17)', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.', ' Overall Number of Participants Analyzed: 39', ' Mean (Standard Deviation)', ' Unit of Measure: days 3.9 (1.35)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/83 (4.82%)', ' Febrile Neutropenia *3/83 (3.61%)', ' Diarrhea *0/83 (0.00%)', ' Pneumonia *0/83 (0.00%)', ' Tumor hemorrhage *1/83 (1.20%)', 'Adverse Events 2:', ' Total: 10/39 (25.64%)', ' Febrile Neutropenia *10/39 (25.64%)', ' Diarrhea *1/39 (2.56%)', ' Pneumonia *0/39 (0.00%)', ' Tumor hemorrhage *0/39 (0.00%)']}
|
{'Clinical Trial ID': 'NCT02995980', 'Intervention': ['INTERVENTION 1: ', ' Contrast Enhanced Mammography', ' Contrast-enhanced spectral mammography for the detection breast cancer .', ' DECE mammography: Contrast mammography', 'INTERVENTION 2: ', ' Standard Digital Mammogram', ' Full field digital mammography for the detection breast cancer', ' digital mammography: routine digital mammography'], 'Eligibility': ['Inclusion Criteria:', ' Signed informed consent', ' At least 19 years old', ' Glomerular filtration rate> 60', ' Heterogeneously or extremely dense breasts (BI-RADS category c or d).', 'Exclusion Criteria:', ' History of iodinated contrast allergy', ' Pregnant or lactating as determined by routine standard practice', ' Personal history of breast cancer', ' History of prior breast excisional biopsy (Patients with a history of core needle biopsy will not be excluded)', ' History of prior breast reduction mammoplasty surgery', ' History of prior breast augmentation surgery', ' Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.'], 'Results': ['Outcome Measurement: ', ' Percent Accuracy of Contrast Mammography', 'The primary endpoint of this study is to determine the accuracy of DE CE mammography when compared to full field digital mammography (FFDM) in patients with increased breast density (Breast Imaging-Reporting And Data System (BI-RADS) category c or d breast density).', 'Time frame: 1 year', 'Results 1: ', ' Arm/Group Title: Contrast Enhanced Mammography', ' Arm/Group Description: Contrast-enhanced spectral mammography for the detection breast cancer .', ' DECE mammography: Contrast mammography', ' Overall Number of Participants Analyzed: 114', ' Measure Type: Number', ' Unit of Measure: percentage of accuracy 100 (29 to 100)', 'Results 2: ', ' Arm/Group Title: Standard Digital Mammogram', ' Arm/Group Description: Full field digital mammography for the detection breast cancer', ' digital mammography: routine digital mammography', ' Overall Number of Participants Analyzed: 114', ' Measure Type: Number', ' Unit of Measure: percentage of accuracy 67 (9 to 99)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/128 (0.00%)', 'Adverse Events 2:', ' ']}
|
95345dbe-446f-4999-8f3e-a429b77ea554
|
Single
|
Intervention
|
NCT00376597
|
the primary trial all undergo surgery twice, first at 2 weeks and then again a month later.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5
] |
[] |
{'Clinical Trial ID': 'NCT00376597', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Lymphedema Education)', ' Six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials. Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months. Patients are also contacted by telephone at 9 and 15 months.', 'INTERVENTION 2: ', ' Arm II (Lymphedema Education, Physical Therapy)', ' Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I. Patients also complete a personalized physical therapy intervention, receive a refrigerator magnet, and a 15-minute video that reinforces information and exercises.'], 'Eligibility': ['Eligibility Criteria:', ' Newly diagnosed with stage I-III cancer of the female breast', ' No prior history of carcinoma in situ, lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive breast cancer', ' * Patients with a history of other invasive malignancies are eligible as long as they have completed treatment and are 5 years post-diagnosis; patients with basal cell and squamous cell cancer of the skin are eligible', ' Neoadjuvant therapy', ' Patients scheduled to receive any type of radiation therapy to the breast or axilla are eligible; however, they must be registered to this study with pre-surgery measures taken prior to receiving neoadjuvant therapy', ' Patients scheduled to receive neoadjuvant chemotherapy are also eligible; however, they must be registered to this study with pre-surgery measurements taken prior to receiving neoadjuvant therapy', ' Patients receiving no neoadjuvant therapy are eligible', ' May be enrolled on other treatment trials; however, patients enrolled on surgery trials where only one treatment arm is full axillary node dissection are not eligible; NOTE: Patients enrolled on American College of Surgeons Oncology Group (ACOSOG)-Z1071 are eligible to participate in this study; patients concurrently enrolled on this study and ACOSOG-Z1071, may not also be enrolled on the ACOSOG-Z1071 lymphedema sub-study', ' No documented cardiac conduction disturbances, unstable angina, dementia, or any other chronic disease which, in the opinion of the treating physician, significantly increases mortality over the next 2 years', ' No diagnosed lymphedema', ' In order to be properly fitted for the elastic sleeve, eligible patients must have arm measurements for axilla, elbow, and wrist that fall within the ranges for one of the six sleeve sizes', ' Not currently homebound or dependent upon a walker or wheelchair for mobility', ' Able to participate in a mild exercise program', ' Willing to return to the study site for the duration of the study (18 months)', ' Sentinel (SND) or full axillary node dissection (AND) (no minimum number of nodes required)', ' Patients with double mastectomy, axillary node dissection and/or radiation on both arms are ineligible; patients who undergo these treatments (i.e., surgery and/or radiation) on the contralateral arm after registration to Step 2 are still eligible to remain in the study; however, it should be documented appropriately on form C-1628 at the conclusion of study participation'], 'Results': ['Outcome Measurement: ', ' Number of Participants Who Were Lymphedema-free 18 Months After Randomization', ' To test, in a group randomized controlled trial, the efficacy of this program versus education only in reducing the incidence of lymphedema. Reported here is the proportion of patients who are lymphedema-free 18 months after randomization between the two arms', ' Time frame: 18 months', 'Results 1: ', ' Arm/Group Title: Arm I (Lymphedema Education)', ' Arm/Group Description: Six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials. Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months. Patients are also contacted by telephone at 9 and 15 months.', ' Overall Number of Participants Analyzed: 242', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 114 47.1%', 'Results 2: ', ' Arm/Group Title: Arm II (Lymphedema Education, Physical Therapy)', ' Arm/Group Description: Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I. Patients also complete a personalized physical therapy intervention, receive a refrigerator magnet, and a 15-minute video that reinforces information and exercises.', ' Overall Number of Participants Analyzed: 312', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 135 43.3%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/0', 'Adverse Events 2:', ' Total: 0/0']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
b05fde86-4004-427f-8baf-2ea4a0a535c7
|
|
Single
|
Eligibility
|
NCT00825734
|
Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection, unstable angina or a grade 4 hemorrhage within the last month.
|
Entailment
|
[
87,
94,
95,
108,
117,
118,
119,
120
] |
[] |
{'Clinical Trial ID': 'NCT00825734', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib and Ixabepilone', ' Oral targeted therapy and Systemic Chemotherapy'], 'Eligibility': ['Inclusion Criteria:', ' Age 18 years.', ' Histologically or cytologically confirmed breast cancer diagnosis', ' with metastatic disease. Patients without pathologic or cytologic', ' confirmation of metastatic disease should have unequivocal', ' evidence of metastasis.', ' 3. Measurable disease, as per RECIST criteria (Therasse et al.', ' 2000). Measurable disease cannot be previously irradiated', ' unless progression was documented. Measurable disease is', ' defined as: at least one lesion that can be accurately measured in', ' at least one dimension [longest diameter to be recorded] as', ' >20 mm with conventional techniques, or as >10 mm with spiral', ' computed tomography (CT) scan. Disease must be measurable,', ' i.e., bone-only disease or evaluable-only disease is not eligible.', ' 4. Patients with brain metastasis may participate if they:', ' have undergone appropriate treatment,', ' are at least 1 month post-treatment,', ' have no neurologic symptoms,', ' are not on steroids,', ' have a follow-up magnetic resonance imaging (MRI) scan that', ' demonstrates no residual active lesions, and', ' have no new untreated lesions.', ' 5 The following prior therapies are allowed:', ' No prior chemotherapy in the metastatic setting. However,', ' patients must have received prior adjuvant or neo-adjuvant', ' chemotherapy.', ' Prior radiation therapy in either the metastatic or early-stage', ' setting, as long as <25% of the bone marrow has been', ' treated. Radiation therapy must be completed at least', ' 14 days prior to study registration, and all radiation-related', ' toxicities must be resolved to grade 1 before the patient is', ' eligible for study inclusion.', ' Any number of hormonal therapies in the neo-adjuvant,', ' adjuvant, or metastatic setting is allowed. Patients must', ' discontinue hormonal therapy at least 1 week prior to starting', ' study treatment.', 'Prior bevacizumab administered >4 weeks before initiation of', ' study treatment is allowed.', ' 6 HER2-negative status. Documentation of HER2 results must be', ' available at the time of study enrollment. HER2-negative is', ' defined as:', ' Immunohistochemical (IHC) 0 or IHC 1+ OR', ' Fluorescence in situ hybridization (FISH) negative (defined by', ' FISH ratio <2.2) OR', ' Silver in-situ hybridization (SISH) negative (defined by SISH', ' ratio <2.2).', ' Patients with an IHC 2+ will need to be validated as HER2-negative', ' by FISH.', ' 7 An Eastern Cooperative Oncology Group (ECOG) performance', ' status of < or = to 2.', ' 8. Normal bone marrow function as defined by:', ' absolute neutrophil count (ANC) >1,500/μL;', ' platelets >100,000/μL;', ' hemoglobin >9 g/dL.', ' 9 Normal hepatic function as defined by:', ' total bilirubin within normal institutional limits;', ' aspartate aminotransferase (AST) and alanine', ' aminotransferase (ALT) <2.5 × the institutional upper limit of', ' normal (ULN) for patients without liver metastasis; <5.0 × ULN', ' for patients with liver metastasis.', ' 10. Normal renal function as defined by creatinine <1.5 × ULN.', ' 11. Left ventricular ejection fraction (LVEF) within institutional limits of', ' normal.', ' 12. International normalized ratio (INR) <1.5 or a prothrombin', ' time/partial thromboplastin time (PT/PTT) within normal limits.', ' Patients receiving anti-coagulation treatment with an agent such', ' as warfarin or heparin may be allowed to participate. The INR', ' should be measured prior to initiation of sorafenib, and for', ' patients on warfarin, INR should be monitored at least weekly', ' following initiation of protocol treatment, until the INR is stable and', ' therapeutic.', ' 13. Life expectancy of >6 months.', ' 14. For women of childbearing potential, negative serum pregnancy', ' test within 7 days prior to starting treatment.', ' 15. For women of childbearing potential and men, agreement to use a', ' method of contraception that is acceptable to their physician from', ' time of first signing the informed consent and for the study', ' duration. Men should use adequate birth control for at least three', ' months after the last administration of sorafenib. If a woman', ' becomes pregnant or suspects she is pregnant while participating', ' in this study, she must agree to inform her treating physician', ' immediately. As applicable, patients must agree to discontinue', ' breast-feeding until at least 3 weeks after their last dose of study', ' drug.', ' 16. Recovery to < grade 1 toxicity due to prior therapy.', ' 17. Ability to understand and willingness to sign a written informed', ' consent document.', ' Exclusion Criteria', ' More than one (>1) prior chemotherapy regimen.', ' Treatment with chemotherapy, biologic agents, or targeted agents', ' within the previous 4 weeks.', ' Previous treatment with sorafenib or ixabepilone.', ' Women who are pregnant or breastfeeding.', ' Neuropathy (motor or sensory) greater than grade 1.', ' Uncontrolled intercurrent illness including (but not limited to)', ' ongoing or active infection >grade 2.', ' Known history of human immunodeficiency virus (HIV), Hepatitis', ' B, or Hepatitis C infection.', ' History of other non-breast cancer malignancy treated with', ' curative intent within the 5 years preceding study enrollment with', ' the exception of carcinoma in situ of the cervix, non-melanoma', ' skin cancer, or follicular thyroid cancer.', ' Concurrent hormonal therapy, chemotherapy other than', ' ixabepilone, or radiation treatments while on study as well as', ' treatment with other investigational agents while on study.', ' Cardiac disease:', 'Congestive heart failure (CHF) greater than New York Heart Association', ' (NYHA) Class II (see Appendix B).', ' Unstable angina (anginal symptoms at rest) or new onset angina', ' (i.e., began within the last 3 months).', ' Myocardial infarction within the past 6 months.', ' Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.', ' Uncontrolled hypertension (systolic blood pressure >150 mmHg', ' or diastolic pressure >100 mmHg despite optimal medical', ' management).', ' Thrombolic or embolic events such as cerebrovascular accident,', ' including transient ischemic attacks, within the past 6 months.', ' Pulmonary hemorrhage or bleeding event grade 2 within', ' 4 weeks of the first dose of study treatment, or any other', ' hemorrhage or bleeding event grade 3 within 4 weeks of the', ' first dose of study treatment.', ' 14. Serious non-healing wound, ulcer, or bone fracture.', ' 15. Evidence or history of bleeding diathesis or coagulopathy.', ' 16. Major surgery, open biopsy or significant traumatic injury within', ' 4 weeks of the first dose of study drugs or anticipation of the need', ' for major surgical procedure.', ' 17. Chronic use of CYP3A4 inducers and use of the following strong', ' CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin,', ' atazanavir, nefazodone, saquinavir, telithromycin, ritonavir,', ' amprenavir, indinavir, nelfinavir, delavirdine, and voriconazole.', ' Use of these agents should be discontinued at least 72 hours', ' prior to initiation of study treatment.', " 18. Use of St. John's Wort or rifampin (rifampicin).", " 19. Any condition that impairs patient's ability to swallow whole pills or", ' gastrointestinal (GI) tract disease that involves an inability to take', ' oral medication, malabsorption syndrome, a requirement for', ' intravenous (IV) alimentation, prior surgical procedures affecting', " absorption, or uncontrolled inflammatory GI disease (e.g., Crohn's", ' disease or ulcerative colitis).', ' 20. Psychiatric illness/social situations that would limit compliance', ' with study requirements.', ' 21. Known or suspected allergy to sorafenib, Cremophor EL', ' (polyoxyethylated castor oil) or a drug formulated in', ' Cremophor EL such as paclitaxel or any other agent given in the', ' course of this trial.', 'Exclusion Criteria:'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS)', ' Measured from Day 1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) - progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions', ' Time frame: every 9 weeks until treatment discontinuation or death on study', 'Results 1: ', ' Arm/Group Title: Sorafenib and Ixabepilone', ' Arm/Group Description: Oral targeted therapy and Systemic Chemotherapy', ' Overall Number of Participants Analyzed: 76', ' Median (95% Confidence Interval)', ' Unit of Measure: months 4.8 (3.5 to 6.3)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/76 (7.89%)', ' ANEMIA 1/76 (1.32%)', ' DEATH 1/76 (1.32%)', ' INFECTION 1/76 (1.32%)', ' WEIGHT LOSS 1/76 (1.32%)', ' BACK PAIN 1/76 (1.32%)', ' ACUTE RENAL FAILURE 1/76 (1.32%)', ' DYSPNEA 2/76 (2.63%)', ' PNEUMONIA 1/76 (1.32%)', ' PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME 1/76 (1.32%)', 'RASH 1/76 (1.32%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
21e24c6c-d282-48fb-8d68-3e723458794e
|
|
Single
|
Intervention
|
NCT00821964
|
the primary trial participants apply topical imiquimod to cutaneous lesions once daily every other day for a total of 14 days every 28 day cycle.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7
] |
[] |
{'Clinical Trial ID': 'NCT00821964', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Biological Therapy, Chemo)', ' Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.', ' imiquimod: Given topically', ' Abraxane: Given IV', ' laboratory biomarker analysis: Correlative studies', ' RNA analysis: Correlative studies', ' immunoenzyme technique: Correlative studies'], 'Eligibility': ['Inclusion Criteria:', ' Patients with advanced stage refractory breast cancer', ' Progressive or relapsed disease following standard therapy with chemotherapy and/or surgery, and/or radiation', ' Patients must have measurable (bi-dimensional) chest wall disease and/or cutaneous metastatic lesions', ' Patients must be at least 7 days from last chemotherapy and 30 days from local radiotherapy and/or systemic steroids', ' Patients on bisphosphonates, trastuzumab, lapatinib and/or hormonal therapy are eligible', ' White blood cell count >= 1000/ul', ' Absolute neutrophil count (ANC) >= 1200/ul', ' Platelets > 75,000/ul', ' Serum creatinine =< 2.0 mg/dL, a creatinine clearance > 60 ml/min', ' Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2 X upper limit normal (ULN)', ' Total bilirubin < 2 X ULN', ' Patients must have a Performance Status Score (Eastern Cooperative Oncology Group [ECOG] Scale) =< 2', ' Patients must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment', ' Men and women of reproductive ability must agree to contraceptive use during the study and for 1 month after imiquimod/Abraxane treatment is discontinued', 'Exclusion Criteria:', ' Patients with prior allergic reaction to taxanes', ' Patients with any clinically significant active autoimmune disease requiring active treatment with systemic steroids or other immunomodulators', ' Pregnant or breast-feeding women', ' Patients with peripheral neuropathy >= Grade 2'], 'Results': ['Outcome Measurement: ', ' Anti-tumor Effects of Imiquimod as Assessed by Modified World Health Organization (WHO) Criteria', ' Tumor responses will be determined using the sum of the products of the largest perpendicular dimensions. Target lesions will be evaluated by the following response criteria: complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).', ' Evaluation of target lesions per modified WHO response criteria:', ' Complete response (CR): complete clearance (100%) of target lesion(s)', ' Partial response (PR): 50% decrease in target lesion size', ' Stable disease (SD): < 50% decrease in target lesion size', ' Progressive (PD): 25% increase in target lesion size Overall Response Rate (ORR) determined at end of study treatment which was 1 week after cycle #3, unless patient was withdrawn from study. If patient was withdrawn from study, then ORR was determined after their last cycle of treatment received.', ' Time frame: Baseline and then every 4 weeks until week 24', 'Results 1: ', ' Arm/Group Title: Treatment (Biological Therapy, Chemo)', ' Arm/Group Description: Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.', ' imiquimod: Given topically', ' Abraxane: Given IV', ' laboratory biomarker analysis: Correlative studies', ' RNA analysis: Correlative studies', ' immunoenzyme technique: Correlative studies', ' Overall Number of Participants Analyzed: 14', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Total Evaluated in this Outcome Measure: 14 100.0%', ' Complete Response (CR): 5 35.7%', ' Partial Response (PR): 5 35.7%', ' Stable Disease (SD): 3 21.4%', ' Progressive Disease (PD): 1 7.1%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/15 (6.67%)', 'Pain 1/15 (6.67%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
d1e579e2-b057-43da-8a2f-64dad964b789
|
|
Comparison
|
Adverse Events
|
NCT00093145
|
NCT00703326
|
Heart-related adverse events were recorded in the secondary trial, but not the primary trial.
|
Contradiction
|
[
0,
3
] |
[
0,
7,
8,
9,
10
] |
{'Clinical Trial ID': 'NCT00093145', 'Intervention': ['INTERVENTION 1: ', ' Albumin-bound Paclitaxel, Carboplatin + Herceptin', ' Participants received albumin-bound paclitaxel, 100 mg/m^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the first week and 2 mg/kg on all subsequent weeks by intravenous (IV) infusion for up to 6 cycles in the absence of disease progression or intolerable toxicity. Participants could continue treatment with chemotherapy beyond 6 cycles at the discretion of the investigator, but Herceptin therapy was to continue to be administered weekly (2 mg/kg) until intercurrent illness, disease progression, unacceptable toxicity, patient withdrawal or administration of any non-protocol anti-cancer treatment.'], 'Eligibility': ['Inclusion Criteria:', ' Confirmed adenocarcinoma of the breast', ' Tumor shows 3+ overexpression of the human epidermal growth factor receptor 2 (HER-2)/proto-oncogene by immunohistochemistry assay, or is fluorescence in situ hybridization (FISH)+', ' Stage IV disease', ' Measurable disease', ' At least 3 weeks since prior cytotoxic chemotherapy', ' At least 4 weeks since radiotherapy with full recovery', ' At least 4 weeks since major surgery with full recovery', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-2', ' At least 18 years old', ' Absolute neutrophil count (ANC) at least 1.5 x 10^9 cells/L', ' Platelets at least 100 x 10^9 cells/L', ' Hemoglobin at least 9 g/dL', ' Aspartame aminotransferase (AST), alanine aminotransferase (ALT) less than 2.5X upper limit normal', ' Alkaline Phosphatase less than 1.5X upper limit normal', ' Creatinine less than 1.5 gm/dL', ' Normal left ventricular ejection fraction', ' Negative pregnancy test', ' Agree to use method to avoid pregnancy', ' Informed Consent is obtained', 'Exclusion Criteria:', ' Up to one regimen of prior neo-adjuvant or adjuvant chemotherapy is allowed. One year since Taxane and Herceptin treatment.', ' Cumulative life-time dose of doxorubicin is greater than 360 mg/m^2', ' Concurrent immunotherapy or hormonal therapy', ' Parenchymal brain metastases, if present, must be documented to be clinically and radiographically stable for at least 6 months after treatment', ' Serious intercurrent medical or psychiatric illness, including serious active infection', ' History of congestive heart failure', ' History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer', ' Patients who have received an investigational drug within the previous 3 weeks', ' Patient is currently enrolled in another clinical study receiving investigational therapies', ' Pregnant or nursing women'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response', ' Percentage of participants who achieved an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. A partial response (PR) is at least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing, or with the persistence of one or more non-target lesions and/or the maintenance of tumor marker level above the normal limits.', ' Time frame: Objective response was evaluated every 2 cycles, up to a maximum of 39 cycles (approximately 39 months)', 'Results 1: ', ' Arm/Group Title: Albumin-bound Paclitaxel, Carboplatin + Herceptin', ' Arm/Group Description: Participants received albumin-bound paclitaxel, 100 mg/m^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the first week and 2 mg/kg on all subsequent weeks by intravenous (IV) infusion for up to 6 cycles in the absence of disease progression or intolerable toxicity. Participants could continue treatment with chemotherapy beyond 6 cycles at the discretion of the investigator, but Herceptin therapy was to continue to be administered weekly (2 mg/kg) until intercurrent illness, disease progression, unacceptable toxicity, patient withdrawal or administration of any non-protocol anti-cancer treatment.', ' Overall Number of Participants Analyzed: 32', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 62.5 (45.7 to 79.3)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/32 (15.63%)', ' Febrile neutropenia 1/32 (3.13%)', ' Supraventricular tachycardia 1/32 (3.13%)', ' Hypersensitivity 2/32 (6.25%)', ' Catheter site infection 1/32 (3.13%)', ' Confusional state 1/32 (3.13%)']}
|
{'Clinical Trial ID': 'NCT00703326', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab (IMC-1121B) + Docetaxel', ' Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', ' Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', 'INTERVENTION 2: ', ' Placebo + Docetaxel', ' Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', ' Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Participant is able to provide signed informed consent', ' Participant is female and 18 years of age or older if required by local laws or regulations', ' Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent. Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis', ' Participant has measurable and/or non-measurable disease', " Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC)", ' Participant has not received prior chemotherapy for metastatic or locally-recurrent and inoperable breast cancer', ' Participant completed (neo) adjuvant taxane therapy at least 6 months prior to randomization', ' Participant completed (neo) adjuvant biologic therapy at least 6 weeks prior to randomization', ' Participant completed all prior radiotherapy with curative intent 3 weeks prior to randomization', ' Participant may have received prior hormonal therapy for breast cancer in the (neo) adjuvant and/or the metastatic setting 2 weeks prior to randomization', " Participant's left ventricular ejection fraction is within normal institutional ranges", ' Participant has resolution to grade 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3 (NCI-CTCAE v 3.0) of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy which must have resolved to grade 2', ' Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1', ' Participant is amenable to compliance with protocol schedules and testing', ' Participant has adequate hematological functions [absolute neutrophil count (ANC) 1500 cells/microliter (mcL), hemoglobin 9 grams/deciliter (g/dL), and platelets 100,000 cells/mcL and 850,000 cells/mcL]', ' Participant has adequate hepatic function [bilirubin within normal limits (WNL), aspartate transaminase (AST) and alanine transaminase (ALT) 2.5 times the upper limit of normal (ULN), or 5.0 times the ULN if the transaminase elevation is due to liver metastases, and alkaline phosphatase 5.0 times the ULN]', ' Participant has serum creatinine 1.5 x ULN. If serum creatinine > 1.5 x ULN the calculated creatinine clearance should be > 40 milliliters/minute (mL/min)', " Participant's urinary protein is 1+ on dipstick or routine urinalysis (UA); if urine protein 2+, a 24-hour urine collection must demonstrate < 1000 milligrams (mg) of protein in 24 hours to allow participation in the study", ' Participant must have adequate coagulation function as defined by international normalized ratio (INR) 1.5 and a partial thromboplastin time (PTT) 1.5 X ULN if not receiving anticoagulation therapy. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin and if on warfarin must have a INR between 2 and 3 and have no active bleeding (defined as within 14 days of randomization) or pathological condition that carries a high risk of bleeding (such as, tumor involving major vessels or known varices)', ' Women of childbearing potential must implement adequate contraception in the opinion of the investigator', ' Participant has not received prior biologic therapy for metastatic or locally recurrent and inoperable breast cancer', 'Exclusion Criteria:', ' Participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that she has been disease free for > 3 years', ' Participant has a known sensitivity to docetaxel or other drugs formulated with polysorbate 80', ' Participant has a known sensitivity to agents of similar biologic composition as ramucirumab or other agents that specifically target vascular endothelial growth factor (VEGF)', ' Participant has a history of chronic diarrheal disease within 6 months prior to randomization', ' Participant has received irradiation to a major bone marrow area as defined as > 25% of bone marrow (such as, pelvic or abdominal radiation) within 30 days prior to randomization', ' Participant has participated in clinical trials of experimental agents within 4 weeks prior to randomization', ' Participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders', ' Participant has active, high risk bleeding (such as, via gastric ulcers or gastric varices) within 14 days prior to randomization', ' Participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy', ' Participant has uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator', ' Participant has brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease', ' Participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness', ' Participant has pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.', ' Participant is pregnant or lactating'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS)', ' PFS was defined as time from randomization until the first evidence of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) or death from any cause; by Investigator assessment. Progressive disease (PD) was defined as at least a 20% increase in sum of longest diameter of target lesions taking as reference the smallest sum longest diameter since baseline, progression in non-target lesions or the appearance of 1 or more new lesion(s). Participants who neither progressed nor died were censored the day of their last radiographic tumor assessment if available or date of randomization if no post initiation radiographic assessment was available. If death or PD occurred after 2 missing radiographic visits, censoring occurred at date of the last radiographic visit prior to the missed visits. The symptomatic/clinical disease progression (deterioration) without documented radiologic progression did not constitute progression.', ' Time frame: Randomization to disease progression or death or until data cutoff of 31 Mar 2013 (up to 56 months)', 'Results 1: ', ' Arm/Group Title: Ramucirumab (IMC-1121B) + Docetaxel', ' Arm/Group Description: Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', ' Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m ) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', ' Overall Number of Participants Analyzed: 759', ' Median (95% Confidence Interval)', ' Unit of Measure: months 9.5 (8.3 to 9.8)', 'Results 2: ', ' Arm/Group Title: Placebo + Docetaxel', ' Arm/Group Description: Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', ' Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m ) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', ' Overall Number of Participants Analyzed: 385', ' Median (95% Confidence Interval)', ' Unit of Measure: months 8.2 (7.1 to 8.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 285/752 (37.90%)', ' Anaemia 2/752 (0.27%)', ' Disseminated intravascular coagulation 2/752 (0.27%)', ' Febrile neutropenia 51/752 (6.78%)', ' Neutropenia 47/752 (6.25%)', ' Thrombocytopenia 2/752 (0.27%)', ' Atrial fibrillation 1/752 (0.13%)', ' Atrial flutter 0/752 (0.00%)', ' Cardiac failure congestive 1/752 (0.13%)', ' Left ventricular dysfunction 0/752 (0.00%)', 'Adverse Events 2:', ' Total: 117/382 (30.63%)', ' Anaemia 3/382 (0.79%)', ' Disseminated intravascular coagulation 0/382 (0.00%)', ' Febrile neutropenia 11/382 (2.88%)', ' Neutropenia 20/382 (5.24%)', ' Thrombocytopenia 0/382 (0.00%)', ' Atrial fibrillation 1/382 (0.26%)', ' Atrial flutter 1/382 (0.26%)', ' Cardiac failure congestive 0/382 (0.00%)', ' Left ventricular dysfunction 1/382 (0.26%)']}
|
5ac83a45-db7d-44d1-bf37-9cbf3c8fabb6
|
Single
|
Adverse Events
|
NCT01234402
|
the primary trial more than 6 different types of cardiac related adverse events.
|
Entailment
|
[
0,
4,
5,
6,
7,
8,
9,
10,
13,
17,
18,
19,
20,
21,
22,
23
] |
[] |
{'Clinical Trial ID': 'NCT01234402', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab + Capecitabine', ' Participants received 10 milligram per kilogram (mg/kg) Ramucirumab intravenously on day 1 of 21 days cycle along with 1000 milligram per square meter (mg/m^2) of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle.', 'INTERVENTION 2: ', ' Icrucumab + Capecitabine', ' Participants received 12 mg/kg Icrucumab intravenously on day 1 and day 8 of 21 day cycle along with 1000 mg/m^2 of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle.'], 'Eligibility': ['Inclusion Criteria:', ' The participant has histologically or cytologically confirmed breast cancer which at the time of study entry is either Stage III disease not amenable to curative therapy or Stage IV disease', ' Has measurable or nonmeasurable disease', ' Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1', ' Has received prior anthracycline therapy', ' Has received prior taxane therapy', ' Participants with human epidermal growth factor receptor-2 (HER2) positive disease must have progressed on or following trastuzumab', ' Participants with hormone receptor-positive disease must have progressed on or following hormone therapy', ' Has received 3 prior chemotherapy regimens in any setting (a regimen is defined as any agent[s] that has been administered for more than 1 cycle; sequential neoadjuvant/adjuvant treatment is considered 1 regimen)', ' Has completed any prior radiotherapy 4 weeks prior to randomization', ' Has completed any prior hormonal therapy 2 weeks prior to randomization', ' Has adverse events (AEs) that have resolved to Grade 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v 4.0) from all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy,or hormonal therapy', ' Has adequate hematologic, coagulation, hepatic and renal function', ' Does not have:', ' cirrhosis at a level of Child-Pugh B (or worse) or', ' cirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis', ' Has urinary protein is 1+ on dipstick or routine urinalysis; if urine protein 2+, a 24-hour urine collection must demonstrate < 1000 mg of protein in 24 hours to allow participation in the study', ' Agrees to use adequate contraception during the study period and for 12 weeks after the last dose of study medication', 'Exclusion Criteria:', ' Has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer, curatively treated cervical carcinoma in situ, or other noninvasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that there has been a disease-free interval for > 3 years', ' Has a known sensitivity to capecitabine, any of its components, or other drugs formulated with polysorbate 80', ' Has a known sensitivity to 5-fluorouracil (5-FU)', ' Has a known dihydropyrimidine dehydrogenase deficiency', ' Has received prior capecitabine treatment for advanced breast cancer', ' Has received investigational therapy within 2 weeks prior to randomization', ' Has received bevacizumab within 4 weeks prior to randomization', ' Has received more than 1 prior antiangiogenic agent for breast cancer', ' Has a known sensitivity to agents of similar biologic composition as ramucirumab DP or Icrucumab (IMC-18F1), or other agents that specifically target vascular endothelial growth factor (VEGF)', ' Has an acute/subacute bowel obstruction or history of chronic diarrhea requiring ongoing medical intervention', ' Has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders', ' Has experienced a Grade 3 bleeding event within 3 months prior to randomization', ' Is receiving prophylactic or therapeutic anticoagulation with warfarin or any other oral anticoagulant', ' Has an uncontrolled intercurrent illness, including, but not limited to uncontrolled hypertension, symptomatic anemia, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorder in the opinion of the investigator', ' Has experienced any arterial thrombotic or thromboembolic events, including, but not limited to myocardial infarction, transient ischemic attack, or cerebrovascular accident within 6 months prior to randomization', ' Has brain metastases, uncontrolled spinal cord compression, or leptomeningeal disease', ' Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy', ' Has received a prior allogeneic organ or tissue transplantation', ' Has undergone major surgery within 4 weeks prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization', ' Has had a serious nonhealing wound, ulcer, or bone fracture within 4 weeks prior to randomization', ' Has known HIV or AIDS infection', ' Has an elective or planned major surgery to be performed during the course of the trial', ' Participant is pregnant or lactating'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS)', ' PFS is defined as the time from the date of randomization until the date of objectively determined progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause, whichever is first. Disease progression is defined as 20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of 5 millimeter (mm) and the appearance of 1 new lesions was progression. Participants who did not progress, were lost to follow-up, or had missed 2 or more scheduled tumor assessments were censored at the day of their last adequate tumor assessment.', ' Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 97 weeks)', 'Results 1: ', ' Arm/Group Title: Ramucirumab + Capecitabine', ' Arm/Group Description: Participants received 10 milligram per kilogram (mg/kg) Ramucirumab intravenously on day 1 of 21 days cycle along with 1000 milligram per square meter (mg/m^2) of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle.', ' Overall Number of Participants Analyzed: 52', ' Median (95% Confidence Interval)', ' Unit of Measure: Weeks 22.1 (12.1 to 36.1)', 'Results 2: ', ' Arm/Group Title: Icrucumab + Capecitabine', ' Arm/Group Description: Participants received 12 mg/kg Icrucumab intravenously on day 1 and day 8 of 21 day cycle along with 1000 mg/m^2 of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle.', ' Overall Number of Participants Analyzed: 49', ' Median (95% Confidence Interval)', ' Unit of Measure: Weeks 7.3 (6.3 to 13.0)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 20/52 (38.46%)', ' Anaemia 0/52 (0.00%)', ' Pancytopenia 1/52 (1.92%)', ' Acute myocardial infarction 0/52 (0.00%)', ' Atrial fibrillation 0/52 (0.00%)', ' Cardiac failure 1/52 (1.92%)', ' Cardiogenic shock 1/52 (1.92%)', ' Palpitations 0/52 (0.00%)', ' Pericardial effusion 0/52 (0.00%)', ' Right ventricular failure 1/52 (1.92%)', ' Abdominal pain 0/52 (0.00%)', ' Ascites 3/52 (5.77%)', 'Adverse Events 2:', ' Total: 25/49 (51.02%)', ' Anaemia 2/49 (4.08%)', ' Pancytopenia 0/49 (0.00%)', ' Acute myocardial infarction 1/49 (2.04%)', ' Atrial fibrillation 1/49 (2.04%)', ' Cardiac failure 0/49 (0.00%)', ' Cardiogenic shock 0/49 (0.00%)', ' Palpitations 1/49 (2.04%)', ' Pericardial effusion 4/49 (8.16%)', ' Right ventricular failure 0/49 (0.00%)', ' Abdominal pain 1/49 (2.04%)', ' Ascites 0/49 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
d130c981-f602-4f17-b1cb-11a7ad632b92
|
|
Single
|
Intervention
|
NCT03329937
|
the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 2 cycles
|
Entailment
|
[
0,
1,
2
] |
[] |
{'Clinical Trial ID': 'NCT03329937', 'Intervention': ['INTERVENTION 1: ', ' Niraparib 200 mg', " Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles. After 2 cycles, participants either underwent surgery, received additional cycles of niraparib (maximum of 6 cycles total), or received neoadjuvant chemotherapy, at physician's discretion. A breast magnetic resonance imaging (MRI) was performed at the end of cycle 2 and breast ultrasounds were performed at the end of each cycle, including any additional cycles beyond cycle 2. After completion of all neoadjuvant therapy participants proceeded to surgery, at which time pathological complete response (pCR) was assessed."], 'Eligibility': ['Inclusion Criteria:', ' Participants age >= 18 years old.', ' Participants with a deleterious or suspected deleterious breast cancer susceptibility gene 1 (BRCA1) or BRCA2 mutation (germline or somatic) may be enrolled into the study based on either local or central laboratory testing of BRCA status.', ' Histologically-confirmed HER2-negative localized breast cancer by core biopsy.', ' Primary operable, non-metastatic invasive carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration is not sufficient. Incisional biopsy is not allowed. In participants with multifocal and/or multicentric, the largest lesion should be measured. Both unilateral and bilateral breast cancer are allowed.', ' Primary tumor size >=1cm.', ' Measurable disease by breast ultrasound and MRI.', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.', ' Adequate organ function defined as:', ' Absolute neutrophil count (ANC) >=1500 per microliters (/μL).', ' Platelets >=100,000/μL.', ' Hemoglobin >=9 grams per deciliter (g/dL).', ' Serum creatinine <=1.5*upper limit of normal (ULN) or calculated creatinine clearance >=50 milliliters per minute (mL/min) using Cockcroft-Gault equation.', " Total bilirubin <=1.5*ULN except in participants with Gilbert's syndrome. Participants with Gilbert's syndrome may enroll if direct bilirubin <=1.5*ULN of the direct bilirubin.", ' Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5*ULN.', ' Participants must have recovered to Grade 1 toxicity from prior cancer therapy (a participant with Grade 2 neuropathy or Grade 2 alopecia is an exception to this criterion and may qualify for this study).', ' Participant able to take oral medications.', ' Participant meets the following criteria:', ' Female participant (of childbearing potential) is not breastfeeding, has a negative serum pregnancy test within 72 hours prior to taking study drug, and agrees to abstain from activities that could result in pregnancy from Screening through 180 days after the last dose of study drug, or is of non-childbearing potential.', ' Female participant is of non-childbearing potential (other than medical reasons) as defined:', ' i) >=45 years of age and has not had menses for >1 year. ii) Amenorrheic for <2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon the screening evaluation.', " iii) Has undergone post hysterectomy, bilateral oophorectomy, or tubal ligation. Documented hysterectomy, oophorectomy or tubal ligation must be confirmed in the medical records, otherwise the participant must be willing to use 2 adequate barrier methods throughout the study starting from the screening visit through 180 days after the last dose of study drug. Information must be captured appropriately within the site's source documents.", ' c) Male participant agrees to use an effective method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.', ' Able to understand the study procedures and agree to participate in the study by providing written informed consent.', 'Exclusion Criteria:', ' Prior anti-cancer therapies for current malignancy.', " Known evidence of distant metastasis. Staging studies are not required. The decision to pursue staging studies is at the discretion of the treating clinician, based on the participant's clinical and pathological findings consistent with standard guidelines.", ' Known hypersensitivity to the components of niraparib components or their formulation excipients.', ' Major surgery within 3 weeks of starting the study or participant has not recovered from any effects of any major surgery.', ' Poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, uncontrolled hypertension, active uncontrolled coagulopathy, bleeding disorder, or any psychiatric disorder that prohibits obtaining informed consent.', " History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study drug, or is not in the best interest of the participant to participate.", ' Participant is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study drug or within the 180-day period after the last dose of study drug.', ' Immunocompromised participants.', ' Known active hepatic disease (Hepatitis B or C).', ' Prior treatment with a known PARP inhibitor.', ' Other active malignancy that warrants systemic therapy.', ' Known history of myelodysplastic syndromes (MDS) or Acute myeloid leukemia (AML).'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Tumor Response Measured by Breast MRI', ' Tumor response measured by breast MRI is defined as >=30 percent (%) reduction of tumor volume from Baseline based on primary lesion after niraparib treatment without any new lesion development. Tumor volume was calculated as (length × width × height × pi [π])/6. Responses were assessed as Clinical complete response (CR): A complete disappearance of all tumor signs in the breast as assessed by imaging test. Clinical partial response (PR): A reduction in the tumor volume of the primary tumor size by >=30% assessed by palpation or imaging test. Clinical stable disease (SD): No significant change in tumor volume during treatment. Clinical progressive disease (cPD): The development of new, previously undetected lesions, or an estimated increase in the size of the primary lesion by greater than 20%. Percentage of participants with tumor response and its 95 percent confidence interval (CI) has been presented. The 95% CI was the binomial exact CI based on Clopper-Pearson method.', ' Time frame: At 2 months', 'Results 1: ', ' Arm/Group Title: Niraparib 200 mg', " Arm/Group Description: Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles. After 2 cycles, participants either underwent surgery, received additional cycles of niraparib (maximum of 6 cycles total), or received neoadjuvant chemotherapy, at physician's discretion. A breast magnetic resonance imaging (MRI) was performed at the end of cycle 2 and breast ultrasounds were performed at the end of each cycle, including any additional cycles beyond cycle 2. After completion of all neoadjuvant therapy participants proceeded to surgery, at which time pathological complete response (pCR) was assessed.", ' Overall Number of Participants Analyzed: 21', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 90.5 (69.6 to 98.8)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/21 (9.52%)', ' Thrombocytopenia 1/21 (4.76%)', ' Ventricular septal defect 1/21 (4.76%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
c1f9982f-c4c9-48dc-887a-7ae05f508c21
|
|
Single
|
Adverse Events
|
NCT00182793
|
The majority of patients in the primary trial experienced an adverse event.
|
Entailment
|
[
0,
1
] |
[] |
{'Clinical Trial ID': 'NCT00182793', 'Intervention': ['INTERVENTION 1: ', ' All Patients', ' Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®), one day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation, no more than 7 weeks later, patients proceed to course 2; OR Patients receive high-dose carboplatin, thiotepa, and cyclophosphamide IV continuously over 4 days followed by autologous PBSC transplantation. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed breast cancer, meeting 1 of the following stage criteria:', ' Stage IIIB or IIIC disease, meeting both of the following criteria:', ' Must have received prior neoadjuvant or adjuvant therapy', ' Must have undergone lumpectomy or mastectomy', ' Stage IV disease, meeting all of the following criteria:', ' Only 1-3 organ sites with disease involvement after induction chemotherapy', ' Achieved at least a partial response after induction chemotherapy', ' No more than 3 lesions in the organ sites combined', ' Inflammatory breast cancer allowed', ' Completed chemotherapy, surgery, or radiotherapy for breast cancer within the past 6 months', ' Hormone receptor status:', ' Not specified', ' PATIENT CHARACTERISTICS:', ' Age', ' 65 and under', ' Sex', ' Male or female', ' Menopausal status', ' Not specified', ' Performance status', ' Karnofsky 80-100%', ' Life expectancy', ' Not specified', ' Hematopoietic', ' Absolute neutrophil count 1,000/mm^3', ' Platelet count 100,000/mm^3', ' Hepatic', ' SGOT or SGPT 2 times upper limit of normal', ' Bilirubin 1.5 mg/dL', ' Renal', ' Creatinine 1.2 mg/dL', ' Creatinine clearance 70 mL/min', ' Cardiovascular', ' LVEF 55% by MUGA or echocardiogram', ' Pulmonary', ' FEV_1 60% of predicted', ' DLCO 60% of the lower limit of predicted value', ' Oxygen saturation > 92% on room air', ' Other', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' No autoimmune disorders', ' No immunosuppressive condition', ' No other malignancy within the past 5 years', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' No prior biologic therapy except trastuzumab (Herceptin®)', ' Chemotherapy', ' See Disease Characteristics', ' Endocrine therapy', ' Not specified', ' Radiotherapy', ' See Disease Characteristics', ' No prior radiotherapy to adjacent or involved sites of disease that would preclude study radiotherapy', ' Surgery', ' See Disease Characteristics', ' Other', ' No other concurrent anticancer therapy'], 'Results': ['Outcome Measurement: ', ' 5-Year Relapse-free Survival Rate', ' Estimated using the product-limit method of Kaplan and Meier. Relapse defined as appearance of any new lesions during or after protocol treatment. Whenever possible, relapses should be documented histologically.', ' Time frame: From time of initial PBPC rescue until death or disease recurrence (disease progression for patients with stage IV disease), whichever came first, up to 5 years post treatment', 'Results 1: ', ' Arm/Group Title: All Patients', ' Arm/Group Description: Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin ), one day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation, no more than 7 weeks later, patients proceed to course 2; OR Patients receive high-dose carboplatin, thiotepa, and cyclophosphamide IV continuously over 4 days followed by autologous PBSC transplantation. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.', ' Overall Number of Participants Analyzed: 27', ' Median (95% Confidence Interval)', ' Unit of Measure: percentage of participants 53 (23 to 77)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 24/32 (75.00%)', ' Disseminated intravascular coagulation * 1/32 (3.13%)', ' Febrile neutropenia * 1/32 (3.13%)', ' Adrenal insufficiency * 1/32 (3.13%)', ' Endocrine disorder * 1/32 (3.13%)', ' Chills * 1/32 (3.13%)', ' Fatigue * 1/32 (3.13%)', ' Fever * 1/32 (3.13%)', ' Multi-organ failure * 1/32 (3.13%)', ' Hepatic failure * 1/32 (3.13%)', ' Infection * 1/32 (3.13%)', ' Sepsis * 1/32 (3.13%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
e966302f-9378-4681-b2c6-9d8b5b5f709f
|
|
Comparison
|
Results
|
NCT02441946
|
NCT00325598
|
the secondary trial has a much longer duration than the primary trial.
|
Entailment
|
[
0,
3
] |
[
0,
3
] |
{'Clinical Trial ID': 'NCT02441946', 'Intervention': ['INTERVENTION 1: ', ' Abemaciclib + Anastrozole', ' Participants were given 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for 2 weeks.', ' All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for an additional 14 weeks.', ' Total treatment duration was 16 weeks.', 'INTERVENTION 2: ', ' Abemaciclib', ' Participants received 150 mg of abemaciclib orally Q12H for 2 weeks.', ' All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole QD for an additional 14 weeks.', ' Total treatment duration was 16 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' Have postmenopausal status.', ' Adenocarcinoma of the breast.', ' Breast tumor 1 centimeter (cm) in diameter, HR+, HER2-.', ' Neoadjuvant endocrine monotherapy is deemed to be a suitable therapy.', ' Primary breast cancer that is suitable for baseline core biopsy.', ' Have adequate organ function.', 'Exclusion Criteria:', ' Bilateral invasive breast cancer.', ' Metastatic breast cancer (local spread to axillary lymph nodes is permitted).', ' Inflammatory breast cancer.', ' Prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in the same breast as currently being treated.', ' Prior radiotherapy to the ipsilateral chest wall for any malignancy.', ' Prior anti-estrogen therapy.'], 'Results': ['Outcome Measurement: ', ' Percent Change From Baseline to 2 Weeks in Ki67 Expression', ' Tumor tissue collected through a core biopsy at baseline and at the end of cycle 1 was used to determine Ki67 expression. Ki67 expression is defined as the percent of cells staining positive by validated central assay.', ' Time frame: Baseline, 2 Weeks', 'Results 1: ', ' Arm/Group Title: Abemaciclib + Anastrozole', ' Arm/Group Description: Participants were given 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for 2 weeks.', ' All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for an additional 14 weeks.', ' Total treatment duration was 16 weeks.', ' Overall Number of Participants Analyzed: 59', ' Geometric Mean (90% Confidence Interval)', ' Unit of Measure: Percent Change -92.86 (-94.82 to -90.16)', 'Results 2: ', ' Arm/Group Title: Abemaciclib', ' Arm/Group Description: Participants received 150 mg of abemaciclib orally Q12H for 2 weeks.', ' All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole QD for an additional 14 weeks.', ' Total treatment duration was 16 weeks.', ' Overall Number of Participants Analyzed: 52', ' Geometric Mean (90% Confidence Interval)', ' Unit of Measure: Percent Change -90.52 (-93.12 to -86.93)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/74 (1.35%)', ' Neutropenia 0/74 (0.00%)', ' Acute coronary syndrome 0/74 (0.00%)', ' Angina pectoris 0/74 (0.00%)', ' Myocardial infarction 0/74 (0.00%)', ' Abdominal pain 1/74 (1.35%)', ' Pancreatitis 0/74 (0.00%)', ' Mastitis 0/74 (0.00%)', ' Fracture 0/74 (0.00%)', ' Alanine aminotransferase increased 1/74 (1.35%)', ' Aspartate aminotransferase increased 1/74 (1.35%)', 'Adverse Events 2:', ' Total: 1/75 (1.33%)', ' Neutropenia 0/75 (0.00%)', ' Acute coronary syndrome 0/75 (0.00%)', ' Angina pectoris 0/75 (0.00%)', ' Myocardial infarction 0/75 (0.00%)', ' Abdominal pain 0/75 (0.00%)', ' Pancreatitis 0/75 (0.00%)', ' Mastitis 0/75 (0.00%)', ' Fracture 0/75 (0.00%)', ' Alanine aminotransferase increased 0/75 (0.00%)', ' Aspartate aminotransferase increased 0/75 (0.00%)']}
|
{'Clinical Trial ID': 'NCT00325598', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1 (36 Gy)', ' 36 Gy in 9 fractions BID x 4 1/2 treatment days', ' Partial Breast Irradiation (PBI)', 'INTERVENTION 2: ', ' Cohort 2 (40 Gy)', ' 40 Gy in 10 fractions BID over 5 treatment days', ' Partial Breast Irradiation (PBI)'], 'Eligibility': ['Inclusion Criteria', ' Histologic Documentation:', ' Patients will have histologically confirmed Unicentric Stage I (T1 N0 M0) invasive ductal breast cancer.', ' Histologically negative tumor margin 2 mm or more from any inked edges, or no tumor in a re-excision specimen or final shaved specimen.', ' Tubular, mucinous and medullary variant histologies of infiltrating ductal carcinoma are permitted.', ' Low-grade DCIS (I and II) of 2 cm or less with histologically negative margins of at least 2 mm margins (or a negative re-excision) are permitted.', ' Women age 70 years or older with T1 invasive ductal carcinoma which are estrogen-receptor positive (ER+) with clinically negative axillary nodes who do not undergo surgical lymph node evaluation are also eligible if patient will take hormonal therapy.', ' Patients with T1N0 (i+) tumors on sentinel lymph node mapping or dissection (i.e. is tumor deposit is 0.2mm or less, regardless of whether the deposit is detected by IHC or H&E staining) will also be eligible, provided that completion axillary dissection has been performed to confirm N0 status.', " In the case where invasive cancer is present, the invasive cancer's pathology will be used regardless if DCIS is also present.", ' Prior Treatment: Patient may have been treated with adjuvant chemotherapy. Patients may be on adjuvant hormonal therapy or begin hormonal therapy following XRT at the discretion of the medical oncologist.', ' Radiation therapy should begin within:', ' 4-12 weeks from definitive surgical procedure', ' 2-6 weeks after chemotherapy, if chemotherapy given first', ' Radiation cannot be delivered concurrently with chemotherapy.', ' Age >= 18 years of age', ' ECOG Performance Status 0-2.', ' Signed Informed Consent', ' Exclusion Criteria', ' The following guidelines are to assist physicians in selecting patients for whom protocol therapy is safe and appropriate. Physicians should recognize that the following may seriously increase the risk to the patient entering this protocol. Patients who meet the following criteria should not be entered in this study:', ' 1a Multicentric IDC of the breast defined as discontiguous tumors separated by at least 5 cm of uninvolved tissue; alternatively, discontiguous tumors that are clinically or mammographically within separate breast quadrants or subareolar central region.', ' b Multifocal IDC of the breast, defined as discontiguous discrete foci of invasive carcinoma, separated by uninvolved intervening tissue, but within an overall span of 5cm, or within the same breast quadrant or subareolar central region.', ' Tumor > 2.0 cm, nodal involvement on H&E staining, or metastatic involvement', ' Histological evidence of:', ' Lymphovascular invasion: as defined by a tumor embolus present in an endothelial-lined space; cases with tumor emboli present in a space not lined by endothelial cells but otherwise very suspicious for an angiolymphatic space were also considered ineligible.', ' EIC (Extensive Intraductal Component): defined as the presence of intraductal carcinoma both within the primary infiltrating ductal tumor (comprising at least 25% of the tumor area) and intraductal carcinoma present clearly beyond the edges of the invasive tumor, or as a predominantly intraductal tumor with one or more areas of focal invasion 7, 55.', ' Invasive Lobular Carcinoma', ' Infiltrating carcinoma with mixed ductal and lobular features: cases with ambiguous or mixed histologic features that showed positive E-cadherin staining throughout the tumor by immunohistochemistry were classified as ductal type and considered eligible 56, 57.', ' Infiltrating papillary carcinoma', ' Margins: In-situ or invasive carcinoma present less than 2 mm from the inked resection margin.', ' History of cosmetic or reconstructive breast surgery', ' Psychiatric illness which would prevent the patient from giving informed consent. Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus or connective tissue diseases (lupus, systemic sclerosis or other collagen vascular diseases) which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.', ' Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and considered by their physician to be at less than 5% risk of relapse within three years.', ' Patients with diffuse (> 1 quadrant or > 5cm) suspicious microcalcifications', ' Women who are pregnant.'], 'Results': ['Outcome Measurement: ', ' Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan', ' -The study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her.', ' Time frame: Within 1 year of protocol registration', 'Results 1: ', ' Arm/Group Title: Cohort 1 (36 Gy)', ' Arm/Group Description: 36 Gy in 9 fractions BID x 4 1/2 treatment days', ' Partial Breast Irradiation (PBI)', ' Overall Number of Participants Analyzed: 50', ' Measure Type: Number', ' Unit of Measure: percentage of participants 100', 'Results 2: ', ' Arm/Group Title: Cohort 2 (40 Gy)', ' Arm/Group Description: 40 Gy in 10 fractions BID over 5 treatment days', ' Partial Breast Irradiation (PBI)', ' Overall Number of Participants Analyzed: 50', ' Measure Type: Number', ' Unit of Measure: percentage of participants 100'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/50 (6.00%)', ' Fever 1/50 (2.00%)', ' Rigors/chills 1/50 (2.00%)', ' Chest pain 1/50 (2.00%)', ' Costochondritis 1/50 (2.00%)', ' Infection (mastitis) 1/50 (2.00%)', ' Breast pain 1/50 (2.00%)', ' Breast edema 1/50 (2.00%)', ' Pelvic pain 1/50 (2.00%)', ' Dyspnea 1/50 (2.00%)', ' Erythema 1/50 (2.00%)', 'Adverse Events 2:', ' Total: 0/50 (0.00%)', ' Fever 0/50 (0.00%)', ' Rigors/chills 0/50 (0.00%)', ' Chest pain 0/50 (0.00%)', ' Costochondritis 0/50 (0.00%)', ' Infection (mastitis) 0/50 (0.00%)', ' Breast pain 0/50 (0.00%)', ' Breast edema 0/50 (0.00%)', ' Pelvic pain 0/50 (0.00%)', ' Dyspnea 0/50 (0.00%)', ' Erythema 0/50 (0.00%)']}
|
75130da8-77be-45d1-bc32-dfc97c1a1dae
|
Comparison
|
Intervention
|
NCT00975676
|
NCT00632489
|
the primary trial uses the same dosage of Triptorelin as the secondary trial uses for Capecitabine and Lapatinib.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5
] |
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] |
{'Clinical Trial ID': 'NCT00975676', 'Intervention': ['INTERVENTION 1: ', ' Triptorelin Plus Tamoxifen', ' Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.', 'INTERVENTION 2: ', ' Triptorelin Plus Exemestane', ' Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed resected breast cancer', ' Concurrent enrollment on clinical trial IBCSG-2402 (SOFT trial) required', ' Randomized to receive triptorelin in combination with either tamoxifen citrate or exemestane', ' Hormone receptor status:', ' Estrogen receptor- and/or progesterone receptor-positive tumor', ' PATIENT CHARACTERISTICS:', ' Premenopausal', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics'], 'Results': ['Outcome Measurement: ', ' Estrogen Levels (Estradiol [E2], Estrone [E1], and Estrone Sulphate [E1S]) at Different Time Points During the First 4 Years of Treatment With Triptorelin (Trip) in Combination With Either Tamoxifen (T) or Exemestane (E), IBCSG 24-02 SOFT-EST Substudy', ' Estrogen levels (estradiol [E2], estrone [E1], and estrone sulphate [E1S]) were measured at the following time points for the SOFT-EST: 0 (baseline), 3, 6, 12, 18, 24, 36, and 48 months after randomization. Some of these samples were not used, including un-scheduled sample, post surgery or vaginal bleeding, samples taken post early discontinuation (ED) or discontinuation of GnRH injections.', ' Time frame: 0 (baseline), 3, 6, 12, 18, 24, 36, and 48 months after randomization', 'Results 1: ', ' Arm/Group Title: Triptorelin Plus Tamoxifen', ' Arm/Group Description: Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.', ' Overall Number of Participants Analyzed: 26', ' Mean (Standard Deviation)', ' Unit of Measure: pg/mL Estradiol (E2) levels at baseline (0 months): 26 participants', ' 109.81 (119.151)', ' Estradiol (E2) levels at 3 months: 25 participants', ' 4.876 (7.123)', ' Estradiol (E2) levels at 6 months: 24 participants', ' 3.761 (2.02)', ' Estradiol (E2) levels at 12 months: 20 participants', ' 4.013 (2.765)', ' Estradiol (E2) levels at 18 months: 20 participants', ' 7.306 (16.325)', ' Estradiol (E2) levels at 24 months: 15 participants', ' 4.453 (3.347)', ' Estradiol (E2) levels at 36 months: 14 participants', ' 3.704 (2.138)', ' Estradiol (E2) levels at 48 months: 14 participants', ' 5.914 (8.959)', ' Estrone (E1) levels at baseline (0 months): 26 participants', ' 60.27 (52.4)', ' Estrone (E1) levels at 3 months: 25 participants', ' 17.8 (6.73)', ' Estrone (E1) levels at 6 months: 24 participants', ' 18.66 (7.54)', ' Estrone (E1) levels at 12 months: 21 participants', ' 19.05 (8.4)', ' Estrone (E1) levels at 18 months: 20 participants', ' 18.64 (9.35)', ' Estrone (E1) levels at 24 months: 15 participants', ' 18.96 (7.63)', ' Estrone (E1) levels at 36 months: 14 participants', ' 19.49 (7.32)', ' Estrone (E1) levels at 48 months: 14 participants', ' 19.14 (7.24)', ' Estrone sulfate (E1S) levels at baseline (0 months): 26 participants', ' 1437 (1825.06)', ' Estrone sulfate (E1S) levels at 3 months: 25 participants', ' 281.4 (183.44)', ' Estrone sulfate (E1S) levels at 6 months: 24 participants', ' 259 (167.23)', ' Estrone sulfate (E1S) levels at 12 months: 21 participants', ' 278.5 (236.38)', ' Estrone sulfate (E1S) levels at 18 months: 20 participants', ' 281.8 (160.6)', ' Estrone sulfate (E1S) levels at 24 months: 14 participants', ' 242.6 (96.75)', ' Estrone sulfate (E1S) levels at 36 months: 14 participants', ' 249.4 (113.27)', ' Estrone sulfate (E1S) levels at 48 months: 13 participants', ' 231.1 (93.46)', 'Results 2: ', ' Arm/Group Title: Triptorelin Plus Exemestane', ' Arm/Group Description: Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.', ' Overall Number of Participants Analyzed: 83', ' Mean (Standard Deviation)', ' Unit of Measure: pg/mL Estradiol (E2) levels at baseline (0 months): 81 participants', ' 96.55 (151.235)', ' Estradiol (E2) levels at 3 months: 67 participants', ' 3.973 (8.439)', ' Estradiol (E2) levels at 6 months: 66 participants', ' 3.672 (8.006)', ' Estradiol (E2) levels at 12 months: 68 participants', ' 2.486 (5)', ' Estradiol (E2) levels at 18 months: 65 participants', ' 2.527 (6.204)', ' Estradiol (E2) levels at 24 months: 62 participants', ' 2.52 (6.566)', ' Estradiol (E2) levels at 36 months: 60 participants', ' 1.654 (2.764)', ' Estradiol (E2) levels at 48 months: 50 participants', ' 9.073 (57.307)', ' Estrone (E1) levels at baseline (0 months): 81 participants', ' 65.42 (78.12)', ' Estrone (E1) levels at 3 months: 67 participants', ' 2.93 (3.33)', ' Estrone (E1) levels at 6 months: 66 participants', ' 2.73 (3.12)', ' Estrone (E1) levels at 12 months: 68 participants', ' 3.71 (6.35)', ' Estrone (E1) levels at 18 months: 65 participants', ' 8.47 (33.42)', ' Estrone (E1) levels at 24 months: 62 participants', ' 4.69 (9.16)', ' Estrone (E1) levels at 36 months: 60 participants', ' 4.93 (9.16)', ' Estrone (E1) levels at 48 months: 50 participants', ' 8.53 (35.07)', ' Estrone sulfate (E1S) levels at baseline (0 months): 81 participants', ' 1371 (1763.84)', ' Estrone sulfate (E1S) levels at 3 months: 67 participants', ' 56.02 (133.71)', ' Estrone sulfate (E1S) levels at 6 months: 66 participants', ' 54.7 (97.66)', ' Estrone sulfate (E1S) levels at 12 months: 68 participants', ' 47.31 (130.45)', ' Estrone sulfate (E1S) levels at 18 months: 64 participants', ' 63.52 (175.19)', ' Estrone sulfate (E1S) levels at 24 months: 59 participants', ' 73.56 (258.29)', ' Estrone sulfate (E1S) levels at 36 months: 60 participants', ' 53.27 (151.03)', ' Estrone sulfate (E1S) levels at 48 months: 46 participants', ' 112 (556.81)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/0', 'Adverse Events 2:', ' Total: 0/0']}
|
{'Clinical Trial ID': 'NCT00632489', 'Intervention': ['INTERVENTION 1: ', ' LBH589 With Capecitabine', ' MTD, LBH589 with Capecitabine', ' LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.', ' Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.', 'INTERVENTION 2: ', ' LBH589 and Lapatinib', ' LBH589 and Lapatinib', ' LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.', ' Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically documented metastatic or locally unresectable, incurable malignancy for which capecitabine is clinically appropriate.', ' Male or female patients aged 18 years old.', ' Maximum of 3 prior regimens in a metastatic setting allowed and may include other targeted agents, immunotherapy and chemotherapy.', ' Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.', ' Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.', ' Baseline MUGA or ECHO must demonstrate LVEF > than the lower limits of the institutional normal.', ' Laboratory values as follows:', ' ANC > 1500/μL', ' Hgb > 9 g/dL', ' Platelets > 100,000/uL', ' Bilirubin < 1.5 mg/dL', ' AST/SGOT < 2.5 x ULN or < 5.0 x ULN and ALT/SGPT in patients with liver metastases', ' Creatinine < 1.5 mg/dL or calculated creatinine clearance > 50 ml/min', ' Albumin > 3 g/dL', ' Potassium > lower limit of normal (LLN)', ' Phosphorous > LLN', ' Calcium > LLN', ' Magnesium > LLN', ' Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment and must commit to begin two acceptable methods of birth control, one highly effective method of birth control and one additional effective method at the same time before starting treatment.', ' Life expectancy > 12 weeks.', ' Accessible for treatment and follow-up.', ' All patients must be able to understand the nature of the study and give written informed consent prior to study entry.', ' Additional Breast Cancer Patient Subset (Part 2 and Part 3) Inclusion Criteria:', ' Incurable carcinoma of the breast, with measurable locally recurrent or metastatic disease.', ' ICH 3+ overexpression or FISH amplification documented by a local laboratory in primary or metastatic tumor tissue.', ' Prior treatment with an anthracycline, taxane, and trastuzumab or not a candidate for such treatment. Patient may have received these drugs in combination or in sequence for the treatment of locally advanced or metastatic disease and/or adjuvant therapy.', 'Exclusion Criteria:', ' Prior treatment with an HDAC inhibitor or current treatment with valproic acid.', ' Previous treatment with capecitabine.', ' Impaired cardiac function including any of the following:', ' Screening ECG with a QTc > 450 msec.', ' Congenital long QT syndrome.', ' History of sustained ventricular tachycardia.', ' Any history of ventricular fibrillation or torsades de pointes.', ' Bradycardia defined as heart rate < 50 beats per minute. Patients with a pacemaker and heart rate > 50 beats per minute are eligible.', ' Myocardial infarction or unstable angina within 6 months of study entry.', ' Congestive heart failure (NY Heart Association class III or IV).', ' Right bundle branch block and left anterior hemiblock (bifascicular block).', ' Atrial fibrillation or flutter.', ' Ongoing therapy with antiarrhythmics or other medications associated with QTc prolongation.', ' Uncorrected hypokalemia or hypomagnesaemia.', ' Uncontrolled hypertension (systolic blood pressure [BP] 180 or diastolic BP > 100 mm Hg) or uncontrolled cardiac arrhythmias.', ' Active CNS disease, including meningeal metastases.', ' Known diagnosis of human immunodeficiency virus (HIV) infection.', ' Unresolved diarrhea > CTCAE grade 1.', ' Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors.', ' Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib.', ' Patients with known hypersensitivity to 5-fluorouracil chemotherapy, investigational drug therapy, major surgery < 4 weeks prior to starting study drug or patients that have not recovered from side effects of previous therapy.', ' Patient is < 5 years free of another primary malignancy except if the other primary malignancy is not currently clinically significant or requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.', ' Concomitant use of any anti-cancer therapy or radiation therapy.', ' Pregnant or breast feeding or female of reproductive potential not using two effective methods of birth control.', ' Male patients whose sexual partners are women of childbearing potential not using effective birth control.', " Patients with gastrointestinal (GI) tract disease, causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis).", ' Other concurrent severe, uncontrolled infection or intercurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.', ' Patients taking any medications listed in "Prohibited Medications" for both capecitabine and lapatinib .', ' Patients with uncontrolled coagulopathy (PT and/or PTT > 1.2 x ULN; patient must also be on stable dose of anticoagulant for a defined medical indication).', ' Abnormal thyroid function (TSH or free T4) detected at screening. Patients with known hypothyroidism who are stable on thyroid replacement are eligible.', ' Additional Breast Cancer Patient Subset (Part 2 and Part 3) Exclusion Criteria:', ' 1. Prior treatment with lapatinib'], 'Results': ['Outcome Measurement: ', ' To Determine the Maximum Tolerated Doses (MTD) and Dose-limiting Toxicities (DLT) of LBH589 in Combination With Capecitabine When Administered to Patients With Refractory and Advanced Tumor Types That Are Sensitive to 5-fluorouracil', ' MTD for Capecitabine, BID', ' Time frame: 18 months', 'Results 1: ', ' Arm/Group Title: LBH589 With Capecitabine', ' Arm/Group Description: MTD, LBH589 with Capecitabine', ' LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.', ' Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.', ' Overall Number of Participants Analyzed: 15', ' Measure Type: Number', ' Unit of Measure: mg/m2 100', 'Results 2: ', ' Arm/Group Title: LBH589 and Lapatinib', ' Arm/Group Description: LBH589 and Lapatinib', ' LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.', ' Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.', ' Overall Number of Participants Analyzed: 0', ' Measure Type: Number', ' Unit of Measure: mg/m2 '], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/15 (40.00%)', ' Constipation 1/15 (6.67%)', ' General disorders and administration site conditions - Other, disease progression 2/15 (13.33%)', ' General disorders and administration site conditions - Other, failure to thrive 0/15 (0.00%)', ' Infections and infestations - Other, unspecified 1/15 (6.67%)', ' Platelet count decreased 1/15 (6.67%)', ' Dehydration 0/15 (0.00%)', 'Adverse Events 2:', ' Total: 3/5 (60.00%)', ' Constipation 0/5 (0.00%)', ' General disorders and administration site conditions - Other, disease progression 1/5 (20.00%)', ' General disorders and administration site conditions - Other, failure to thrive 1/5 (20.00%)', ' Infections and infestations - Other, unspecified 0/5 (0.00%)', ' Platelet count decreased 0/5 (0.00%)', ' Dehydration 1/5 (20.00%)', ' Dysarthria 0/5 (0.00%)']}
|
c71cbcd6-3786-4b90-8991-b3c6e159ae77
|
Comparison
|
Intervention
|
NCT03167359
|
NCT01385137
|
Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in the secondary trial. but not the primary trial.
|
Contradiction
|
[
0,
1,
2,
3
] |
[
0,
1,
2,
3,
4,
5
] |
{'Clinical Trial ID': 'NCT03167359', 'Intervention': ['INTERVENTION 1: ', ' Participants With Stage 0-III Breast Cancer', ' Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.', ' Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.'], 'Eligibility': ['Inclusion Criteria:', ' Participants must have one or more of the following characteristics and be eligible for breast or chest wall with or without regional nodal radiotherapy:', ' Prior Chemotherapy for Breast Cancer', ' Greater than 25 cm of breast separation (the largest distance on an axial slice of the planning CT simulation scan between the entry and exit points of the radiation beam on the body)', ' Non-Caucasian Race', ' Less than or equal to 50 years of age', ' Requiring regional nodal irradiation without evidence of N3 disease', 'Exclusion Criteria:', ' Males will be excluded', ' Women who are pregnant or nursing a child may not take part in this study'], 'Results': ['Outcome Measurement: ', ' Number of Participants Per Cutaneous Toxicity Grade (0, 1, 2, 3, 4)', ' Cutaneous toxicity rate will be assessed by the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) v.3 grading scale. THe NCI CTCAE grades go from 0 to 4. Grade 0: none. Grade 1: Mild or localized; topical intervention indicated. Grade 2: Intense or widespread; intermittent; skin changes from scratching (e.g., edema, papulation, excoriations, lichenification, oozing/crusts); limiting instrumental ADLs. Grade 3-4: Severe or life-threatening. The higher the grade, the worse the outcome.', ' Time frame: Duration of Study (Up to 18 months)', 'Results 1: ', ' Arm/Group Title: Participants With Stage 0-III Breast Cancer', ' Arm/Group Description: Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.', ' Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.', ' Overall Number of Participants Analyzed: 71', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Grade 0: 60 84.5%', ' Grade 1: 11 15.5%', ' Grade 2: 0 0.0%', ' Grade 3: 0 0.0%', 'Grade 4: 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/74 (4.05%)', ' Recurrance *3/74 (4.05%)']}
|
{'Clinical Trial ID': 'NCT01385137', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Omega-3-fatty Acid)', ' Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Arm II (Placebo)', ' Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed primary invasive adenocarcinoma of the breast', ' Stage I, II, or IIIA disease', ' No metastatic disease', ' Must have undergone modified radical mastectomy or breast-sparing surgery and recovered', ' Estrogen-receptor positive (ER+) and/or progesterone-receptor positive (PR+)', ' Currently taking a third-generation aromatase inhibitor (AI) [e.g., anastrozole (Arimidex®), letrozole (Femara®), or exemestane (Aromasin®)] for 90 days prior to registration with plans to continue for 180 days after registration', ' Must have completed the S092 Brief Pain Inventory (BPI)-Short Form within the past 14 days, and must have a worst pain/stiffness of 5 on the BPI (item #2) that has started or increased with AI therapy', ' PATIENT CHARACTERISTICS:', ' Postmenopausal', ' Zubrod performance status 0-2', ' Willing to submit blood for serum-free estradiol, total estradiol, serum inflammatory markers (IL6, TNF-α, CRP), DHA and EPA, lipid profile (LDL, HDL, triglycerides), and DNA analysis (CYP19A1)', ' Able to complete study questionnaires in English', ' At least 5 years since other malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, ductal carcinoma in situ of the breast or adequately treated stage I or II cancer from which the patient is currently in complete remission', ' Patients must not have a known allergy to soy, given that the placebo is suspended in soybean oil', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' At least 3 months since prior omega-3 fatty acid supplements and must agree to refrain from omega-3-fatty acid supplements from sources outside of this study', ' More than 28 days since prior investigational agents', ' No other medical therapy, alternative therapy, or physical therapy for joint pain/stiffness within the past 30 days', ' Patients must not be on anticoagulation medication (i.e., heparin/warfarin) because of increased risk of bleeding within 28 days prior to registration', ' Patients must not have a history of bone fracture or surgery of the afflicted knees and/or hands within 6 months prior to registration', ' Patients must not be on narcotics within 14 days of registration', ' Patients may have received corticosteroid treatment; however, the following criteria apply:', ' Patients must not have received oral or intramuscular corticosteroids within the 28 days prior to registration', ' Patients must not have received intra-articular steroids to the study, or any other, joint within 28 days prior to registration', ' Patients must not have received topical analgesics (e.g., capsaicin preparations) to the study joint or any other analgesics (e.g., opiates, tramadol; with the exception of nonsteroidal antiinflammatory drugs (NSAIDs) and acetaminophen) within 14 days prior to registration'], 'Results': ['Outcome Measurement: ', ' Week 12 Brief Pain Inventory (BPI) Worst Pain/Stiffness Score', ' Linear regression model-adjusted week 12 mean score by treatment group.', ' Purpose: To assess the severity of pain Population: Patients with pain from chronic diseases or conditions such as cancer, osteoarthritis and low back pain, or with pain from acute conditions such as postoperative pain Responsiveness: Responds to both behavioral and pharmacological pain interventions Method: Self-report or interview Scoring: Higher scores indicate more pain Range: 0-10', ' Time frame: 12 weeks post-registration', 'Results 1: ', ' Arm/Group Title: Arm I (Omega-3-fatty Acid)', ' Arm/Group Description: Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity', ' Overall Number of Participants Analyzed: 102', ' Mean (95% Confidence Interval)', ' Unit of Measure: BPI score 5.3 (4.68 to 5.91)', 'Results 2: ', ' Arm/Group Title: Arm II (Placebo)', ' Arm/Group Description: Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity', ' Overall Number of Participants Analyzed: 107', ' Mean (95% Confidence Interval)', ' Unit of Measure: BPI score 5.47 (4.86 to 6.09)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/117 (0.00%)', 'Adverse Events 2:', ' Total: 0/124 (0.00%)']}
|
ed48936e-4933-437b-a7ba-e65b4c1fd276
|
Comparison
|
Adverse Events
|
NCT02102490
|
NCT00768222
|
In contrast to the secondary trial, the primary trial did not record any cases of Skin lymphangitis, Bone marrow suppression or Allergic shock.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] |
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] |
{'Clinical Trial ID': 'NCT02102490', 'Intervention': ['INTERVENTION 1: ', ' Abemaciclib', ' 200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.'], 'Eligibility': ['Inclusion Criteria.', ' Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer.', ' Recurrent, locally advanced, unresectable or metastatic breast cancer with disease progression following anti-estrogen therapy.', ' Prior treatment with at least 2 chemotherapy regimens:', ' At least 1 of these regimens must have been administered in the metastatic setting.', ' At least 1 of these regimens must have contained a taxane.', ' No more than 2 prior chemotherapy regimens in the metastatic setting.', ' Have a performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group scale.', ' Have discontinued all previous therapies for cancer.', ' Have the presence of measureable disease as defined by Response Evaluation Criteria in Solid Tumors Version 1.1.', 'Exclusion Criteria:', ' Have either a history of central nervous system (CNS) metastasis or evidence of CNS metastasis on the magnetic resonance image of brain obtained at baseline.', ' Received prior therapy with another cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor.', ' Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug.', ' Have had major surgery within 14 days of the initial dose of study drug.', ' Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])', ' ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.', ' Time frame: From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)', 'Results 1: ', ' Arm/Group Title: Abemaciclib', ' Arm/Group Description: 200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.', ' Overall Number of Participants Analyzed: 132', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 19.7 (13.3 to 27.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 33/132 (25.00%)', ' Febrile neutropenia 1/132 (0.76%)', ' Haematotoxicity 1/132 (0.76%)', ' Neutropenia 1/132 (0.76%)', ' Sinus bradycardia 1/132 (0.76%)', ' Tachycardia 1/132 (0.76%)', ' Abdominal pain 2/132 (1.52%)', ' Abdominal pain upper 1/132 (0.76%)', ' Constipation 1/132 (0.76%)', ' Large intestinal obstruction 1/132 (0.76%)', ' Nausea 3/132 (2.27%)']}
|
{'Clinical Trial ID': 'NCT00768222', 'Intervention': ['INTERVENTION 1: ', ' Chinese Silk Suture', ' Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern', 'INTERVENTION 2: ', ' VICRYL* Plus Suture', ' Synthetic absorbable surgical suture composed of a copolymer of 90% glycolide and 10% L-lactide and containing triclosan antibacterial, used in a subcuticular closure technique'], 'Eligibility': ['Inclusion Criteria:', ' 18 years of age or older with written informed consent', ' Scheduled for a modified radical mastectomy', ' Surgical wound classified Class I/Clean using the CDC SSI Surgical Wound Classification', 'Exclusion Criteria:', ' Unable to give consent and unlikely to comply with study requirements and complete the 90-day follow up visit', ' Undergoing surgery for modified radical mastectomy with immediate breast reconstruction, cosmetic breast operations, reduction, expansion, insertion of prothesis, duct ectasia or infective breast disease or implant', ' Surgical wounds classified as Class II, III or IV using CDC SSI Surgical Wound Classification', ' Has inflammatory cancers or skin ulceration', ' Has known allergy or intolerance to triclosan', ' Has compromised wound healing or chronic immune deficiency, for example diabetes, prolonged steroid use, AIDS or substance abuse', ' Has serious heart and/or lung disease', ' Has skin scar history or family history', ' Has direct relationship to or involvement in this or other studies under the direction of the investigator or center', ' Received an experimental drug or device within 30 days prior to the planned start of treatment'], 'Results': ['Outcome Measurement: ', ' Mean Score on Cosmetic Outcome Visual Analog Scale (VAS)', ' Post-operative cosmetic outcome assessed on surgical site photographs by an independent blinded central assessor using a validated 100 mm visual analog scale, with 0 representing the worst possible scar and 100 representing the best possible scar', ' Time frame: 30 days (+/- 5) post-operative', 'Results 1: ', ' Arm/Group Title: Chinese Silk Suture', ' Arm/Group Description: Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern', ' Overall Number of Participants Analyzed: 50', ' Mean (Standard Deviation)', ' Unit of Measure: score on scale 45.4 (12.0)', 'Results 2: ', ' Arm/Group Title: VICRYL* Plus Suture', ' Arm/Group Description: Synthetic absorbable surgical suture composed of a copolymer of 90% glycolide and 10% L-lactide and containing triclosan antibacterial, used in a subcuticular closure technique', ' Overall Number of Participants Analyzed: 51', ' Mean (Standard Deviation)', ' Unit of Measure: score on scale 67.2 (18.2)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/50 (6.00%)', ' Skin lymphangitis 1/50 (2.00%)', ' Bone marrow suppression 0/50 (0.00%)', ' Allergic shock 1/50 (2.00%)', ' Deep incisional SSI 1/50 (2.00%)', 'Adverse Events 2:', ' Total: 1/51 (1.96%)', ' Skin lymphangitis 0/51 (0.00%)', ' Bone marrow suppression 1/51 (1.96%)', ' Allergic shock 0/51 (0.00%)', ' Deep incisional SSI 0/51 (0.00%)']}
|
b01e966e-6624-4740-b477-a8bbbd8eec50
|
Single
|
Adverse Events
|
NCT00820872
|
Diarrhea was the most common adverse event in cohort 1 of the primary trial.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] |
[] |
{'Clinical Trial ID': 'NCT00820872', 'Intervention': ['INTERVENTION 1: ', ' Group 1', ' Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1, trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15, and oral lapatinib ditosylate on days 1-21 (TCHL). Treatment with TCHL repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30-90 minutes on day 1 and oral lapatinib ditosylate on days 1-21 (days 1-7 of course 12 only) (LT). Treatment with LT repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 8 years.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed primary invasive adenocarcinoma of the breast fulfilling the following criteria:', ' Nonmetastatic disease', ' Operable and adequately excised', ' Patients with nonresectable deep margin invasion are eligible provided they have had or will receive radiotherapy to the region', ' Patients with histologically documented infiltration of the skin (pT4) are eligible provided they have undergone or will receive radiotherapy encompassing the tumor bed', ' Node-positive OR -negative and determined eligible to receive adjuvant trastuzumab (Herceptin®)', ' No positive or suspicious internal mammary nodes by SNS that have not been or will not be irradiated', ' No supraclavicular lymph node involvement (confirmed by fine needle aspiration or biopsy)', ' Over expression and/or amplification of HER2 in the invasive component of the primary tumor, according to one of the following:', ' 3+ over-expression by IHC (> 30% of invasive tumor cells)', ' 2+ or 3+ (in 30% or less neoplastic cells) over-expression by IHC AND in situ hybridization (FISH/CISH) test demonstrating HER2 gene amplification', ' HER2 gene amplification by FISH/CISH (> 6 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene copies to chromosome 17 signals] of > 2.2.)', ' Negative or equivocal overall result (FISH test ratio of < 2.2, < 6.0 HER2-gene copies per nucleus) and staining scores of 0, 1+, 2+, or 3+ (in 30% or less neoplastic cells) by IHC not allowed', ' Hormone receptor status known (estrogen receptor with or without progesterone receptor)', ' PATIENT CHARACTERISTICS:', ' Menopausal status not specified', ' ECOG performance status 0-1', ' Hemoglobin 10.0 g/dL', ' ANC 1,500/mm^3', ' Platelet count 100,000/mm^3', ' Serum creatinine 2.0 times upper limit of normal (ULN)', ' AST and ALT 2.5 times ULN', ' Alkaline phosphatase 2.5 times ULN', ' Bilirubin 1.5 times ULN ( 2.0 times ULN if known Gilbert syndrome)', ' Baseline LVEF 50% measured by ECHO or MUGA scan', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' No serious cardiac illness or medical condition including, but not limited to, any of the following:', ' History of documented congestive heart failure (any NYHA class) or systolic dysfunction (LVEF < 50%)', ' High-risk uncontrolled arrhythmias (e.g., ventricular tachycardia, high-grade atrioventricular-block [second degree or higher], or supraventricular arrhythmias that are not adequately rate-controlled)', ' Angina pectoris requiring antianginal medication', ' Clinically significant valvular heart disease', ' Evidence of transmural infarction on ECG', ' Poorly controlled hypertension (any reading of systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg)', ' No other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions or illness', ' None of the following:', ' Ulcerative colitis', ' Malabsorption syndrome', ' Any disease significantly affecting gastrointestinal function', ' Inability to swallow oral medication', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' No prior mediastinal irradiation except internal mammary-node irradiation for the present breast cancer', ' No prior anti-HER2 therapy for any reason', ' No prior biologic or immunotherapy for breast cancer', ' No prior resection of the stomach or small bowel', ' No other concurrent anticancer therapy including chemotherapeutic agents, biologic agents, or radiotherapy', ' No concurrent anticancer treatment in another investigational trial with hormone therapy or immunotherapy unless approved by the study chair', ' No concurrent CYP3A4 inhibitors or inducers', ' No concurrent epoetin alfa, including darbepoetin alfa', ' No concurrent oprelvekin'], 'Results': ['Outcome Measurement: ', ' Proportion of Patients Experiencing Grade 3 or 4 Diarrhea as Measured by NCI CTCAE v3.0', ' [Not Specified]', ' Time frame: Up to 10 years', 'Results 1: ', ' Arm/Group Title: Group 1', ' Arm/Group Description: Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1, trastuzumab (Herceptin ) IV over 30-90 minutes on days 1, 8, and 15, and oral lapatinib ditosylate on days 1-21 (TCHL). Treatment with TCHL repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30-90 minutes on day 1 and oral lapatinib ditosylate on days 1-21 (days 1-7 of course 12 only) (LT). Treatment with LT repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 8 years.', ' Overall Number of Participants Analyzed: 30', ' Measure Type: Number', ' Unit of Measure: percentage of patients 43'], 'Adverse Events': ['Adverse Events 1:', ' Total: 10/30 (33.33%)', ' Hemoglobin decreased 2/30 (6.67%)', ' Abdominal pain 1/30 (3.33%)', ' Colitis 1/30 (3.33%)', ' Diarrhea 7/30 (23.33%)', ' Nausea 2/30 (6.67%)', ' Rectal hemorrhage 1/30 (3.33%)', ' Fatigue 1/30 (3.33%)', ' Skin infection 1/30 (3.33%)', ' Neutrophil count decreased 1/30 (3.33%)', ' Platelet count decreased 3/30 (10.00%)', ' Dehydration 1/30 (3.33%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
92acd36d-ea44-4b98-acbc-e51382233089
|
|
Single
|
Eligibility
|
NCT01401062
|
A patient who underwent T-cell transfer therapy in the past 6 months prior, and has fully recovered from the associated toxicities, would be excluded from the primary trial.
|
Contradiction
|
[
4,
8
] |
[] |
{'Clinical Trial ID': 'NCT01401062', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (Fresolimumab 1 mg/kg)', ' Fresolimumab is administered intravenously (i.v.) at a dose of 1 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).', ' Fresolimumab', 'Radiation Therapy', 'INTERVENTION 2: ', ' Arm 2 (Fresolimumab 10 mg/kg)', ' Fresolimumab is administered intravenously (i.v.) at a dose of 10 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).', ' Fresolimumab', 'Radiation Therapy'], 'Eligibility': ['Inclusion Criteria:', ' Biopsy-proven breast cancer, metastatic (persistent or recurrent).', ' Failed 1 line of therapy (endocrine or chemotherapy) for metastatic disease.', ' Min. 3 distinct metastatic sites, at least one measurable lesion which is at least 1 cm or larger in largest diameter.', ' Must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia):', ' major surgery;', ' radiotherapy;', ' chemotherapy ( 6 weeks since therapy if a nitrosourea, mitomycin, or monoclonal antibodies such as bevacizumab);', ' immunotherapy;', ' biotherapy/targeted therapies.', ' >18 years of age.', ' Life expectancy >6 months.', ' Eastern Cooperative Oncology Group (ECOG) status 0 or 1.', ' Adequate organ function including:', ' Hemoglobin 10.0g/dL, absolute neutrophil count (ANC) 1,500/mm3, and platelets 100,000/mm3.', " Hepatic: Serum total bilirubin 1.5x upper limit of normal (ULN) (Patients with Gilbert's Disease may be included if total bilirubin is 3.0mg/dL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) 2.5xULN. If patient has known liver metastases, ALT and/or AST 5xULN are allowed.", ' Renal: creatinine clearance 60mL/min.', ' Prothrombin (PT) and partial thromboplastin times (PTT) <ULN.', ' Negative for hepatitis viruses B and C unless consistent with prior vaccination or prior infection with full recovery.', ' Patients of childbearing potential must agree to use effective contraception while on study, and for 3 months after last treatment.', ' Understand and sign written informed consent document. No consent by durable power of attorney.', 'Exclusion Criteria:', ' Second malignancy - unless following curative intent therapy, has been disease free for 2 years with probability of recurrence <5%. Curatively treated early-stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia (CIN) are allowed.', ' Concurrent cancer therapy.', ' Uncontrolled central nervous system (CNS) metastases, meningeal carcinomatosis, malignant seizures, or disease that causes or threatens neurologic compromise (e.g. unstable vertebral metastases).', ' History of ascites or pleural effusions, unless successfully treated.', ' Organ transplant, including allogeneic bone marrow transplant.', ' Immunosuppressive therapy including:', ' Systemic corticosteroid therapy, including replacement therapy for hypoadrenalism. Inhaled or topical corticosteroids are allowed (if therapy is <5 days and is limited to systemic steroids as antiemetics);', ' Cyclosporine A, tacrolimus, or sirolimus.', ' Investigational agents within 4 weeks prior to study enrollment ( 6 weeks if treatment was long-acting agent such as monoclonal antibody).', ' Significant or uncontrolled medical illness, e.g. congestive heart failure (CHF), myocardial infarction, symptomatic coronary artery disease, significant ventricular arrhythmias within the last 6 months, or significant pulmonary dysfunction. Patients with remote history of asthma or active mild asthma may participate.', ' Active infection, including unexplained fever (>38.5°C).', ' Systemic autoimmune disease (e.g. systemic lupus erythematosus, active rheumatoid arthritis).', ' Known allergy to any component of GC1008.', ' Active thrombophlebitis, thromboembolism, hypercoagulability states, bleeding, or anti-coagulation therapy (including anti platelet agents i.e. aspirin, clopidogrel, ticlopidine, dipyridamole, other agents inducing long-acting platelet dysfunction). Patients with history of deep venous thrombosis are allowed if treated, completely resolved, and no treatment for >4months.', ' Calcium >11.0mg/dL (2.75mmol/L) unresponsive or uncontrolled in response to standard therapy (e.g. bisphosphonates).', ' Patients who, in the opinion of the Investigator, have significant medical or psychosocial problems, including, but not limited to:', ' Other serious non-malignancy-associated conditions that may be expected to limit life expectancy or significantly increase the risk of SAEs;', ' Conditions, psychiatric, substance abuse, or other, that, in the opinion of the Investigator, would preclude informed consent, consistent follow-up, or compliance with any aspect of the study;', ' Pregnant or nursing women.'], 'Results': ['Outcome Measurement: ', ' Abscopal Response Rate', ' Defined as the percentage of patients who have responses (complete or partial) outside the irradiated lesions. The abscopal response is assessed at 15 weeks, and confirmed minimum 4 weeks later. The abscopal response is evaluated based on immune-related response criteria (irRC) (Wolchok et al, 2009).', ' Time frame: up to 20 weeks', 'Results 1: ', ' Arm/Group Title: Arm 1 (Fresolimumab 1 mg/kg)', ' Arm/Group Description: Fresolimumab is administered intravenously (i.v.) at a dose of 1 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).', ' Fresolimumab', ' Radiation Therapy', ' Overall Number of Participants Analyzed: 11', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 11 100.0%', 'Results 2: ', ' Arm/Group Title: Arm 2 (Fresolimumab 10 mg/kg)', ' Arm/Group Description: Fresolimumab is administered intravenously (i.v.) at a dose of 10 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).', ' Fresolimumab', ' Radiation Therapy', ' Overall Number of Participants Analyzed: 12', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 12 100.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/11 (27.27%)', ' atrial fibrillation2/11 (18.18%)', ' Hypercalcemia1/11 (9.09%)', ' Dyspnea0/11 (0.00%)', ' Disease progression2/11 (18.18%)', ' Cord compression1/11 (9.09%)', 'Adverse Events 2:', ' Total: 3/12 (25.00%)', ' atrial fibrillation0/12 (0.00%)', ' Hypercalcemia1/12 (8.33%)', ' Dyspnea1/12 (8.33%)', ' Disease progression2/12 (16.67%)', ' Cord compression0/12 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
01280892-ca31-4e46-831b-a076426f65e5
|
|
Single
|
Results
|
NCT00393939
|
Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] |
[] |
{'Clinical Trial ID': 'NCT00393939', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel + Sunitinib', ' Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks, or sunitinib 37.5 mg daily in continuous dosing (in absence of docetaxel), or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib).', 'INTERVENTION 2: ', ' Docetaxel', ' Docetaxel 100 mg/m^2 every 3 weeks'], 'Eligibility': ['Inclusion Criteria:', ' Breast cancer with evidence of unresectable locally recurrent, or metastatic disease', ' Her-2 negative tumors', 'Exclusion Criteria:', ' Patients for whom docetaxel is contraindicated', ' Clinical presentation of inflammatory carcinoma with no other measurable disease'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS)', ' PFS defined as time from date of randomization to date of the first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4.', ' Time frame: Baseline up to Month 33', 'Results 1: ', ' Arm/Group Title: Docetaxel + Sunitinib', ' Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks, or sunitinib 37.5 mg daily in continuous dosing (in absence of docetaxel), or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib).', ' Overall Number of Participants Analyzed: 296', ' Median (95% Confidence Interval)', ' Unit of Measure: months Independent radiology assessment: 8.6 (8.2 to 10.3)', " Investigator's assessment: 8.2 (7.3 to 8.6)", 'Results 2: ', ' Arm/Group Title: Docetaxel', ' Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks', ' Overall Number of Participants Analyzed: 297', ' Median (95% Confidence Interval)', ' Unit of Measure: months Independent radiology assessment: 8.3 (7.7 to 9.6)', " Investigator's assessment: 6.9 (6.5 to 7.3)"], 'Adverse Events': ['Adverse Events 1:', ' Total: 112/295 (37.97%)', ' Anaemia 4/295 (1.36%)', ' Febrile neutropenia 20/295 (6.78%)', ' Leukopenia 5/295 (1.69%)', ' Lymphatic disorder 1/295 (0.34%)', ' Neutropenia 11/295 (3.73%)', ' Thrombocytopenia 1/295 (0.34%)', ' Angina pectoris 0/295 (0.00%)', ' Atrial fibrillation 1/295 (0.34%)', ' Atrioventricular block 1/295 (0.34%)', ' Cardiac arrest 1/295 (0.34%)', ' Cardiac disorder 1/295 (0.34%)', 'Adverse Events 2:', ' Total: 79/293 (26.96%)', ' Anaemia 2/293 (0.68%)', ' Febrile neutropenia 13/293 (4.44%)', ' Leukopenia 7/293 (2.39%)', ' Lymphatic disorder 0/293 (0.00%)', ' Neutropenia 16/293 (5.46%)', ' Thrombocytopenia 0/293 (0.00%)', ' Angina pectoris 1/293 (0.34%)', ' Atrial fibrillation 0/293 (0.00%)', ' Atrioventricular block 0/293 (0.00%)', ' Cardiac arrest 0/293 (0.00%)', ' Cardiac disorder 0/293 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
959bd67a-1b2a-48da-ae44-211cbab4b665
|
|
Single
|
Intervention
|
NCT01432145
|
the primary trial patients are administered cyclophosphamide more often and in higher dosages than Methotrexate and 6-Mercaptopurine.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5
] |
[] |
{'Clinical Trial ID': 'NCT01432145', 'Intervention': ['INTERVENTION 1: ', ' 6-Mercaptopurine and Methotrexate (6MP/MTX)', ' 6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Methotrexate: Methotrexate 20mg/m2 will be taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression.', ' The reduced doses were 55mg/m2 of 6MP orally once a day, and 15mg/m2 of Methotrexate orally once a week.'], 'Eligibility': ['Inclusion Criteria:', ' Patients with proven BRCA1 or BRCA2 mutations and after appropriate exposure to standard treatment, as defined by:', ' Breast Cancer', ' Patients with initially histologically or cytologically proven locally advanced or metastatic breast cancer who may have received up to 3 previous lines of chemotherapy in the locally advanced or metastatic breast cancer setting.', ' Patients must have previously had a taxane and an anthracycline in either the adjuvant or metastatic setting, provided that these were not contraindicated.', ' Patients with hormone responsive disease should have had at least 1 line of hormone therapy for metastatic disease.', ' Prior treatment with a poly-Adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor is permissible.', ' OR Ovarian Cancer', ' Patients with initially histologically or cytologically proven ovarian cancer.', ' Patients must have disease that is platinum resistant or in whom further platinum based therapy is inappropriate.', ' Prior treatment with a PARP inhibitor is permissible.', ' Patients must have measurable disease on computerized tomography (CT) or Magnetic resonance imaging (MRI) scan as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria.', ' Age 18 years.', ' Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.', ' Life expectancy >12 weeks.', ' Written informed consent.', ' Patient willing and able to comply with all protocol requirements.', ' No prior anti-cancer treatment in previous 4 weeks, other than palliative radiotherapy (RT).', ' Haematological and biochemical indices within the ranges shown below.', ' Laboratory Test Value required', ' Haemoglobin (Hb) > 10g/dL', ' White Blood Count (WBC) > 3x109/L', ' Platelet count > 100,000/μL', ' Absolute Neutrophil count > 1.5x109/L;', ' Serum bilirubin 2 x Upper limit normal (ULN)', ' Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) and alanine aminotransferase (ALT) or ALT 5 x ULN (liver metastasis)', ' or 3 x ULN (no liver metastasis)', ' Alkaline phosphatase 5 x ULN', ' Serum creatinine 1.5 x ULN', ' Ascites and pleural effusions must be drained prior to therapy.', 'Exclusion Criteria:', ' Patients with any of the following contra-indications to thiopurines (6MP or 6TG) or methotrexate:', ' family history of severe liver failure;', ' alcoholism;', ' porphyria;', ' diffuse infiltrative pulmonary or pericardial disease;', ' known hypersensitivity to either trial agent.', ' Patients found to have a Low/Low genotype on thiopurine methyltransferase (TPMT) testing will be excluded.', ' Pregnant or breast-feeding women or women of childbearing potential unless highly effective methods of contraception are used.', ' Other active malignancy, with the exception of adequately treated in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.', ' Patients known or tested to be serologically positive for Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV).', ' Patients with active central nervous system (CNS) lesions are excluded (i.e., those with radiographically unstable, symptomatic lesions). However, patients treated with stereotactic therapy or surgery and/or whole brain radiotherapy are eligible if the patient remains without evidence of disease progression in brain 3 months prior to registration date . They must also be off corticosteroid therapy for 3 weeks prior to registration date.', ' Patients who have received anticancer agent(s) or an investigational agent within 28 days prior to study drug administration.', ' Subjects who have not recovered to within one grade level (not to exceed grade 2) of their baseline following a significant adverse event or toxicity attributed to previous anticancer treatment are excluded.'], 'Results': ['Outcome Measurement: ', ' Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population.', ' 1st stage: If less than 3/30 evaluable patients respond at 8 weeks the trial will be stopped for futility. If 3 or more out of 30 evaluable patients respond then a further 35 patients will be recruited (2nd stage) - this was met.', ' The proportion of patients responding to treatment (complete response, partial response or stable disease) at the second stage will be presented per Response Evaluation Criteria In Solid Tumours (RECIST) criteria version 1.1 measured radiologically with computerised tomography (CT) and/or magnetic resonance imaging (MRI); the same method is used at baseline and at follow-up: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Patients who yield progressive disease (PD) are classed as non-responders.', ' Time frame: 8 weeks after start of treatment', 'Results 1: ', ' Arm/Group Title: 6-Mercaptopurine and Methotrexate (6MP/MTX)', ' Arm/Group Description: 6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Methotrexate: Methotrexate 20mg/m2 will be taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression.', ' The reduced doses were 55mg/m2 of 6MP orally once a day, and 15mg/m2 of Methotrexate orally once a week.', ' Overall Number of Participants Analyzed: 67', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 22 32.8%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 33/67 (49.25%)', ' Pancytopenia 1/67 (1.49%)', ' Febrile neutropenia 1/67 (1.49%)', ' Palpitations 1/67 (1.49%)', ' Abdominal pain 5/67 (7.46%)', ' Ascites 1/67 (1.49%)', ' Colonic obstruction 1/67 (1.49%)', ' Constipation 1/67 (1.49%)', ' Nausea 1/67 (1.49%)', ' Pancreatitis 1/67 (1.49%)', ' Small intestinal obstruction 1/67 (1.49%)', ' Vomiting 2/67 (2.99%)', ' Fever 2/67 (2.99%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
92923765-76d4-4a27-a240-101690d9fea4
|
|
Comparison
|
Intervention
|
NCT00429507
|
NCT00038467
|
Unlike the secondary trial, the primary trial does not administer any medication orally or intravenously.
|
Contradiction
|
[
0,
1,
2
] |
[
0,
1,
2,
3,
4,
5
] |
{'Clinical Trial ID': 'NCT00429507', 'Intervention': ['INTERVENTION 1: ', ' Samarium 153-EDTMP + Stem Cell Transplant', ' Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones, receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose. Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP.'], 'Eligibility': ['Inclusion Criteria:', ' Stage IV breast cancer metastatic to bone and/or bone marrow only.', ' Age between 18 and 65 years.', ' Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1', ' Subjects with breast tumors with hormone receptor positive disease (ER+/PR+, ER+/PR-, or ER-/PR+) must have failed at least one hormonal-based therapy for bone only disease.', ' Subjects with breast tumors with hormone receptor negative disease must have failed at least one anthracycline and/or taxane-based therapy for bone only disease.', ' White blood cell count (WBC) >/= 3.5 x10^9/L, Hb >/= 10 g/dL, platelets >/= 100 x10^9/L.', ' Adequate pulmonary function defined as forced expiratory volume at one second (FEV1), forced vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO) (corrected for hemoglobin) >/= 50% of predicted.', ' Adequate cardiac function as evidenced by left ventricular ejection fraction (LVEF) of >/= 45%.', ' Serum total bilirubin < 2x upper limit of normal (ULN), and ALT/serum glutamate pyruvate transaminase (SGPT) < 3x ULN', ' Creatinine clearance of >/= 75 mL/min for subjects up to 50 years of age, and adjusted for age by a 10% decrease per decade for subjects of more than 50 years of age.', ' Ability to understand the study and provide informed consent.', 'Exclusion Criteria:', ' Any metastatic disease or history of metastatic disease other than skeletal metastases', ' Impending fracture, spinal cord compression, and/or potentially unstable compression fracture of vertebral body with possibility of cord compression.', ' Previous strontium-89 or samarium-153 treatment for any skeletal involvement.', ' Cumulative external beam radiation to > 20% of marrow volume or > 40 Gy to any single region of the spinal cord.', ' Prior radiation to the bladder or kidney, defined as radiation portals that directly include any volume of either kidney and/or the bladder.', ' Life expectancy severely limited by concomitant illness (less than 6 months).', ' Prior nephrectomy.', ' History of hemorrhagic cystitis obstructive uropathy or hydronephrosis.', ' Uncontrolled arrhythmia or symptomatic cardiac disease.', ' Current gross hematuria in urinalysis (UA) in the absence of vaginal bleeding.', ' Evidence of HIV-seropositivity.', ' Inability to stop any chemotherapy treatment for breast cancer within 3 weeks preceding high dose Samarium.', ' Use of any investigational agent within 30 days preceding enrollment.', ' Pregnant or lactating women.', ' Other current or prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.', ' Myelodysplastic syndrome.', ' Subject weight of more than 125 kg.'], 'Results': ['Outcome Measurement: ', ' Time to Progression', ' Time to progression is measured as the time from study entry to the development of disease progression.', ' Time frame: 7.5 Years, Study period was March 2007 to November 2014.', 'Results 1: ', ' Arm/Group Title: Samarium 153-EDTMP + Stem Cell Transplant', ' Arm/Group Description: Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones, receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose. Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP.', ' Overall Number of Participants Analyzed: 12', ' Median (Full Range)', ' Unit of Measure: Days 317 (105 to 1339)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/12 (0.00%)']}
|
{'Clinical Trial ID': 'NCT00038467', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period.', 'INTERVENTION 2: ', ' Tamoxifen', ' Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period.'], 'Eligibility': ['Inclusion Criteria:', ' postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease', 'Exclusion Criteria:', ' unresectable breast cancer', ' ER negative primary tumor'], 'Results': ['Outcome Measurement: ', ' Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study', ' DFS defined as time from randomization to earliest documentation of breast cancer relapse or death from any cause. DFS at Month 36 post-randomization was defined as probability of participants alive and disease-free at 36 months after the randomization. Participants withdrawn from the study for any reason in the absence of relapse were censored at the date they were last seen. Relapse was categorized as follows: loco-regional: ipsilateral breast or axillary nodal relapse; distant: distant relapse, including supraclavicular nodes; second primary breast cancer: contralateral breast cancer, excluding ductal carcinoma in situ.', ' Time frame: Baseline up to Month 36', 'Results 1: ', ' Arm/Group Title: Exemestane', ' Arm/Group Description: Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period.', ' Overall Number of Participants Analyzed: 2352', ' Measure Type: Number', ' Unit of Measure: probability of DFS 0.90 (0.89 to 0.92)', 'Results 2: ', ' Arm/Group Title: Tamoxifen', ' Arm/Group Description: Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period.', ' Overall Number of Participants Analyzed: 2372', ' Measure Type: Number', ' Unit of Measure: probability of DFS 0.86 (0.85 to 0.88)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 383/2320 (16.51%)', ' Anaemia * 2/2320 (0.09%)', ' Disseminated intravascular coagulation * 1/2320 (0.04%)', ' Granulocytopenia * 0/2320 (0.00%)', ' Hypofibrinogenaemia * 0/2320 (0.00%)', ' Iron deficiency anaemia * 1/2320 (0.04%)', ' Lymphadenitis * 1/2320 (0.04%)', ' Lymphadenopathy * 0/2320 (0.00%)', ' Thrombocytopenia * 1/2320 (0.04%)', ' Acute myocardial infarction * 5/2320 (0.22%)', 'Adverse Events 2:', ' Total: 439/2338 (18.78%)', ' Anaemia * 4/2338 (0.17%)', ' Disseminated intravascular coagulation * 0/2338 (0.00%)', ' Granulocytopenia * 1/2338 (0.04%)', ' Hypofibrinogenaemia * 1/2338 (0.04%)', ' Iron deficiency anaemia * 0/2338 (0.00%)', ' Lymphadenitis * 0/2338 (0.00%)', ' Lymphadenopathy * 1/2338 (0.04%)', ' Thrombocytopenia * 5/2338 (0.21%)', ' Acute myocardial infarction * 0/2338 (0.00%)']}
|
437cb2c2-63e8-4d9b-a501-4b6a35db8d2b
|
Comparison
|
Eligibility
|
NCT02872103
|
NCT02995980
|
Adequate renal, hepatic and blood work is required for entry to the primary trial and the secondary trial, this includes the following criteria; hemoglobin 11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN.
|
Contradiction
|
[
6,
7
] |
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] |
{'Clinical Trial ID': 'NCT02872103', 'Intervention': ['INTERVENTION 1: ', ' F-627', ' F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.', 'INTERVENTION 2: ', ' Placebo', ' Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.'], 'Eligibility': ['Inclusion Criteria:', ' Show evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.', ' Females 18 years of age and < 75 years of age.', ' Diagnosed with Stage II-IV breast cancer.', ' Subject is scheduled to undergo 4 cycles of TA chemotherapy (docetaxel, doxorubicin, 75, and 60 mg/m2, respectively).', ' ECOG Performance status of 2.', ' White Blood Cell count (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and a platelet count 150 109/L.', ' Demonstrate adequate renal, hepatic function (Liver function tests (ALT, AST, alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.', ' All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.', 'Exclusion Criteria:', ' Subject is <18 or 75 years of age.', ' Disease progression has occurred while receiving a taxane regimen.', ' Subject has undergone radiation therapy within 4 weeks of enrollment.', ' Subject has undergone bone marrow or stem-cell transplantation.', ' Subject has a history of prior malignancy other than breast cancer that is NOT in remission.', ' Subjects that have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e. lithium) within 6 weeks of the screening period are excluded.', ' Subject has had chemotherapy within 365 days of screening.', ' Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, ECG test, or any other relevant test.', ' History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.', ' Unwillingness to participate in the study.', " Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.", ' Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment.', ' Any condition, which can cause splenomegaly.', ' Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.', ' ALT, AST, alkaline phosphatase, total bilirubin 2.5 upper limit of normal.', ' Subject with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.', ' Women who are pregnant or breast-feeding.', ' Subject known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.', ' Subject with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.', ' Subjects with Sickle Cell disease', " Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug."], 'Results': ['Outcome Measurement: ', ' The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo', " Subjects will be randomized to F-627 or Placebo at 2:1 ratio. About 24 hours after chemotherapy, subjects will either receive 20mg fixed dose F-627 or Placebo. The subject's absolute neutrophil count (ANC) will be monitored each day post chemotherapy administration until the ANC level exceeds 2.0x10^9/L, then the value will be monitored every three days until the next chemotherapy cycle is entered. The duration of grade 4 neutropenia (ANC <0.5x10^9/L) in this cycle is the primary efficacy endpoint.", ' Time frame: The first of 4, 21 Day Chemotherapy Cycles, an average of 3 weeks', 'Results 1: ', ' Arm/Group Title: F-627', ' Arm/Group Description: F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.', ' Overall Number of Participants Analyzed: 83', ' Mean (Standard Deviation)', ' Unit of Measure: days 1.3 (1.17)', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.', ' Overall Number of Participants Analyzed: 39', ' Mean (Standard Deviation)', ' Unit of Measure: days 3.9 (1.35)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/83 (4.82%)', ' Febrile Neutropenia *3/83 (3.61%)', ' Diarrhea *0/83 (0.00%)', ' Pneumonia *0/83 (0.00%)', ' Tumor hemorrhage *1/83 (1.20%)', 'Adverse Events 2:', ' Total: 10/39 (25.64%)', ' Febrile Neutropenia *10/39 (25.64%)', ' Diarrhea *1/39 (2.56%)', ' Pneumonia *0/39 (0.00%)', ' Tumor hemorrhage *0/39 (0.00%)']}
|
{'Clinical Trial ID': 'NCT02995980', 'Intervention': ['INTERVENTION 1: ', ' Contrast Enhanced Mammography', ' Contrast-enhanced spectral mammography for the detection breast cancer .', ' DECE mammography: Contrast mammography', 'INTERVENTION 2: ', ' Standard Digital Mammogram', ' Full field digital mammography for the detection breast cancer', ' digital mammography: routine digital mammography'], 'Eligibility': ['Inclusion Criteria:', ' Signed informed consent', ' At least 19 years old', ' Glomerular filtration rate> 60', ' Heterogeneously or extremely dense breasts (BI-RADS category c or d).', 'Exclusion Criteria:', ' History of iodinated contrast allergy', ' Pregnant or lactating as determined by routine standard practice', ' Personal history of breast cancer', ' History of prior breast excisional biopsy (Patients with a history of core needle biopsy will not be excluded)', ' History of prior breast reduction mammoplasty surgery', ' History of prior breast augmentation surgery', ' Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.'], 'Results': ['Outcome Measurement: ', ' Percent Accuracy of Contrast Mammography', 'The primary endpoint of this study is to determine the accuracy of DE CE mammography when compared to full field digital mammography (FFDM) in patients with increased breast density (Breast Imaging-Reporting And Data System (BI-RADS) category c or d breast density).', 'Time frame: 1 year', 'Results 1: ', ' Arm/Group Title: Contrast Enhanced Mammography', ' Arm/Group Description: Contrast-enhanced spectral mammography for the detection breast cancer .', ' DECE mammography: Contrast mammography', ' Overall Number of Participants Analyzed: 114', ' Measure Type: Number', ' Unit of Measure: percentage of accuracy 100 (29 to 100)', 'Results 2: ', ' Arm/Group Title: Standard Digital Mammogram', ' Arm/Group Description: Full field digital mammography for the detection breast cancer', ' digital mammography: routine digital mammography', ' Overall Number of Participants Analyzed: 114', ' Measure Type: Number', ' Unit of Measure: percentage of accuracy 67 (9 to 99)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/128 (0.00%)', 'Adverse Events 2:', ' ']}
|
5a5695e8-9b84-42ad-9f34-6dd043153943
|
Single
|
Eligibility
|
NCT01847001
|
Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial.
|
Entailment
|
[
0,
1,
2
] |
[] |
{'Clinical Trial ID': 'NCT01847001', 'Intervention': ['INTERVENTION 1: ', ' Propranolol + Neoadjuvant Chemotherapy', ' Subjects will receive 2 types of chemotherapy regimens plus propranolol treatment.', ' Regimen I, involves paclitaxel (may be substituted with nab-paclitaxel; maybe given with premedication), and', ' Regimen II involves doxorubicin (maybe given with anti-nausea therapy) and cyclophosphamide (maybe given with Pegfilgrastim).', ' If your tumor is HER2 positive, you will also receive trastuzumab and pertuzumab.', ' After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor.', ' DOT imaging will be done at 4 additional time points, including beo.', ' Propranolol: Propranolol starting dose is 20mg b.i.d.; propranolol dose is up-titrated to 40mg b.i.d. to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' English or Spanish speaking women age 18', ' Heart Rate > 60 bpm', ' Systolic Blood Pressure > 100 mm/Hg', ' Deemed eligible to receive neoadjuvant chemotherapy with 12 cycles of weekly taxane therapy (paclitaxel 80mg/m2 or Abraxane 100 mg/m2 if there is a shortage of paclitaxel) followed by 4 cycles of Adriamycin (60mg/m2) and cyclophosphamide (600 mg/m2) given every 2 weeks with growth-factor support.', ' Echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) with ejection fraction > 50%.', ' Patients with hormone receptor +/- and human epidermal growth factor receptor 2 protein (HER2) +/- breast cancer are eligible', ' If a patient has HER2-positive breast cancer, Herceptin and Perjeta will be given along with taxane therapy', ' Any stage invasive breast cancer provided the primary breast tumor size is 1 cm', ' Agree to participate in research blood collection at 4 different time periods (20 ml = 4 teaspoons)', ' Agree to the evaluation of already collected core biopsy, as well as surgical resection tissue, for predictive biomarkers. The biopsy prior to Taxol #1 is optional.', 'Exclusion Criteria:', ' Patients failing to meet the inclusion criteria', ' Corrected QT interval (QTc) prolongation as defined by > 470 milliseconds on electrocardiogram (ECG)', ' First-degree Atrioventricular (AV) block on ECG in which P-R interval lengthened > 200 milliseconds; Second Degree; or Third Degree', ' On beta-blocker treatment. If discontinued, patients must have been off beta-blockers for at least 3 months.', ' History of asthma, given concern for β-blockade in this population'], 'Results': ['Outcome Measurement: ', ' Mean Adherence to Propranolol', ' Propranolol adherence was documented biweekly by pill counts and drug diary checks.', ' Time frame: Approximately 6 months', 'Results 1: ', ' Arm/Group Title: Propranolol + Neoadjuvant Chemotherapy', ' Arm/Group Description: Subjects will receive 2 types of chemotherapy regimens plus propranolol treatment.', ' Regimen I, involves paclitaxel (may be substituted with nab-paclitaxel; maybe given with premedication), and', ' Regimen II involves doxorubicin (maybe given with anti-nausea therapy) and cyclophosphamide (maybe given with Pegfilgrastim).', ' If your tumor is HER2 positive, you will also receive trastuzumab and pertuzumab.', ' After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor.', ' DOT imaging will be done at 4 additional time points, including beo.', ' Propranolol: Propranolol starting dose is 20mg b.i.d.; propranolol dose is up-titrated to 40mg b.i.d. to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.', ' Overall Number of Participants Analyzed: 10', ' Mean (Full Range)', ' Unit of Measure: Percentage of propanolol adherence 96 (89 to 100)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/10 (10.00%)', ' Colitis * [1]1/10 (10.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
33634c51-0fb9-4de1-966d-14784bca93f8
|
|
Comparison
|
Intervention
|
NCT02297412
|
NCT02667626
|
Cohort 2 of the secondary trial and the primary trial are control groups.
|
Entailment
|
[
0,
1,
2,
3,
4,
5
] |
[
0,
1,
2,
3,
4,
5,
6,
7
] |
{'Clinical Trial ID': 'NCT02297412', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Minocycline Hydrochloride)', ' Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.', 'INTERVENTION 2: ', ' Arm II (Placebo)', ' Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Ability to complete questionnaires by themselves or with assistance', ' Planned paclitaxel at a dose of 80 mg/m2 IV given, in the adjuvant breast cancer (postoperative or neo-adjuvant) setting, every week for a planned course of 12 weeks without any other concurrent cytotoxic chemotherapy (trastuzumab and/or other antibody and/or small molecule treatment is allowed, except for PARP inhibitors)', ' Life expectancy > 6 months', ' Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1', ' Negative pregnancy test (serum or urine) done =< 7 days prior to registration, for women of childbearing potential only (determined per clinician discretion)', 'Exclusion Criteria:', ' Any of the following:', ' Pregnant women', ' Nursing women', ' Men or women of childbearing potential who are unwilling to employ adequate contraception', ' Previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause', ' History of allergic or other adverse reactions to minocycline', ' Prior exposure to neurotoxic chemotherapy', ' Diagnosis of fibromyalgia', ' Current or planned use of methoxyflurane, oral contraceptives, isotretinoin, penicillin, or ergot alkaloids', ' History of allergic or other adverse reactions to tetracycline'], 'Results': ['Outcome Measurement: ', ' Area Under the Curve (AUC) Per Assessment (aAUCpa) of Average Pain (Item 3 on the Daily Post-Paclitaxel Questionnaire)', ' Average Area Under the Curve (AUC) per assessment (aAUCpa) of average pain (item 3 on the Daily Post-Paclitaxel Questionnaire; "Please rate the same aches/pain by circling the ONE number that best describes your aches/pains on the AVERAGE in the last 24 hours.") over 12 weeks. Scores are reported on a 0-100 scale, where 100=better outcome quality of life (QOL). The aAUCpa is the average of each AUC between each sequential assessment from treatment-initiation to the week-12 assessment.', ' Time frame: Up to 12 weeks', 'Results 1: ', ' Arm/Group Title: Arm I (Minocycline Hydrochloride)', ' Arm/Group Description: Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.', ' Overall Number of Participants Analyzed: 20', ' Median (Full Range)', ' Unit of Measure: scores on a scale 96.0 (54.4 to 100.0)', 'Results 2: ', ' Arm/Group Title: Arm II (Placebo)', ' Arm/Group Description: Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.', ' Overall Number of Participants Analyzed: 20', ' Median (Full Range)', ' Unit of Measure: scores on a scale 84.3 (46.5 to 99.7)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/22 (13.64%)', ' Lung infection 1/22 (4.55%)', ' Lymphocyte count decreased 2/22 (9.09%)', ' Rash maculo-papular 0/22 (0.00%)', 'Adverse Events 2:', ' Total: 1/23 (4.35%)', ' Lung infection 0/23 (0.00%)', ' Lymphocyte count decreased 0/23 (0.00%)', ' Rash maculo-papular 1/23 (4.35%)']}
|
{'Clinical Trial ID': 'NCT02667626', 'Intervention': ['INTERVENTION 1: ', ' SCPR Intervention', ' Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks.', ' Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence', 'INTERVENTION 2: ', ' Control', ' Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR.', ' Control: Web-based resource lists and text-based study adherence reminders'], 'Eligibility': ['Inclusion:', ' Breast cancer (Stages 0-III) diagnosis', ' Breast cancer diagnosis age 45 years', ' 5 years since breast cancer diagnosis', ' Current age 18 to 50 years', ' Completed treatment with surgery, radiation and chemotherapy (if applicable)', ' Able to read English', ' Able to consent to the study', ' Access to an Internet connection', ' Exclusion:', ' Women who are pregnant at recruitment'], 'Results': ['Outcome Measurement: ', ' Number of Participants With a 50% Decrease in Hot Flash Score', ' 50% decrease in hot flash score. The hot flash score is calculated as the weighted sum of the number of hot flashes in each severity category multiplied by a severity-exclusive weight (1-mild, 2-moderate, 3-severe, 4-very severe). The minimum is 0 and there is no maximum. For example a woman can experience an unlimited number of hot flashes per day. Higher score indicates worse outcome.', ' Time frame: Baseline and 24 weeks', 'Results 1: ', ' Arm/Group Title: SCPR Intervention', ' Arm/Group Description: Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks.', ' Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence', ' Overall Number of Participants Analyzed: 86', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 50 58.1%', 'Results 2: ', ' Arm/Group Title: Control', ' Arm/Group Description: Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR.', ' Control: Web-based resource lists and text-based study adherence reminders', ' Overall Number of Participants Analyzed: 96', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 53 55.2%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/86 (0.00%)', 'Adverse Events 2:', ' Total: 0/96 (0.00%)']}
|
8e46dc77-fa36-4231-a124-0ff6392891a1
|
Single
|
Intervention
|
NCT00407888
|
Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] |
[] |
{'Clinical Trial ID': 'NCT00407888', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given orally', ' filgrastim: Given SC', ' paclitaxel albumin-stabilized nanoparticle formulation: Given IV', ' trastuzumab: Given IV', ' laboratory biomarker analysis: Correlative studies', ' quality-of-life assessment: Ancillary studies'], 'Eligibility': ['Inclusion Criteria:', ' Have a histologically confirmed diagnosis of primary breast carcinoma that has been surgically resected; (this regimen is not intended for neoadjuvant treatment)', ' 4 + nodes', ' OR if 1-3 + nodes, either ER OR HER-2/neu+', ' OR have high-risk node negative disease that is HER-2/neu positive OR >= 2.0 cm tumor size', ' HER-2/new + definition: patient has known tumor HER-2/new expression = 3+ by IHC or, if 2+ by IHC confirmed to be FISH positive', ' Patients with clinically apparent cardiac disease, or history of same, are not eligible; patients who are >= 60 years of age or who have a history of hypertension must have an echocardiogram or MUGA prior to enrollment; patients with breast cancer that is HER-2/neu positive and a treatment plan that includes Herceptin must have an echocardiogram or MUGA scan prior to enrollment; the LVEF must be within the institutional normal range; if LVEF is > 75%, the investigator should consider having the LVEF reviewed or repeating the MUGA prior to registration', ' WBC >= 4,000', ' ANC >= 1,500', ' Platelet count >= 100,000', ' Serum creatinine =< 1.5 x IULN', ' Bilirubin =< 2.0', ' SGOT/SGPT/alkaline phosphatase =< 2 x IULN', ' Elevations greater than these require metastatic work up', ' Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific screening procedures', 'Exclusion Criteria:', ' Except for the following, no other malignancy is allowed: synchronous ipsilateral breast cancer of the same subtype (ER/PR, HER-2/neu), adequately treated basal cell or squamous cell skin cancer, in situcervical cancer or other stage I or II cancer from which the patient has been disease free for at least 5 years', ' Patients with cardiac disease that would preclude the use of Adriamycin, Taxol or Herceptin are not eligible; this includes:', ' Angina pectoris that requires the use of antianginal medication', ' Cardiac arrhythmia requiring medication', ' Severe conduction abnormality', ' Clinically significant valvular disease', ' Cardiomegaly on chest x-ray', ' Ventricular hypertrophy on EKG', ' Uncontrolled hypertension, (diastolic greater than 100 mm/Hg or systolic > 200 mm/hg)', ' Current use of digitalis or beta blockers for CHF', ' Clinically significant pericardial effusion', ' Myocardial infarction documented as a clinical diagnosis or by EKG or any other test', ' Documented congestive heart failure', ' Documented cardiomyopathy', ' Documented arrhythmia or cardiac valvular disease that requires medication or is medically significant', ' Patients who have received prior chemotherapy or radiotherapy are not eligible', ' Patients who are pregnant or breastfeeding are not eligible; women of child bearing potential must agree to practice adequate contraception', ' Patients with active infection are not eligible', ' Patients who are known to be infected with HIV, hepatitis B or hepatitis C are not eligible; testing is not required unless there is a high index of clinical suspicion', ' Patients suffering from psychiatric impairment are not eligible'], 'Results': ['Outcome Measurement: ', ' Disease-free Survival Following a Dose-intensive Weekly Regimen of Adriamycin + Oral Cyclophosphamide Augmented With G-CSF Support Followed by Abraxane and Herceptin', ' [Not Specified]', ' Time frame: 2 years', 'Results 1: ', ' Arm/Group Title: Arm I', ' Arm/Group Description: Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given orally', ' filgrastim: Given SC', ' paclitaxel albumin-stabilized nanoparticle formulation: Given IV', ' trastuzumab: Given IV', ' laboratory biomarker analysis: Correlative studies', ' quality-of-life assessment: Ancillary studies', ' Overall Number of Participants Analyzed: 60', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 56 93.3%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/60 (8.33%)', ' Febrile Neutopenia1/60 (1.67%)', ' Hemorrhoidal Hemorrhage1/60 (1.67%)', ' Mucositis1/60 (1.67%)', ' Fever1/60 (1.67%)', ' Possible Pneumoncystis Pneumonia1/60 (1.67%)', ' Dehydration1/60 (1.67%)', ' Musculoskeletal Chest Pain1/60 (1.67%)', ' Pneumothorax due to MVA1/60 (1.67%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
d11b0673-42a9-46c0-887f-d5a9b038264f
|
|
Single
|
Eligibility
|
NCT03197389
|
All women (regardless of Reproductive status) must use adequate methods of contraception to be eligible for the primary trial.
|
Contradiction
|
[
0,
16,
17,
18
] |
[] |
{'Clinical Trial ID': 'NCT03197389', 'Intervention': ['INTERVENTION 1: ', ' Cohort A1', ' Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.', ' Pembrolizumab: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.', 'INTERVENTION 2: ', ' Cohort A2', ' Cohort A2 will include patients with ER/PR negative and Her2 positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.', ' Pembrolizumab: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.'], 'Eligibility': ['Inclusion Criteria:', ' Be willing and able to provide written informed consent/assent for the trial.', ' Be 18 years of age on day of signing informed consent.', ' Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion if needed. Newly obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 0. Subjects for whom newly obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor.', ' Have a performance status of 0 or 1 on the ECOG Performance Scale.', ' Have non-metastatic operable newly diagnosed primary invasive carcinoma of the breast that is:', ' Histologically confirmed', ' ER/PR negative or ER positive. ER/PR status will be evaluated with Allred score (semi-quantitative measurement) following ASCO CAP guidelines 2009.', ' HER2 negative of positive. HER2 status will be evaluated using IHC followed by FISH with dual probe (ASCO CAP guidelines 2013).', ' Primary tumor size greater than 1 cm, measured by any of clinical examination, mammography, ultrasound or magnetic resonance imaging', ' Any clinical nodal status', ' Have evaluable core biopsy for IHC', ' Be willing to provide plasma/blood samples', ' After neo-adjuvant chemotherapy (cohort B1 and B2) patients must have residual tumor >1cm and must be willing to provide evaluable new tumor biopsy for IHC', ' Demonstrate adequate organ function, all screening labs should be performed within 14 days of treatment initiation.', ' Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.', ' Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception, for the course of the study through 120 days after receiving the study medication.', ' Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.', ' Male subjects of childbearing potential (Section 5.7.1) must agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception, until 120 after receiving the study therapy.', ' Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.', 'Exclusion Criteria:', ' Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of receiving the treatment dose.', ' Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to receiving the trial treatment.', ' Has a known history of active TB (Bacillus Tuberculosis)', ' Hypersensitivity to pembrolizumab or any of its excipients.', ' Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.', ' Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 0 or who has not recovered (i.e., Grade 1 or at baseline) from adverse events due to a previously administered agent.', ' Note: Subjects with Grade 2 neuropathy are an exception to this criterion and may qualify for the study.', ' Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.', ' Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.', ' Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.', ' Has known history of (non-infectious) pneumonitis that required steroids or current pneumonitis.', ' Has an active infection requiring systemic therapy.', " Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.", ' Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.', ' Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.', ' Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent or co-inhibitory T-cell receptor therapy (e.g. OX40-CD137, CTLA-4)', ' Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).', ' Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).', ' Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.'], 'Results': ['Outcome Measurement: ', ' PD-1 Expression', ' PD-1 expression after a single dose of pembrolizumab.', " Immunohistochemical stains were performed on 5-μm thick sections using an automatic immunostainer (Bond Max Autostainer, Leica) according to the manufacturer's instructions.", ' A monoclonal antibodie was used for PD1 (clone NAT105, Abcam). PD1 expression on sTIL was assessed semi quantitatively.', ' Time frame: 2 years', 'Results 1: ', ' Arm/Group Title: Cohort A1', ' Arm/Group Description: Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda ) administered intravenously at 200 mg 10 +/- 4 days before surgery.', ' Pembrolizumab: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.', ' Overall Number of Participants Analyzed: 15', ' Median (Full Range)', ' Unit of Measure: percentage 0 (0 to 10)', 'Results 2: ', ' Arm/Group Title: Cohort A2', ' Arm/Group Description: Cohort A2 will include patients with ER/PR negative and Her2 positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda ) administered intravenously at 200 mg 10 +/- 4 days before surgery.', ' Pembrolizumab: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.', ' Overall Number of Participants Analyzed: 4', ' Median (Full Range)', ' Unit of Measure: percentage 0 (0 to 1)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/16 (0.00%)', 'Adverse Events 2:', ' Total: 0/5 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
e08c196a-e3f0-420b-a252-7e2818949038
|
|
Comparison
|
Adverse Events
|
NCT01901146
|
NCT00209092
|
Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial.
|
Entailment
|
[
0,
2
] |
[
0,
4
] |
{'Clinical Trial ID': 'NCT01901146', 'Intervention': ['INTERVENTION 1: ', ' ABP 980', ' Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.', 'INTERVENTION 2: ', ' Trastuzumab', ' Participants received trastuzumab at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.'], 'Eligibility': ['Inclusion Criteria:', ' Females 18 years of age', ' Histologically confirmed invasive breast cancer', ' Planning for surgical resection of breast tumor and sentinel node or axillary lymph node resection', ' Planning neoadjuvant chemotherapy', ' HER2 positive disease', ' Measurable disease in the breast after diagnostic biopsy, defined as longest diameter 2.0 cm', ' Known estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at study entry', ' Normal bone marrow function', ' Normal hepatic function', ' Normal renal function', ' Subjects must sign an Institutional Review Board/Ethics Committee (IRB/EC)-approved informed consent form before any study specific procedures', ' Inclusion Criteria for Randomization:', ' Left ventricular ejection fraction (LVEF) of 55% by 2D echocardiogram', ' Complete all 4 cycles of run-in chemotherapy', 'Exclusion Criteria:', ' Bilateral breast cancer', ' Presence of known metastases', ' Received prior treatment, including chemotherapy, biologic therapy, radiation or surgery with the exception of diagnostic biopsy for primary breast cancer', ' Other concomitant active malignancy or history of malignancy in the past 5 years except treated basal cell carcinoma of the skin or carcinoma in situ of the cervix', ' Pre-existing clinically significant ( grade 2) peripheral neuropathy', ' Any history of documented or current congestive heart failure, current high-risk uncontrolled arrhythmias, current angina pectoris requiring a medicinal product, current clinically significant valvular disease, current evidence of transmural infarction on electrocardiogram (ECG), or current poorly controlled hypertension', ' Severe dyspnea at rest requiring supplementary oxygen therapy', ' History of positivity for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus (HIV)', ' Recent infection requiring a course of systemic anti-infectives that were completed 14 days before enrollment (with the exception of uncomplicated urinary tract infection)', ' Woman of childbearing potential who is pregnant or is breast feeding', ' Woman of childbearing potential who is not consenting to use highly effective methods of birth control (eg, true abstinence [periodic abstinence (eg calendar ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception], sterilization, or other non-hormonal forms of contraception) during treatment and for at least 7 months after the last administration of the protocol specified treatment', ' Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study', ' Other investigational procedures while participating in this study are excluded', ' Subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products, trastuzumab, murine proteins, or to any of the excipients', ' Subject previously has enrolled and/or has been randomized in this study', ' Subject likely to not be available to complete all protocol required study visits or procedures', ' History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With a Pathologic Complete Response', ' Pathologic complete response (pCR) was defined as the absence of invasive tumor cells in the breast tissue and in axillary lymph nodes, regardless of residual ductal carcinoma in situ (DCIS).', ' Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.', ' Time frame: 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase', 'Results 1: ', ' Arm/Group Title: ABP 980', ' Arm/Group Description: Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m paclitaxel Q3W for 4 cycles.', ' Overall Number of Participants Analyzed: 358', ' Measure Type: Number', ' Unit of Measure: percentage of participants 48.0', 'Results 2: ', ' Arm/Group Title: Trastuzumab', ' Arm/Group Description: Participants received trastuzumab at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m paclitaxel Q3W for 4 cycles.', ' Overall Number of Participants Analyzed: 338', ' Measure Type: Number', ' Unit of Measure: percentage of participants 40.5'], 'Adverse Events': ['Adverse Events 1:', ' Total: 18/364 (4.95%)', ' Febrile neutropenia 3/364 (0.82%)', ' Atrial fibrillation 1/364 (0.27%)', ' Cardio-respiratory arrest 1/364 (0.27%)', ' Sinus bradycardia 1/364 (0.27%)', ' Ventricular extrasystoles 0/364 (0.00%)', ' Enterocolitis 0/364 (0.00%)', ' Faecaloma 0/364 (0.00%)', ' Gastric ulcer perforation 0/364 (0.00%)', ' Gastrointestinal toxicity 0/364 (0.00%)', ' Pancreatitis acute 0/364 (0.00%)', 'Adverse Events 2:', ' Total: 5/361 (1.39%)', ' Febrile neutropenia 0/361 (0.00%)', ' Atrial fibrillation 0/361 (0.00%)', ' Cardio-respiratory arrest 0/361 (0.00%)', ' Sinus bradycardia 0/361 (0.00%)', ' Ventricular extrasystoles 0/361 (0.00%)', ' Enterocolitis 0/361 (0.00%)', ' Faecaloma 0/361 (0.00%)', ' Gastric ulcer perforation 0/361 (0.00%)', ' Gastrointestinal toxicity 1/361 (0.28%)', ' Pancreatitis acute 0/361 (0.00%)']}
|
{'Clinical Trial ID': 'NCT00209092', 'Intervention': ['INTERVENTION 1: ', ' Arm A:Sequential Therapy', ' Docetaxel will be given at 100mg/m^2 intravenously Day1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth D1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).', 'INTERVENTION 2: ', ' Arm B:Concurrent Therapy', ' Docetaxel will be given at 50mg/m^2 intravenously Day 1 concomitantly with capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed breast carcinoma.', ' Early stage breast cancer (stage 1, 2, 3).', ' No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes.', ' 18 years of age or older.', ' Final eligibility for a clinical trial is determined by the health professionals conducting the trial.', 'Exclusion Criteria:', ' Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer.', ' Major surgery within 28 days of study entry.', ' Evidence of central nervous system (CNS) metastases.', ' Final eligibility for a clinical trial is determined by the health professionals conducting the trial.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Complete Pathologic Response Rate to Pre-operative Treatment in Arm A (Docetaxel for 4 Cycles Followed by Capecitabine for 4 Cycles) or Arm B (Docetaxel + Capecitabine for 8 Cycles) in Patients With Early Stage Breast Cancer.', ' Pathologic complete response (pCR): Absence of invasive breast cancer in the breast.', ' Overall Clinical Response=Complete response(CR-complete disappearance of all measurable malignant disease)+partial response(PR-reduction by at least 30%)', ' Stable disease (SD): No decrease or <25% increase in the sum of the products of the longest perpendicular diameters of all measurable lesions.', ' Progressive disease (PD): A 20% or greater increase in a single lesion, OR reappearance of any lesion which has disappeared, OR clear worsening of any evaluable disease OR appearance of any new lesion/site.', 'Time frame: 1 year', 'Results 1: ', ' Arm/Group Title: Arm A:Sequential Therapy', ' Arm/Group Description: Docetaxel will be given at 100mg/m^2 intravenously Day1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth D1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).', ' Overall Number of Participants Analyzed: 25', ' Measure Type: Number', ' Unit of Measure: participants Pathologic Complete Response-Overall population: 2', ' Overall Clinical Response: 15', ' Stable disease: 3', ' Progressive Disease: 7', 'Results 2: ', ' Arm/Group Title: Arm B:Concurrent Therapy', ' Arm/Group Description: Docetaxel will be given at 50mg/m^2 intravenously Day 1 concomitantly with capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).', ' Overall Number of Participants Analyzed: 26', ' Measure Type: Number', ' Unit of Measure: participants Pathologic Complete Response-Overall population: 3', ' Overall Clinical Response: 23', ' Stable disease: 1', ' Progressive Disease: 2'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/25 (24.00%)', ' Neutropenia *3/25 (12.00%)', ' Anemia *0/25 (0.00%)', ' Febrile Neutropenia *0/25 (0.00%)', ' Chest Pain *0/25 (0.00%)', ' Diarrhea *1/25 (4.00%)', ' Fatigue *1/25 (4.00%)', ' Liver Tests *0/25 (0.00%)', ' Neuropathy *0/25 (0.00%)', ' Syncope *0/25 (0.00%)', ' Hand and Foot Syndrome *1/25 (4.00%)', 'Adverse Events 2:', ' Total: 11/26 (42.31%)', ' Neutropenia *3/26 (11.54%)', ' Anemia *1/26 (3.85%)', ' Febrile Neutropenia *1/26 (3.85%)', ' Chest Pain *1/26 (3.85%)', ' Diarrhea *1/26 (3.85%)', ' Fatigue *0/26 (0.00%)', ' Liver Tests *1/26 (3.85%)', ' Neuropathy *1/26 (3.85%)', ' Syncope *1/26 (3.85%)', ' Hand and Foot Syndrome *1/26 (3.85%)']}
|
83511f04-e07c-438d-bf1e-f680fa49b384
|
Single
|
Adverse Events
|
NCT00290758
|
There was one genitourinary adverse events recorded in the primary trial.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] |
[] |
{'Clinical Trial ID': 'NCT00290758', 'Intervention': ['INTERVENTION 1: ', ' Arm A (Genistein)', ' Patients receive oral genistein once daily for up to 6 months.', 'INTERVENTION 2: ', ' Arm B (Placebo)', ' Patients receive oral placebo once daily for up to 6 months.'], 'Eligibility': ['Inclusion Criteria:', ' No known soy intolerance', ' At increased risk of developing breast cancer in >= 1 previously unaffected breast, as defined by any of the following:', ' Estimated 5-year risk of developing breast cancer using the Gail model, as defined by 1 of the following:', ' Gail score >= 1.66%', ' Gail score >= 0.1% for women age 20-29 years', ' Gail score >= 1.0% for women age 30-39 years', ' Estimated 5-year risk of developing breast cancer using the Claus model:', ' Claus score >= 1.66%', ' Claus score >= 0.1% for women age 20-29 years', ' Claus score >= 1.0% for women age 30-39 years', ' Prior diagnosis of unilateral in situ or invasive breast cancer OR history of atypical hyperplasia, BRCA 1 and/or BRCA 2 positivity', ' History of lobular carcinoma in situ', ' No evidence of breast cancer, as determined by a negative mammogram within the past 6 months and a history and physical', ' No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago', ' Pre- or postmenopausal', ' ECOG performance status 0-1', ' Hemoglobin > 10.0 g/dL', ' Platelet count > 100,000/mm^3', ' Absolute neutrophil count > 1,000/mm^3', ' Creatinine < 2.0 mg/dL', ' SGPT < 82 U/L', ' SGOT < 68 U/L', ' Bilirubin < 3 mg/dL* [Note: * Patients with a higher level of bilirubin due to a familial metabolism may be eligible at the discretion of the investigator]', ' Life expectancy > 2 years', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective barrier contraception', ' Must be willing to keep a dietary diary', ' No venous thrombosis within the past year', ' No unrecognized or poorly controlled thyroid disease', ' No other cancer within the past 5 years except nonmelanomatous skin cancer or noninvasive cervical cancer', ' No other medical condition that, in the opinion of the investigator, would jeopardize either the patient or the integrity of the data obtained', ' None of the following for >= 2 weeks before the first random fine needle aspiration and during study participation:', ' Oral contraceptives', ' Soy supplements', ' High soy-containing foods', ' Fish oil supplements', ' Multivitamins', ' Vitamins C and E', ' Daily aspirin or nonsteroidal', ' Anti-inflammatory drugs', ' No other concurrent investigational agents', ' No concurrent warfarin or other blood thinners', ' Female patient', 'Exclusion Criteria:', ' Women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously', ' Currently pregnant, or planning to become pregnant during the study period', ' History of venous thrombosis within past year', ' Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained', ' History of other cancer within the past five years, excluding non-melanomatous skin cancer, and non-invasive cervical cancer', ' Known soy intolerance', " Unrecognized or uncontrolled thyroid disease, subjects may be on synthroid, but thyroid function must be in normal range or the patient's physician must document that the patient's thyroid is controlled.", ' Currently receiving any other investigational agents', ' Currently on coumadin, or other blood thinners', ' History of breast augmentation implants.', ' Rusults from patients who have <4000 epithelial cells in either the first or the second random Fine-needle aspiration (rFNA) will not be included in the study.'], 'Results': ['Outcome Measurement: ', ' Change in Breast Epithelial Cell Proliferation as Measured by Ki-67 Labeling', ' Breast epithelial tissue samples are used to measure the expression of the cell proliferation marker Ki-67, by counting the percentage of positive MIB-1 immunostained cells, denoted the Ki-67 labeling index. Mean change in the Ki-67 labeling index is assessed from baseline to 6 month follow up.', ' Time frame: 6 months - baseline', 'Results 1: ', ' Arm/Group Title: Arm A (Genistein)', ' Arm/Group Description: Patients receive oral genistein once daily for up to 6 months.', ' Overall Number of Participants Analyzed: 49', ' Mean (Standard Deviation)', ' Unit of Measure: Ki-67 labeling index Postmenopausal with ER- Cancer: 4 participants', ' .325 (.343)', ' Postmenopausal with ER+ Cancer: 2 participants', ' -.418 (.191)', ' Postmenopausal Without Cancer: 14 participants', ' -.092 (.525)', ' Premonopausal with ER- Cancer: 2 participants', ' -.335 (.930)', ' Premenopausal with ER+ Cancer: 4 participants', ' -.387 (.806)', ' Premenopausal without cancer: 23 participants', ' 1.171 (2.922)', 'Results 2: ', ' Arm/Group Title: Arm B (Placebo)', ' Arm/Group Description: Patients receive oral placebo once daily for up to 6 months.', ' Overall Number of Participants Analyzed: 49', ' Mean (Standard Deviation)', ' Unit of Measure: Ki-67 labeling index Postmenopausal with ER- Cancer: 2 participants', ' .289 (.541)', ' Postmenopausal with ER+ Cancer: 5 participants', ' -.461 (.458)', ' Postmenopausal Without Cancer: 15 participants', ' -.122 (.735)', ' Premonopausal with ER- Cancer: 2 participants', ' .873 (.786)', ' Premenopausal with ER+ Cancer: 4 participants', ' -.204 (1.329)', ' Premenopausal without cancer: 21 participants', ' 0.557 (1.546)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/62 (9.68%)', ' Musculoskeletal * 1/62 (1.61%)', ' Mood Alteration: Depression * 1/62 (1.61%)', ' renal - Other * 1/62 (1.61%)', ' Obstruction, GU: Uterus * 1/62 (1.61%)', ' Sexual * 0/62 (0.00%)', ' Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%)', ' Ulceration * 1/62 (1.61%)', 'Adverse Events 2:', ' Total: 1/64 (1.56%)', ' Musculoskeletal * 0/64 (0.00%)', ' Mood Alteration: Depression * 0/64 (0.00%)', ' renal - Other * 0/64 (0.00%)', ' Obstruction, GU: Uterus * 0/64 (0.00%)', ' Sexual * 1/64 (1.56%)', ' Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%)', ' Ulceration * 0/64 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94
|
|
Single
|
Adverse Events
|
NCT00475670
|
compared to cohort 1 of the primary trial, there are more cases of every observed adverse event in cohort 2.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] |
[] |
{'Clinical Trial ID': 'NCT00475670', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Monotherapy', ' Participants received either an initial loading dose of trastuzumab 4 mg/kg, IV, on Day 1, followed by 2 mg/kg, IV, once per week, or an initial loading dose of 8 mg/kg IV on Day 1, followed by 6 mg/kg IV once every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.', 'INTERVENTION 2: ', ' Trastuzumab, Taxane', " Participants received either an initial loading dose of trastuzumab 4 mg/kg IV on Day 1, followed by 2 mg/kg IV once per week, or an initial loading dose of 8 mg/kg IV on Day 1, followed by 6 mg/kg IV every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death. Participants also received one of the following taxanes (at the investigator's discretion) for at least 18 weeks: docetaxel 100 mg/m^2, IV, once every 3 weeks, OR, paclitaxel 75 mg/m^2, IV, once per week, OR, paclitaxel 175 mg/m^2, IV, once every 3 weeks."], 'Eligibility': ['Inclusion Criteria:', ' at least 10 months of Herceptin treatment for HER2-positive early breast cancer;', ' metastatic breast cancer >=12 months after discontinuation of Herceptin;', ' measurable disease.', 'Exclusion Criteria:', ' previous chemotherapy for metastatic breast cancer;', ' brain metastases;', ' invasive malignancy other than metastatic breast cancer.'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Guidelines', ' CR was defined for target lesions (TLs) as the disappearance of all lesions, and for nontarget lesions (NTLs) as the disappearance of all nontarget nonmeasurable lesions. PR was defined for TLs as at least a 30 percent (%) decrease from baseline (BL) in the sum of longest diameter (SLD) of TLs. 95% confidence interval for one-sample binomial using Pearson-Clopper method.', ' Time frame: Baseline (BL); Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited', 'Results 1: ', ' Arm/Group Title: Trastuzumab Monotherapy', ' Arm/Group Description: Participants received either an initial loading dose of trastuzumab 4 mg/kg, IV, on Day 1, followed by 2 mg/kg, IV, once per week, or an initial loading dose of 8 mg/kg IV on Day 1, followed by 6 mg/kg IV once every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.', ' Overall Number of Participants Analyzed: 0', ' Measure Type: Number', ' Unit of Measure: percentage of participants ', 'Results 2: ', ' Arm/Group Title: Trastuzumab, Taxane', " Arm/Group Description: Participants received either an initial loading dose of trastuzumab 4 mg/kg IV on Day 1, followed by 2 mg/kg IV once per week, or an initial loading dose of 8 mg/kg IV on Day 1, followed by 6 mg/kg IV every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death. Participants also received one of the following taxanes (at the investigator's discretion) for at least 18 weeks: docetaxel 100 mg/m^2, IV, once every 3 weeks, OR, paclitaxel 75 mg/m^2, IV, once per week, OR, paclitaxel 175 mg/m^2, IV, once every 3 weeks.", ' Overall Number of Participants Analyzed: 41', ' Measure Type: Number', ' Unit of Measure: percentage of participants 61.0 (48.7 to 80.4)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/3 (0.00%)', ' Febrile Neutropenia * 0/3 (0.00%)', ' Neutropenia * 0/3 (0.00%)', ' Sudden Death * 0/3 (0.00%)', ' Bacterial Infection * 0/3 (0.00%)', ' Bronchitis * 0/3 (0.00%)', ' Sepsis * 0/3 (0.00%)', ' Lymphoedema * 0/3 (0.00%)', 'Adverse Events 2:', ' Total: 6/41 (14.63%)', ' Febrile Neutropenia * 1/41 (2.44%)', ' Neutropenia * 1/41 (2.44%)', ' Sudden Death * 1/41 (2.44%)', ' Bacterial Infection * 1/41 (2.44%)', ' Bronchitis * 1/41 (2.44%)', ' Sepsis * 1/41 (2.44%)', ' Lymphoedema * 1/41 (2.44%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
72bb3c6e-66b0-4380-9da2-5a5867d715fd
|
|
Single
|
Adverse Events
|
NCT01365845
|
More than 18 participants in the primary trial had radiation dermatitis.
|
Contradiction
|
[
3
] |
[] |
{'Clinical Trial ID': 'NCT01365845', 'Intervention': ['INTERVENTION 1: ', ' Conventional Photon Plan', ' Photon: 50.4 Gray (Gy) to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction', 'INTERVENTION 2: ', ' 3D-Proton/Conventional Plan or 3D-proton Only', ' 3D-Proton/Conventional plan or 3D-proton only: 50.4 Cobalt Gray Equivalent (CGE)/Gray (Gy) to the breast/chest wall and peripheral lymph nodes at 1.8 CGE/Gy per fraction'], 'Eligibility': ['Inclusion Criteria:', ' Pathologically confirmed invasive adenocarcinoma of the breast stage I-III (TX, T0-4, N0-3) with medially located tumor and/or axillary node invasion.', ' Patients must have undergone either mastectomy or breast conservation surgery.', ' Patients are required to have axillary staging which can include sentinel node biopsy alone if sentinel node is negative.', ' Patient must require peripheral lymph node radiation per physician discretion.', 'Exclusion Criteria:', ' Evidence of distant metastasis (M1).', ' Prior radiotherapy to the area of interest.', ' Prior history of cardiovascular disease per physician discretion.', ' Prior or concurrent cancer other than non-melanomatous skin cancer unless disease free for at least 5 years.', ' Collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active skin rash, systemic lupus erythematosis or scleroderma.'], 'Results': ['Outcome Measurement: ', ' Volume of Heart Receiving 5 Gray (Gy)/Cobalt Gray Equivalent (CGE)', ' A reduction of 50% in heart volume exposed to radiation doses 5 Gy/CGE was considered preferred outcome in this study plan.', ' Time frame: 2 weeks prior to starting radiation therapy.', 'Results 1: ', ' Arm/Group Title: Conventional Photon Plan', ' Arm/Group Description: Photon: 50.4 Gray (Gy) to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction', ' Overall Number of Participants Analyzed: 18', ' Median (Full Range)', ' Unit of Measure: % of heart receiving >= 5 Gray (Gy) 34.7 (6.9 to 60.0)', 'Results 2: ', ' Arm/Group Title: 3D-Proton/Conventional Plan or 3D-proton Only', ' Arm/Group Description: 3D-Proton/Conventional plan or 3D-proton only: 50.4 Cobalt Gray Equivalent (CGE)/Gray (Gy) to the breast/chest wall and peripheral lymph nodes at 1.8 CGE/Gy per fraction', ' Overall Number of Participants Analyzed: 18', ' Median (Full Range)', ' Unit of Measure: % of heart receiving >= 5 Gray (Gy) 2.7 (0.1 to 12.3)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/18 (33.33%)', ' Skin infection [1]2/18 (11.11%)', ' Radiation dermatitis 2 [1]4/18 (22.22%)', 'Adverse Events 2:', ' ']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
1b433096-f36a-4205-b16e-f9a370be3d05
|
|
Comparison
|
Intervention
|
NCT01490892
|
NCT02364388
|
The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial provides almost no details in the intervention section.
|
Entailment
|
[
0,
1,
2,
3
] |
[
0,
1,
2
] |
{'Clinical Trial ID': 'NCT01490892', 'Intervention': ['INTERVENTION 1: ', ' 3D HI and SHI of UCA', ' Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)', ' 3D HI and SHI of UCA: Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)'], 'Eligibility': ['Inclusion Criteria:', ' Be a female diagnosed by x-ray mammography (performed within 90 days prior to the study procedure) as having a solid breast mass or abnormal area without a mass.', ' Be scheduled for a biopsy (core / excisional / lumpectomy) of the mass or region of abnormality or for mastectomy within 30 days after this study procedure.', ' Be at least 18 years of age.', ' Be medically stable.', ' If a female of child-bearing potential, must have a negative pregnancy test.', ' Have signed Informed Consent to participate in the study.', 'Exclusion Criteria:', ' Males', ' Females who are pregnant or nursing.', ' Patients whose breast lesion is unequivocally a cyst by unenhanced US.', ' Patients currently on chemotherapy or with other primary cancers requiring systemic treatment.', ' Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:', ' Patients on life support or in a critical care unit.', ' Patients with unstable occlusive disease (eg, crescendo angina)', ' Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia.', ' Patients with uncontrolled congestive heart failure (NYHA Class IV)', ' Patients with recent cerebral hemorrhage.', ' Patients with clinically significant and unstable renal and/or liver disease (eg, transplant recipients in rejection)', ' Patients who have undergone surgery within 24 hours prior to the study sonographic examination.', ' Patients with known hypersensitivity to perflutren', ' Patients who have received any contrast medium (X-ray, MRI, CT, of US) in the 24 hours prior to the research US exam', ' Patients with cardiac shunts.', ' Patients with congenital heart defects.', ' Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli.', ' Patients with confirmed or suspected liver lesions.', ' Patients with respiratory distress syndrome.', ' Patients who have had excisional biopsy/lumpectomy of the current area of interest within the past 6 weeks.'], 'Results': ['Outcome Measurement: ', ' Number of Breast Cancer Lesions Characterized as Malignant or Benign With 3D SHI, Harmonic Imaging (HI) or Power Doppler Imaging (PDI)', ' Characterization of benign and malignant breast cancer lesions is compared by each imaging method which evaluates vascular activity. Imaging methods to be compared are 3D Subharmonic imaging (SHI) or pulse inversion harmonic imaging (HI), fundamental grayscale ultrasound (US) or power Doppler imaging (PDI). Data will be analyzed qualitatively.', ' Time frame: 2 hours', 'Results 1: ', ' Arm/Group Title: 3D HI and SHI of UCA', ' Arm/Group Description: Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)', ' 3D HI and SHI of UCA: Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)', ' Overall Number of Participants Analyzed: 219', ' Measure Type: Number', ' Unit of Measure: lesions Power Doppler Imaging (PDI) : Benign: 69', ' Power Doppler Imaging (PDI) : Malignant: 24', ' Power Doppler Imaging (PDI) : Not Characterized: 126', ' 3D SHI : Benign: 58', '3D SHI : Malignant: 25', ' 3D SHI : Not Characterized: 136', ' Harmonic Imaging (HI) : Benign: 3', ' Harmonic Imaging (HI) : Malignant: 5', ' Harmonic Imaging (HI) : Not Characterized: 211'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/219 (0.00%)']}
|
{'Clinical Trial ID': 'NCT02364388', 'Intervention': ['INTERVENTION 1: ', ' MAESTRO', 'Baseline'], 'Eligibility': ['Inclusion Criteria', ' Female', ' 18 years of age or older', ' Have an undiagnosed suspicious finding which may include more than one solid or complex cystic suspicious mass, classified by CDU as BI-RADS 4a or 4b within 3 weeks of their baseline Imagio Scan', 'Exclusion Criteria:', ' Have a condition or impediment that could interfere with the intended field of view (within one probe length or 4 cm of the mass), (i.e., breast implants within the previous 12 months, or tattoos)', ' Pregnant or lactating', ' Patient has received chemotherapy for any type of cancer within 90 days from date of screening CDU'], 'Results': ['Outcome Measurement: ', ' OA/US Specificity (Downgrade (%) for BI-RADS 4A & 4B) of Benign Masses', ' Outcome is the percentage of benign masses correctly downgraded by (OA/US) ultrasonography from a suspicious abnormality (4A or 4B) to benign or probably benign (BI-RADS 2 or 3). BI-RADS is the Breast Imaging Reporting and Data System established the American College of Radiology. BI-RADS scores range from 0 to 6, with increase in score indicating an increase in the probability of malignancy. A BI-RADS score of 4 or more indicates the need for biopsy. Specificity is reported with a 96% confidence interval using a normal approximation.', ' Time frame: CDU images and decision to biopsy to be done at Screening. OA/US imaging to be done within 10 days of Screening. Biopsy to be done within 30 days of Screening.', 'Results 1: ', ' Arm/Group Title: MAESTRO', ' Arm/Group Description: Baseline', ' Overall Number of Participants Analyzed: 143', ' Overall Number of Units Analyzed', ' Type of Units Analyzed: Masses Mean (96% Confidence Interval)Unit of Measure: percentage of masses: 41.1 (33.1 to 49.6)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/217 (0.00%)']}
|
076ead15-ce03-4c33-9050-1f6eb13764a1
|
Comparison
|
Adverse Events
|
NCT00323479
|
NCT03078751
|
There were more cases of Pulmonary embolisms in the primary trial than the secondary trial.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] |
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] |
{'Clinical Trial ID': 'NCT00323479', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole 1 mg', ' Anastrozole 1 mg once daily'], 'Eligibility': ['Inclusion Criteria:', ' Post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole', ' WHO performance status 0, 1 or 2', ' Provision of written informed consent', 'Exclusion Criteria:', ' Recurrence of breast cancer, inflammatory rheumatism', ' treatment by chondromodulator, oral glucocorticoid, aromatase inhibitor, anti estrogen, Herceptin', ' Diabetes treated by insulin', ' Severe renal or hepatic disease', ' Known hypersensitivity to anastrozole'], 'Results': ['Outcome Measurement: ', ' Number of Participants With New Events of Arthralgia', ' [Not Specified]', ' Time frame: 12 months', 'Results 1: ', ' Arm/Group Title: Anastrozole 1 mg', ' Arm/Group Description: Anastrozole 1 mg once daily', ' Overall Number of Participants Analyzed: 106', ' Measure Type: Number', ' Unit of Measure: Participants 37'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/110 (5.45%)', ' Sudden death unexplained 1/110 (0.91%)', ' General body pain 1/110 (0.91%)', ' Lymphangitis 1/110 (0.91%)', ' Femur fracture 1/110 (0.91%)', ' Parathyroid adenoma 1/110 (0.91%)', ' Depression worsened 1/110 (0.91%)', ' Calculus urinary bladder 1/110 (0.91%)', ' Pneumopathy 1/110 (0.91%)']}
|
{'Clinical Trial ID': 'NCT03078751', 'Intervention': ['INTERVENTION 1: ', ' Ribociclib + Adjuvant Endocrine Therapy (ET)', ' Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen (Tamoxifen no longer permitted after protocol amendment 2)', 'INTERVENTION 2: ', ' Placebo + Adjuvant Endocrine Therapy (ET)', ' Patients in this arm took Placebo in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen'], 'Eligibility': ['Key Inclusion Criteria:', ' Histologically confirmed unilateral primary invasive adenocarcinoma of the breast', ' Estrogen receptor-positive and/or progesterone receptor-positive, HER2-negative breast cancer', ' Patient is after surgical resection of the tumor where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor and with available archival tumor tissue from the surgical specimen', ' Patient who received adjuvant chemotherapy and have AJCC 8th edition Prognostic Stage Group III tumor; or patient who received neoadjuvant chemotherapy and have 1 or more ipsilateral axillary lymph nodes with residual tumor metastases greater than 2.0 mm in lymph node(-s) and residual tumor greater than 10.0 mm in breast tissue', ' Patient has completed multi-agent adjuvant or neoadjuvant chemotherapy of 4 cycles or 12 weeks which included taxanes prior to screening', ' Patient has completed adjuvant radiotherapy (if indicated) prior to screening', ' Patient may already have initiated adjuvant endocrine therapy (ET) at the time of randomization, but randomization must take place within 52 weeks of date of initial histological diagnosis of breast cancer and within 12 weeks of initiating ET', ' ECOG Performance Status 0 or 1', ' Adequate bone marrow and organ function', ' Sodium, potassium, phosphorus, magnesium and total calcium laboratory values within normal limits', ' QTcF interval < 450 msec and mean resting heart rate 50-90 bpm', ' Key Exclusion Criteria:', ' Prior treatment with CDK4/6 inhibitor', ' Prior treatment with tamoxifen, raloxifen or aromatase inhibitors for reduction in risk (chemoprevention) of breast cancer and/or treatment for osteoporosis within last 2 years', ' Prior treatment with anthracyclines at cumulative doses of 450 mg/m² or more for doxorubicin or 900 mg/m² or more for epirubicin', ' Distant metastases of breast cancer beyond regional lymph nodes', ' Patient has not recovered from clinical and laboratory acute toxicities of chemotherapy, radiotherapy and surgery', ' Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality, or clinically significant cardiac arrhythmias', ' Uncontrolled hypertension with systolic blood pressure >160 mmHg', ' Patient is currently receiving any of the prohibited substances that cannot be discontinued 7 days prior to Cycle 1 Day 1: concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYP3A4/5; medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5; systemic corticosteroids 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment; concomitant medications with a known risk to prolong the QT interval and/or known to cause torsades de points that cannot be discontinued or replaced by safe alternative medication.', ' Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the study', ' Women of child-bearing potential unless they are using highly effective methods of contraception during the study treatment and for 21 days after stopping the study treatment.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Adverse Events and Serious Adverse Events', ' These are the number of participants who had adverse events or serious adverse events regardless of whether is was suspected to be drug-related or not', ' Time frame: Up to 26 months', 'Results 1: ', ' Arm/Group Title: Ribociclib + Adjuvant Endocrine Therapy (ET)', ' Arm/Group Description: Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen (Tamoxifen no longer permitted after protocol amendment 2)', ' Overall Number of Participants Analyzed: 26', ' Measure Type: Number', ' Unit of Measure: Participants Adverse Events: 25', ' Serious Adverse Events: 4', 'Results 2: ', ' Arm/Group Title: Placebo + Adjuvant Endocrine Therapy (ET)', ' Arm/Group Description: Patients in this arm took Placebo in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen', ' Overall Number of Participants Analyzed: 24', ' Measure Type: Number', ' Unit of Measure: Participants Adverse Events: 21', ' Serious Adverse Events: 2'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/26 (15.38%)', ' Disseminated intravascular coagulation 1/26 (3.85%)', ' Cardiac failure congestive 1/26 (3.85%)', ' Breast cellulitis 1/26 (3.85%)', ' Cellulitis 1/26 (3.85%)', ' Acute myeloid leukaemia 1/26 (3.85%)', ' Seizure 0/26 (0.00%)', ' Pulmonary embolism 1/26 (3.85%)', 'Adverse Events 2:', ' Total: 2/24 (8.33%)', ' Disseminated intravascular coagulation 0/24 (0.00%)', ' Cardiac failure congestive 0/24 (0.00%)', ' Breast cellulitis 0/24 (0.00%)', ' Cellulitis 1/24 (4.17%)', ' Acute myeloid leukaemia 0/24 (0.00%)', ' Seizure 1/24 (4.17%)', ' Pulmonary embolism 0/24 (0.00%)']}
|
0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76
|
Single
|
Results
|
NCT01042535
|
The Maximum Tolerated Dose (MTD) of of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] |
[] |
{'Clinical Trial ID': 'NCT01042535', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Vaccine Therapy, 1-methyl-d-tryptophan)', ' Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses. Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with stable disease) for up to 12 courses in the absence of disease progression or unacceptable toxicity.', ' adenovirus-p53 transduced dendritic cell (DC) vaccine: Given intradermally (ID)', ' 1-methyl-d-tryptophan: Given orally (PO)', ' Laboratory biomarker analysis: Correlative studies'], 'Eligibility': ['Inclusion Criteria:', ' In the phase I patients with any solid tumor positive for p53 by IHC (>= 5% of cells with any degree of nuclear staining) staining; for the phase II, patients must have histologically or cytologically confirmed metastatic invasive breast cancer that is positive for p53 staining by IHC (>= 5% of cells with any degree of nuclear staining); patients will sign a separate consent for the p53 testing, and those that meet the above requirements will then be allowed to sign the vaccine trial consent', ' Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan', ' There are no restrictions on prior therapies for the phase I part of the trial; for the phase II, patients may have received up to 2 prior lines of chemotherapy (not counting endocrine therapy lines) with the last dose of chemotherapy given 3 weeks (6 weeks for nitrosoureas and mitomycin C) prior to initiation on this study', ' Life expectancy of greater than 4 months', ' Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)', ' Leukocytes >= 3,000/μL', ' Absolute neutrophil count >= 1,500/μL', ' Platelets >= 100,000/μL', " Total bilirubin within normal institutional limits unless patient has Gilbert's disease", ' Aspartate aminotransferase (AST) /serum glutamic oxaloacetic transaminase (SGOT) /alanine aminotransferase (ALT) /serum glutamic pyruvate transaminase (SGPT) =< 2.5 X institutional upper limit of normal', ' Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal', ' Thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), adrenocorticotropic hormone (ACTH) showing normal pituitary function; these values may deviate if in the opinion of the investigator these are normal pituitary responses to another endocrine condition such as suboptimally treated hypothyroidism', ' Patients with known brain metastases will only be eligible after their tumors have been treated with definitive resection and/or radiotherapy and they are neurologically stable for at least 1 month off steroids', " No history of gastrointestinal disease causing malabsorption or obstruction such as but not limited to Crohn's disease, celiac sprue, tropical sprue, bacterial overgrowth/blind loop syndrome, gastric bypass surgery, strictures, adhesions, achalasia, bowel obstruction, or extensive small bowel resection", ' Sexually active women of child-bearing potential must agree to use two forms of contraception (hormonal and barrier method of birth control or abstinence) prior to study entry and for the duration of study participation; males should use barrier contraception or abstinence during the study; use of contraception or abstinence should continue for a minimum of 1 month after completion of the study; should a woman become pregnant or suspect she is pregnant while participating in this study, she should discontinue the study drug and inform her treating physician immediately; a pregnancy test is required prior to study enrollment and monthly while on treatment with 1-MT for all women of child-bearing potential; also men should be discouraged from fathering children while on treatment', ' Ability to understand and the willingness to sign a written informed consent document', 'Exclusion Criteria:', ' Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier', ' Patients may not receive any other investigational agents or chemotherapy to treat their underlying malignancy while on study; patients who are stable on prior endocrine therapies (i.e. aromatase inhibitors, tamoxifen, and fulvestrant) may stay on these treatments', ' Patients with known untreated brain metastases are excluded from this clinical trial; patients with stable previously treated lesions in a patient off steroids and radiation for 1 month are not excluded', ' History of allergic reactions (significant urticaria, angioedema, anaphylaxis) attributed to compounds of similar chemical or biologic composition to 1-methyl-D-tryptophan; this would include L-tryptophan or 5-hydroxy-tryptophan supplements', ' No supplements containing L-tryptophan or derivatives thereof are allowed to be taken while on study; also ingestion of antacid compounds should be timed a minimum of 2 hours before or after ingestion of 1-MT', ' Patients with any active autoimmune disease (i.e. psoriasis, extensive atopic dermatitis, asthma, inflammatory bowel disease ([IBD), multiple sclerosis (M.S.), uveitis, vasculitis), chronic inflammatory condition, or any condition requiring concurrent use of any systemic immunosuppressants or steroids for any reason would be excluded from the study; any patient with an allo-transplant of any kind would be excluded as well; this would include those with a xenograft heart valve to avoid the potential risk of any immune reaction causing valvular degeneration; mild-intermittent asthma requiring only occasional beta-agonist inhaler use or mild localized eczema will not be excluded', " Uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction or percutaneous coronary interventions within the last 6 months, cardiac arrhythmia, active autoimmune diseases, or major psychiatric illness/social situations that would limit compliance with study requirements as judged by the primary investigator at each site; those with well controlled, chronic medical conditions under the supervision of the patient's primary physician (i.e. hypertension, hyperlipidemia, coronary heart disease, diabetes mellitus) would not be excluded", ' Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with 1-methyl-D-tryptophan', ' Human immunodeficiency virus (HIV)-positive patients and those with other acquired/inherited immunodeficiencies are ineligible', ' Patients with more than one active malignancy at the time of enrollment', ' Patients who have received any prior experimental active immunotherapy consisting of targeted monoclonal antibodies or pharmaceutical compounds are excluded; prior experimental vaccine patients may be enrolled if approved by the principal investigator (PI); patients who have received commercially available active immunotherapies such as adjuvant interferon must have completed therapy over 1 year prior to enrollment and have no evidence of autoimmune sequelae; prior therapy with approved monoclonal antibodies such as bevacizumab, cetuximab, panitumumab, or trastuzumab is allowed; concurrent treatment with these agents and the study treatment is not allowed', ' Human epidermal growth factor receptor 2 positive (HER2+) patients (IHC 3+ and/or fluorescent in situ hybridization [FISH] HER2/centromere portion of chromosome 17 [CEP17] ratio > 2) who require treatment with trastuzumab or lapatinib are not eligible for this study'], 'Results': ['Outcome Measurement: ', ' Phase 1 - Maximum Tolerated Dose (MTD) in Milligrams (mg)', ' MTD of 1-methyl-d-tryptophan (indoximod) given by mouth (PO), twice a day (BID), with up to 6 fixed doses Ad.p53 DC vaccinations every 2 weeks (q2wks). This phase 1 study used a 3+3 design with 7 indoximod dose levels (DL) (100 mg, 200 mg, 400 mg, 800 mg daily (QD) then 800 mg, 1,200 mg, and 1,600 mg PO BID +up to 6 fixed dose Ad.p53 DC vaccinations q2wks. Toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. The MTD is the highest dose level below the maximally administered dose (MAD) that is safely tolerated among 6 treated patients, that is, 0 or 1 out of 6 patients experiences a dose limiting toxicity (DLT).', ' Time frame: Up to 4 weeks', 'Results 1: ', ' Arm/Group Title: Treatment (Vaccine Therapy, 1-methyl-d-tryptophan)', ' Arm/Group Description: Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses. Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with stable disease) for up to 12 courses in the absence of disease progression or unacceptable toxicity.', ' adenovirus-p53 transduced dendritic cell (DC) vaccine: Given intradermally (ID)', ' 1-methyl-d-tryptophan: Given orally (PO)', ' Laboratory biomarker analysis: Correlative studies', ' Overall Number of Participants Analyzed: 30', ' Measure Type: Number', ' Unit of Measure: indoximod dose in mg 1600'], 'Adverse Events': ['Adverse Events 1:', ' Total: 14/41 (34.15%)', ' Anemia 1/41 (2.44%)', ' Febrile neutropenia 1/41 (2.44%)', ' Eye disorders - Other, Visual disturbance 1/41 (2.44%)', ' Abdominal pain 1/41 (2.44%)', ' Constipation 1/41 (2.44%)', ' Nausea 1/41 (2.44%)', ' Fever 1/41 (2.44%)', ' Pain 1/41 (2.44%)', ' Skin infection 2/41 (4.88%)', ' Alkaline phosphatase increased 1/41 (2.44%)', ' Aspartate aminotransferase increased 1/41 (2.44%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
3e1037fd-cc1e-4229-892f-95d0987d9a68
|
|
Comparison
|
Intervention
|
NCT00343382
|
NCT00798135
|
Cohort 2 of the primary trial recieves the same dose of Pilocarpine as cohort 2 of the secondary trial recieves of oral itraconazole.
|
Contradiction
|
[
3,
4,
5
] |
[
0,
1,
2
] |
{'Clinical Trial ID': 'NCT00343382', 'Intervention': ['INTERVENTION 1: ', ' Collective Placebo', ' Patients receive 1 capsule of placebo 2 times per day for 6 weeks and; patients receive 1 capsule of placebo 4 times per day for 6 weeks.', 'INTERVENTION 2: ', ' Pilocarpine 2 Times Per Day', ' Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks.'], 'Eligibility': ['Required Characteristics:', ' Adult post menopausal women or women with no childbearing potential ( 18 years) with a history of breast cancer (currently no evidence of disease) or women who do not want to take vaginal estrogen for a fear of an increased risk of breast cancer. Postmenopausal status will be determined by the primary physician.', ' Significant vaginal complaints defined as persistent vaginal dryness and/or itching of sufficient severity to make a patient desire therapeutic intervention. Symptoms should have been present 2 months prior to randomization.', ' Life expectancy > 6 months', ' Ability to complete questionnaire(s) by themselves or with assistance.', ' Contraindications:', ' Initiation or discontinuation of tamoxifen or aromatase inhibitors 2 months prior to randomization or plans to initiate or discontinue any of these medications during the 6-week study.', ' Active vaginal infection', ' Concurrent chemotherapy', ' Acute iritis', ' Current or past use of pilocarpine (regardless of purpose)', ' Planned use of any vaginal preparations during the study period (including any over the counter or herbal preparations). Note: Lubricants used during sexual intercourse are permitted.', ' Use of any vaginal preparations 1 week prior to study entry (Exception: If patient has used vaginal preparations during the previous week but will stop, then they can be placed on study with plans to start with pretreatment questionnaire one week later). Note: Lubricants used during sexual intercourse are permitted.', ' Current ( 4weeks prior to randomization), or planned during the study period, use of any estrogen product.', ' A diagnosis of asthma, COPD, CAD or narrow angle glaucoma, or known cholelithiasis.', ' Hepatic or renal insufficiency defined as a history of an elevation of SGOT 1.5 x ULN or creatinine 1.5 x ULN within the past year.', ' Concurrent use of other anticholinergics', ' Use of pharmacologic soy preparations', " Known history of cardiac arrhythmia. (Patients with occasional PVC's or PAC's that do not require treatment are eligible.)", ' Prior or concurrent pelvic radiation therapy', ' Prior radical pelvic surgery (TAH/BSO is allowed)', ' Use of beta adrenergic antagonists', ' Diagnosis of any of the following conditions:', ' Vulvar and vaginal dysplasia', ' Essential vulvodynia', ' Vulvar vestibulitis', ' Vaginal prolapse', ' Bartholin cyst/abscess', ' History of Bartholin gland surgery', ' Lichen sclerosis', ' Lichen planus of the vulvovaginal region', ' Desquamative vaginitis'], 'Results': ['Outcome Measurement: ', ' Average Vaginal Dryness Scores Via Area Under the Curve (AUC) Summary Statistics', ' Vaginal dryness was measured by the numerical analogue scale at baseline and through the six weeks of treatment. The item scores was transformed into 0 to 100 scales with 0=poor quality of life (QOL) and 100=best possible QOL. The average AUC values were calculated by dividing 6 from AUC values for participants who completed item on all 6 weeks. If a participant completed the item at baseline, week 1, 2 and 3 but did not complete the item at week 4 to week 6, the AUC values of the item was prorated, which is (((AUC values * 6) / 3) / 6). The average pro-rated AUC for vaginal dryness scores was compared in each of the Pilocarpine arms against the collective placebo arm.', ' Time frame: Baseline to Week 6', 'Results 1: ', ' Arm/Group Title: Collective Placebo', ' Arm/Group Description: Patients receive 1 capsule of placebo 2 times per day for 6 weeks and; patients receive 1 capsule of placebo 4 times per day for 6 weeks.', ' Overall Number of Participants Analyzed: 61', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 63.6 (24.04)', 'Results 2: ', ' Arm/Group Title: Pilocarpine 2 Times Per Day', ' Arm/Group Description: Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks.', ' Overall Number of Participants Analyzed: 61', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 55.8 (27.69)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/65 (0.00%)', 'Adverse Events 2:', ' Total: ']}
|
{'Clinical Trial ID': 'NCT00798135', 'Intervention': ['INTERVENTION 1: ', ' Itraconazole', ' oral itraconazole 200mg a day until disease progression or unacceptable toxicities.'], 'Eligibility': ['Inclusion Criteria:', ' - Patients must have a pathologically confirmed diagnosis of invasive carcinoma of the breast. - Patients must carry a diagnosis of metastatic breast cancer. - Patients must be able to swallow oral medications. - Patients with HER 2+ tumors must have received trastuzumab in the past and may have had lapatinib. - Patients must have an ECOG performance status of 0-1. - Patients must be informed of the investigational nature of the study and must sign and give written informed consent. - Patients must have recovered to grade <1 from all acute toxicity of previous therapy for breast cancer with the exception of alopecia. - Adequate hematologic and hepatic function: 1)Absolute neutrophil count >= 1,500 mm3 2) Platelet count >= 100,000 mm3 3) Bilirubin <= 1.5mg/dL x ULN 4) AST and/or ALT <= 2 x ULN (< 5 x ULN in presence of known liver metastasis). - Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and must practice an effective method of birth control. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should also practice an effective method of birth control. - All WOCBP MUST have a negative serum or urine pregnancy test within 4 weeks prior to the start of study drug administration.', 'Exclusion Criteria:', ' Use of the following concomitant medications within 14 days of starting protocol therapy is prohibited: Cisapride, dofetilide, ergot derivatives, levomethadyl, lovastatin, midazolam, pimozide, quinidine, simvastatin, or triazolam.', ' Patients who are taking alprazolam (Xanax) are excluded from the trial.', ' Patients must not have an active infection requiring the use of intravenous antibiotics. The use of oral antibiotics is allowed.', ' Hypersensitivity to itraconazole, any component of the formulation, or to other azoles.', ' Patients with uncontrolled CNS metastasis are excluded. If patients have CNS metastasis they must have completed brain radiation at least 2 weeks prior to registration and must be off steroids for CNS metastasis.', ' Known preexisting congestive heart failure or left ventricular dysfunction. Patients with risk factors (ex. uncontrolled hypertension with BP >160/90) for cardiac dysfunction but no preexisting diagnosis of congestive heart failure or left ventricular dysfunction will have a screening EKG prior to enrollment. Subsequently, those patients with an abnormal EKG, as judged by the treating physician, will be excluded from the study.'], 'Results': ['Outcome Measurement: ', ' Pharmacokinetics (PK) of Oral Itraconazole', ' To determine the pharmacokinetics (PK) of oral itraconazole in patients with MBC by measuring mean trough plasma levels at steady state at weeks 2 and 4.', ' Time frame: pre-dose at Weeks 2 and 4', 'Results 1: ', ' Arm/Group Title: Itraconazole', ' Arm/Group Description: oral itraconazole 200mg a day until disease progression or unacceptable toxicities.', ' Overall Number of Participants Analyzed: 12', ' Mean (Standard Deviation)', ' Unit of Measure: ng/mL Week 2 Intraconazole Concentration: 230.7 (216.8)', ' Week 4 Intraconazole Concentration: 305.8 (334.8)', ' Week 2 6-OH Itraconazole Concentration: 454.8 (429.3)', ' Week 4 6-OH Itraconazole Concentration: 501.6 (502.6)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/13 (23.08%)', ' NAUSEA *1/13 (7.69%)', ' PAIN - ABDOMEN NOS *1/13 (7.69%)', ' VOMITING *1/13 (7.69%)', ' HEMORRHAGE, GI - UPPER GI NOS *1/13 (7.69%)', ' PAIN - BACK *1/13 (7.69%)', ' MUSCLE WEAKNESS, GENERALIZED OR SPECIFIC AREA (NOT DUE TO NEUROPATHY) - EXTREMITY-LOWER *1/13 (7.69%)', ' PLEURAL EFFUSION (NON-MALIGNANT) *1/13 (7.69%)', ' THROMBOSIS/THROMBUS/EMBOLISM *1/13 (7.69%)']}
|
f25adbc7-c0a0-44ed-af93-02f4bced7208
|
Comparison
|
Adverse Events
|
NCT00394082
|
NCT01033032
|
the primary trial recorded cases of pleural effusion and Spinal compression fracture, neither of these were observed in the secondary trial.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] |
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] |
{'Clinical Trial ID': 'NCT00394082', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 Plus Bevacizumab', ' ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.'], 'Eligibility': ['Inclusion Criteria:', ' Pathologically confirmed adenocarcinoma of the breast.', ' Stage IV disease.', ' Measurable disease (defined as the presence of at least one lesion that can be accurately measured in at least one dimension with longest diameter greater or = 1.0 cm with spiral computed tomography (CT) scan).', ' Patients must not be a candidate for Herceptin therapy (i.e., patients with HER-2 positive disease (gene amplification by fluorescence in situ hybridization (FISH) or 3 + overexpression by ICH) and patients with unknown HER-2 status are ineligible unless the treating physicians has determined that Herceptin-based therapy would be inappropriate or not indicated).', " For subjects with prior anthracycline exposure, normal cardiac function including a baseline left ventricle ejection fraction >50% or above institution's lower limit of normal and a normal electrocardiogram (ECG) (as assessed by the investigator).", ' At least 2 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation portal or there must be pathologic proof of progressive disease within the radiation portal.', ' International Normalized Ratio (INR) < 1.5 and activated partial thromboplastin time within normal limits (APTT WNL).', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.', ' Female > 18 years of age.', ' Patients have the following blood counts at Baseline: absolute neutrophil count (ANC) greater or equal to 1.5 x 10^9 cells/L; platelets greater or equal 100 x 10^9 cells/L; hemoglobin (Hgb) greater or equal to 9g/dL.', ' Patients have the following blood chemistry levels at Baseline: aspartate aminotransferase (AST or SGOT), alanine aminotransferase (ALT or SGPT) less than or equal 2.5x upper limit of normal (ULN) range (less than or equal 5x ULN if patient has known liver metastases); total bilirubin greater than or equal to ULN; creatinine greater or equal to 1.5mg/dL.', ' if female of childbearing potential, pregnancy test is negative within 72 hours of first dose of study drug.', ' if fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study.', ' Informed consent has been obtained.', 'Exclusion Criteria:', ' No prior chemotherapy for metastatic or locally recurrent disease is allowed.', ' Prio neo-adjuvant chemotherapy is allowed, and patients must have recovered from the acute toxicity of such therapies.', ' if a taxane was part of the adjuvant regimen, at least 12 months must have elapsed between the last dose of the taxane and the date of diagnosis of metastatic disease.', ' if a non-taxane-based adjuvant therapy was administered, at least six months must have elapsed between the last dose of the non- taxane-containing chemotherapy and the date of diagnosis of metastatic disease.', ' Concurrent immunotherapy or hormonal therapy.', ' Parenchymal brain metastases, including leptomeningeal involvement.', ' Uncontrolled hypertension (defined as blood pressure of > 150/100 mmHg)', ' NYHA Grade 2 or greater congestive heart failure', ' History of coagulopathy, bleeding diathesis, therapeutic anticoagulation other than low dose or chronic ASA greater than or equal to 325 mg per day. Low dose coumadin for anticoagulation of venous access device or low dose molecular weight heparin (LMWH)for deep vein thrombosis prophylaxis or low dose (325 mg or less) ASA prophylaxis are allowed, but are best avoided if the treating physician feels it is safe to do so.', ' Urine protein:creatinine ratio less than or equal to 1.0 at screening.', ' No history of cerebrovascular accident within six months of study entry.', ' Active symptomatic peripheral vascular disease (e.g. aortic aneurysm, claudication) within six months of study entry.', ' Uncontrolled or severe cardiovascular disease including myocardial infarction or unstable angina within six months of study entry.', ' No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal process within six months of study entry.', ' No serious non-healing wound, ulcer, or bone fracture', ' Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to first dose, or anticipation of need for major surgical procedure during the course of the study. No minor surgical procedure within seven days of study entry. Serious intercurrent medical or psychiatric illness, including serious active infection.', ' History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer.', ' Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study.', ' Pregnant or nursing women.', ' Patients with current sensory neuropathy of > Grade 1 will be excluded.'], 'Results': ['Outcome Measurement: ', ' Participants With At Least One Treatment-Emergent Adverse Event (TEAE)', ' Count of study participants who had at least one treatment-emergent adverse event (TEAE) defined as any adverse event that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug.', ' Time frame: up to 25 months', 'Results 1: ', ' Arm/Group Title: ABI-007 Plus Bevacizumab', ' Arm/Group Description: ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.', ' Overall Number of Participants Analyzed: 50', ' Measure Type: Number', ' Unit of Measure: participants 50'], 'Adverse Events': ['Adverse Events 1:', ' Total: 13/50 (26.00%)', ' Febrile neutropenia 3/50 (6.00%)', ' Neutropenia 1/50 (2.00%)', ' Pancreatitis 1/50 (2.00%)', ' Cholangitis 1/50 (2.00%)', ' Cholelithiasis 1/50 (2.00%)', ' Anaphylactic reaction [1]1/50 (2.00%)', ' Pneumonia 1/50 (2.00%)', ' Pneumonitis chemical 1/50 (2.00%)', ' Spinal compression fracture 1/50 (2.00%)', ' Dehydration 1/50 (2.00%)', ' Electrolyte imbalance 1/50 (2.00%)']}
|
{'Clinical Trial ID': 'NCT01033032', 'Intervention': ['INTERVENTION 1: ', ' Amrubicin', ' Systemic therapy with amrubicin'], 'Eligibility': ['Inclusion Criteria:', ' Females >=18 years of age.', ' Histologic diagnosis of HER2-negative breast cancer. HER-2 negativity must be confirmed by one of the following:', ' FISH-negative (FISH ratio <2.2), or', ' IHC 0-1+, or', ' IHC 2-3+ AND FISH-negative (FISH ratio <2.2)', ' Evidence of metastatic or locally advanced, inoperable breast cancer.', ' Minimum of 1 and maximum of 2 prior metastatic breast cancer chemotherapy regimens.', ' Patients with prior anthracycline therapy are eligible, provided their previous anthracycline was 6 months prior to study entry.', ' Measurable disease per RECIST criteria version 1.1', ' Left ventricular ejection fraction (LVEF) ³50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA).', ' Patients must have QTc interval of <=450 msec.', ' No intercurrent significant medical conditions or cardiac illness.', ' Patients must be >=3 weeks since last chemotherapy, and recovered from all acute toxicities, with the exception of alopecia.', ' Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2.', ' Adequate organ function including the following:', ' ANC >=1500 cells/mL', ' Platelet count >=100,000 cells/mL', ' Hemoglobin >=9 g/dL', ' Total bilirubin <=1.5 x ULN; AST/ALT <=2.5 x ULN, (except if due to hepatic metastases, then <=5 x ULN)', ' Serum creatinine <1.5 x ULN', ' Women of childbearing potential must have a negative serum or urine pregnancy test performed <=7 days prior to start of treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately.', ' Patients must be accessible for treatment and follow-up.', ' Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry.', " Patients who are on anticoagulation are acceptable if the therapeutic anticoagulation is stable. Additionally, the patient's INR must be adequate if the patient is receiving treatment with coumadin.", " Prior hormonal therapy for metastatic breast cancer is permitted; however, the therapy must be discontinued prior to the patient's enrollment in this study.", 'Exclusion Criteria:', ' Any concurrent therapy with other investigational, chemotherapeutic, or hormonal therapy.', " Prior treatment with >=3 regimens of cytotoxic therapy in the advanced disease setting. (Any number of previous hormonal therapies are acceptable, as long as the therapy is discontinued prior to the patient's enrollment into this study).", ' Major surgery or systemic therapy <=3 weeks of study treatment.', ' Prior high-dose chemotherapy requiring hematopoietic stem cell support.', ' Prior radiation therapy to >25% of the bone marrow.', ' Uncontrolled brain metastases. Patients with treated brain metastases (resection or radiotherapy) are eligible if brain metastases have responded to treatment as documented by CT or MRI scan obtained at >=2 weeks after completion of radiation therapy, neurologic symptoms are absent, and steroids have been discontinued.', ' Suspected, diffuse idiopathic interstitial lung disease or pulmonary fibrosis.', ' Diagnosis of second malignancy within the last 3 years (with the exception of carcinoma in situ of the cervix, squamous or basal cell skin cancer, thyroid cancer, ductal carcinoma in situ [DCIS], or lobular carcinoma in situ [LCIS]).', ' Any of the following <=12 months prior to starting study treatment:', ' myocardial infarction;', ' severe unstable angina;', ' congestive heart failure;', ' ongoing cardiac dysrhythmia.', ' Family history of idiopathic cardiomyopathy or uncontrolled heart arrhythmia.', ' Patients with previous allergy or hypersensitivity to anthracyclines.', ' Patients who have had a 10% drop in LVEF on previous anthracycline therapy.', ' Palliative radiotherapy to areas of metastatic breast cancer must have been completed >7 days prior to the first dose of study treatment. The exception is radiotherapy for brain metastases, which must be completed >=21 days prior to study treatment. (Note: Any measurable lesion that has been previously irradiated will not be considered as a target lesion).', ' Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.', ' History of seropositive HIV, or patients who are receiving immunosuppressive medications that increase the risk of neutropenic complications.', ' Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study.', ' Use of any non-approved or investigational agent <=30 days of administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS) of MTD/Phase II Patients', ' Progression-free survival is measured from Day 1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death on the study. Progression is defined in RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions. This outcome measure is reported for all patients treated at the same dose level and is not separated into Phase I and Phase II. The phase I and phase II results are not separated as the timing of enrollment (early in phase 1 or later phase II) is not relevant to the outcome measure.', ' Time frame: every 6 weeks until progressive disease', 'Results 1: ', ' Arm/Group Title: Amrubicin', ' Arm/Group Description: Systemic therapy with amrubicin', ' Overall Number of Participants Analyzed: 66', ' Median (95% Confidence Interval)', ' Unit of Measure: months 4.0 (2.5 to 5.8)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/3 (33.33%)', ' FEBRILE NEUTROPENIA 0/3 (0.00%)', ' LYMPH NODE PAIN 0/3 (0.00%)', ' NEUTROPHIL COUNT DECREASED 0/3 (0.00%)', ' THROMBOCYTOPENIA 0/3 (0.00%)', ' CHEST PAIN 0/3 (0.00%)', ' DEHYDRATION 0/3 (0.00%)', ' PLEURAL EFFUSION 1/3 (33.33%)', ' PNEUMONITIS 0/3 (0.00%)', ' PULMONARY INFILTERATES 0/3 (0.00%)', ' ALOPECIA 0/3 (0.00%)']}
|
99951bae-37c8-4299-8ec1-4577a97d0b81
|
Single
|
Eligibility
|
NCT00149214
|
Prior use of Anthracycline drugs for anticancer therapy is prohibted for patients in the primary trial.
|
Entailment
|
[
4,
5
] |
[] |
{'Clinical Trial ID': 'NCT00149214', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed Plus Doxorubicin, Followed by Docetaxel', ' pemetrexed: 500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)', 'INTERVENTION 2: ', ' Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel', ' cyclophosphamide: 600 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed diagnosis of primary early breast cancer, tumor size greater than or equal to 2 centimeters (cm), of Stages T2-T4/N0-2.', ' Performance status 0-2 Eastern Cooperative Oncology Group (ECOG).', ' Adequate organ function (bone marrow, hepatic, renal, cardiac).', 'Exclusion Criteria:', ' Prior anthracyclines as part of prior anticancer therapy.', ' Concurrent antitumor therapy.', ' Second primary malignancy.', ' Serious concomitant systemic disorder.', ' Pre-existing sensorial or motor neuropathy', 'Grade 1.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With a Pathological Complete Response', ' pathological assessment of tissue removed during surgery to determine if tumor tissue is still present after chemotherapy', ' Time frame: surgery after eight 21-day cycles of chemotherapy', 'Results 1: ', ' Arm/Group Title: Pemetrexed Plus Doxorubicin, Followed by Docetaxel', ' Arm/Group Description: pemetrexed: 500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)', ' Overall Number of Participants Analyzed: 127', ' Measure Type: Number', ' Unit of Measure: participants Pathological Complete Response: 21', ' Tumor Cells Still Present: 99', 'Not evaluable: 7', 'Results 2: ', ' Arm/Group Title: Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel', ' Arm/Group Description: cyclophosphamide: 600 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)', ' Overall Number of Participants Analyzed: 119', ' Measure Type: Number', ' Unit of Measure: participants Pathological Complete Response: 24', ' Tumor Cells Still Present: 89', 'Not evaluable: 6'], 'Adverse Events': ['Adverse Events 1:', ' Total: 15/134 (11.19%)', ' Anaemia 0/134 (0.00%)', ' Chronic lymphocytic leukaemia 0/134 (0.00%)', ' Febrile neutropenia 4/134 (2.99%)', ' Leukopenia 4/134 (2.99%)', ' Neutropenia 1/134 (0.75%)', ' Cardiovascular insufficiency 0/134 (0.00%)', ' Myocardial infarction 0/134 (0.00%)', ' Diarrhoea 1/134 (0.75%)', ' Nausea 2/134 (1.49%)', ' Stomatitis 1/134 (0.75%)', ' Vomiting 3/134 (2.24%)', 'Adverse Events 2:', ' Total: 25/123 (20.33%)', ' Anaemia 1/123 (0.81%)', ' Chronic lymphocytic leukaemia 1/123 (0.81%)', ' Febrile neutropenia 5/123 (4.07%)', ' Leukopenia 9/123 (7.32%)', ' Neutropenia 3/123 (2.44%)', ' Cardiovascular insufficiency 1/123 (0.81%)', ' Myocardial infarction 1/123 (0.81%)', ' Diarrhoea 1/123 (0.81%)', ' Nausea 0/123 (0.00%)', ' Stomatitis 0/123 (0.00%)', ' Vomiting 0/123 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
b66b62c4-902d-4e19-929e-2086b349bd93
|
|
Comparison
|
Eligibility
|
NCT00334802
|
NCT00167414
|
There is no age limit for either the secondary trial or the primary trial. Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] |
[
0,
1
] |
{'Clinical Trial ID': 'NCT00334802', 'Intervention': ['INTERVENTION 1: ', ' Dose Level 1', ' Gemcitabine: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles', 'INTERVENTION 2: ', ' Dose Level 2', ' Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles'], 'Eligibility': ['Inclusion Criteria:', ' Histologically and/or cytologically confirmed breast cancer', ' Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen', ' To have at least one measurable region', ' Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1', ' To have adequate organ function (bone marrow, liver and renal function)', 'Exclusion Criteria:', ' To have interstitial pneumonia or pulmonary fibrosis', ' To have inflammatory breast cancer', ' Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery', ' To have brain metastases with symptoms', ' To have severe complication (cardiac infarction, infection, drug hypersensitivity or diabetes)'], 'Results': ['Outcome Measurement: ', ' Tumor Response', ' Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Responders are patients with complete response or partial response.', ' Time frame: baseline to measured progressive disease', 'Results 1: ', ' Arm/Group Title: Dose Level 1', ' Arm/Group Description: Gemcitabine: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Number', ' Unit of Measure: participants Complete Response: 0', ' Partial Response: 3', ' Stable Disease: 1', ' Progressive Disease: 1', 'Not Evaluable: 1', 'Results 2: ', ' Arm/Group Title: Dose Level 2', ' Arm/Group Description: Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles', ' Overall Number of Participants Analyzed: 56', ' Measure Type: Number', ' Unit of Measure: participants Complete Response: 0', ' Partial Response: 25', ' Stable Disease: 17', ' Progressive Disease: 11', 'Not Evaluable: 3'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1', ' Pneumonia 0/6 (0.00%)', ' Haemoglobin decreased 1/6 (16.67%)', ' Anorexia 0/6 (0.00%)', ' Panic disorder 0/6 (0.00%)', 'Adverse Events 2:', ' Total: 3', ' Pneumonia 1/56 (1.79%)', ' Haemoglobin decreased 0/56 (0.00%)', ' Anorexia 1/56 (1.79%)', ' Panic disorder 1/56 (1.79%)']}
|
{'Clinical Trial ID': 'NCT00167414', 'Intervention': ['INTERVENTION 1: ', ' Hypofractionated Stereotactic Body Radiation Therapy', ' Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.'], 'Eligibility': ['Inclusion Criteria:', ' Age: no limit', ' Karnofsky performance status (KPS) 70', ' No more than 5 metastatic sites involving one or more different organs (liver, lung or bone).', ' The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol.', ' Previously treated lesions are not eligible unless the prescribed dose can be safely delivered.', ' Concurrent therapy is allowed and recommended. The chemotherapy protocol type and schedule are at the discretion of the medical oncologist.', ' Informed consent must be obtained.', ' Pregnancy test must be negative for women of child bearing potential', 'Exclusion Criteria:', ' Inability of patient to be followed longitudinally as specified by protocol.', ' Technical inability to achieve required dose based on safe dose constraints required for radiosurgery.', ' Women who are pregnant or nursing.', ' Failure to meet requirements in Inclusion Criteria', ' Contraindications to radiation.'], 'Results': ['Outcome Measurement: ', ' Overall Survival', ' The percent of patients that survived from date of enrollment until 2 year follow-up visit.', ' Time frame: 2 years', 'Results 1: ', ' Arm/Group Title: Hypofractionated Stereotactic Body Radiation Therapy', ' Arm/Group Description: Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.', ' Overall Number of Participants Analyzed: 39', ' Measure Type: Number', ' Unit of Measure: percentage of participants 74'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/39 (0.00%)']}
|
c789e79c-a254-4bb1-9d15-73d1726da8a6
|
Single
|
Adverse Events
|
NCT02481050
|
There is only 1 adverse event in the primary trial that occurred more than once.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] |
[] |
{'Clinical Trial ID': 'NCT02481050', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Participants with histologically confirmed HER2-negative MBC who were previously treated with 2 to 5 chemotherapy regimens received eribulin mesylate 1.4 mg/m^2, intravenous infusion over 2 to 5 minutes on Day 1 and Day 15 of each 28-days treatment cycle until intercurrent illness, unacceptable toxicity, disease progression occurred, or until the participant withdrew consent (up to 16 cycles).'], 'Eligibility': ['Inclusion Criteria:', ' Histological or cytological adenocarcinoma of the breast.', ' Females, aged greater than or equal to 18 years at time of informed consent.', ' HER2-negative as determined by fluorescence in situ hybridization (FISH); or 0 or 1+ by immunohistochemistry (IHC) staining .', ' Participants with metastatic breast cancer who have received at least 2 and not more than 5 prior chemotherapy regimens.', ' Participants with at least one measurable lesion greater than or equal to 10 mm in the longest diameter for a non-lymph node or greater than or equal to 15 mm in the short-axis diameter for a lymph node as determined by investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).', ' Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2.', ' Life expectancy of greater than or equal to 3 months.', ' Any neuropathy must recover to Grade less than or equal to 2 prior to enrollment.', ' Adequate renal function as evidenced by serum creatinine less than or equal to 1.5 mg/dL or calculated creatinine clearance greater than or equal to 50 mL/minute according to the Cockcroft and Gault formula.', ' Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater than or equal to 1.5 X 10^9/L, hemoglobin greater than or equal to 10.0 g/dL (can be corrected by growth factor or transfusion), and platelet count greater than or equal to 100 X 10^9/L.', ' Adequate liver function as evidenced by total bilirubin less than or equal to 1.5 X upper limit of normal (ULN), alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (less than or equal to 5 X ULN in the case of liver metastases), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.', ' Are willing and able to comply with all aspects of the treatment protocol.', ' Provide written informed consent.', 'Exclusion Criteria:', ' Previous treatment with eribulin.', ' Hypersensitivity to eribulin/excipients or halichondrin B or known intolerance of eribulin.', ' Current enrollment in another clinical study or used of any investigational drug or device within the past 28 days preceding informed consent.', ' Previous treatment with chemotherapy, radiation, biological, or targeted therapy within the last 2 weeks or 5 X half-life, whichever is longer, preceding informed consent.', ' Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin ([B-hCG] test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.', ' All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).', ' Females of childbearing potential who had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period or for 28 days after study drug discontinuation.', ' Females who are currently abstinent and do not agree to use a double barrier method as described above or to refrain from sexual activity during the study period or for 28 days after study drug discontinuation.', ' Females who are using hormonal contraceptives but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study or for 28 days after study drug discontinuation.', ' Known central nervous system (CNS) disease, except for those participants with treated brain metastasis who are stable for at least 1 month with no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids.', ' Known human immunodeficiency virus (HIV) positive.', ' Existing anticancer, therapy-related toxicities of Grades greater than or equal to 2, with the exception of alopecia.', ' A prior malignancy other than carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated greater than 5 years previously with no subsequent evidence of recurrence.', ' Clinically significant cardiovascular impairment (congestive heart failure of New York Heart Association [NYHA] Classification greater than II, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia).', ' Clinically significant ECG abnormality, including a marked Baseline prolonged QT/QTc interval (ie, a repeated demonstration of a QTc interval greater than 500 milliseconds).', ' Pulmonary lymphangitic involvement that resulted in pulmonary dysfunction requiring active treatment, including the use of oxygen.', " History of concomitant medical condition(s) that, in the opinion of the investigator, would compromise the participant's ability to safely complete the study.", " The investigator's belief that the participant is medically unfit to receive eribulin or unsuitable for any other reason."], 'Results': ['Outcome Measurement: ', ' Objective Response Rate (ORR) by Investigator Assessment', ' ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) measured by response evaluation criteria in solid tumors (RECIST) 1.1. CR defined as disappearance of all target lesions (a short diameter is less than [<] 10 millimeter [mm] if it exists in a lymph node). PR defined as at least 30 percent (%) decrease in the sum of the long diameter (LD) of all target lesions, as compared with Baseline summed LD.', ' Time frame: From first dose of study drug until intercurrent illness, unacceptable toxicity, disease progression, or until the participant withdrew consent (approximately up to 2.3 years)', 'Results 1: ', ' Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2', ' Arm/Group Description: Participants with histologically confirmed HER2-negative MBC who were previously treated with 2 to 5 chemotherapy regimens received eribulin mesylate 1.4 mg/m^2, intravenous infusion over 2 to 5 minutes on Day 1 and Day 15 of each 28-days treatment cycle until intercurrent illness, unacceptable toxicity, disease progression occurred, or until the participant withdrew consent (up to 16 cycles).', ' Overall Number of Participants Analyzed: 57', ' Measure Type: Number', ' Unit of Measure: percentage of participants 12.3 (5.08 to 23.68)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 14/58 (24.14%)', ' Constipation 1/58 (1.72%)', ' Vomiting 1/58 (1.72%)', ' Upper gastrointestinal haemorrhage 1/58 (1.72%)', ' Asthenia 1/58 (1.72%)', ' Chest pain 1/58 (1.72%)', ' Pain 1/58 (1.72%)', ' Sepsis 2/58 (3.45%)', ' Fall 1/58 (1.72%)', ' Spinal compression fracture 1/58 (1.72%)', ' Neutrophil count decreased 1/58 (1.72%)', ' Dehydration 1/58 (1.72%)', ' Hypovolaemia 1/58 (1.72%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
2b182323-9357-486a-87aa-09ddc6230bf1
|
|
Single
|
Results
|
NCT02162667
|
The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] |
[] |
{'Clinical Trial ID': 'NCT02162667', 'Intervention': ['INTERVENTION 1: ', ' CT-P6', ' Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study.', 'INTERVENTION 2: ', ' Herceptin', ' Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study.'], 'Eligibility': ['Inclusion Criteria:', ' Patient who has histologically confirmed and newly diagnosed breast cancer', ' Patient who has clinical stage I, II, or IIIa operable breast cancer according to AJCC (American Joint Committee on Cancer) Breast Cancer Staging 7th edition', ' Patient who has HER2-positive status confirmed locally, defined as 3+ score by IHC (immuno-histochemistry).', 'Exclusion Criteria:', ' Patient who has bilateral breast cancer', ' Patient who has received prior treatment for breast cancer, including chemotherapy, biologic therapy, hormone therapy, immunotherapy, radiation or surgery, including any prior therapy with anthracyclines.'], 'Results': ['Outcome Measurement: ', ' The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)', ' Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period.', ' The primary endpoint, Pathological complete response, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.', ' Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks)', 'Results 1: ', ' Arm/Group Title: CT-P6', ' Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study.', ' Overall Number of Participants Analyzed: 248', ' Measure Type: Number', ' Unit of Measure: percentage of responders 46.77 (40.43 to 53.19)', 'Results 2: ', ' Arm/Group Title: Herceptin', ' Arm/Group Description: Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study.', ' Overall Number of Participants Analyzed: 256', ' Measure Type: Number', ' Unit of Measure: percentage of responders 50.39 (44.10 to 56.68)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 22/271 (8.12%)', ' Anemia1/271 (0.37%)', ' Febrile neutropenia6/271 (2.21%)', ' Leukocytosis0/271 (0.00%)', ' Neutropenia2/271 (0.74%)', ' Acute myocardial infarction0/271 (0.00%)', ' Adams-Stokes syndrome1/271 (0.37%)', ' Angina pectoris0/271 (0.00%)', ' Congestive cardiomyopathy0/271 (0.00%)', ' Myocardial infarction0/271 (0.00%)', ' Dacryostenosis acquired0/271 (0.00%)', 'Adverse Events 2:', ' Total: 36/278 (12.95%)', ' Anemia3/278 (1.08%)', ' Febrile neutropenia3/278 (1.08%)', ' Leukocytosis1/278 (0.36%)', ' Neutropenia3/278 (1.08%)', ' Acute myocardial infarction1/278 (0.36%)', ' Adams-Stokes syndrome0/278 (0.00%)', ' Angina pectoris1/278 (0.36%)', ' Congestive cardiomyopathy1/278 (0.36%)', ' Myocardial infarction1/278 (0.36%)', ' Dacryostenosis acquired1/278 (0.36%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
9681ec15-7545-455e-ac8c-1052fc199b11
|
|
Comparison
|
Eligibility
|
NCT00256243
|
NCT00721630
|
the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] |
[
0,
1
] |
{'Clinical Trial ID': 'NCT00256243', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy With GM-CSF', ' Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6) This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented. Two weeks after completion of the last dose of AC, weekly Carboplatin/paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 12. Each clinic visit will last approximately 1 hour.'], 'Eligibility': ['Eligibility Criteria:', ' Patients must be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast carcinoma. Histologic confirmation shall be by either core needle biopsy or incisional biopsy. Punch biopsy is allowed if invasive breast cancer is documented.', ' Patients must meet one of the criteria defined below (indicate one):', ' a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an experienced breast surgeon; or otherwise deemed appropriate candidates for neoadjuvant treatment.', ' b. Stage IIIB (T4, Any N, M0) or (Any T, N3, M0) disease.', ' Physical examination, chest x-ray and any x-rays or scans needed for tumor assessment must be performed within 90 days prior to registration.', ' Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible. Patients with hypertension or age > 60 years must have a Multiple Gated Acquisition (MUGA) or echocardiogram scan performed within 90 days prior to registration (indicate not applicable (NA) if no MUGA required) and Left Ventricular Ejection Fraction (LVEF) % must be greater than the institutional lower limit of normal.', ' Patients must have a serum creatinine and bilirubin the institutional upper limit of normal, and an Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT) 2x the institutional upper limit of normal. These tests must have been performed within 90 days prior to registration.', ' Patients must have an Absolute neutrophil count (ANC) of 1,500/μl and a platelet count of 100,000/μl. These tests must have been performed within 90 days prior to registration.', ' Patients must have a performance status of 0-2 by Zubrod criteria', ' Pregnant or nursing women may not participate due to the possibility of fetal harm or of harm to nursing infants from this treatment regimen. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. A urine pregnancy test is required for women of childbearing potential.', ' All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.'], 'Results': ['Outcome Measurement: ', ' Clinical Response Rate', " Clinical response (CR): Normal breast on physical exam. No mass, no thickening, no erythema, no peau d'orange.", ' Time frame: 5 years', 'Results 1: ', ' Arm/Group Title: Chemotherapy With GM-CSF', ' Arm/Group Description: Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6) This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented. Two weeks after completion of the last dose of AC, weekly Carboplatin/paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 12. Each clinic visit will last approximately 1 hour.', ' Overall Number of Participants Analyzed: 47', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 47 100.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/38 (0.00%)']}
|
{'Clinical Trial ID': 'NCT00721630', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine + Lapatinib', ' The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.', ' capecitabine, lapatinib: Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).'], 'Eligibility': ['Inclusion Criteria:', ' Patients with a diagnosis of invasive adenocarcinoma of the breast confirmed by histology or cytology at MSKCC.', ' Clinical evidence of metastatic breast cancer.', ' HER2 overexpression and/or amplification as determined by immunohistochemistry (3+) or FISH ( 2.0).', ' Progressive disease following treatment with trastuzumab for metastatic breast cancer or as adjuvant therapy (either single-agent or combination therapy)', ' Prior therapy inclusion:', ' No more than two prior chemotherapy regimens allowed for advanced stage disease', ' No prior fluoropyrimidine in the metastatic setting. Adjuvant fluoropyrimidine is permitted if >6 months prior to treatment on study.', ' No restriction for prior hormonal therapy. No concurrent use of endocrine therapy is permitted.', ' No more than 450mg/m2 cumulative dose of prior doxorubicin', ' At least 3 weeks since prior chemotherapy or radiation therapy', ' Age or = to 18. Because no dosing or adverse event data are currently available on the use of lapatinib in patients <18 years of age, children are excluded from this study.', ' Patients must be willing to discontinue sex hormonal therapy e.g., birth control pills, ovarian hormonal replacement therapy, etc., prior to enrollment. Women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter.', ' Negative HCG pregnancy test for premenopausal women of reproductive capacity and for women less than 12 months after the menopause.', ' Asymptomatic, central nervous system metastases are permitted if patients remain clinically stable after discontinuation of corticosteroids and anticonvulsants.', ' ECOG performance status < or = to 2', ' Life expectancy of greater than 12 weeks', ' Patients must have normal organ and marrow function as defined below:', ' leukocytes or = to 3,000/μL', ' absolute neutrophil count or = 1,500/μL', ' platelets or = 100,000/μL', ' total bilirubin within normal institutional limits AST (SGOT)/ALT(SGPT) or = 2.5x institutional upper limit of normal serum creatinine within normal institutional limits', ' Cardiac ejection fraction at or above the lower limit of normal of 50% as measured by multigated radionuclide angiography (MUGA) scan. If LVEF is greater than 70%, and ECHO should be performed as well. Baseline and on treatment scans should be performed using the same modality and preferably at the same institution.', ' Ability to understand and the willingness to sign a written informed. consent document.', ' Able to swallow and retain oral medication.', 'Exclusion Criteria:', ' Patients may not be receiving any concurrent anticancer therapy or investigational agents with the intention of treating breast cancer.', ' History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib or capecitabine.', ' Known DPD deficiency.', ' Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within 6 months of study entry, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.', ' Pregnant women are excluded from this study because lapatinib is member of the 4- anilinoquinazoline class of kinase inhibitors with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lapatinib, breastfeeding should be discontinued if the mother is treated with lapatinib.', ' HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with lapatinib. Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.', " Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption,uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).", ' Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors:', ' Medications that inhibit or induce CYP3A4 are prohibited. Eligibility of patients receiving medications or substances known to affect, or with the potential to affect the activity or pharmacokinetics of lapatinib will be determined following review of their use by the Principal Investigator.', ' Renal function as measured by creatinine clearance < 30ml/min', ' Patients are permitted to participate in other non-therapeutic clinical trials while receiving treatment on this study (ie, experimental imaging, minor procedures necessary for tissue acquisition on study)'], 'Results': ['Outcome Measurement: ', ' Estimate Efficacy of Capecitabine 7/7 in Combination With Lapatinib in Patients With HER2 Overexpressed/Amplified, Trastuzumab-refractory, Metastatic Breast Cancer as Determined by Overall Response Rate (Complete Response (CR) + Partial Response (PR))', ' Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR', ' Time frame: 6 months', 'Results 1: ', ' Arm/Group Title: Capecitabine + Lapatinib', ' Arm/Group Description: The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.', ' capecitabine, lapatinib: Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).', ' Overall Number of Participants Analyzed: 23', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Partial Response: 5 21.7%', ' Stable Disease >/= 6 months: 6 26.1%', ' Stable disease <6 months: 11 47.8%', ' Progression of disease: 1 4.3%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 9/23 (39.13%)', ' Anemia 1/23 (4.35%)', ' Diarrhea 1/23 (4.35%)', ' Nausea 1/23 (4.35%)', ' Fracture 1/23 (4.35%)', ' ALT 1/23 (4.35%)', ' AST 1/23 (4.35%)', ' INR 1/23 (4.35%)', ' PTT 1/23 (4.35%)', ' Glucose, high 1/23 (4.35%)', ' Limb Pain 1/23 (4.35%)', ' Ataxia 2/23 (8.70%)', ' Neurology - Other 1/23 (4.35%)', ' Seizure 1/23 (4.35%)', ' Syncope 1/23 (4.35%)', ' Confusion 1/23 (4.35%)']}
|
8ca512c3-72d8-4179-a63e-51d83d76445f
|
Single
|
Intervention
|
NCT00046891
|
cohort 1 of the primary trial recieves 60 mg of Ginkgo Biloba twice daily.
|
Entailment
|
[
0,
1,
2
] |
[] |
{'Clinical Trial ID': 'NCT00046891', 'Intervention': ['INTERVENTION 1: ', ' Ginkgo Biloba', ' Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID)', 'INTERVENTION 2: ', ' Placebo', ' Placebo: Patients will take 1 tablet BID'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Newly diagnosed breast cancer', ' Planned standard doses of adjuvant chemotherapy with or without a taxane', ' PATIENT CHARACTERISTICS:', ' Age', ' 18 and over', ' Sex', ' Female', ' Menopausal status', ' Any status', ' Performance status', ' Eastern Cooperative Oncology Group (ECOG) 0-1', ' Life expectancy', ' At least 6 months', ' Hematopoietic', ' No bleeding diathesis', ' Hepatic', ' serum glutamate oxaloacetate transaminase (SGOT) no greater than 1.5 times upper limit of normal (ULN)', ' Alkaline phosphatase no greater than 1.5 times ULN', ' Renal', ' Creatinine no greater than 1.5 times ULN', ' Cardiovascular', ' No arterial vascular disease', ' Other', ' Able to complete questionnaires alone or with assistance', ' No diabetes', ' No dementia', ' No diagnosis of a psychiatric disorder within the past 5 years that would preclude study compliance', ' No other significant comorbidity', ' No known allergy to ginkgo biloba', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' No concurrent stem cell transplantation', ' Chemotherapy', ' No concurrent high-dose chemotherapy', ' Other', ' More than 6 months since prior EGb761', ' No concurrent antithrombotic therapy (e.g., daily aspirin or anticoagulants)', ' Anticoagulants used for central or peripheral line maintenance (i.e., warfarin 1 mg/day or heparin flushes) allowed', ' No concurrent dose-intensive regimens', ' No concurrent aspirin or aspirin-like medicines (e.g., indomethacin, ibuprofen, or some antihistamines or heparin or warfarin [except as used above])', ' No concurrent regimen expected to cause thrombocytopenia', ' No concurrent trazodone, monoamine oxidase inhibitors, or thiazide diuretics (e.g., chlorothiazide, hydrochlorothiazide, indapamide, or metolazone)'], 'Results': ['Outcome Measurement: ', ' The Level of Cognitive Dysfunction as Measured by the High Sensitivity Cognitive Screen (HSCS) Overall Score.', ' The primary analysis involved compiling each subscale score for the HSCS into area under the curve (AUC) scores for the data points from baseline to the 12 month data point. HSCS instrument contains questions regarding Memory (0-39), Language (0-30), Visual-motor (0-10), Spatial (0-8), Attention and Concentration (0-25), Self-Regulation and Planning (0-6) on a varying scales. Total is calculated by summing afore mentioned subscales, values of Total ranged from 0 to 125. Lower scores are better.', ' Time frame: Baseline, 12 months after starting Chemotherapy.', 'Results 1: ', ' Arm/Group Title: Ginkgo Biloba', ' Arm/Group Description: Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID)', ' Overall Number of Participants Analyzed: 107', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale*months Memory: 12.2 (9.18)', ' Language: 3.9 (6.84)', ' Visual-motor: 1.1 (1.29)', ' Spatial: 1.4 (0.92)', ' Attention/concentration: 2.2 (3.59)', ' Self-regulation: 2.4 (2.14)', ' Total: 20.7 (19.59)', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Placebo: Patients will take 1 tablet BID', ' Overall Number of Participants Analyzed: 103', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale*months Memory: 12.6 (9.16)', ' Language: 2.6 (2.72)', ' Visual-motor: 0.7 (0.84)', ' Spatial: 1.3 (0.92)', ' Attention/concentration: 1.8 (2.16)', ' Self-regulation: 2.0 (2.10)', ' Total: 18.0 (12.26)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/104 (3.85%)', ' Febrile neutropenia 0/104 (0.00%)', ' Infection with grade 3 or 4 neutropenia 1/104 (0.96%)', ' Leukocyte count decreased 1/104 (0.96%)', ' Neutrophil count decreased 4/104 (3.85%)', ' Platelet count decreased 1/104 (0.96%)', 'Adverse Events 2:', ' Total: 3/101 (2.97%)', ' Febrile neutropenia 1/101 (0.99%)', ' Infection with grade 3 or 4 neutropenia 0/101 (0.00%)', ' Leukocyte count decreased 2/101 (1.98%)', ' Neutrophil count decreased 2/101 (1.98%)', ' Platelet count decreased 0/101 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
171d0a20-8943-4994-a48a-7dff124e62ee
|
|
Single
|
Intervention
|
NCT01923168
|
Intervention 1 of the primary trial require participants to take a total of 150 mg alpelisib every two days.
|
Contradiction
|
[
0,
1,
2
] |
[] |
{'Clinical Trial ID': 'NCT01923168', 'Intervention': ['INTERVENTION 1: ', ' Alpelisib + Letrozole', ' Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.', 'INTERVENTION 2: ', ' Placebo + Letrozole', ' Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.'], 'Eligibility': ['Inclusion Criteria:', ' Patient is an adult, female 18 years old at the time of informed consent', ' Patient has a histologically and/or cytologically confirmed diagnosis of breast cancer', ' Patient is postmenopausal.', ' Patient has T1c-T3, any N, M0, operable breast cancer', ' Patients must have measurable disease', ' Patient has diagnostic biopsy available for the analysis of PIK3CA mutation and Ki67 level.', ' Patient has estrogen-receptor and/or progesterone positive breast cancer as per local laboratory testing', ' Patient has HER2 negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0 or 1+ as per local laboratory testing', 'Exclusion Criteria:', ' Patient has locally recurrent or metastatic disease', ' Patient has received any systemic therapy (e.g. chemotherapy, targeted therapy, immunotherapy) or radiotherapy for current breast cancer disease before randomization.', ' Patient with type 1 diabetes mellitus or not adequately controlled type 2 diabetes mellitus', ' History of acute pancreatitis within 1 year of study entry', ' Uncontrolled hypertension'], 'Results': ['Outcome Measurement: ', ' Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort', ' Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.', ' Time frame: After 24 weeks of treatment', 'Results 1: ', ' Arm/Group Title: Alpelisib + Letrozole', ' Arm/Group Description: Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.', ' Overall Number of Participants Analyzed: 60', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants 1.7 (0.2 to 6.3)', 'Results 2: ', ' Arm/Group Title: Placebo + Letrozole', ' Arm/Group Description: Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.', ' Overall Number of Participants Analyzed: 67', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants 3.0 (0.8 to 7.7)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 21/130 (16.15%)', ' Atrial fibrillation 0/130 (0.00%)', ' Cardiac disorder 0/130 (0.00%)', ' Cardiac failure 1/130 (0.77%)', ' Stress cardiomyopathy 1/130 (0.77%)', ' Iritis 0/130 (0.00%)', ' Colitis 1/130 (0.77%)', ' Diarrhoea 1/130 (0.77%)', ' Nausea 1/130 (0.77%)', ' Stomatitis 1/130 (0.77%)', ' Vomiting 1/130 (0.77%)', ' Disease progression 1/130 (0.77%)', 'Adverse Events 2:', ' Total: 22/81 (27.16%)', ' Atrial fibrillation 2/81 (2.47%)', ' Cardiac disorder 1/81 (1.23%)', ' Cardiac failure 0/81 (0.00%)', ' Stress cardiomyopathy 0/81 (0.00%)', ' Iritis 1/81 (1.23%)', ' Colitis 2/81 (2.47%)', ' Diarrhoea 1/81 (1.23%)', ' Nausea 0/81 (0.00%)', ' Stomatitis 0/81 (0.00%)', ' Vomiting 0/81 (0.00%)', ' Disease progression 0/81 (0.00%)', ' General physical health deterioration 1/81 (1.23%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
25cc9a6e-656d-44ee-a301-93f5879407a0
|
|
Single
|
Results
|
NCT00347919
|
56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] |
[] |
{'Clinical Trial ID': 'NCT00347919', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Lapatinib 1500 mg', ' Lapatinib 1500 milligrams (mg) administered orally once a day', 'INTERVENTION 2: ', ' Cohort 1: Lapatinib 1000 mg/Pazopanib 400 mg', ' Lapatinib 1000 mg and Pazopanib 400 mg administered orally once a day'], 'Eligibility': ['Inclusion Criteria:', ' A subject will be eligible for inclusion in this study only if all of the following criteria apply:', ' Women 18 years of age with a life expectancy of 12 weeks.', " Note: National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders Association (ADRDA).)", ' Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.', ' Histologically confirmed invasive breast cancer with incurable stage IIIb, stage IIIc with T4 lesion, or stage IV disease at primary diagnosis or at relapse after curative-intent surgery.', ' No prior chemotherapy, immunotherapy, biologic therapy or anti-ErbB1/ErbB2 therapy for metastatic or recurrent disease (other than neoadjuvant or adjuvant therapy). Prior hormonal therapy (e.g., tamoxifen, raloxifen or an aromatase inhibitor) for advanced or metastatic disease is permitted provided at least 2 weeks have elapsed between the completion of the prior therapy and start of study drugs.', ' Note: Subjects must have documented progressive disease (PD) or be intolerant to hormonal therapy. This must be documented in the source documentation.', ' Prior neoadjuvant therapy and/or adjuvant therapy is permitted.', ' Note:', ' (a) Subjects who have received both neoadjuvant and adjuvant therapies must have at least 6 months between completion of the chemotherapy-component of adjuvant therapy and start of study drug(s)', ' (b) Subjects who have received only adjuvant therapy must have at least 6 months between completion of the chemotherapy-component of adjuvant therapy and start of study drug(s)', ' (c) Subjects who have received only neoadjuvant therapy must have at least 6 months between completion of neoadjuvant therapy and start of study drug(s)', ' (d) Subjects who have received trastuzumab or hormonal agents as all or part of adjuvant therapy are eligible provided: (1) 2 weeks have elapsed since last dose (2) 6 months have elapsed between the start of trastuzumab or hormonal therapy and start of study drugs.', ' Radiotherapy prior to initiation of randomized therapy to a limited area (e.g., palliative treatment for painful disease) other than the sole site of measurable and assessable disease is allowed however, subjects must have completed treatment at least 4 weeks prior to starting study drugs, and must have recovered from all treatment-related toxicities prior to starting pazopanib and/or lapatinib.', ' Documented amplification of ErbB2 by Fluorescence In Situ Hybridization (FISH) in either the primary or metastatic tumor tissue. Archived tumor tissue must be provided for ErbB2 FISH testing by the central laboratory, which will be used to determine eligibility.', ' Note: Subjects that have documented ErbB2 amplification based on prior FISH testing or documented ErbB2 overexpression based on prior immunohistochemistry (IHC) with a value of 3+ are eligible, however, archived tumor tissue must be provided for confirmation by the central laboratory. If the results from prior testing are not confirmed by the central laboratory, then the subject can continue to receive study drug(s) at the discretion of the investigator, but will be excluded from the statistical analysis.', ' Archived tumor tissue (paraffin-embedded) must be available to correlate tumor response with intra-tumoral genetic changes as well as expression levels of relevant biomarkers. Results of biomarkers will not be used to determine subject eligibility for the study.', ' Ability to swallow and retain oral medication.', ' Disease must be measurable according to Response Evaluation Criteria in Solid Tumors (RECIST).', ' Subjects must have chosen treatment with lapatinib and/or pazopanib as initial treatment over other initial treatments (such as cytotoxic chemotherapy regimens or trastuzumab as a single agent) for locally advanced or metastatic disease.', ' Adequate organ function as defined below:', ' System (Laboratory Values)', ' Hematologic:Absolute neutrophil count (ANC) ( 1.5 X 109/L) Platelets ( 100 X 109/L)', " Hepatic:Albumin( 2.5 g/dL)Serum bilirubin( 1.5 X upper limit of normal (ULN) unless due to Gilbert's syndrome) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ( 2.0 X ULN)", ' Renal:Calculated creatinine clearance1 ( 50 mL/min) Urine Protein2', ' (Negative, trace or +1 by dipstick urinalysis or <1.0 gram determined by 24 hour urine protein analysis).', ' A patient should first be screened with dipstick urinalysis. If urine protein by dipstick analysis is 2+, then a 24-hour urine protein must be assessed and 24 hour urine protein must be <1 g protein to be eligible.', ' Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram. Multigated acquisition (MUGA) scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive or where MUGA scans are the accepted standard. Subjects with known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure are not eligible.', ' A female is eligible to enter and participate in this study if she is of:', ' Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had:', ' A hysterectomy', ' A bilateral oophorectomy (ovariectomy)', ' A bilateral tubal ligation', ' Is post-menopausal (total cessation of menses for 1 year)', ' Childbearing potential, has a negative serum pregnancy test within 2 weeks of the first dose of study medication, and agrees to use adequate contraception during study participation and for a minimum of 2 menstrual cycles after the last dose of study medication. GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows:', ' An intrauterine device with a documented failure rate of less than 1% per year.', " Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.", ' Complete abstinence from sexual intercourse for 14 days before exposure to investigation product, through the clinical trial, and for at least 2 menstrual cycles after the last dose of investigational product.', ' Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).', ' Oral contraceptives are not reliable due to the potential drug-drug interactions.', ' Subjects must complete all screening assessments as outlined in the protocol.', ' Subjects must provide written informed consent prior to performance of any study-specific procedures or assessments and are willing to comply with treatment and follow-up.', 'Exclusion Criteria:', ' A subject will not be eligible for inclusion in this study if any of the following criteria apply:', ' Subjects with bilateral breast cancer or bone metastases as the only disease site.', ' Patients with high disease burden defined as >30% replacement of hepatic parenchyma with metastases, symptomatic pulmonary metastases (e.g., clinically significant dyspnea, cough, or chest pain attributable to pulmonary metastases), or >3 visceral organs with tumor involvement.', ' History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.', ' Sarcoma histology.', " Concurrent disease or condition that would make the subject inappropriate for study participation including (1) any unresolved or unstable, serious toxicity from prior administration of another investigational drug, (2) any serious medical disorder that would interfere with the subject's safety, obtaining informed consent or compliance to the study.", ' History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or antiseizure medication for ³ 2 months prior to study enrollment. Routine screening with CNS imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated or if the subject has a history of CNS metastases.', ' Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.', ' Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to beginning therapy.', ' Presence of uncontrolled infection.', ' Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization).', ' Concurrent treatment with an investigational agent or participation in another clinical trial.', ' Use of an investigational anti-cancer drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of pazopanib and/or lapatinib.', ' Prior use of an investigational or licensed drug that targets either vascular endothelial growth factor (VEGF) or VEGF receptors, or ErbB2 (except for trastuzumab when used in the neo-adjuvant/adjuvant setting).', ' Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or lapatinib.', ' Has taken/is taking prohibited medications, Lapatinib-related, orPazopanib-related.', ' Corrected QT interval (QTc) prolongation defined as QTc interval > 480 msecs.', ' History of any one of the following cardiac conditions within the past 6 months:', ' Cardiac angioplasty or stenting', ' Myocardial infarction', ' Unstable angina', ' History of cerebrovascular accident within the past 6 months.', ' Poorly controlled hypertension (systolic blood pressure (SBP) of 140mmHg, or diastolic blood pressure (DBP) of 90mmHg).', ' Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. The blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 24 hours. The mean SBP/DBP values from both BP assessments must be < 140/90mmHg in order for a subject to be eligible for the study.', ' Presence of any non-healing wound, fracture, or ulcer, or the presence of symptomatic peripheral vascular disease.', ' Evidence of bleeding diathesis or coagulopathy.', ' Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study; minor surgical procedures such as fine needle aspiration or core biopsy within 1 week prior to beginning therapy are also excluded.', ' Pregnant or lactating female.', ' Has Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.', ' History of untreated deep venous thrombosis (DVT) within the past 6 months (e.g. calf vein thrombosis).'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Progressive Disease at Week 12 in Cohort 1', ' The percentage of participants with progressive disease (PD) 12 weeks after randomization was measured. Per Response Evaluation Criteria In Solid Tumors (RECIST), a response of PD is defined as a >=20% increase in target lesions. Participants were also classified as having PD if their response at Week 12 was unknown or missing. Response was determined by an independent radiologist and by an investigator.', ' Time frame: Week 12', 'Results 1: ', ' Arm/Group Title: Cohort 1: Lapatinib 1500 mg', ' Arm/Group Description: Lapatinib 1500 milligrams (mg) administered orally once a day', ' Overall Number of Participants Analyzed: 72', ' Measure Type: Number', ' Unit of Measure: percentage of participants Independently Evaluated: 38.9', ' Investigator Evaluated: 43.1', 'Results 2: ', ' Arm/Group Title: Cohort 1: Lapatinib 1000 mg/Pazopanib 400 mg', ' Arm/Group Description: Lapatinib 1000 mg and Pazopanib 400 mg administered orally once a day', ' Overall Number of Participants Analyzed: 69', ' Measure Type: Number', ' Unit of Measure: percentage of participants Independently Evaluated: 36.2', ' Investigator Evaluated: 37.7'], 'Adverse Events': ['Adverse Events 1:', ' Total: 10/73 (13.70%)', ' Anaemia 0/73 (0.00%)', ' Febrile neutropenia 0/73 (0.00%)', ' Thrombocytopenia 0/73 (0.00%)', ' Left ventricular dysfunction 0/73 (0.00%)', ' Diarrhoea 2/73 (2.74%)', ' Oesophagitis 0/73 (0.00%)', ' Vomiting 1/73 (1.37%)', ' Abdominal pain upper 0/73 (0.00%)', ' Colitis 0/73 (0.00%)', ' Fatigue 0/73 (0.00%)', ' Pyrexia 0/73 (0.00%)', ' Cholecystitis 0/73 (0.00%)', 'Adverse Events 2:', ' Total: 18/76 (23.68%)', ' Anaemia 2/76 (2.63%)', ' Febrile neutropenia 0/76 (0.00%)', ' Thrombocytopenia 0/76 (0.00%)', ' Left ventricular dysfunction 2/76 (2.63%)', ' Diarrhoea 1/76 (1.32%)', ' Oesophagitis 1/76 (1.32%)', ' Vomiting 0/76 (0.00%)', ' Abdominal pain upper 0/76 (0.00%)', ' Colitis 0/76 (0.00%)', ' Fatigue 1/76 (1.32%)', ' Pyrexia 1/76 (1.32%)', ' Cholecystitis 0/76 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
d9b4d4aa-0094-405e-83a3-cf2978cfda38
|
|
Single
|
Intervention
|
NCT00038467
|
The patient groups in the primary trial each receive the same doses of different oral medication, either Tamoxifen or Exemestane.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5
] |
[] |
{'Clinical Trial ID': 'NCT00038467', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period.', 'INTERVENTION 2: ', ' Tamoxifen', ' Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period.'], 'Eligibility': ['Inclusion Criteria:', ' postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease', 'Exclusion Criteria:', ' unresectable breast cancer', ' ER negative primary tumor'], 'Results': ['Outcome Measurement: ', ' Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study', ' DFS defined as time from randomization to earliest documentation of breast cancer relapse or death from any cause. DFS at Month 36 post-randomization was defined as probability of participants alive and disease-free at 36 months after the randomization. Participants withdrawn from the study for any reason in the absence of relapse were censored at the date they were last seen. Relapse was categorized as follows: loco-regional: ipsilateral breast or axillary nodal relapse; distant: distant relapse, including supraclavicular nodes; second primary breast cancer: contralateral breast cancer, excluding ductal carcinoma in situ.', ' Time frame: Baseline up to Month 36', 'Results 1: ', ' Arm/Group Title: Exemestane', ' Arm/Group Description: Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period.', ' Overall Number of Participants Analyzed: 2352', ' Measure Type: Number', ' Unit of Measure: probability of DFS 0.90 (0.89 to 0.92)', 'Results 2: ', ' Arm/Group Title: Tamoxifen', ' Arm/Group Description: Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period.', ' Overall Number of Participants Analyzed: 2372', ' Measure Type: Number', ' Unit of Measure: probability of DFS 0.86 (0.85 to 0.88)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 383/2320 (16.51%)', ' Anaemia * 2/2320 (0.09%)', ' Disseminated intravascular coagulation * 1/2320 (0.04%)', ' Granulocytopenia * 0/2320 (0.00%)', ' Hypofibrinogenaemia * 0/2320 (0.00%)', ' Iron deficiency anaemia * 1/2320 (0.04%)', ' Lymphadenitis * 1/2320 (0.04%)', ' Lymphadenopathy * 0/2320 (0.00%)', ' Thrombocytopenia * 1/2320 (0.04%)', ' Acute myocardial infarction * 5/2320 (0.22%)', 'Adverse Events 2:', ' Total: 439/2338 (18.78%)', ' Anaemia * 4/2338 (0.17%)', ' Disseminated intravascular coagulation * 0/2338 (0.00%)', ' Granulocytopenia * 1/2338 (0.04%)', ' Hypofibrinogenaemia * 1/2338 (0.04%)', ' Iron deficiency anaemia * 0/2338 (0.00%)', ' Lymphadenitis * 0/2338 (0.00%)', ' Lymphadenopathy * 1/2338 (0.04%)', ' Thrombocytopenia * 5/2338 (0.21%)', ' Acute myocardial infarction * 0/2338 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
caa55802-329d-4a1f-a9a7-b99afc44fd67
|
|
Comparison
|
Intervention
|
NCT02525718
|
NCT02606708
|
Patients in group 1 of the secondary trial and the primary trial receive the same dosage of oral placebo.
|
Contradiction
|
[
0,
1,
2,
3
] |
[
0,
1,
2,
3
] |
{'Clinical Trial ID': 'NCT02525718', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.', ' Saline: If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)', 'INTERVENTION 2: ', ' 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone', ' Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone. The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue.', ' Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.', ' 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone: If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.', '(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively.'], 'Eligibility': ['Inclusion Criteria:', ' Patients who undergo mastectomy surgery with immediate reconstruction involving insertion of a tissue expander performed by the principal investigator beginning from the time of study approval until study enrollment is complete.', 'Exclusion Criteria:', ' Patients under the age of 18, or over the age of 79', ' Allergy to local anesthetics or corticosteroids', ' Patients with history of chronic pain or with chronic use of opioid analgesics', ' Patients with history of lung disease or prior anterior thoracotomy or median sternotomy'], 'Results': ['Outcome Measurement: ', ' Quality of Recovery Score', ' The primary outcome measure is a well-validated and widely used survey measuring the quality of recovery from anesthesia entitled the "Global 40 Item Quality of Recovery" survey. This is a 40 question survey administered to patients to allow them to rate their quality of recovery along a number of different dimensions, including emotional state, physical comfort, psychological support, physical independence, and pain. The score ranges from 40 to 200, with 40 representing a very poor overall quality of recovery and 200 representing the best possible recovery. The following reference explains the Global 40 Item Quality of Recovery survey in detail:', ' Myles, P.S., et al., Validity and reliability of a postoperative quality of recovery score: the QoR-40. Br J Anaesth, 2000. 84(1): p. 11-5.', ' PMID: 10740540', ' Time frame: 24 hours post-operatively', 'Results 1: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.', ' Saline: If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)', ' Overall Number of Participants Analyzed: 22', ' Median (Inter-Quartile Range)', ' Unit of Measure: score on a scale 165 (143 to 179)', 'Results 2: ', ' Arm/Group Title: 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone', ' Arm/Group Description: Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone. The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue.', ' Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.', ' 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone: If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.', '(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively.', ' Overall Number of Participants Analyzed: 23', ' Median (Inter-Quartile Range)', ' Unit of Measure: score on a scale 169 (155 to 182)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/22 (0.00%)', 'Adverse Events 2:', ' Total: 0/23 (0.00%)']}
|
{'Clinical Trial ID': 'NCT02606708', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Intensity Modulated Radiation Therapy (AIMRT)', ' All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.', ' Accelerated intensity modulated radiation therapy (AIMRT)'], 'Eligibility': ['Inclusion Criteria:', ' Pre- or post-menopausal women with Stage I and II breast cancer', ' Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm', ' Status post segmental mastectomy. and after sentinel node biopsy and/or axillary node dissection', ' At least 2 weeks from last chemotherapy', ' Tumors < 5 mm do not require nodal assessment', 'Exclusion Criteria:', ' Previous radiation therapy to the ipsilateral breast.', ' More than 3 involved nodes identified at axillary staging, requiring adjuvant axillary radiation.', ' Active connective tissue disorders, such as lupus or scleroderma.', ' Prior or concurrent malignancy other than basal or squamous cell skin cancer or carcinoma in-situ of the cervix, unless disease-free > 5 years.', ' Pregnant or lactating women.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Local Recurrence in Breast', ' Defined by the discovery of invasive disease or DCIS in the same region of the breast after segmental mastectomy and radiation, by clinical or radiographic means.', ' Time frame: 5 years', 'Results 1: ', ' Arm/Group Title: Accelerated Intensity Modulated Radiation Therapy (AIMRT)', ' Arm/Group Description: All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.', ' Accelerated intensity modulated radiation therapy (AIMRT)', ' Overall Number of Participants Analyzed: 314', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 6 1.9%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/314 (0.00%)']}
|
6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0
|
Comparison
|
Intervention
|
NCT00262834
|
NCT01106898
|
In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients. Whereas all the primary trial participants receive the same treatment.
|
Entailment
|
[
0,
1,
2
] |
[
0,
1,
2,
3,
4
] |
{'Clinical Trial ID': 'NCT00262834', 'Intervention': ['INTERVENTION 1: ', ' Vorinostat', ' Women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid), with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or biopsy).'], 'Eligibility': ['Inclusion Criteria:', ' No prior or concurrent hormonal therapy for breast cancer', ' Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment (e.g., preoperative/neoadjuvant systemic treatment) for breast cancer', ' ECOG 0-2 OR Karnofsky 60-100%', ' Absolute neutrophil count 1,500/mm^3', ' Platelet count 100,000/mm^3', ' Bilirubin normal', ' AST and ALT 2.5 times upper limit of normal', ' PT 14 seconds', ' Creatinine normal', ' No symptomatic congestive heart failure', ' No unstable angina pectoris', ' No cardiac arrhythmia', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' No ongoing or active infection', ' No psychiatric illness or social situation that would preclude study compliance', ' No other uncontrolled intercurrent illness', ' No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat', ' At least 30 days since prior hormone replacement therapy (e.g., estrogen and/or progestin)', ' Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed', ' No concurrent birth control pills', ' No prior radiotherapy to the ipsilateral breast', ' No prior or concurrent radiotherapy for breast cancer', ' No prior or concurrent novel therapy for breast cancer', ' At least 14 days since prior valproic acid or another histone deacetylase inhibitor', ' No other concurrent investigational agents', ' No concurrent combination antiretroviral therapy for HIV-positive patients', ' No other concurrent therapy for this cancer', ' WBC 3,000/mm^3', 'Exclusion criteria:', ' Patients must not be recieving any other investigational agents', ' History of allergic reactions attributed to compounds of similar chemical or biologic composition to SAHA.', ' Patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA.', ' Women who are pregnant.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Adverse Events', ' Participants were evaluated for adverse events due to vorinostat to assess if it was safe to give the drug prior to surgery. 17 of 25 participants who received vorinostat experienced at least 1 adverse event believed to be related to the study drug; no adverse events were severe, and the treatment was considered safe.', ' Time frame: After 3 days of vorinostat', 'Results 1: ', ' Arm/Group Title: Vorinostat', ' Arm/Group Description: Women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid), with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or biopsy).', ' Overall Number of Participants Analyzed: 25', ' Measure Type: Number', ' Unit of Measure: participants 17'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/25 (0.00%)']}
|
{'Clinical Trial ID': 'NCT01106898', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Chemotherapy With or Without Maintenance Therapy)', ' SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.', ' MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity.', ' cyclophosphamide, paclitaxel, trastuzumab: Given IV'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed newly diagnosed stage I-II breast cancer', ' Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment', ' Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Absolute neutrophil count greater than or equal to 1,500/mcl', ' Platelet count equal to or greater than 150,000/mcl', ' Hemoglobin > 11 gm/dl', ' Alkaline phosphatase equal or less than 1.5 times the upper limit of normal (ULN)', ' Total bilirubin equal to or less than 1.5 times the ULN', ' Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times the ULN', ' Creatinine less than 1.5 times the ULN', ' Able to give informed consent', ' All included patients must have normal cardiac function as defined by an ejection fraction of > 50% by echocardiogram', ' Able to return for treatment and follow-up on the specified days', 'Exclusion Criteria:', ' Prior malignancy; except for adequately treated basal cell or squamous cell skin cancer or noninvasive carcinomas', ' Patients with preexisting grade II peripheral neuropathy', ' Patients with prior chemotherapy', ' Stage IV or metastatic breast cancer', ' Pregnant or nursing women', ' Inability to cooperate with treatment protocol', ' No active serious infections or other conditions precluding chemotherapy', ' Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol (e.g. unstable angina, myocardial infarction within 6 months, severe infection, etc.)', ' Known hypersensitivity to any component of required drugs in the study', ' Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C or active hepatitis', ' Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form', ' Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any electrocardiograph (ECG) abnormality at screening has to be documented by the investigator as not medically relevant'], 'Results': ['Outcome Measurement: ', ' Recurrence-free Survival', ' Recurrence-free survival curves will be plotted for subjects treated with stage I and II disease.', ' Time frame: Time from the start of treatment to recurrence, second malignancy, or death as a first event, assessed up to 3 years', 'Results 1: ', ' Arm/Group Title: Treatment (Chemotherapy With or Without Maintenance Therapy)', ' Arm/Group Description: SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.', ' MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity.', ' cyclophosphamide, paclitaxel, trastuzumab: Given IV', ' Overall Number of Participants Analyzed: 100', ' Measure Type: Number', ' Unit of Measure: percentage of subjects 98 (92.2 to 99.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 16/102 (15.69%)', ' Febrile Neutropenia 3/102 (2.94%)', ' SinusTachycardia 1/102 (0.98%)', ' Abdominal pain 2/102 (1.96%)', ' Duodenal perforation 1/102 (0.98%)', ' Constipation 1/102 (0.98%)', ' Diarrhea 1/102 (0.98%)', ' Fever 1/102 (0.98%)', ' Anaphylaxis 1/102 (0.98%)', ' Skin Infection [1]1/102 (0.98%)', ' Urinary Tract Infection 1/102 (0.98%)', ' Sepsis 1/102 (0.98%)']}
|
0880bb0b-9e8d-4fce-8795-2ec6526d9bfb
|
Single
|
Intervention
|
NCT02780713
|
Both cohorts of the primary trial are administered the same drugs in different doses .
|
Contradiction
|
[
0,
1,
2,
3,
4,
5
] |
[] |
{'Clinical Trial ID': 'NCT02780713', 'Intervention': ['INTERVENTION 1: ', ' Treatment Period 1', ' Participants received AZD9496 - Variant A (100 mg).', 'INTERVENTION 2: ', ' Treatment Period 2', ' Participants received AZD9496 - Reference (100 mg).'], 'Eligibility': ['Inclusion Criteria:', ' Provision of signed and dated, written informed consent prior to any study specific procedures.', ' Healthy male and/or female subjects aged 18 to 65 years with suitable veins for cannulation or repeated venipuncture.', ' Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at screening by fulfilling 1 of the following criteria: Post-menopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and FSH levels in the post-menopausal range (OR) Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation', ' Male subjects aged 18 to 39 years must be vasectomized. Male subjects aged 40 to 65 years must either be vasectomized or have no intention of fathering a child for a period of 6 months after receiving the last dose of IMP.', ' Have a body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive, and weigh at least 50 kg and no more than 100 kg, inclusive.', ' Values for AST, ALT, TBL, GGT and ALP must be at or below the upper limit of normal ranges at screening.', 'Exclusion Criteria:', " History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.", ' History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.', ' Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.', ' Previous history of venous or arterial thromboembolism or thrombophilia.', ' History of endometrial polyps, endometrial cancer, atypical endometrial hyperplasia, or other endometrial disorders unless subjects have undergone total hysterectomy and there is no evidence of active disease (females only).', ' Any clinically significant abnormalities in clinical chemistry (other than Inclusion no.6), hematology, or urinalysis results at screening, as judged by the investigator.', ' Any clinically significant abnormal findings in supine vital signs, after 10 minutes of supine rest, at screening and/or admission to the unit, defined as: (a) Systolic blood pressure < 90 mmHg or 150 mmHg (b) Diastolic blood pressure < 50 mmHg or 95 mmHg and (c) Heart rate < 45 or > 90 beats per minute', ' Any clinically important abnormalities in rhythm, conduction or morphology of the resting 12-lead ECG that, as judged by the investigator, that may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology or pronounced left ventricular hypertrophy.', ' Prolonged QTcF > 460 ms for females and QTcF > 450 ms for males or family history of long QT syndrome.', ' PR (PQ) interval shortening < 110 ms or evidence of ventricular pre-excitation).', ' PR (PQ) interval prolongation > 240 ms, intermittent second (Wenckebach block while asleep is not exclusive) or third degree AV block.', ' Persistent or intermittent complete bundle branch block with QRS > 120 ms or evidence of pronounced ventricular hypertrophy or pre-excitation.', ' Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) antibody.', ' Known or suspected history of drug abuse, as judged by the investigator.', ' Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening.', ' Known or suspected history of alcohol or drug abuse or excessive intake of alcohol, as judged by the investigator.', ' Positive screen for drugs of abuse, alcohol or cotinine at screening or on each admission to the unit.', ' History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9496.', ' Excessive intake of caffeine/xanthine containing drinks or food (e.g., coffee, tea, chocolate), as judged by the investigator.', " Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.", ' Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life Note: Hormonal replacement therapy is not allowed for females.', ' Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening', ' Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion is 3 months after the final dose from previous study or 1 month after the last visit of previous study, whichever is the longest. ote: Subjects consented and screened, but not dosed in this study or a previous phase I study, are not excluded.', ' Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives', ' Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.', ' Subjects who are vegans or have medical dietary restrictions.', ' Subjects who cannot communicate reliably with the investigator.', ' Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.'], 'Results': ['Outcome Measurement: ', ' Pharmacokinetics: Maximum Plasma Concentration (Cmax) for AZD9496 and Its Metabolites at Each Treatment Period.', ' To evaluate maximum observed plasma concentration (Cmax) for AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation.', ' Time frame: Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period', 'Results 1: ', ' Arm/Group Title: Treatment Period 1', ' Arm/Group Description: Participants received AZD9496 - Variant A (100 mg).', ' Overall Number of Participants Analyzed: 14', ' Geometric Mean (Geometric Coefficient of Variation)', ' Unit of Measure: ng/mL AZD9496: 64.85 (73.54%)', ' M3: 10.30 (98.93%)', ' M5: 1.102 (85.27%)', 'Results 2: ', ' Arm/Group Title: Treatment Period 2', ' Arm/Group Description: Participants received AZD9496 - Reference (100 mg).', ' Overall Number of Participants Analyzed: 14', ' Geometric Mean (Geometric Coefficient of Variation)', ' Unit of Measure: ng/mL AZD9496: 381.0 (55.83%)', ' M3: 62.98 (76.91%)', ' M5: 7.409 (75.18%)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/14 (0.00%)', 'Adverse Events 2:', ' Total: ']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
baea8eb9-a6e7-4473-9b4b-28a4fdb531ad
|
|
Single
|
Eligibility
|
NCT00054275
|
A patient with severe anginal syndrome but angiographically normal coronary arteries would be unable to participate in the primary trial.
|
Entailment
|
[
33,
35
] |
[] |
{'Clinical Trial ID': 'NCT00054275', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel and OSI-774', ' docetaxel IV over 1 hour once weekly for 3 weeks and oral erlotinib once daily'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed stage IV or recurrent adenocarcinoma of the breast', ' Measurable disease', ' Disease recurrence must not be within 1 year of receiving prior adjuvant docetaxel', ' Stable brain metastases allowed', ' Hormone receptor status:', ' Not specified', ' PATIENT CHARACTERISTICS:', ' Age', ' 18 and over', ' Sex', ' Male or female', ' Menopausal status', ' Not specified', ' Performance status', ' ECOG (Eastern Cooperative Oncology Group) 0-2 OR', ' Karnofsky 60-100%', ' Life expectancy', ' More than 6 months', ' Hematopoietic', ' WBC(White Blood Count) at least 3,000/mm^3', ' Platelet count at least 100,000/mm^3', ' Absolute neutrophil count at least 1,500/mm^3', ' Hemoglobin at least 8 g/dL', ' Hepatic', ' Bilirubin normal', ' AST(aspartate aminotransferase)/ALT(alanine aminotransferase) no greater than 2.5 times upper limit of normal', ' Renal', ' Creatinine normal OR', ' Creatinine clearance at least 60 mL/min', ' No clinically significant proteinuria', ' No significant impairment of renal function', ' Cardiovascular', ' No New York Heart Association class III or IV heart disease', ' No symptomatic congestive heart failure', ' No unstable angina pectoris', ' No cardiac arrhythmia', ' No inadequately controlled hypertension', ' Other', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective barrier contraception', ' No prior severe hypersensitivity reaction to docetaxel or drugs formulated with polysorbate 80', ' No other malignancy within the past 10 years except inactive nonmelanoma skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, or bilateral breast cancer', ' No ongoing or active infection', ' No peripheral neuropathy greater than grade 1', ' No other concurrent uncontrolled medical condition that would preclude study participation', ' No psychiatric illness or social situation that would preclude study compliance', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' Prior trastuzumab (Herceptin) allowed', ' Chemotherapy', ' See Disease Characteristics', ' No prior chemotherapy for recurrent or metastatic disease', ' Prior adjuvant chemotherapy allowed', ' Endocrine therapy', ' Prior hormonal therapy allowed', ' Radiotherapy', ' Not specified', ' Surgery', ' Not specified', ' Other', ' No other concurrent investigational agents'], 'Results': ['Outcome Measurement: ', ' Disease Response (Tumor Measurements)Per RECIST Criteria v. 2000', ' Response and progression will be evaluated in this study using the criteria by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria. Partial Response: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions. Progressive Disease: At least a 20% increase in the sum of the LD of target lesions. Stable Disease: Neither sufficient shrinkage nor sufficient increase.', ' Time frame: after 6 course (6 months) of combination therapy', 'Results 1: ', ' Arm/Group Title: Docetaxel and OSI-774', ' Arm/Group Description: docetaxel IV over 1 hour once weekly for 3 weeks and oral erlotinib once daily', ' Overall Number of Participants Analyzed: 28', ' Measure Type: Number', ' Unit of Measure: participants Partial response: 11', ' Disease progression: 14', 'Stable disease: 3'], 'Adverse Events': ['Adverse Events 1:', ' Total: 28/39 (71.79%)', ' Anemia 1/39 (2.56%)', ' Leukopenia 4/39 (10.26%)', ' Neutropenia 4/39 (10.26%)', ' Chest Pain 1/39 (2.56%)', ' Pericarditis 1/39 (2.56%)', ' Sinus Tach. 1/39 (2.56%)', ' Sinus Tachycardia 1/39 (2.56%)', ' Eye tearing 1/39 (2.56%)', ' Diarrhea 7/39 (17.95%)', ' Mucositis 3/39 (7.69%)', ' Nausea 2/39 (5.13%)', ' Vomiting [1]1/39 (2.56%)', ' Fatigue 6/39 (15.38%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
01f89936-1621-4dd5-93b7-8b0c64b397fd
|
|
Single
|
Intervention
|
NCT00320411
|
the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily.
|
Entailment
|
[
0,
1,
2
] |
[] |
{'Clinical Trial ID': 'NCT00320411', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib Monotherapy', ' Lapatinib: 1500 mg (six 250 mg tablets) orally once daily'], 'Eligibility': ['Inclusion Criteria:', ' A subject will be considered eligible for inclusion in this study only if all of the following criteria apply:', ' Life expectancy of 16 weeks from the start of lapatinib therapy;', ' Signed informed consent obtained from the patient;', ' Subjects must have histologically confirmed breast cancer with advanced (Stage IIIb, IIIc with T4 lesion) or metastatic disease (including recurrent patients);', ' Subjects must meet the following criteria regarding prior therapy:', ' Anthracyclines, taxanes:', ' If anthracycline- and taxane-containing regimens are administered sequentially;', ' Subjects should have been provided with at least 2 cycles each and at least 4 cycles in total.', ' If anthracycline- and taxane-containing regimen are administered concurrently;', ' Subjects should have been provided with at least 4 cycles in total. or', ' Subjects should have been provided with at least 2 cycles in total and provided progressive disease occurred.', ' If anthracycline- and taxane-containing regimen are administered separately;', ' Subjects should have been provided with at least 4 cycles each. or', ' Subjects should have been provided with at least 2 cycles each and provided progressive disease occurred each regimen.', ' Trastuzumab:', ' Prior treatment must contain trastuzumab alone or in combination with other chemotherapy for at least 6 weeks of standard doses.', ' Subjects must meet the following criteria regarding ErbB2 expression (defined by the following status before undergoing trastuzumab therapy.)', ' Patients with ErbB2 overexpression:', ' 3+ by IHC, or FISH+', ' 2+ by IHC and FISH+ are also eligible. However, patients with "2+ by IHC" who have previously been treated with trastuzumab should undergo FISH before study entry, if they have not had this test performed before, and are considered eligible only if their tumours are categorised as FISH+.', ' Documentation of tumor progression or relapse after the most recent treatment is required.', ' Archived tumor tissue must be available to compare tumor response with intra-tumoral expression levels of biomarkers (ErbB1 and ErbB2).', ' Measurable lesion(s) according to RECIST (Response Evaluation Criteria in Solid Tumors); (See "6.3. Efficacy")', ' A female, 20 and 74 years (at the time of giving consent), is eligible to enter and participate in this study if she is of:', ' Non-childbearing potential (i.e., women with functioning ovaries who have a current documented tubal ligation or hysterectomy, or women who are post-menopausal, i.e., at least 1 year has past since the last menstrual period); or is', ' The subject has a negative serum pregnancy test at screening, and agrees to one of the following from 2 weeks prior to administration of the first dose of lapatinib until 28 days after the final dose of lapatinib＊.', ' Complete abstinence from intercourse:', ' Consistent and correct use of one of the following acceptable methods of birth control:', ' Injectable progestogen;', ' Any intrauterine device (IUD);', ' Oral contraceptives (either combined or Progestogen only);', ' Barrier methods including diaphragm or condom with a spermicide.', ' At least 3 weeks since the last dose of prior last chemotherapy, immunotherapy, biologic therapy, hormonal therapy, or radiotherapy (except for local radiation therapy to pain relief) for cancer or since the date of completion of surgery (except for minor surgical procedures) before beginning treatment with lapatinib, except for trastuzumab which must be discontinued at least 2 weeks prior to beginning of study drug. Subjects must have recovered or stabilized sufficiently from side effects associated with prior therapy;', ' Prior to enrollment, radiation therapy is allowed to a limited field (e.g. painful bone mets, painful lumps), if it is not the sole site of measurable and/or assessable disease. Patients must have completed treatment and adequately recovered, in particular from bone marrow suppression.', ' Subjects who are not on bisphosphonate therapy. Bisphosphonates initiated prior to study medication are allowed; however, initiation of bisphosphonate following the first dose of study medication is not allowed. Prophylactic use of bisphosphonates is only permitted for treatment of osteoporosis.', ' Subjects with stable CNS metastasis (asymptomatic and off systemic steroids and anticonvulsants for at least 3 months) are also eligible;', ' ECOG Performance Status of 0 to 2;', ' Able to swallow and retain oral medication;', " Left ventricular ejection fraction (LVEF), measured by echocardiogram (ECHO), above the institutional's lower limit of normal (LVEF of 50% in such case as normal range of LVEF is not provided by institution).", ' Subjects must have adequate organ function as defined below:', ' Myelofunction:', ' Neutrophil count 1500 /mm3 Hemoglobin 9 g/dL (at least 2 weeks after blood transfusion if needed) Platelet count 100,000 /mm3', ' Hepatic function:', ' Albumin 2.5 g/dL Total bilirubin 1.5xULN AST, ALT: 3xULN (without liver metastases), 5xULN (if documented liver metastases)', ' Renal function:', ' Serum creatinine 1.5 mg/dL, or creatinine clearance 40 mL/min (calculated by the Cockcroft and Gault Method)', ' Subjects who can visit the hospital once weekly (±3 days) at least in the first month after the start of lapatinib therapy and then every 4 weeks (±1 week) until the last assessment.', 'Exclusion Criteria:', ' A subject will not be eligible for inclusion in this study if any of the following criteria apply:', ' Pregnant or lactating females;', ' Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded;', ' History of other malignancy. Subjects who have been disease free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;', " Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety * [* Grade 3 (according to NCI-CTCAE Version 3.0), as a general rule];", ' Active or uncontrolled infection;', ' Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure;', ' Known history of or clinical evidence of leptomeningeal carcinomatosis;', ' Participated in a clinical study within the past 28 days of the first dose of lapatinib;', ' Prior therapy with an ErbB1inhibitor (e.g., gefinitib) and/or ErbB2 inhibitor other than trastuzumab;', ' Has taken/received prohibited inhibitors (including foods) of CYP3A4 within 7 days prior to the first dose of study medication or has taken/received prohibited inducers inducers (including foods) of CYP3A4 within 14 days prior to the first dose of study medication(Refer to Appendix 7).', ' The subject has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to lapatinib or excipients', ' Patients ineligible for participation in the study in the judgment of the investigator/sub investigator.'], 'Results': ['Outcome Measurement: ', ' Overall Tumor Response', ' Tumor response was measured as the number of participants achieving either a complete response (CR; disappearance of all target lesions) or partial response (PR; 30% decrease in the sum of the longest diameter of target lesions) among all participants who received study treatment. Tumor response was evaluated as the best response in accordance with response evaluation criteria in solid tumors (RECIST). Progressive disease: a 20% increase in the sum of the longest diameter of target lesions. Stable disease: small changes that do not meet the above-mentioned criteria.', ' Time frame: Baseline and then followed every 4 weeks until disease progression or death. If treatment was terminated due to adverse events, then followed every 12 weeks until disease progression is noted.', 'Results 1: ', ' Arm/Group Title: Lapatinib Monotherapy', ' Arm/Group Description: Lapatinib: 1500 mg (six 250 mg tablets) orally once daily', ' Overall Number of Participants Analyzed: 58', ' Measure Type: Number', ' Unit of Measure: participants Complete response: 1', ' Partial response: 8', ' Stable disease: 18', ' Progressive disease: 29', 'Unknown: 2'], 'Adverse Events': ['Adverse Events 1:', ' Total: 14/58 (24.14%)', ' Ventricular dysfunction 1/58 (1.72%)', ' Nausea 1/58 (1.72%)', ' Diarrhea 1/58 (1.72%)', ' Vomiting 1/58 (1.72%)', ' Malaise 1/58 (1.72%)', ' Disease progression 1/58 (1.72%)', ' Hepatic function abnormal 2/58 (3.45%)', ' Hepatomegaly 1/58 (1.72%)', ' Pneumonia 2/58 (3.45%)', ' Cellulitis 1/58 (1.72%)', ' Lymphocyte count decreased 1/58 (1.72%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
ee7fe82e-de91-45c7-bd12-bff5d6c887a3
|
|
Comparison
|
Adverse Events
|
NCT00266110
|
NCT00879086
|
the primary trial had a much higher rate of adverse events than the secondary trial.
|
Contradiction
|
[
0,
1,
2,
3,
4
] |
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] |
{'Clinical Trial ID': 'NCT00266110', 'Intervention': ['INTERVENTION 1: ', ' Dendritic Cell Vaccine', ' Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion', ' sargramostim: All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.', ' therapeutic autologous dendritic cells: patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.', ' trastuzumab: Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration.'], 'Eligibility': ['PATIENT ELIGIBILITY', ' 4.1 Inclusion Criteria 4.1.1 Histologically proven metastatic breast cancer with measurable or evaluable disease per investigator discretion.', ' 4.1.2 Patients must be 18 years of age or older. Women of child bearing potential must be practicing barrier or oral contraception for the duration of the study, or documented as surgically sterile or one year post-menopausal.', ' 4.1.3 Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (See Appendix A).', ' 4.1.5 Cardiac function by multigated acquisition scan (MUGA) with an ejection fraction (EF) > 45% or an echocardiogram that shows normal left ventricle (LV) function.', ' 4.1.6 Serum Creatinine < 2.0 mg/dl. 4.1.7 Hepatic transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) 3.0 times the upper limit of normal if no liver metastases or 5 times the upper limit of normal if liver metastases are present.', ' 4.1.8 Bilirubin no more than 2 times normal.', ' 4.1.9 Seronegative for HIV.', ' 4.1.10 Negative for Hepatitis B surface antigen.', ' 4.1.11 Signed and dated informed consent.', ' 4.1.12 HLA A0201+ by DNA genotyping.', ' 4.1.13 Absolute neutrophil count greater than 1,500/mm3. Platelet count greater 100,000/mm3 and hemoglobin greater than or equal to 10', ' 4.1.14. 3+ expression of HER-2/neu from original pathology (diagnostic) tumor sample by Immunohistochemistry (IHC) or 2+ expression by IHC with gene amplification by fluorescence in situ hybridization (FISH).', ' 4.1.15. Patients will be eligible even if they have failed treatment for metastatic breast cancer with trastuzumab and a chemotherapy agent other than vinorelbine or if they have progressed within 12 months of receiving adjuvant chemotherapy using trastuzumab and a taxane.', ' 4.2 Exclusion Criteria', ' 4.2.1 Patients with any serious medical, cardiac, or psychiatric condition which, in the opinion of the investigator, would make the patient unsuitable for study participation or would impede probable compliance with the protocol.', ' 4.2.2 Patients with central nervous system metastases must have stable disease for at least 3 months prior to study entry.', ' 4.2.3 Patient is currently taking steroid medications. Systemic steroid treatment is not allowed.', ' 4.2.4 Patients that have failed prior therapy with vinorelbine + trastuzumab will not be eligible for therapy.', ' 4.2.5 Patient has received hormonal or cytotoxic chemotherapy within 14 days of apheresis and within 28-30 days prior to study treatment.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Response', ' Response: Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', ' Time frame: 5-6 years', 'Results 1: ', ' Arm/Group Title: Dendritic Cell Vaccine', ' Arm/Group Description: Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion', ' sargramostim: All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.', ' therapeutic autologous dendritic cells: patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.', ' trastuzumab: Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration.', ' Overall Number of Participants Analyzed: 17', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/17 (11.76%)', ' Nausea * 1/17 (5.88%)', ' Pain - Abdomen NOS * 1/17 (5.88%)', ' Constipation * 1/17 (5.88%)']}
|
{'Clinical Trial ID': 'NCT00879086', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate was given at a dose of 1.4 mg/m^2 as a 2 to 5 minute IV bolus on Days 1 and 8 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cycle of the Treatment Phase, participants who demonstrated clinical benefit could continue treatment during the Extension Phase for an indefinite number of cycles for as long as clinical benefit was sustained (up to 211 weeks).', 'INTERVENTION 2: ', ' Ixabepilone', ' Ixabepilone was given at a starting dose of 32 or 40 mg/m^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cycle of the Treatment Phase, participants who demonstrated clinical benefit could continue treatment during the Extension Phase for an indefinite number of cycles for as long as clinical benefit was sustained (up to 211 weeks).'], 'Eligibility': ['Inclusion criteria:', ' 1. Female subjects with confirmed locally recurrent or metastatic carcinoma of the breast who have received prior taxane therapy and at least one prior cytotoxic chemotherapy regimen for advanced disease.', 'Exclusion criteria:', ' Subjects who have received prior ixabepilone therapy.', ' Subjects with prior participation in an eribulin clinical study, even if not assigned to eribulin treatment.', ' Subjects with pre-existing neuropathy Grade greater than or equal to 2.', ' Subjects with a history of diabetes mellitus Type 1 or 2.', ' Subjects with bilateral mastectomy which included bilateral axillary lymph node dissection.', ' Subjects with missing digits required for vibration assessment.', ' Subjects with any other concurrent diseases or conditions that would be expected to interfere with neuropathy assessments, which may include vitamin deficiency, sequelae of cerebrovascular disease, thyroid insufficiency, lumbar or cervical radiculopathy, or alcoholic or inflammatory neuropathy.'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Treatment-Emergent Neuropathy Adverse Events (AEs)', ' Neuropathy AEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and coded according to the current version of the Medical Dictionary for Regulatory Activities (MedDRA). Neuropathy AEs included the broad list of preferred terms (PTs) defined in the Standard MedDRA Query for Neuropathy and the following additional PTs: neuropathy, hyperesthesia, painful response to normal stimuli, pallanesthesia, and allodynia. If the post-baseline maximum CTCAE grade of the combined term "neuropathy" was greater than the baseline maximum CTCAE grade of the combined term, then the event was considered as treatment emergent neuropathy adverse events per CTCAE grade. For a single participant, 1) a neuropathy AE occurring more than once during the study, whether defined with the same or different MedDRA PTs, was counted only once, 2) a neuropathy AE with different CTCAE grades had only the highest grade AE counted.', ' Time frame: From administration of first dose up to approximately 5 years', 'Results 1: ', ' Arm/Group Title: Eribulin Mesylate', ' Arm/Group Description: Eribulin mesylate was given at a dose of 1.4 mg/m^2 as a 2 to 5 minute IV bolus on Days 1 and 8 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cycle of the Treatment Phase, participants who demonstrated clinical benefit could continue treatment during the Extension Phase for an indefinite number of cycles for as long as clinical benefit was sustained (up to 211 weeks).', ' Overall Number of Participants Analyzed: 51', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 33.3 (20.8 to 47.9)', 'Results 2: ', ' Arm/Group Title: Ixabepilone', ' Arm/Group Description: Ixabepilone was given at a starting dose of 32 or 40 mg/m^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cycle of the Treatment Phase, participants who demonstrated clinical benefit could continue treatment during the Extension Phase for an indefinite number of cycles for as long as clinical benefit was sustained (up to 211 weeks).', ' Overall Number of Participants Analyzed: 50', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 50.0 (35.5 to 64.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 19/51 (37.25%)', ' Febrile neutropenia 6/51 (11.76%)', ' Anaemia 1/51 (1.96%)', ' Leukopenia 1/51 (1.96%)', ' Neutropenia 1/51 (1.96%)', ' Thrombocytopenia 0/51 (0.00%)', ' Pericarditis 1/51 (1.96%)', ' Atrial flutter 0/51 (0.00%)', ' Cardiac failure congestive 0/51 (0.00%)', ' Visual impairment 0/51 (0.00%)', ' Dysphagia 1/51 (1.96%)', ' Abdominal pain 0/51 (0.00%)', ' Chills 1/51 (1.96%)', 'Adverse Events 2:', ' Total: 17/50 (34.00%)', ' Febrile neutropenia 0/50 (0.00%)', ' Anaemia 1/50 (2.00%)', ' Leukopenia 0/50 (0.00%)', ' Neutropenia 1/50 (2.00%)', ' Thrombocytopenia 1/50 (2.00%)', ' Pericarditis 0/50 (0.00%)', ' Atrial flutter 1/50 (2.00%)', ' Cardiac failure congestive 1/50 (2.00%)', ' Visual impairment 1/50 (2.00%)', ' Dysphagia 0/50 (0.00%)', ' Abdominal pain 1/50 (2.00%)', ' Chills 0/50 (0.00%)']}
|
888a8d39-3ad6-401e-acf2-cf5e01a73bf2
|
Single
|
Adverse Events
|
NCT00679211
|
1 patient in the primary trial presented a fever, in addition to either a cough or a sore throat.
|
Entailment
|
[
0,
12
] |
[] |
{'Clinical Trial ID': 'NCT00679211', 'Intervention': ['INTERVENTION 1: ', ' 6 Months of Follow-up', ' Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.', 'INTERVENTION 2: ', ' 9 Months of Follow-up', ' Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.'], 'Eligibility': ['Inclusion Criteria:', ' Signed study-specific Informed Consent Form(s)', ' Age 18 years', ' Histologically documented breast cancer', ' HER2-positive disease', ' Metastatic breast cancer', ' Disease progression on the last chemotherapy regimen received in the metastatic setting', ' Prior treatment with an anthracycline, trastuzumab, a taxane, lapatinib, and capecitabine in the neoadjuvant, adjuvant, locally advanced, or metastatic setting and prior treatment with at least two lines of therapy (a line of therapy can be a combination of two agents or single-agent chemotherapy) in the metastatic setting', ' At least two lines of anti-HER2 therapy must have been given in the metastatic setting as monotherapy or combined with chemotherapy or hormonal therapy. The HER2-targeted agent can include trastuzumab, lapatinib, or an investigational agent with HER2-inhibitory activity.', ' A minimum of 6 weeks of trastuzumab for the treatment of metastatic disease is required', ' Patients must have had at least 14 days of exposure in the metastatic setting to lapatinib and capecitabine (given together or separately) unless they were intolerant of lapatinib and/or capecitabine', 'Exclusion Criteria:', ' Chemotherapy 21 days before enrollment', ' Trastuzumab 21 days before enrollment', ' Hormone therapy 7 days before enrollment', ' Granulocyte-stimulating agent < 14 days before enrollment', ' Investigational therapy 28 days before enrollment', ' Previous radiotherapy for treatment of metastatic breast cancer 21 days before enrollment', ' Brain metastases that are untreated, symptomatic, or require therapy to control symptoms; or any radiation, surgery, or other therapy to control symptoms from brain metastases within 3 months of the first study treatment', ' History of intolerance (including Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins', ' History of exposure to the following cumulative doses of anthracyclines: Doxorubicin or liposomal doxorubicin > 500 mg/m^2; Epirubicin > 900 mg/m^2; Mitoxantrone > 120 mg/m^2 and idarubicin > 90 mg/m^2', ' Peripheral neuropathy of Grade 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0', ' History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma', ' Current unstable angina', ' History of symptomatic congestive heart failure (CHF), or ventricular arrhythmia requiring treatment', ' History of myocardial infarction within 6 months of enrollment', ' Left ventricular ejection fraction (LVEF) < 50% within 28 days of enrollment', ' History of decreased LVEF to < 50% or symptomatic CHF with previous adjuvant trastuzumab treatment', ' Severe dyspnea at rest due to complications of advanced malignancy or requiring current continuous oxygen therapy', ' Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)', ' Major surgical procedure or significant traumatic injury within 28 days before enrollment or anticipation of the need for major surgery during the course of study treatment', ' Current pregnancy or lactation', ' Current known infection with human immunodeficiency virus (HIV), active hepatitis B, and/or hepatitis C virus', ' Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With an Objective Response as Assessed Through Independent Radiologic Review', ' Objective response was defined as a complete response (CR) or partial response (PR) determined on two consecutive occasions 4 weeks apart, assessed using Response Evaluation Criteria in Solid Tumors (RECIST).', ' CR: the disappearance of all target lesions and all nontarget lesions and normalization of tumor marker level and no new lesions.', ' PR: disappearance of all target lesions and persistence of 1 nontarget lesion(s) and/or the maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diameter of target lesions, and no new lesions or unequivocal progression of existing nontarget lesions.', ' The primary data cut-off date was 17 September 2009 (approximately 6 months after the last patient was enrolled). The final efficacy analysis was performed using a data cut-off date of 1 January 2010 (approximately 9 months after the last patient was enrolled).', ' Time frame: From randomization until the primary analysis data cut-off date of September 2009 (6 months after last patient enrolled) and until the final efficacy analysis cut-off date of 1 January 2010 (approximately 9 months after the last patient enrolled).', 'Results 1: ', ' Arm/Group Title: 6 Months of Follow-up', ' Arm/Group Description: Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.', ' Overall Number of Participants Analyzed: 110', ' Measure Type: Number', ' Unit of Measure: percentage of participants 32.7 (24.1 to 42.1)', 'Results 2: ', ' Arm/Group Title: 9 Months of Follow-up', ' Arm/Group Description: Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.', ' Overall Number of Participants Analyzed: 110', ' Measure Type: Number', ' Unit of Measure: percentage of participants 32.7 (24.1 to 42.1)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 29/110 (26.36%)', ' Atrial fibrillation 1/110 (0.91%)', ' Nausea 2/110 (1.82%)', ' Abdominal pain 1/110 (0.91%)', ' Abdominal pain upper 1/110 (0.91%)', ' Constipation 1/110 (0.91%)', ' Pancreatitis 1/110 (0.91%)', ' Vomiting 1/110 (0.91%)', ' Pyrexia 3/110 (2.73%)', ' Axillary pain 2/110 (1.82%)', ' Chest pain 1/110 (0.91%)', ' Influenza like illness 1/110 (0.91%)', 'Adverse Events 2:', ' ']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
13466cbb-9f78-46ff-a983-09e2e9ad5a2c
|
|
Single
|
Results
|
NCT00374322
|
the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients, however, there was less than a 30% difference in DFS rate between the two cohorts.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] |
[] |
{'Clinical Trial ID': 'NCT00374322', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib 1500 mg', ' Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal.', 'INTERVENTION 2: ', ' Placebo', ' Participants received matching placebo orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal.'], 'Eligibility': ['Inclusion Criteria:', ' Have histologically or cytologically confirmed ErbB2-overexpressing invasive carcinoma (TX or T1-4) of the breast at the time of the initial diagnosis and have undergone adequate excision of tumor;', ' Had tumors that overexpress ErbB2 defined as 3+ by IHC or c-erbB2 gene amplification by FISH (ErbB2 expression/amplification must be documented prior to study entry; however, a tumor tissue sample must be sent to a central laboratory for subsequent re-analysis of ErbB2 status);', ' Have Stage I through Stage IIIc disease according to the American Joint Committee on Cancer (6th edition) staging criteria for breast cancer and meet one of the following criteria:', ' node-positive disease defined as: one positive lymph node by sentinel node biopsy OR at least 1 positive lymph node found among at least 6 axillary nodes examined on axillary node dissection OR status post axillary radiotherapy for sterilization if clinically evaluated as cN1 or cN2 (if sentinel node biopsy is positive, subject may either undergo an axillary node dissection or radiotherapy to the axilla).', ' node-positive disease evaluated as: ipsilateral axillary lymph nodes cN0-2 by clinical evaluation and axillary lymph nodes pNX, pN0(i+), or pN1-3 by pathological evaluation [patients with pN3 (Stage IIIc disease) must be disease free following completion of neoadjuvant or adjuvant chemotherapy for at least 12 months and must not have been lost to follow up].', ' OR node-negative disease defined as: negative sentinel node biopsy OR no positive lymph nodes found among at least 6 axillary nodes examined on axillary node dissection OR status post axillary radiotherapy for sterilization if clinically evaluated as cN0.', ' node-negative disease categorized as: high-risk disease (tumor >2.0 cm if ER and/or progesterone receptor (PgR) positive disease is present or tumor >1.0 cm if ER and PgR negative disease) OR intermediate-risk disease (tumor 1.0-2.0 cm and ER and/or PgR positive disease).', ' Women with synchronous bilateral invasive breast cancer or synchronous DCIS of either the contralateral or ipsilateral breast at the time of the initial diagnosis are also eligible;', ' Have undergone either mastectomy OR lumpectomy;', ' Have received and completed treatment with a neoadjuvant or adjuvant chemotherapy regimen containing either an anthracycline or a taxane; or any cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regimen;', ' May continue to receive endocrine therapy while taking study medication, if endocrine therapy was initiated as either adjuvant therapy for treatment of the initial diagnosis of invasive breast cancer or for ovarian function suppression; however, endocrine therapy may not be initiated while taking study medication. Endocrine therapy agents may be switched while participating in this study (e.g., stop tamoxifen and start letrozole);', ' May have received prior radiotherapy as treatment for primary tumor; however, is not required for study entry;', ' May continue to receive radiotherapy while taking study medication, if radiotherapy was initiated as adjuvant therapy for treatment of the initial diagnosis of invasive breast cancer;', ' May continue to receive bisphosphonates only for treatment of documented osteoporosis, but not as treatment or prophylaxis of bone metastases;', ' All women eligible for adjuvant treatment with trastuzumab, including those diagnosed and treated within the last six months, must be considered for such treatment prior to being offered participation in this study. Participation in this study will be allowed only if the physician and patient have considered and discussed at length the advantages of trastuzumab, but have mutually decided against initiating trastuzumab therapy.', ' Have clinical and radiologic assessments that are negative for local or regional recurrence of disease or metastatic disease at the time of study entry;', ' if signs or symptoms suggestive of either recurrence of disease or metastatic disease are present, the appropriate radiological imaging must be performed', ' if the following laboratory results are present, the appropriate radiological imaging must be performed:', ' for AST/ALT 2×ULN or ALP 2×ULN (not in the bone fraction), an abdominal CT or MRI must be done', ' for ALP 2×ULN in the bone fraction, a bone scan must be done; a confirmatory x-ray, CT scan or MRI scan or biopsy is required if the results of the bone scan are inconclusive', ' Have a unilateral/bilateral mammogram within 12 months prior to study entry;', ' Have an analysis of both ER and PgR on the primary tumor prior to study entry;', ' Have a cardiac ejection fraction within institutional range of normal as measured by either echocardiogram or multigated acquisition scans;', ' Have an Eastern Cooperative Oncology Group Performance Status of 0 to 1;', ' Women with a history of non-breast malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence. Women with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical carcinoma in situ, melanoma in situ, and basal cell or squamous cell carcinoma of the skin;', ' Are able to swallow and retain oral medication;', ' Have a paraffin-embedded tissue block from an archived tumor tissue from the primary tumor or twenty (20) slides of paraffin-embedded tissue available for biomarker analysis;', ' Have adequate organ function defined as: absolute neutrophil count 1.5× 10^9/L; hemoglobin 9 g/dL; platelets 75 × 10^9/L; albumin 2.5 g/dL; serum bilirubin 1.25 ×ULN; aspartate aminotransferase and alanine aminotransferase 3 × ULN and serum creatinine 2.0 mg/dL or calculated creatinine clearance 40 mL/min', ' Have signed the informed consent form (ICF);', ' Women of child-bearing potential must have a negative serum pregnancy test at screening and agree to complete abstinence from intercourse or consistent and correct use of an acceptable methods of birth control from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication:', 'Exclusion Criteria:', ' Have clinical and radiologic evidence of local or regional recurrence of disease or metastatic disease at the time of study entry;', ' Had metachronous invasive breast cancer (breast cancers diagnosed at different times);', ' Have a prior history of other breast cancer malignancies, including DCIS;', ' Are unable to provide archived tumor tissue samples for assay;', ' Had prior therapy with an ErbB1 and/or ErbB2 inhibitor; women who experienced a hypersensitivity or allergic reaction to trastuzumab during the first infusion and were unable to complete this infusion are eligible;', ' Receive concurrent anti-cancer therapy (chemotherapy, immunotherapy, and biologic therapy) while taking study medication;', ' Have unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment;', ' Have malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Women with ulcerative colitis are also excluded;', " Have a concurrent disease or condition that would make the woman inappropriate for study participation, or any serious medical disorder that would interfere with the woman's safety;", ' Have an active or uncontrolled infection;', ' Have dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent;', ' Have a known history of uncontrolled or symptomatic angina, arrhythmias, or CHF;', ' Are pregnant or breastfeeding;', ' Receive concurrent treatment with an investigational agent; women, who are in follow-up in another clinical trial where the primary endpoint has been met and the interval between assessments is 12 months and radiological imaging is not required at these assessments, are eligible;', ' Receive concurrent treatment with a selected list of strong inducers and inhibitors of CYP3A4;', ' Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication;', ' Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to lapatinib or excipients;'], 'Results': ['Outcome Measurement: ', ' Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])', ' DFS=interval between the date of randomization and the date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause. The date of the event is the earliest date of the occurrence of any of the following: local recurrence (LR) following mastectomy; LR in ipsilateral breast following lumpectomy; regional recurrence; distant recurrence; contralateral breast cancer, including ductal carcinoma in situ; other second primary cancer (excluding squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, or lobular carcinoma in situ of the breast); death from any cause without a prior event. Par. who started additional anti-cancer adjuvant therapy prior to the recurrence of their disease were to be censored. Par. who did not withdraw from the study and did not experience a specified event or death were to be censored (follow-up ongoing) at the last visit date available at which progression was assessed.', ' Time frame: From randomization until date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause (assessed up to 6 years; 1 year of treatment, 5 years of follow-up [median of 5.3 years for final analysis])', 'Results 1: ', ' Arm/Group Title: Lapatinib 1500 mg', ' Arm/Group Description: Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal.', ' Overall Number of Participants Analyzed: 1571', ' Measure Type: Number', ' Unit of Measure: Participants Any recurrence or death: 252', ' Censored, New Anti-cancer Agent/Radiotherapy: 1', ' Censored, Follow-up Ended: 1318', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Participants received matching placebo orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal.', ' Overall Number of Participants Analyzed: 1576', ' Measure Type: Number', ' Unit of Measure: Participants Any recurrence or death: 290', ' Censored, New Anti-cancer Agent/Radiotherapy: 1', ' Censored, Follow-up Ended: 1285'], 'Adverse Events': ['Adverse Events 1:', ' Total: 99/1573 (6.29%)', ' Neutropenia 2/1573 (0.13%)', ' Left ventricular dysfunction 3/1573 (0.19%)', ' Cardiac failure 0/1573 (0.00%)', ' Myocardial infarction 2/1573 (0.13%)', ' Acute myocardial infarction 0/1573 (0.00%)', ' Atrial fibrillation 0/1573 (0.00%)', ' Atrioventricular block first degree 1/1573 (0.06%)', ' Myocardial ischaemia 0/1573 (0.00%)', ' Pericardial effusion 1/1573 (0.06%)', 'Adverse Events 2:', ' Total: 78/1574 (4.96%)', ' Neutropenia 0/1574 (0.00%)', ' Left ventricular dysfunction 1/1574 (0.06%)', ' Cardiac failure 3/1574 (0.19%)', ' Myocardial infarction 0/1574 (0.00%)', ' Acute myocardial infarction 1/1574 (0.06%)', ' Atrial fibrillation 1/1574 (0.06%)', ' Atrioventricular block first degree 0/1574 (0.00%)', ' Myocardial ischaemia 1/1574 (0.06%)', ' Pericardial effusion 0/1574 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
0beaef44-a39a-462c-a084-d3f824857673
|
|
Single
|
Intervention
|
NCT01432145
|
the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate.
|
Entailment
|
[
0,
1,
2,
3,
4,
5
] |
[] |
{'Clinical Trial ID': 'NCT01432145', 'Intervention': ['INTERVENTION 1: ', ' 6-Mercaptopurine and Methotrexate (6MP/MTX)', ' 6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Methotrexate: Methotrexate 20mg/m2 will be taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression.', ' The reduced doses were 55mg/m2 of 6MP orally once a day, and 15mg/m2 of Methotrexate orally once a week.'], 'Eligibility': ['Inclusion Criteria:', ' Patients with proven BRCA1 or BRCA2 mutations and after appropriate exposure to standard treatment, as defined by:', ' Breast Cancer', ' Patients with initially histologically or cytologically proven locally advanced or metastatic breast cancer who may have received up to 3 previous lines of chemotherapy in the locally advanced or metastatic breast cancer setting.', ' Patients must have previously had a taxane and an anthracycline in either the adjuvant or metastatic setting, provided that these were not contraindicated.', ' Patients with hormone responsive disease should have had at least 1 line of hormone therapy for metastatic disease.', ' Prior treatment with a poly-Adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor is permissible.', ' OR Ovarian Cancer', ' Patients with initially histologically or cytologically proven ovarian cancer.', ' Patients must have disease that is platinum resistant or in whom further platinum based therapy is inappropriate.', ' Prior treatment with a PARP inhibitor is permissible.', ' Patients must have measurable disease on computerized tomography (CT) or Magnetic resonance imaging (MRI) scan as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria.', ' Age 18 years.', ' Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.', ' Life expectancy >12 weeks.', ' Written informed consent.', ' Patient willing and able to comply with all protocol requirements.', ' No prior anti-cancer treatment in previous 4 weeks, other than palliative radiotherapy (RT).', ' Haematological and biochemical indices within the ranges shown below.', ' Laboratory Test Value required', ' Haemoglobin (Hb) > 10g/dL', ' White Blood Count (WBC) > 3x109/L', ' Platelet count > 100,000/μL', ' Absolute Neutrophil count > 1.5x109/L;', ' Serum bilirubin 2 x Upper limit normal (ULN)', ' Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) and alanine aminotransferase (ALT) or ALT 5 x ULN (liver metastasis)', ' or 3 x ULN (no liver metastasis)', ' Alkaline phosphatase 5 x ULN', ' Serum creatinine 1.5 x ULN', ' Ascites and pleural effusions must be drained prior to therapy.', 'Exclusion Criteria:', ' Patients with any of the following contra-indications to thiopurines (6MP or 6TG) or methotrexate:', ' family history of severe liver failure;', ' alcoholism;', ' porphyria;', ' diffuse infiltrative pulmonary or pericardial disease;', ' known hypersensitivity to either trial agent.', ' Patients found to have a Low/Low genotype on thiopurine methyltransferase (TPMT) testing will be excluded.', ' Pregnant or breast-feeding women or women of childbearing potential unless highly effective methods of contraception are used.', ' Other active malignancy, with the exception of adequately treated in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.', ' Patients known or tested to be serologically positive for Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV).', ' Patients with active central nervous system (CNS) lesions are excluded (i.e., those with radiographically unstable, symptomatic lesions). However, patients treated with stereotactic therapy or surgery and/or whole brain radiotherapy are eligible if the patient remains without evidence of disease progression in brain 3 months prior to registration date . They must also be off corticosteroid therapy for 3 weeks prior to registration date.', ' Patients who have received anticancer agent(s) or an investigational agent within 28 days prior to study drug administration.', ' Subjects who have not recovered to within one grade level (not to exceed grade 2) of their baseline following a significant adverse event or toxicity attributed to previous anticancer treatment are excluded.'], 'Results': ['Outcome Measurement: ', ' Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population.', ' 1st stage: If less than 3/30 evaluable patients respond at 8 weeks the trial will be stopped for futility. If 3 or more out of 30 evaluable patients respond then a further 35 patients will be recruited (2nd stage) - this was met.', ' The proportion of patients responding to treatment (complete response, partial response or stable disease) at the second stage will be presented per Response Evaluation Criteria In Solid Tumours (RECIST) criteria version 1.1 measured radiologically with computerised tomography (CT) and/or magnetic resonance imaging (MRI); the same method is used at baseline and at follow-up: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Patients who yield progressive disease (PD) are classed as non-responders.', ' Time frame: 8 weeks after start of treatment', 'Results 1: ', ' Arm/Group Title: 6-Mercaptopurine and Methotrexate (6MP/MTX)', ' Arm/Group Description: 6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Methotrexate: Methotrexate 20mg/m2 will be taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression.', ' The reduced doses were 55mg/m2 of 6MP orally once a day, and 15mg/m2 of Methotrexate orally once a week.', ' Overall Number of Participants Analyzed: 67', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 22 32.8%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 33/67 (49.25%)', ' Pancytopenia 1/67 (1.49%)', ' Febrile neutropenia 1/67 (1.49%)', ' Palpitations 1/67 (1.49%)', ' Abdominal pain 5/67 (7.46%)', ' Ascites 1/67 (1.49%)', ' Colonic obstruction 1/67 (1.49%)', ' Constipation 1/67 (1.49%)', ' Nausea 1/67 (1.49%)', ' Pancreatitis 1/67 (1.49%)', ' Small intestinal obstruction 1/67 (1.49%)', ' Vomiting 2/67 (2.99%)', ' Fever 2/67 (2.99%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
8e45da73-f016-4ca0-b106-a3fabc960b36
|
|
Comparison
|
Intervention
|
NCT01420146
|
NCT00077376
|
the primary trial and the secondary trial are both single arm clinical trials.
|
Entailment
|
[
0,
1,
2
] |
[
0,
1,
2,
3
] |
{'Clinical Trial ID': 'NCT01420146', 'Intervention': ['INTERVENTION 1: ', ' Zr89-trastuzumab PET/CT', ' Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm'], 'Eligibility': ['Inclusion criteria:', ' All patients selected for this imaging study are patients scheduled to start trastuzumab-based therapy for advanced HER2 positive breast cancer (This includes trastuzumab alone, trastuzumab + chemotherapy, trastuzumab + endocrine therapy).', ' Histologically confirmed HER 2 positive (defined as FISH amplification ratio more than 2.2) invasive carcinoma of the breast (primary tumor at diagnosis) with locally recurrent or metastatic disease.', ' Patients with FDG-PET positive metastatic lesions.', ' Brain metastases are allowed provided they are controlled and they are not the sole site of metastatic disease.', ' Patient planned to have metastatic site biopsy for HER2 status control.', ' Age 18 years', ' Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1', ' For women of childbearing potential a pregnancy test will be done and an agreement to use a highly-effective non hormonal form of contraception.', ' Agreement from the patient to participate in this imaging study and if indicated agreement to biopsy one or two accessible lesions.', ' Signed written informed consent (approved by the Ethics Committee) obtained prior to any study procedure', 'Exclusion criteria:', ' Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)', ' Pregnant or lactating women', ' Current known infection with HIV, HBV, or HCV', ' Known severe hypersensitivity to trastuzumab', ' Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol', ' Patients with bone only metastases are not eligible', ' Psychiatric illness/social situations that would limit compliance with study requirements', ' Patients who received lapatinib within the 7 days prior to HER immunoPET/CT.'], 'Results': ['Outcome Measurement: ', ' Test the Diagnostic Accuracy of the HER2 Imaging Using the Labelled Monoclonal Antibody Trastuzumab by Correlating the HER2 PET/CT Imaging With the FDG-PET/CT and Molecular Characterization of Tumor Samples With Discordant Image Findings', ' A visual \'patient-based\' classification capturing the whole disease burden was developed by using a side-by-side display, comparing baseline FDG-PET/CT(showing all FDG-positive mets independent of their HER2-imaging status) & day4 HER2-PET/CT. Pts were grouped into 4 HER2-PET/CT patterns according to the proportion of FDG avid tumour load showing relevant 89Zr-T uptake. Pattern A: entire tumor load showed pertinent tracer uptake; B: dominant part of tumour load showed tracer uptake; C: minor part of tumor load showed tracer uptake; D: entire tumor load lacked tracer uptake. Patterns A+B=\'HER2-positive\' & C+D=\'HER2-negative\'. In the 20 pts: 4 pts were classified "A", 5"B", 1"C" & 10"D". This classification indicates substantial heterogeneity of 89Zr-T uptake within this so called \'HER2-positive\' pt population. After dichotomization, 11(55%) pts were considered as HER2-PET/CT negative. Furthermore, HER2-PET/CT revealed intrapatient heterogeneity of tumour uptake(pts classified B or C).', ' Time frame: 4 years', 'Results 1: ', ' Arm/Group Title: Zr89-trastuzumab PET/CT', ' Arm/Group Description: Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm', ' Overall Number of Participants Analyzed: 20', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Pattern A: 4 20.0%', ' Pattern B: 5 25.0%', ' Pattern C: 1 5.0%', ' Pattern D: 10 50.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/20 (5.00%)', ' Nausea - Pyrexia - Myalgia [1]1/20 (5.00%)']}
|
{'Clinical Trial ID': 'NCT00077376', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab/Ixabepilone/Carboplatin', ' During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV), H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker), and at least a 5-HT3 antagonist and dexamethasone.', ' After completion of 24 weekly trastuzumab doses (induction therapy), trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose. Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Patients with histologically confirmed adenocarcinoma of the breast which is metastatic and is known to overexpress HER2/neu who have received no prior chemotherapy for metastatic breast cancer; prior hormonal therapy for metastatic disease is allowed; NOTE: for this protocol, HER2 overexpression will be defined as 3+ HER2 positivity as measured by immunohistochemistry using the HercepTest (DAKO) or HER2 gene amplification as measured by fluorescent in-situ hybridization (FISH, e.g. Vysis); representative diagnostic tissue must be submitted for central diagnostic review', ' Patients must not be pregnant or breast feeding because of the teratogenic potential of these drugs; it is recommended that all females of childbearing potential have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective non-hormonal method of contraception', ' Patients must have at least one objective measurable disease parameter; baseline measurements and evaluations using RECIST criteria guidelines must be obtained within 4 weeks prior to registration to the study; NOTE: all areas of disease should be recorded and followed', ' Patients must have an ECOG performance status of 0 or 1', ' Patients must be disease free of prior malignancy for >= 5 years with the exception of curatively treated basal cell carcinoma or squamous cell carcinomas of the skin or carcinoma in situ of the cervix', ' Patients must not have a history of untreated brain metastasis or brain metastasis currently undergoing radiation; patients with brain metastasis representing the sole site of disease are not eligible for this study; patients with previously treated brain metastasis who have responded to brain radiotherapy and/or surgery and continue in response are eligible provided the brain is not the only site of measurable disease', ' Patients must not have peripheral neuropathy of any grade', ' Patients must not have a history of prior severe (grade 3 or 4) hypersensitivity reaction to a drug formulated in polyoxyethylated castor oil (Cremophor EL)', ' Patients must have left ventricular ejection fraction by MUGA scan or echocardiogram that is at or above the lower institutional limits of normal obtained within 6 weeks prior to registration', ' Patients must not have a history of New York Heart Association class 3 or 4 heart failure', ' Serum creatinine =< 1.5 mg/dl', ' Granulocytes >= 1500/mm^3', ' Platelets >= 100,000/mm^3', ' SGOT(AST) and SGPT(ALT) =< 1.5 x upper limit of normal (unless liver is involved by tumor, in which case SGOT(AST) and SGPT(ALT) can be =< 2.0 x upper limit of normal)', ' Patients must have no history of prior therapy with trastuzumab (Herceptin), Ixabepilone (BMS-247550) or carboplatin for metastatic disease; patients who develop metastatic disease =< 6 months after completing adjuvant trastuzumab (Herceptin), paclitaxel, docetaxel, carboplatin, or Ixabepilone (BMS-247550) are considered to have had prior therapy for metastatic disease and are excluded from study participation', ' Patients must not have received a cumulative dose of doxorubicin of greater than 360 mg/m^2 or epirubicin of greater than 640 mg/m^2', ' Concurrent use of hormonal therapy is not permitted; concurrent radiation therapy is not permitted; hormonal therapy must have been discontinued >= 1 week prior to registration; radiation therapy must have been completed >= 2 weeks prior to registration', ' Patients may have had prior radiation therapy, but the previously irradiated tumors cannot be used to assess a clinical response; patients will not be eligible if they do not have other areas of measurable disease; an exception will be given for patients who have had tumor recurrence in an area that received adjuvant radiation treatments, such as the axilla or chest wall'], 'Results': ['Outcome Measurement: ', ' Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study)', ' To assess objective response, it is necessary to estimate the overall tumor burden at baseline to which subsequent measurements will be compared. The same method of assessment and the same technique should be used to characterize each lesion at baseline and during follow-up.', ' The best overall response based on RECIST is the best response recorded from registration until disease progression/recurrence, taking as reference for progressive disease the smallest measurements recorded since registration. The best response was determined based on the tumor responses in target and nontarget lesions, with or without new lesions. To be assigned a status of complete or partial response, changes in tumor measurements must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. To be assigned a status of stable disease, measurements must have met the stable disease criteria at least once after study entry at a minimum interval of 8 weeks.', ' Time frame: Assessed every 3 cycles during induction therapy and every 6 cycles during maintenance therapy until disease progression or up to 5 years', 'Results 1: ', ' Arm/Group Title: Trastuzumab/Ixabepilone/Carboplatin', ' Arm/Group Description: During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV), H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker), and at least a 5-HT3 antagonist and dexamethasone.', ' After completion of 24 weekly trastuzumab doses (induction therapy), trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose. Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity.', ' Overall Number of Participants Analyzed: 39', ' Measure Type: Number', ' Unit of Measure: Participants Complete Response: 3', ' Partial Response: 13', ' No Change/ Stable: 10', ' Progression: 11', 'Unevaluable: 2'], 'Adverse Events': ['Adverse Events 1:', ' Total: 39/59 (66.10%)', ' Anemia 7/59 (11.86%)', ' Hematologic-other 1/59 (1.69%)', ' Diarrhea w/o prior colostomy 4/59 (6.78%)', ' Nausea 4/59 (6.78%)', ' Vomiting 2/59 (3.39%)', ' Abdomen, pain 1/59 (1.69%)', ' Fatigue 7/59 (11.86%)', ' Death NOS 1/59 (1.69%)', ' Allergic reaction 2/59 (3.39%)', ' Infection with Grade 0-2 neutrophils, urinary tract 2/59 (3.39%)', ' Leukopenia 19/59 (32.20%)']}
|
37dc56a4-4756-4ab0-8055-7637bf579740
|
Comparison
|
Intervention
|
NCT02115607
|
NCT01823107
|
Patients in the primary trial receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, whereas in the secondary trial subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix.
|
Contradiction
|
[
0,
1,
2,
3
] |
[
0,
1,
2
] |
{'Clinical Trial ID': 'NCT02115607', 'Intervention': ['INTERVENTION 1: ', ' Definity Infusion', ' Infusion of Definity (Perflutren Lipid Microspheres)', ' Definity infusion: 3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min'], 'Eligibility': ['Inclusion Criteria:', ' Females', ' Be diagnosed with T1 or greater LABC, any N and M0.', ' Be scheduled for neoadjuvant chemotherapy', ' Be at least 21 years of age.', ' Be medically stable.', ' If a female of child-bearing potential, must have a negative pregnancy test.', ' Have signed Informed Consent to participate in the study.', 'Exclusion Criteria:', ' Males', ' Females who are pregnant or nursing.', ' Patients with other primary cancers requiring systemic treatment.', ' Patients with any metastatic disease.', ' Patients undergoing neoadjuvant endocrine therapy.', ' Patients with known hypersensitivity or allergy to any component of Definity.', ' Patients with cardiac shunts or congenital heart defects.', ' Patients with unstable cardiopulmonary conditions or respiratory distress syndrome.', ' Patients with uncontrollable emphysema, pulmonary vasculitis, pulmonary hypertension or a history of pulmonary emboli.', ' Patients who have received any contrast medium (X-ray, MRI, CT or US) in the 24 hours prior to the research US exam.'], 'Results': ['Outcome Measurement: ', ' Subharmonic Aided Pressure Estimation (SHAPE) After Treatment for Complete Responders', ' To evaluate the ability of SHAPE, used with Definity, to track changes in interstitial fluid pressure (IFP) by studying women undergoing neoadjuvant chemotherapy before as well as with around 10% and 30% of the neoadjuvant chemotherapy treatment delivered and comparing results to MRI and pathology.', ' Time frame: from baseline to completion of neoadjuvant chemotherapy, average of 6 months', 'Results 1: ', ' Arm/Group Title: Definity Infusion', ' Arm/Group Description: Infusion of Definity (Perflutren Lipid Microspheres)', ' Definity infusion: 3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min', ' Overall Number of Participants Analyzed: 6', ' Mean (Standard Deviation)', ' Unit of Measure: dB 10% completion of neoadjuvant chemotherapy for: 3.23 (1.41)', ' 30% completion of neoadjuvant chemotherapy: 1.67 (1.09)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/17 (0.00%)']}
|
{'Clinical Trial ID': 'NCT01823107', 'Intervention': ['INTERVENTION 1: ', ' Meso BioMatrix Acellular Peritoneum Matrix', ' All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction. After tissue expansion, the tissue expander was replaced with a breast implant during the second stage of reconstruction.'], 'Eligibility': ['Inclusion Criteria:', ' Non-smoker', ' Undergoing unilateral or bilateral, two-stage, tissue expander-assisted breast reconstruction', ' Life expectancy greater than 18 months', ' Agreement to return for the trial required follow-up visits', 'Exclusion Criteria:', ' Body mass index 35', ' Prior reconstructive breast surgery, breast augmentation, mastopexy or reduction mammoplasty', ' History of chronic corticosteroid use', ' Type I Diabetes', ' History of radiation therapy to the chest', ' Pre-operative treatment with induction chemotherapy for breast cancer', ' Pregnancy', ' Participating in another investigational drug or device trial that has not completed the follow-up period'], 'Results': ['Outcome Measurement: ', ' Rate of Breast Related Adverse Events', ' Investigators evaluated each subject and each reconstructed breast for the occurrence of an adverse event from the first stage of reconstruction through the final follow-up visit. A breast related adverse event was defined as any untoward medical occurrence related to a reconstructed breast.', ' Time frame: 18 months', 'Results 1: ', ' Arm/Group Title: Meso BioMatrix Acellular Peritoneum Matrix', ' Arm/Group Description: All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction. After tissue expansion, the tissue expander was replaced with a breast implant during the second stage of reconstruction.', ' Overall Number of Participants Analyzed: 25', ' Overall Number of Units Analyzed', ' Type of Units Analyzed: Reconstructed breasts Measure Type: NumberUnit of Measure: Reconstructed breasts affected: 12'], 'Adverse Events': ['Adverse Events 1:', ' Total: 7/25 (28.00%)', ' Hematoma 1/25 (4.00%)', ' Fever 1/25 (4.00%)', ' Seroma 1/25 (4.00%)', ' Wound dehiscence 4/25 (16.00%)', ' Skin flap necrosis 1/25 (4.00%)']}
|
65e370b7-7726-477e-8730-8cea734d1609
|
Single
|
Adverse Events
|
NCT03012477
|
One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhea.
|
Entailment
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] |
[] |
{'Clinical Trial ID': 'NCT03012477', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin + AZD1775', ' Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.', ' AZD1775 will be administered 200 mg as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days.', ' At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3).'], 'Eligibility': ['Inclusion Criteria:', ' Participants must have histologically or cytologically confirmed invasive breast cancer, with stage IV disease. Patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation.', ' Either the primary invasive tumor and/or the metastasis must be triple-negative, defined as:', ' hormone-receptor poor, ER- and PR-negative, or staining present in <1% by immunohistochemistry (IHC)', ' HER2-negative: 0 or 1+ by IHC, or FISH<2.0', ' Participants must have at least one lesion that is not within a previously radiated field that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version 1.1. Bone lesions are not considered measurable by definition. See Section 11 for the evaluation of measurable disease.', 'Prior chemotherapy: Patients may have received 0-1 prior chemotherapeutic regimen for metastatic breast cancer and must have been off treatment with chemotherapy for at least 21 days before enrollment in the study. The number of patients with 0 prior chemotherapeutic regimen will be limited to a maximum of n = 20.', ' Prior biologic therapy: Patients must have discontinued all biologic therapy at least 21 days before participation.', ' Prior radiation therapy: Patients may have received prior radiation therapy in either the metastatic or early-stage setting. Radiation therapy must be completed at least 14 days prior to study participation and patients should have recovered from adverse effects of radiation to grade 1.', ' Age 18', ' ECOG performance status 1', ' Participants must have normal organ and marrow function as defined below:', ' Absolute neutrophil count 1500/mm3', ' Platelets 100,000/mm3', ' Hemoglobin 9 g/dL', ' Total Bilirubin 1.5 mg/dL', ' Serum creatinine 1.5 mg/dL OR measured creatinine clearance (CrCl) 45 mL/min as calculated by the Cockcroft-Gault method OR 24-hour measured urine CrCl 45mL/min', ' Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 times the upper limit of normal. For patients with documented liver metastases, AST/ALT 5.0 times the upper limit of normal.', ' Patients on bisphosphonates may continue receiving bisphosphonate therapy during study treatment.', ' Availability of a tissue block from initial breast cancer diagnosis and/or metastatic recurrence. If a tissue block is not available, 10-20 unstained slides may be provided as an alternative. If unstained slides will be provided, they should not be sent until specifically requested by the DFCI study coordinator. If archival tumor tissue is not available, a fresh biopsy may be performed.', ' In the first stage of the trial, at least 10 patients with biopsy-accessible disease must be willing to undergo paired research biopsies. These biopsies will occur 5-48 hours after the C1D1 cisplatin dose (ie. C1D2or C1D3) and 5-8hrs (+/- 24hrs) after the last dose of AZD1775 on C2D3. The exact timing of the biopsy relative to receipt of study treatment should be accurately recorded.', ' Biopsies may be done with local anesthesia or intravenous conscious sedation, according to standard institutional guidelines.', " Research biopsies requiring general anesthesia are not allowed on this protocol unless a biopsy is being obtained simultaneously for clinical reasons, in the judgment of the patients' treating physician.", ' Patients who undergo an attempted on-treatment research biopsy and in whom inadequate tissue is obtained are still eligible to continue protocol therapy. They will not be required to undergo a repeat biopsy attempt.', ' If dosing is delayed placing the biopsy outside of the allowable window, the biopsy should be rescheduled to be within the window. If not feasible, the biopsy should be obtained as close to within the window as possible.', ' Fine needle aspirates (FNA) is not allowed', ' Female subjects of childbearing potential must have a negative serum pregnancy test at screening.', ' The effects of AZD1775 on the developing human fetus are unknown. Women of child-bearing potential and men must agree to use enhanced methods of contraception. All women are considered to be of childbearing potential unless they fulfill one of the following criteria at screening:', ' Post-menopausal defined as age 50 and amenorrheic for at least 12 months OR Women age <50 if they have been amenorrheic for at least 12 months and have a serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) level in the postmenopausal range (per institutional standards).', ' If women have documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, or bilateral tubal ligation, they are considered post-menopausal.', ' Appropriate contraception should be used from the time of screening, throughout the duration of study participation, and for four months after the last dose of AZD1775. Acceptable methods of contraception include abstinence, tubal ligation, intra-uterine devices, and vasectomised partner. All methods of contraception (with the exception of total abstinence) should be used in combination with the use of a condom by the male sexual partner for intercourse. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the participants treating physician should be informed immediately. Additionally, male patients should refrain from donating sperm from the start of dosing until 6 months after discontinuing AZD1775. If male patients wish to father children they should be advised to arrange for freezing of sperm samples prior to the start of study treatment.', ' Participant must be able to swallow pills.', ' Participant may not have a percutaneous endoscopic gastrostomy (PEG) tube or be receiving total parenteral nutrition (TPN).', ' Ability to understand and the willingness to sign a written informed consent document.', 'Exclusion Criteria:', ' Participants who are receiving any other investigational agents within 21 days of the first dose of study drug.', ' Major surgical procedures <28 days from beginning study treatment.', ' Participants who have received a prior inhibitor of Wee1 kinase activity', ' Participants who have received prior platinum chemotherapy', ' Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms. Patients with a history of treated central nervous system (CNS) metastases are eligible. Treated brain metastases are defined as those having no evidence of progression for 1 month after treatment, or hemorrhage for 2 weeks after treatment and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging or CT scan) during the screening period. Any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for 2 weeks before the first study drug. Treatment for brain metastases may include whole brain radiotherapy, radiosurgery, or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 1 month before day 1 of study treatment will be excluded.', ' Patients with grade >1 neuropathy or grade >1 toxicity (except alopecia or anorexia) from prior therapy', ' History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or Cisplatin.', ' Participants receiving any medications, substances, or foods (ie, grapefruit juice) listed below are ineligible (Please refer to Section 5.4 for list of restricted co-medications):', ' prescription or non-prescription drugs or other products known to be sensitive CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors/inducers of CYP3A4 which cannot be discontinued 2 weeks prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study drug. sensitive substrates of CYP2C8, CYP2C9, CYP2C19, or substrates of these enzymes with narrow therapeutic range', ' inhibitors or substrates of P-gp', ' Participants who have an uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, congestive heart failure-New York Heart Association Class III or IV (Appendix B), active ischemic heart disease, myocardial infarction within the previous six months, uncontrolled diabetes mellitus, gastric or duodenal ulceration diagnosed within the previous 6 months, chronic liver or renal disease, or severe malnutrition. In addition, patients are ineligible if they have a psychiatric illness or a social situation that could limit their ability to comply with the study requirements.', ' Participants who have refractory nausea and vomiting, chronic gastrointestinal diseases, or previous significant bowel resection that would preclude adequate absorption of AZD1775.', ' Pregnant women are excluded from this study because AZD1775 is a Wee1 inhibitor agent with the potential for teratogenic or abortifacient effects.', ' Lactating or breastfeeding women are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AZD1775, breastfeeding should be discontinued prior to being treated with AZD1775. These potential risks may also apply to other agents used in this study.', ' Known HIV-positive participants are ineligible because these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy.', ' Participant with mean resting corrected QT interval (specifically QTc calculated using the Fridericia formula [QTcF]) > 450 msec for males and > 470 msec for females, from 3 electrocardiograms (ECGs) performed within 2-5 minutes apart at study entry, or congenital long QT syndrome.'], 'Results': ['Outcome Measurement: ', ' Objective Response Rate', ' The objective response rate (ORR) was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.', ' Time frame: Evaluated every 6 weeks from the time of their first treatment, per RECIST 1.1. Duration of therapy will depend on individual response, evidence of disease progression and tolerance, up to 1 year', 'Results 1: ', ' Arm/Group Title: Cisplatin + AZD1775', ' Arm/Group Description: Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.', ' AZD1775 will be administered 200 mg as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days.', ' At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3).', ' Overall Number of Participants Analyzed: 34', ' Measure Type: Number', ' Unit of Measure: percentage of participants 26 (13 to 44)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 13/34 (38.24%)', ' Anemia 3/34 (8.82%)', ' Diarrhea 7/34 (20.59%)', ' Nausea 2/34 (5.88%)', ' Sepsis 1/34 (2.94%)', ' Urinary tract infection 1/34 (2.94%)', ' Alkaline phosphatase increased 1/34 (2.94%)', ' Neutrophil count decreased 2/34 (5.88%)', ' Dehydration 1/34 (2.94%)', ' Headache 1/34 (2.94%)', ' Thromboembolic event 1/34 (2.94%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
affdd551-15e2-4a47-8c20-209cc01570ec
|
|
Comparison
|
Intervention
|
NCT02176083
|
NCT03061175
|
Neither the primary trial or NCT0306117 use chemotherapy, adverse event management courses or radiotherapy in their intervention.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6
] |
[
0,
1,
2,
3,
4,
5,
6,
7,
8
] |
{'Clinical Trial ID': 'NCT02176083', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness', ' Text message management prompts', 'INTERVENTION 2: ', ' Control', ' Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness'], 'Eligibility': ['Inclusion Criteria:', ' Breast cancer', ' Female', ' Completed primary breast cancer treatment', 'Age <=45'], 'Results': ['Outcome Measurement: ', ' Hot Flash Frequency', ' Median number of daily hot flashes over 4th week of study', 'Time frame: 1 week', 'Results 1: ', ' Arm/Group Title: Intervention', ' Arm/Group Description: Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness', ' Text message management prompts', ' Overall Number of Participants Analyzed: 11', ' Median (Inter-Quartile Range)', ' Unit of Measure: daily hot flashes 2.2 (1.2 to 3.6)', 'Results 2: ', ' Arm/Group Title: Control', ' Arm/Group Description: Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness', ' Overall Number of Participants Analyzed: 27', ' Median (Inter-Quartile Range)', ' Unit of Measure: daily hot flashes 1.4 (0.7 to 2.3)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/11 (0.00%)', 'Adverse Events 2:', ' Total: 0/27 (0.00%)']}
|
{'Clinical Trial ID': 'NCT03061175', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Web-Based CPM-DA)', ' Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA.', ' Internet-Based Intervention: Receive web-based CPM-DA', ' Survey Administration: Ancillary studies', 'INTERVENTION 2: ', ' Arm II (Usual Care)', ' Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM.', ' Survey Administration: Ancillary studies'], 'Eligibility': ['Inclusion Criteria:', ' PHASE I: Has a first, primary diagnosis of unilateral stage 0, 1, 2, or 3a breast cancer (patients with bilateral breast cancer will be excluded from participation)', ' PHASE I: Speaks and reads English', ' PHASE I: Women with sporadic cancers (WSC) (does not have hereditary breast/ovarian cancer syndrome [BReast CAncer gene (BRCA) carrier, strong family history]); if there is any uncertainty, the surgeon will use the Tyrer-Cuzick (Tyrer et al., 2004) risk model to calculate risk; the Tyrer-Cuzick model calculates a personal lifetime risk of breast cancer based on multiple factors; it has become the standard model because it incorporates not only factors such as estrogen exposure and first degree relatives, but also second degree relatives and paternal lineage; a lifetime risk of 20% or greater is considered high risk and would necessitate increased screening methods to the traditional annual mammogram; for this study, anyone with a lifetime risk up to 19% on the Tyrer-Cuzick model will be considered average risk for breast cancer; anyone with a lifetime risk of 20% or greater will be excluded from participation', ' PHASE I: Able to provide meaningful informed consent', ' PHASE II: Completed initial surgical consult with breast cancer surgeon at Cancer Institute of New Jersey (CINJ)/Massachusetts General Hospital (MGH)/Memorial Sloan Kettering Cancer Center (MSKCC) and is considering CPM, regardless of the surgical treatment of their primary breast cancer (lumpectomy/mastectomy)', ' PHASE II: Has home internet access', ' PHASE II: Has a first, primary diagnosis of unilateral stage 0, 1, 2, or 3a breast cancer', ' PHASE II: Speaks and reads English', ' PHASE II: WSC (does not have hereditary breast/ovarian cancer syndrome [BRCA carrier, strong family history]); if there is any uncertainty, the surgeon will use the Tyrer-Cuzick (Tyrer et al., 2004) risk model to calculate risk; for this study, anyone with a lifetime risk up to 19% on the Tyrer-Cuzick model will be considered average risk for breast cancer; anyone with a lifetime risk of 20% or greater will be excluded from participation', ' PHASE II: Able to provide meaningful informed consent'], 'Results': ['Outcome Measurement: ', ' Contralateral Prophylactic Mastectomy (CPM) Knowledge Assessed by Surveys for CPM-DA Participants vs. UC Participants', " CPM knowledge is a 10-item multiple-choice measure developed by author Kirsten and Smith. Scores range from 0-100% correct with a higher score equaling more correct knowledge items. Items assessed understanding of the definition of CPM, surgical recovery time and risks/side effects, whether or not CPM improves survival, and whether CPM reduced the risk for disease progression. Will characterize the data using standard methods (estimated marginal means, standard errors, and Cohen's d effect sizes) separately by study arm. At follow-up scores will be reported as the difference between the knowledge score at two time points- the baseline knowledge score and follow-up knowledge score for both the CPM-DA arm and the UC arm.", ' Time frame: 2-4 week follow up', 'Results 1: ', ' Arm/Group Title: Arm I (Web-Based CPM-DA)', ' Arm/Group Description: Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA.', ' Internet-Based Intervention: Receive web-based CPM-DA', ' Survey Administration: Ancillary studies', ' Overall Number of Participants Analyzed: 39', ' Mean (Standard Error)', ' Unit of Measure: score on a scale 62.47 (3.40)', 'Results 2: ', ' Arm/Group Title: Arm II (Usual Care)', ' Arm/Group Description: Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM.', ' Survey Administration: Ancillary studies', ' Overall Number of Participants Analyzed: 44', ' Mean (Standard Error)', ' Unit of Measure: score on a scale 51.33 (3.24)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/46 (0.00%)', 'Adverse Events 2:', ' Total: ']}
|
2152f503-4fa4-4f32-b766-a05a4c69742f
|
Single
|
Adverse Events
|
NCT01300351
|
At least 1 participant in each cohort of the primary trial showed signs of poor liver function.
|
Contradiction
|
[
0,
7
] |
[] |
{'Clinical Trial ID': 'NCT01300351', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 500 mg', ' Fulvestrant 500 mg intramuscular (im) every 28 (± 3) days plus an additional 500 mg on Day 15 (± 3) of first month only', 'INTERVENTION 2: ', ' Fulvestrant 250 mg', ' Fulvestrant 250 mg im every 28 (± 3) days'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women defined as a woman who has stopped having menstrual periods', ' Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor', ' Requiring hormonal treatment', ' Oestrogen-receptor positive tumour', ' Written informed consent to participate in the trial', 'Exclusion Criteria:', ' Treatment with an investigational or non-approved drug within one month', ' An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures', ' A history of allergies to any active or inactive ingredients of fulvestrant (i.e. castor oil)', ' Treatment with more than one regimen of chemotherapy for advanced breast cancer', ' Treatment with more than one regimen of hormonal treatment for advanced breast cancer'], 'Results': ['Outcome Measurement: ', ' Progression-free Survival', ' Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, or unequivocal progression of existing non-target lesions, or the appearance of new lesions, or death (by any cause in the absence of progression). The primary analysis for PFS was the log rank test stratified by last endocrine therapy received prior to fulvestrant (AO vs. AI). The treatment effect was estimated using the HR of 500 mg fulvestrant to 250 mg fulvestrant together with the corresponding 95% CI and p value.', ' Time frame: 36 months', 'Results 1: ', ' Arm/Group Title: Fulvestrant 500 mg', ' Arm/Group Description: Fulvestrant 500 mg intramuscular (im) every 28 ( 3) days plus an additional 500 mg on Day 15 ( 3) of first month only', ' Overall Number of Participants Analyzed: 111', ' Median (Inter-Quartile Range)', ' Unit of Measure: months 8.0 (2.8 to 16.6)', 'Results 2: ', ' Arm/Group Title: Fulvestrant 250 mg', ' Arm/Group Description: Fulvestrant 250 mg im every 28 ( 3) days', ' Overall Number of Participants Analyzed: 110', ' Median (Inter-Quartile Range)', ' Unit of Measure: months 4.0 (2.7 to 11.1)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/109 (3.67%)', ' Anaemia * 0/109 (0.00%)', ' Haemolytic uraemic syndrome * 0/109 (0.00%)', ' Leukopenia * 0/109 (0.00%)', ' Cardiac failure * 0/109 (0.00%)', ' Pyrexia * 1/109 (0.92%)', ' Hepatic function abnormal * 1/109 (0.92%)', ' Arthritis bacterial * 0/109 (0.00%)', ' Lung infection * 0/109 (0.00%)', ' Haemoglobin decreased * 1/109 (0.92%)', ' Neutrophil count decreased * 0/109 (0.00%)', 'Adverse Events 2:', ' Total: 9/110 (8.18%)', ' Anaemia * 1/110 (0.91%)', ' Haemolytic uraemic syndrome * 0/110 (0.00%)', ' Leukopenia * 0/110 (0.00%)', ' Cardiac failure * 1/110 (0.91%)', ' Pyrexia * 2/110 (1.82%)', ' Hepatic function abnormal * 0/110 (0.00%)', ' Arthritis bacterial * 2/110 (1.82%)', ' Lung infection * 0/110 (0.00%)', ' Haemoglobin decreased * 1/110 (0.91%)', ' Neutrophil count decreased * 0/110 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
a7903e59-9620-457a-8d83-eb6eb5dd8a2b
|
|
Single
|
Eligibility
|
NCT00186121
|
Patients with E2 outside the premenopausal range are ineligible for the primary trial.
|
Entailment
|
[
5
] |
[] |
{'Clinical Trial ID': 'NCT00186121', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole + Goserelin', ' Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily.'], 'Eligibility': ['INCLUSION CRITERIA', ' Histologically-confirmed, bi-dimensionally measurable, recurrent or metastatic carcinoma of the breast that is progressive', ' Premenopausal, defined as any of:', ' Last menstrual period within 3 months, or', ' Post-hysterectomy without bilateral oophorectomy and with follicle-stimulating hormone (FSH) in the premenopausal range, or,', ' If tamoxifen administered within the past 3 months, plasma estradiol must be in the premenopausal range', ' Either positive estrogen and/or progesterone receptor determination by Immunohistochemistry (IHC) or competitive binding assay on metastatic disease, or if not performed on their metastatic disease a positive result on their primary breast cancer specimen.', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2', ' Granulocytes > 1500/mm^3', ' Platelets > 100,000/mm^3', ' Serum glutamic oxaloacetic transaminase (SGOT) < 2.5 x upper limit of normal', ' Total bilirubin < 1.5 mg/dL', ' May have received irradiation to bony sites of disease for pain control or for prevention of fracture. The irradiated site(s) will NOT be evaluable for disease response.', ' Must be using effective contraception or not be of childbearing potential', ' Signed written informed consent', ' INCLUSION CRITERIA', ' Active, unresolved infection', ' Active malignancy other than breast cancer, in situ carcinoma of the cervix, or non-melanomatous skin cancers in the past 5 years', ' Prior treatment with an aromatase inhibitor or inactivator', ' Prior treatment with an luteinizing hormone-releasing hormone (LH/RH) agonist/antagonist', ' Adjuvant chemotherapy within 6 months of study entry.', ' Received chemotherapy or hormonal therapy in the 3 weeks prior to enrollment', ' Central nervous system metastasis', ' Lymphangitic pulmonary metastasis', ' Pregnant or lactating'], 'Results': ['Outcome Measurement: ', ' Objective Response Rate (ORR)', ' ORR was determined as the sum of the Complete Response (CR) rate + Partial Response (PR) rates.', ' CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.', ' PR = 50% decrease in tumor size for at least 4 weeks, without any new lesion or any 25% increase in size of any lesion.', ' All measurements by ruler or calipers.', ' Time frame: 3 months', 'Results 1: ', ' Arm/Group Title: Anastrozole + Goserelin', ' Arm/Group Description: Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily.', ' Overall Number of Participants Analyzed: 32', ' Measure Type: Number', ' Unit of Measure: percentage of participants 37.5 (21 to 56)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/32 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
dc7e7fbe-eed9-4307-b584-30ecaeb77c95
|
|
Single
|
Intervention
|
NCT02006979
|
Neither cohort of the primary trial need to perform low intensity exercise prior to each cycle of anthracyclines.
|
Entailment
|
[
0,
1,
2,
3,
4,
5
] |
[] |
{'Clinical Trial ID': 'NCT02006979', 'Intervention': ['INTERVENTION 1: ', ' Exercise', ' an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise', 'INTERVENTION 2: ', ' Usual Care', ' no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines'], 'Eligibility': ['Inclusion Criteria:', ' newly diagnosed with stage I-IIIA breast cancer', ' scheduled to receive neoadjuvant or adjuvant doxorubicin chemotherapy in cycles of 2-3 weeks long', " receive their oncologist's approval to exercise", ' be able to complete first time point of data collection prior to first chemotherapy cycle', ' be able to understand and provide written informed consent in English', 'Exclusion Criteria:', ' concurrent participation in a structured exercise program or study', ' have orthopedic limitations to exercise', ' pre-existing cardiovascular disease', ' uncontrolled hypertension (blood pressure 140/90 mmHg)', ' uncontrolled diabetes', ' respiratory disease', ' current smoking status'], 'Results': ['Outcome Measurement: ', ' Global Longitudinal Strain', ' Assessed with 2D speckle tracking echocardiography', ' Time frame: 24-48 hours after first doxorubicin and 7-14 days after completion of last doxorubicin cycle', 'Results 1: ', ' Arm/Group Title: Exercise', ' Arm/Group Description: an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise', ' Overall Number of Participants Analyzed: 13', ' Mean (Standard Deviation)', ' Unit of Measure: % deformation Baseline: 19.2 (1.9)', ' 24-48 h post first doxorubicin: 21.4 (1.8)', ' 7-14 days post last doxorubicin: -18.7 (1.4)', 'Results 2: ', ' Arm/Group Title: Usual Care', ' Arm/Group Description: no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines', ' Overall Number of Participants Analyzed: 11', ' Mean (Standard Deviation)', ' Unit of Measure: % deformation Baseline: -19.6 (1.9)', ' 24-48 h post first doxorubicin: -21.5 (1.6)', ' 7-14 days post last doxorubicin: -20.3 (1.6)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/13 (0.00%)', 'Adverse Events 2:', ' Total: 0/11 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
a34c6194-b6d9-49c3-8ddb-72de10c8a18c
|
|
Single
|
Adverse Events
|
NCT01120184
|
At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder.
|
Entailment
|
[
0,
6
] |
[] |
{'Clinical Trial ID': 'NCT01120184', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Taxane', " Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day 1 of each subsequent 3-week cycle; plus a minimum of 6 cycles with docetaxel 75 or 100 mg/m^2 IV on Day 1 of each 3-week cycle. Option 2: trastuzumab 4 mg/kg IV on Day 1 of Cycle 1, then 2 mg/kg IV weekly beginning on Day 8 of Cycle 1; plus a minimum of 18 weeks with paclitaxel 80 mg/m^2 IV weekly. Treatment continued until disease progression, unacceptable toxicity, or study termination. If trastuzumab or docetaxel were discontinued for toxicity, the other agent could be continued as monotherapy.", 'INTERVENTION 2: ', ' Trastuzumab Emtansine + Placebo', ' Participants received trastuzumab emtansine plus pertuzumab-placebo. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the placebo IV infusion, on Day 1 of each 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.'], 'Eligibility': ['Inclusion Criteria:', ' Adult participants >/=18 years of age', ' HER2-positive breast cancer', ' Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease, and be a candidate for chemotherapy. Participants with locally advanced disease must have recurrent or progressive disease, which must not be amenable to resection with curative intent.', ' Participants must have measurable and/or non-measurable disease which must be evaluable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1', ' Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1', ' Adequate organ function as determined by laboratory results', 'Exclusion Criteria:', ' History of prior (or any) chemotherapy for metastatic breast cancer or recurrent locally advanced disease', ' An interval of <6 months from the last dose of vinca-alkaloid or taxane cytotoxic chemotherapy until the time of metastatic diagnosis', ' Hormone therapy <7 days prior to randomization', ' Trastuzumab therapy and/or lapatinib (neo- or adjuvant setting) <21 days prior to randomization', ' Prior trastuzumab emtansine or pertuzumab therapy'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Death or Disease Progression According to Independent Review Facility (IRF) Assessment', ' Tumor assessments were performed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. Disease progression was defined as a greater than or equal to ( ) 20 percent (%) and 5-millimeter (mm) increase in sum of diameters of target lesions, taking as reference the smallest sum obtained during the study, or appearance of new lesion(s). The percentage of participants with death or disease progression was calculated as [number of participants with event divided by the number analyzed] multiplied by 100.', ' Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)', 'Results 1: ', ' Arm/Group Title: Trastuzumab + Taxane', " Arm/Group Description: Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day 1 of each subsequent 3-week cycle; plus a minimum of 6 cycles with docetaxel 75 or 100 mg/m^2 IV on Day 1 of each 3-week cycle. Option 2: trastuzumab 4 mg/kg IV on Day 1 of Cycle 1, then 2 mg/kg IV weekly beginning on Day 8 of Cycle 1; plus a minimum of 18 weeks with paclitaxel 80 mg/m^2 IV weekly. Treatment continued until disease progression, unacceptable toxicity, or study termination. If trastuzumab or docetaxel were discontinued for toxicity, the other agent could be continued as monotherapy.", ' Overall Number of Participants Analyzed: 365', ' Measure Type: Number', ' Unit of Measure: percentage of participants 63.3', 'Results 2: ', ' Arm/Group Title: Trastuzumab Emtansine + Placebo', ' Arm/Group Description: Participants received trastuzumab emtansine plus pertuzumab-placebo. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the placebo IV infusion, on Day 1 of each 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.', ' Overall Number of Participants Analyzed: 367', ' Measure Type: Number', ' Unit of Measure: percentage of participants 64.3'], 'Adverse Events': ['Adverse Events 1:', ' Total: 81/353 (22.95%)', ' Febrile neutropenia * 13/353 (3.68%)', ' Anaemia * 21/353 (0.28%)', ' Neutropenia * 25/353 (1.42%)', ' Thrombocytopenia * 20/353 (0.00%)', ' Hypercoagulation * 21/353 (0.28%)', ' Leukopenia * 21/353 (0.28%)', ' Atrial fibrillation * 1/353 (0.28%)', ' Cardiac failure * 0/353 (0.00%)', ' Cardiac failure congestive * 0/353 (0.00%)', ' Myocardial infarction * 1/353 (0.28%)', 'Adverse Events 2:', ' Total: 86/361 (23.82%)', ' Febrile neutropenia * 0/361 (0.00%)', ' Anaemia * 25/361 (1.39%)', ' Neutropenia * 20/361 (0.00%)', ' Thrombocytopenia * 22/361 (0.55%)', ' Hypercoagulation * 20/361 (0.00%)', ' Leukopenia * 20/361 (0.00%)', ' Atrial fibrillation * 0/361 (0.00%)', ' Cardiac failure * 0/361 (0.00%)', ' Cardiac failure congestive * 0/361 (0.00%)', ' Myocardial infarction * 0/361 (0.00%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
da00532d-57a8-4fe2-a2de-acc525161fd9
|
|
Comparison
|
Eligibility
|
NCT02511730
|
NCT00193206
|
Patients with prior chemotherapy are excluded from the secondary trial and the primary trial.
|
Contradiction
|
[
0,
1,
2,
3
] |
[
0,
6
] |
{'Clinical Trial ID': 'NCT02511730', 'Intervention': ['INTERVENTION 1: ', ' FFDM Plus DBT', ' Breast Images with FFDM and DBT', ' FFDM Plus DBT: Fujifilm Aspire Cristalle System', 'INTERVENTION 2: ', ' FFDM', ' Breast Images with FFDM alone', ' FFDM: Fujifilm Aspire Cristalle System'], 'Eligibility': ['Inclusion Criteria:', ' Female subjects participating in FMSU004A protocol with known clinical status', 'Exclusion Criteria:', ' Subjects with unknown clinical status not participating in FMSU004A protocol.'], 'Results': ['Outcome Measurement: ', ' Compare Per Subject Area Under Curve (AUC): FFDM Only vs DBT Plus FFDM', " Breast AUC performance metrics to determine if FFDM plus DBT improved cancer detection rate, requiring correct lesion localization. Statistician to estimate AUCs for each reader in each review condition (FFDM read in conjunction with FFDM plus DBT read) based on their Probability of Malignancy (POM) scores. POM scores will require correct lesion localization, such that in a case with cancer if the reader recorded one or more findings in the case but none of them are determined by the truther to match the location(s) of any proven malignancies, a POM score of 0 will be assigned to the case. Statistician to provide graphical representations of each reader's ROC curve for each review condition. For each reader the difference between the AUC for the FFDM read in conjunction with the FFDM plus DBT will be presented. Statistician to perform MRMC comparison of AUC's between FFDM read in conjunction with FFDM plus DBT using the MRMC method of Dorfman, Berbaum & Metz (1992).", ' Time frame: 1 month', 'Results 1: ', ' Arm/Group Title: FFDM Plus DBT', ' Arm/Group Description: Breast Images with FFDM and DBT', ' FFDM Plus DBT: Fujifilm Aspire Cristalle System', ' Overall Number of Participants Analyzed: 100', ' Mean (Standard Error)', ' Unit of Measure: Probability 100 (0.812)', 'Results 2: ', ' Arm/Group Title: FFDM', ' Arm/Group Description: Breast Images with FFDM alone', ' FFDM: Fujifilm Aspire Cristalle System', ' Overall Number of Participants Analyzed: 100', ' Mean (Standard Error)', ' Unit of Measure: Probability 100 (0.780)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/100 (0.00%)', 'Adverse Events 2:', ' Total: 0/100 (0.00%)']}
|
{'Clinical Trial ID': 'NCT00193206', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' Systemic Therapy', ' ABI-007 : ABI-007 175 mg/m2 D1 q 14 days x 6 cycles', ' Epirubicin : Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles', ' Gemcitabine : Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles'], 'Eligibility': ['Inclusion Criteria:', ' To be included in this study, you must meet the following criteria:', ' Locally advanced/inflammatory adenocarcinoma of the breast', ' 18 years of age or older', ' Normal heart function', ' Able to perform activities of daily living with minimal assistance', ' No prior chemotherapy for breast cancer', ' Adequate bone marrow, liver and kidney function', ' No evidence or history of significant cardiovascular abnormalities', ' Sentinel node or axillary dissection', ' Sign an informed consent form', 'Exclusion Criteria:', ' You cannot participate in this study if any of the following apply to you:', ' Pregnant or breast feeding', ' History of heart disease with congestive heart failure', ' Heart attack within the previous 6 months', ' Prior chemotherapy or hormone therapy for breast cancer', ' History of active uncontrolled infection', ' Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.'], 'Results': ['Outcome Measurement: ', ' Pathologic Complete Response', ' For the purpose of this study, a pathologic complete response (pCR) was defined as no evidence of residual invasive tumor in the breast (pT0) and axillary lymph nodes (pN0), gross or microscopic, in the sample removed at the time of surgical resection. Residual ductal or lobular carcinoma in situ was not considered in pCR assessments. Percentage of participants who experienced pCR is reported.', ' Time frame: 18 months', 'Results 1: ', ' Arm/Group Title: Intervention', ' Arm/Group Description: Systemic Therapy', ' ABI-007 : ABI-007 175 mg/m2 D1 q 14 days x 6 cycles', ' Epirubicin : Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles', ' Gemcitabine : Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles', ' Overall Number of Participants Analyzed: 116', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 23 19.8%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 22/123 (17.89%)', ' Cardiac Ischemia/Infarction [1]1/123 (0.81%)', ' Pain - Chest 2/123 (1.63%)', ' Dehydration 2/123 (1.63%)', ' Death [2]1/123 (0.81%)', ' Weakness 1/123 (0.81%)', ' Pain - Liver 1/123 (0.81%)', ' Infection - Skin [3]3/123 (2.44%)', ' Infection - Gastrointestinal [4]1/123 (0.81%)', ' Infection - Vein [5]2/123 (1.63%)', ' Infection - Pneumonia 1/123 (0.81%)']}
|
f90364e9-caee-4075-b444-2db1bf846d3a
|
Single
|
Eligibility
|
NCT01908101
|
Prior exposure to doxatel is obligatory for patients in the primary trial.
|
Contradiction
|
[
0,
1,
2
] |
[] |
{'Clinical Trial ID': 'NCT01908101', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Eribulin Mesylate)', ' Patients receive eribulin mesylate IV over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.', ' Eribulin Mesylate: Given IV', ' Laboratory Biomarker Analysis: Correlative studies'], 'Eligibility': ['Inclusion Criteria:', ' Ability to provide written informed consent', ' Prior exposure to taxane in the adjuvant, neoadjuvant or metastatic setting', ' At least one prior regimen of chemotherapy in the setting of metastatic breast cancer; no upper limit on the number of prior endocrine regimens for metastatic breast cancer, however no more than 6 chemotherapeutic regimens may have been given in the metastatic setting', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2', ' Patients must have baseline imaging within 30 days prior to the start of therapy and satisfy one of the following:', ' Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria', ' At least one non lymph node lesion of >= 1.0 cm or lymph node >= 1.5 cm in short axis by computerized tomography (CT) scan (CT scan thickness no greater than 5 mm which is serially measurable according to RECIST 1.1 using either computerized tomography (CT) or magnetic resonance imaging (MRI)', ' Lesions that have had radiotherapy must show evidence of progressive disease (PD) based on RECIST 1.1 to be deemed a target lesion', ' Non-measurable disease by RECIST 1.1 criteria (includes bone only disease and lesions < 10 mm or lymph nodes < 15 mm in short axis) with rising serum CA15-3 or CA 27.29 or CEA documented by two consecutive measurements taken at least 14 days apart with the most recent measurement being within 42 days prior to registration. The second CA 15-3 or CA 27.29 value must have at least a 20% increase over the first and for CA 15-3 or CA27.29 be greater than or equal to 40 units/mL or for CEA be greater than or equal to 4 ng/mL', ' Absolute neutrophil count >= 1,500/mm^3', ' Hemoglobin >= 10 g/dL', ' Platelets >= 100,000/mm^3', ' Creatinine =< 1.5 x upper limit of normal (ULN)', ' Total bilirubin =< 1.5 x ULN', ' Alkaline phosphatase =< 3.0 x ULN; up to 5 x ULN is acceptable if due to bone metastases in the absence of liver metastases', ' Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal, unless due to liver metastases (=< 5 x ULN)', ' Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation', ' Life expectancy of > 12 weeks', 'Exclusion Criteria:', ' Prior treatment with eribulin', ' Plan to administer any other systemic antitumor including endocrine therapy except for following standard of care treatment:', ' Trastuzumab at standard dosing human epidermal growth factor receptor 2 (HER2) positive tumors', ' Denosumab or bisphosphonates to treat metastatic bone disease', ' Plan to administer concurrent radiation therapy now or for progressive symptoms during treatment', ' Patients with known central nervous system (CNS) metastases must have stable disease off steroids after treatment with surgery or radiation therapy', ' Second primary malignancy that is clinically detectable or clinically significant at the time of consideration for study enrollment', ' Patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic and/or moderate (creatinine clearance [CrCl] 30-50 mL/min) renal impairment', ' Radiotherapy within 14 days of study treatment', ' Major surgery within 21 days of study treatment; minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgery', ' Treatment with any systemic chemotherapy or investigational agents within 3 weeks of the start of study treatment; endocrine treatment must be stopped prior to initiating study treatment; subjects must have recovered from toxicities of prior therapy', ' Patients with peripheral neuropathy > grade 2 regardless of etiology', ' Significant cardiovascular impairment: congestive heart failure > class II according to the New York Heart Association (NYHA), unstable angina or myocardial infarction within 6 months of enrollment, or serious cardiac arrhythmia (> grade 2)', ' Concomitant severe or uncontrolled medical disease', ' Significant psychiatric or neurologic disorder which would compromise participation in the study', ' Pregnant or breast-feeding females'], 'Results': ['Outcome Measurement: ', ' PFS', ' Kaplan-Meier survival curves will be used to describe PFS, overall and stratified by number of prior metastatic treatment regimens. A 95% confidence interval for the median PFS will be calculated using the method of Brookmeyer and Crowley.', ' Time frame: From study enrollment until the earliest date of disease progression or death, assessed up to 1 year', 'Results 1: ', ' Arm/Group Title: Treatment (Eribulin Mesylate)', ' Arm/Group Description: Patients receive eribulin mesylate IV over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.', ' Eribulin Mesylate: Given IV', ' Laboratory Biomarker Analysis: Correlative studies', ' Overall Number of Participants Analyzed: 59', ' Median (95% Confidence Interval)', ' Unit of Measure: months 3.5 (2.6 to 4.6)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/59 (3.39%)', ' Sepsis 1/59 (1.69%)', ' myocardial infarction 1/59 (1.69%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
deb78676-8f04-44c4-a5f6-389740d8a268
|
|
Single
|
Adverse Events
|
NCT00591851
|
There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial.
|
Contradiction
|
[
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] |
[] |
{'Clinical Trial ID': 'NCT00591851', 'Intervention': ['INTERVENTION 1: ', ' AC Followed by Paclitaxel + Trastuzumab', ' Doxorubicin and Cyclophosphamide (60/600 mg/m2) X 4 followed by Paclitaxel (175 mg/m2) X 4 every 2 weekly with pegfilgrastim (6mg on day 2) + Trastuzumab x 1 year.'], 'Eligibility': ['Inclusion Criteria:', ' adenocarcinoma breast cancer', ' ECOG performance status of 0 or 1', ' peripheral neuropathy less than or equal to 1', ' discontinued hormonal therapy as a chemoprevention while onstudy', ' LVEF by MUGA > 55%?', ' Absolute neutrophil count (ANC)> 1000/µL)', ' platelet count > 100,000/µL)', ' SGOT OR SGPT < 92.5 units/L', 'Exclusion Criteria:', ' Stage IV breast cancer', ' any chemotherapy, radiation therapy, immunotherapy, or biotherapy for a CURRENT breast cancer', ' pregnant or lactating patients', ' active second malignancy, other than adequately treated non-melanoma skin cancers or in situ cervical cancer', ' previous allergy/hypersensitivity to Doxorubicin, Cyclophosphamide, Paclitaxel, or other drugs formulated in Cremophor EL?', ' unstable angina, congestive heart failure, current use of digitalis, beta-blockers, or calcium blockers for therapy of congestive heart failure, arrhythmia requiring medical therapy, or a history of a myocardial infarction within 12 months', ' psychiatric illness that prevents her from understanding the nature of this study and complying with protocol requirements?', ' active, unresolved infections', ' sensitivity to E. coli derived proteins', ' prior chemotherapy with an anthracycline', ' prior Herceptin therapy'], 'Results': ['Outcome Measurement: ', ' Cardiac Saftey', ' LVEF by Muga scan', ' Time frame: Baseline-18 months', 'Results 1: ', ' Arm/Group Title: AC Followed by Paclitaxel + Trastuzumab', ' Arm/Group Description: Doxorubicin and Cyclophosphamide (60/600 mg/m2) X 4 followed by Paclitaxel (175 mg/m2) X 4 every 2 weekly with pegfilgrastim (6mg on day 2) + Trastuzumab x 1 year.', ' Overall Number of Participants Analyzed: 70', ' Median (Full Range)', ' Unit of Measure: percentage of LVEF LVEF at Baseline: 68 (55 to 81)', ' LVEF at Month 2: 67 (58 to 79)', ' LVEF at Month 6 (67/70 pts): 66 (52 to 75)', ' LVEF at Month 9 (68/70 pts): 65 (50 to 75)', ' LVEF at Month 18 (48/70 pts): 66 (57 to 75)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 19/70 (27.14%)', ' Febrile Neutropenia 24/70 (5.71%)', ' Pericarditis 21/70 (1.43%)', ' Sinus bradycardia 21/70 (1.43%)', ' Abdominal Pain 2/70 (2.86%)', ' Diarrhea 21/70 (1.43%)', ' Lower gastrointestinal hemorrhage 21/70 (1.43%)', ' Nausea 21/70 (1.43%)', ' Non Cardiac-Chest pain 22/70 (2.86%)', ' Fever 24/70 (5.71%)', ' Skin infection 41/70 (1.43%)', ' Neutrophil count decreased 31/70 (1.43%)']}
|
{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}
|
a06d1ca5-c890-4157-b1d2-0b70fd0092bd
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.